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This thesis investigates the problem of treatment sequencing within health economic 
evaluations. For some chronic conditions, sequences of treatments can be used. When there 
are a lot of alternative treatments, then the number of possible sequences becomes very 
large. When undertaking an economic evaluation, it may not be feasible to estimate the costs 
and benefits of every alternative treatment sequence. The objective of the thesis is to test the 
feasibility of simulation optimisation methods to find an optimal or set of near-optimal 
sequences of disease modifying treatments for rheumatoid arthritis in an economic evaluation 
framework. 
A large number of economic evaluations have been undertaken to estimate the costs and 
benefits associated with different treatments for rheumatoid arthritis. Many of these have not 
considered the downstream sequence of treatments provided, and no published study has 
considered identifying the best, or optimal, treatment sequence. The published evidence is 
therefore of limited applicability if the objective is to maximise patient benefit while 
constrained by a finite budget. It is plausible that decision-makers have developed sub-optimal 
guidance for rheumatoid arthritis, and this could extend to other chronic conditions. 
A simulation model can provide an expectation of the population mean costs and benefits for 
alternative treatment sequences. These models are routinely used to inform health economic 
evaluations. However, they can be computationally expensive to run, and therefore the 
evaluation of potentially millions of treatment sequences is not feasible. However, simulation 
optimisation methods exist to identify a good solution from a simulation model within a 
feasible period of time. Using these methods within an economic evaluation of treatment 
sequences has not previously been investigated. 
In this thesis I highlight the importance of the treatment sequencing problem, review and 
assess relevant simulation optimisation methods, and implement a simulated annealing 
algorithm to explore its feasibility and appropriateness.  From the implementation case study 
within rheumatoid arthritis, simulation optimisation via simulated annealing appears to be a 
feasible method to identify a set of good treatment sequences. However, the method requires 
a significant amount of time to implement and execute, which may limit its appropriateness 
for health resource allocation decision making. Further research is required to investigate the 
generalisability of the method, and further consideration regarding its use in a decision-making 



























CHAPTER 1: INTRODUCTION 
 
1.1 MOTIVATION 
Economic evaluation is a framework to provide a formal quantification of the costs and 
benefits of alternative allocations of health care resources. The evidence provided by 
economic evaluations enables decision makers to make informed decisions regarding the 
allocation of scarce health resources. These decisions may involve the development of a 
hospital, the introduction of a screening programme, or the funding of a medical treatment.  
The efficacy of many treatments can be uncertain, and even if they provide short term 
benefits, these may not persist. Therefore a switch may be made to an alternative treatment, 
and longer term and chronic conditions may be treated with a sequence of treatments. This 
sequence can provide disease control and symptomatic relief over a patient’s lifetime. 
Therefore, for an economic evaluation to capture the full future costs and benefits, a 
comparison is required between alternative treatment sequences, rather than alternative 
individual treatments. 
Evidence of the costs and benefits of competing alternatives or sequences are often 
unobserved, especially when accrued over a long time. Therefore decision analytic models are 
used to estimate expected future costs and benefits. These incorporate a range of evidence 
and assumptions, and for complex chronic conditions, a simulation model may be built to 
accurately reflect patient heterogeneity and capture future health events.  
Simulation models may be more appropriate for chronic conditions, especially when patient 
heterogeneity has an impact on future costs and benefits. However, they are often 
computationally expensive. 
In some chronic conditions, there can be a large number of treatments available. This is 
especially the case for rheumatoid arthritis (RA), where there are at least 13 unique 
treatments, and many treatments can be used in combination. There is a very large number of 
possible treatment sequences to be compared in an economic evaluation, so that the best 
sequence can be identified and the optimal use of health resources recommended. However, 
this large number of sequences, coupled with a simulation model which takes time to evaluate 
each sequence, means that it is not feasible to evaluate every possible sequence. This is the 
‘treatment sequencing problem’. 
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This problem can be framed as an optimisation problem, and simulation optimisation methods 
can be applied to determine a good enough solution within a feasible amount of time. 
However, applying a simulation optimisation method to address a treatment sequencing 
problem has not been conducted before. 
The motivation for this thesis is to review simulation optimisation methods which can be 
applied to this treatment sequencing problem. The implementation of a method in this thesis 
for the RA treatment sequencing problem will enable a consideration about whether it is 
feasible for use in other treatment sequencing problems, and other large health economic 
evaluation problems more generally. 
RESEARCH QUESTION 
The primary research question for this PhD thesis is ‘How can economic evaluations of 
sequential therapies for chronic conditions improve health resource allocation decision 
making?’ The PhD uses RA as a case study. 
The formal aims and objectives of the thesis are stated in Chapter 3, section 3.7. 
 
1.2 OVERVIEW OF THESIS 
Chapter 2 provides an introduction to economic evaluation. The theoretical basis to economic 
evaluation is explored and the decision analytic methods used to inform economic evaluations 
for decision makers are introduced. Chapter 3 provides a rationale for this thesis. It defines 
treatment sequences, considers a taxonomy for where treatment sequences may be used, and 
explains why treatment sequences represent a unique challenge when developing decision 
analytic models to inform an economic evaluation. Chapter 4 supports the rationale of this 
thesis by reporting a systematic review of economic evaluations of disease modifying anti-
rheumatic therapies (DMARDs) for RA. It highlights that no previously conducted economic 
evaluation has attempted to estimate the optimal treatment sequence for RA. 
In Chapter 5, a health economic model is developed to inform the currently ongoing NICE 
Technology Appraisal for biologic DMARDs. This allows a model to be utilised for the 
application of simulation-optimisation methods, which are reviewed in Chapter 6. Chapter 7 
reports the application of simulation optimisation via simulated annealing (SOSA) for the RA 
treatment sequencing problem. The thesis ends with Chapter 8, a discussion about the 
strengths and limitations of the work undertaken, recommendations for policy makers and 
further research, and overall conclusions. 
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1.3 RHEUMATOID ARTHRITIS 
EPIDEMIOLOGY 
Rheumatoid arthritis (RA) is a chronic inflammatory disease. It is characterised by progressive 
and irreversible joint damage, as well as impaired joint function, pain, and tenderness. The 
condition leads to disability and reduced quality of life.1 RA is associated with significant direct 
costs, as well as indirect costs due to reduced productivity.2,3 Evidence strongly suggests that 
patients with RA have a reduced life expectancy.4,5 
An estimated 400,000 people in England and Wales have RA,6 and it is more prevalent in 
females (1.16%) than males (0.44%).7 The majority of cases of RA are diagnosed when patients 
are between 40 and 70 years old.8 
ASSESSMENT 
In 1987, classification criteria for RA were produced by the American College of Rheumatology 
(ACR).9 In summary, for a diagnosis of RA, a patient must have at least four of the seven 
criteria: morning stiffness lasting for at least one hour; swelling in three or more joints; 
swelling in hand joints; symmetric joint swelling; x-ray imaging showing joint erosion or 
decalcification; rheumatoid nodules; and abnormal serum rheumatoid factor. The European 
League Against Rheumatism (EULAR) have also developed classification criteria, but these 
focus more on the identification of persistent synovitis, rather than satisfying the ACR 
criteria.10 
The EULAR and ACR classification systems have led to the development of two measures of 
improvement in RA symptoms: ACR responses,11 and EULAR responses.12 
An ACR20 response requires: a 20% improvement in swollen joint counts; and a 20% 
improvement in at least three of the following five ‘core set items’: Physician global 
assessment; Patient global assessment; patient pain; self-reported disability (using a validated 
instrument); and Erythrocyte sedimentation rate / C-reactive protein. ACR50 and ACR70 are 
also routine measure of improvement, with 50% and 70% improvements required, rather than 
20%. ACR response measures are routinely used in randomised controlled trials (RCTs). 
In the UK and across Europe, the disease activity score of 28 joints (DAS28)) is a routinely used 
measure of RA. The DAS28 can be used to classify both disease activity, and the level of 
improvement. The EULAR response criteria combine baseline DAS28 level, and the size of the 
DAS28 change, to classify response into ‘good’, ‘moderate’ and ‘none’. The method for 
determining the EULAR response classification is provided later in the thesis, in Table 5.14. 
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A commonly used measure of patient functional capacity is the health assessment 
questionnaire (HAQ). The HAQ instrument has established reliability and validity and is 
routinely used in RCTs and observational registries. It is commonly used to provide a profile of 
functional worsening over time due to RA. HAQ scores range from 0 to 3, best to worst. The 
scale is discrete, with step values of 0.125, which results in 25 HAQ values. 
TREATMENT 
The traditional medical treatments for RA involve conventional disease-modifying anti-
rheumatic drugs (cDMARDs), which include methotrexate (MTX), sulfasalazine (SSZ), 
hydroxycholorquine HCQ), leflunomide (LEF) and gold injections. Alongside these disease 
modifying treatments, analgesics, steroids, and non-steroidal anti-inflammatories were (and 
still are) commonly prescribed. 
However, more recently, a group of genetically-engineered biological therapies have been 
developed. Such drugs have been labelled as biologic DMARDs (bDMARDs). These treatments 
have amassed a significant amount of evidence to support their superiority over monotherapy 
cDMARDs, and their introduction to clinical practice has significantly improved the prognosis 
for patients with severe RA. However, the benefits provided by bDMARDs come with a 
significant price, and the introduction of bDMARDs has significantly increased spending on 
medical care for RA patients. The area of application within this thesis considers the cost-








Economics is the study of how choices are made and how the resources of society are used.13 
Resources are scarce, meaning there are not enough resources to satisfy the desires of all 
people. The scarcity of resources is the fundamental problem which economic theory and 
analysis look to address. Often, the definition of the social science of economics is posed as 
three related questions: “what is to be produced?”; “how is it to be produced?”; “who gets the 
output?”.14  
Health itself is an economic good, which allows the analysis of its demand, production and 
consumption in similar ways to the analysis of other goods and services.15 However, health has 
particular characteristics, and is often viewed as a ‘basic pleasure’16 or a ‘fundamental 
commodity’.17,18 Health has a significant impact on people’s welfare or utility, both directly as a 
consumption good, but also indirectly as an investment good, because it provides more 
healthy days which can lead to additional earnings and utility.18 Because health itself cannot be 
purchased or traded, economic analysis has to focus on the production and allocation of health 
care resources, which have demand derived from the demand for health. People’s desire for 
health in turn sees desire for more tangible goods and services which are considered a means 
to create health. This heightens the need for analytical insights into the allocation of health 
resources, because of the significant impact they have on people’s welfare. 
With scarcity of health care resources, an economic problem is observed in the field of health. 
The scarcity of resources must be considered alongside the objectives of a particular health 
system, such as maximising societal health. The production of health care is constrained by 
finite resources (factors of production) and technical possibilities, the two together 
represented by a production-possibility frontier. With a constrained supply of health care 
resources, decisions have to be made about how these scarce resources are allocated. The 
best allocation is that which satisfies the objective of the system, subject to the constrained 
supply of resources and the technologies available.  
This chapter will look to discuss the economic theory and methods that have been used to 
inform the allocation of scarce health resources. The objective is not to provide a 
comprehensive discussion about every aspect of health economic theory, but to instead 




2.2 OBJECTIVES OF A UNIVERSAL HEALTH SYSTEM 
A health care system is regularly defined as “the sum total of all the organisations, institutions 
and resources whose primary purpose is to improve health.”* This definition has been argued 
as being reductionist, by ignoring interrelations between components of the system, by 
removing the role of the population in a health care system, and by limiting its goal to just 
improving health.19 Kleczkowski (1984) provides a model of a health system, with five 
contributory components (Table 2.1).20 
Table 2.1: Kleczkowski model of a health care system 
 Component of a health care system 
1.  Development of health resources 
2.  Organised arrangement of resources 
3.  Delivery of health care 
4.  Economic support 
5.  Management 
 
Kleczkowski’s model defines a health care system in terms of the production of health care 
resources, and also the delivery of health care and the overarching management of the 
system. The model also reveals the broad objective of a health care system; the efficient use of 
health resources at a population level. In economics, efficiency is concerned with both the 
production of goods and services (technical efficiency), as well as the distribution of goods and 
services (allocative efficiency). An allocatively efficient distribution of goods is where the social 
surplus is maximised, and therefore the marginal benefits equal the marginal costs.  
The concept of allocative efficiency is aligned with the moral and political philosophy of 
distributive justice – what is just, or right, in allocating goods within a society.21 Two prominent 
moral theories of distributive justice are utilitarianism and egalitarianism, and they have a 
particular place in current health care resource allocation theory.22 
In utilitarianism, efficiency can broadly be defined as “greatest happiness of the greatest 
number”. Therefore the objective, to a utilitarian, is to maximise total social happiness, and a 
sacrifice from a minority that promotes the happiness of a majority is a worthy endeavour 
because the total social happiness has increased. Utilitarianism therefore makes no 
distributional judgement with regard to who ‘wins’ and who ‘loses’, and so equity of health 
                                                          
*
 http://www.who.int/topics/health_systems/qa/en/index.html - Accessed June 2015 
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care resource allocation would not be of concern. Egalitarianism is concerned with a 
distribution of resources so each member of society receives an equal share.22 
However, equity, along with efficiency, is an important policy objective in health care, as well 
as social policy more generally.23 Equity incorporates a particular goal for which equality is 
desired. Equity in health care can be concerned with both the financing of health care, as well 
as the distribution of health care resources. With respect to the distribution of health care, 
equity can be considered in two dimensions. Vertical equity is the consideration that unequal 
people should be treated unequally, with horizontal equity the equal treatment of equal 
people. Defining how people are equal or unequal is specified by the equity goal. The quantity 





An objective of ‘equal access for equal need’ requires the conditions where the opportunities 
to access health care are equal for those with equal need – horizontal equity. The corollary, for 
vertical equity, is that those with unequal needs have unequal opportunities to access health 
care. It is the case that equal access does not necessarily translate to equal utilisation, perhaps 
due to varying individual preferences. The acceptability of these reasons for differential 
utilisation should be considered. Equity of access, equity of utilisation and equity of outcomes 
as equity goals have different implications in terms of the delivery and allocation of health 
resources.  
Equity and efficiency do not align as objectives. In practice, maximising health outcomes may 
be at the expense of an equity goal (known as the ‘equity-efficiency trade-off’25). The corollary 
is that the achievement of an equity goal may be at the expense of health maximisation. 
 
2.3 WELFARE ECONOMICS AND HEALTH CARE ALLOCATION 
Welfare economics is the systematic analysis of the social desirability of any set of 
arrangements.15 With respect to resource allocation, it is the development of value 
judgements which allow a logical and consistent ranking of all alternative social states. With a 
scarce pool of health care resources, welfare economics allows informed and rational decision-
making for resource allocation. Welfare economics recognises that value judgements, and 
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normative economics, cannot be avoided. A fundamental question for health economics is 
how to determine the relative desirability of alternative ways of providing health care.  
Welfare economics is distinguished by four key underlying assumptions. Firstly, welfarism is a 
central axiom.  Welfarism is the requirement that “…the evaluation of any social state be 
based exclusively on the utilities generated in that state.”26 Secondly, it is underpinned by 
individualism, where social choices are constructed with only the views of those individuals 
affected considered. This assumes that individuals are the best (and only) judge of their own 
welfare, with perfect information and rational behaviour always motivating them towards 
achieving utility-maximisation. The third assumption is consequentialism, where the 
judgement of an action is based on its impact. Finally, welfare economics is defined by 
aggregation, which estimates social welfare as the aggregate of individual welfare. Welfare, or 
utility, is treated as ordinal in modern economics.  This requires a value judgement to rank 
different states of the world, or the observation of preference relations in the real world – 
revealed preference theory.  
If utility is considered a cardinal concept as defined in the early neoclassical approach,27 then 
the state with maximum utility could be identified via the aggregation of numeric utility, within 
a defined unit of measurement. With cardinal utility, equation [2.1] provides a social welfare 
function for state of the world (𝑋), which is a function of the utility obtained by each individual 
(𝑈) in that state. 
𝑊(𝑋) = 𝑓(𝑈1(𝑋), 𝑈2(𝑋), … , 𝑈𝑛(𝑋)) [2.1] 
However, economists moved away from the belief that by observing the purchasing of goods 
by consumers, that you can attach a numerical value in terms of the utility derived. Many 
economists now assume that utility is only measurable in an ordinal sense. You may observe a 
preference for a particular good by consumers, but not the relative strength of that 
preference. 
Vilfredo Pareto was one such economist, and his influential work at the turn of the 20th century 
highlighted that an improvement (a Pareto improvement) in social welfare is possible via a 
reallocation of resources that makes one person better off without making anyone else worse 
off. A Pareto optimum is achieved when all Pareto improvements have been made, and 
therefore the only possible way to make one individual better off is to make another worse off. 
Adam Smith’s ‘invisible hand’ is confirmed by the First Welfare Theorem – that a competitive 
market finds equilibrium at a Pareto optimum.  
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Pareto efficiency can identify between optimal and non-optimal states of the world, however 
it cannot rank between multiple points of optimality. Also, achieving Pareto optimality in 
practice is likely to be impossible. The difficulty of achieving the criterion of Pareto optimality 
stems from the fact that a person’s utility can only be inferred from revealed preferences, and 
so an evaluation of a distribution of resource that impacts on a large population becomes 
impossible. Instead, Kaldor-Hicks optimality is a less stringent criterion for an efficient 
allocation of resources. A Kaldor-Hicks allocation is superior to the status quo if the gains could 
be theoretically be used to compensate all those made worse off by the new distribution. A 
Kaldor-Hicks optimum is where no more Kaldor-Hicks improvements can be achieved. The 
difference between Pareto and Kaldor-Hicks is that the compensation does not actually have 
to be paid. If it is, then the losers do not lose and Pareto holds. The Kaldor-Hicks criterion is an 
attempt at being less restrictive; however flaws of the method have been identified. These 
include the fact that individuals require the same marginal utility of income,28 and also the 
possibility that after an improvement to increase social welfare, a move back to the original 
allocation could again increase welfare - the Scitovsky paradox.29 It is important to remember 
that Pareto and Kaldor-Hicks are neutral to any equity or distributional concerns,28 in particular 
when considering how compensation will have an impact on the distribution of income. 
The theoretical concepts of economic efficiency, Pareto and Kaldor-Hicks compensation, have 
been transferred to applied economics and policy evaluation. If the benefits of a policy are 
greater than the costs, then in principle the losers could be fully compensated with a net 
benefit remaining.30 There are numerous market failures associated with the provision of 
health care, meaning perfectly competitive markets in health are unlikely to exist.31 Therefore, 
the evaluation of policy and government provision and regulation of healthcare is required to 
ensure efficiency and welfare maximisation. 
 
2.4 ECONOMIC EVALUATION TO INFORM HEALTH CARE ALLOCATION 
When considering resource-allocation processes, a useful classification of ‘economic 
processes’ and ‘non-economic processes’ has been determined by several authors.32,33 The 
fundamental difference is that economic methods explicitly account for the scarcity of 
resources. By deploying a particular resource, it has been exhausted, and can be valued in 
terms of its opportunity cost, or the benefit foregone from the next best alternative. Each 
decision to deploy a resource is therefore explicitly valued by the next best alternative that 
could have been used in its place. Non-economic processes may be undertaken by determining 
a core set of services, a minimum requirement of need for a population, or via the ‘decibel 
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approach’ and political processes.32 However, these non-economic processes do not account 
for the opportunity cost of the deployment of resources and the differential preferences and 
demand for health care resources across a population.  
The economic processes of health care resource allocation are underpinned by the welfare 
economic theory detailed in 2.3. Brouwer and Koopmanschap (2000) discuss two competing 
views regarding economic evaluation in health care; the welfarist approach, and the 
pragmatist approach.34 The key distinction being that welfarists may try to ground economic 
evaluation on individualistic models of welfare, compared to pragmatists (or decision-makers) 
basing their recommendations for economic evaluation on societal values and on more 
pragmatic assumptions. The limitation of welfare economics in estimating cardinal measures 
of welfare, in particular to allow interpersonal comparisons of utility has been discussed and 
debated.35 This saw the development of Paretian theories and the Kaldor-Hicks criterion, as 
explained in Section 2.3. 
These theories have been operationalised as cost-benefit analysis (CBA), with the objective to 
identify Pareto improvements, or potential-Pareto improvements. CBA requires a consistent 
unit of measurement for both costs and benefits (usually monetary). The aim is to therefore 
identify those competing alternatives with a positive net benefit. The link to welfare 
economics is enhanced when considering Kaldor-Hicks, because the quantification of an 
individual utility change by compensation can be aggregated across all individuals who are 
affected. If the sum of compensation across individuals is positive, then this satisfies the 
Kaldor-Hicks criterion, and is equivalent to the net benefit estimated in the CBA. The primary 
decision rule for a CBA is to undertake activities with a positive net benefit when compared to 
the current status quo, and with a constrained budget the appropriate rule is to prioritise in 
order of the activity with the largest net benefit. Undertaking a CBA requires the identification 
of potential Pareto improvements, and also the identification of all costs and benefits which 
are relevant to a decision maker. Analyses that are explicitly limited in their capture of costs 
and benefits are known as partial CBA. Box 2.1 presents the usual summary measures from a 
CBA, the net present value (NPV) and the cost-benefit ratio. The NPV is the sum of the present 
value (PV) of both benefits and costs. 
The limitations of Paretian theory have seen a movement of welfare economics towards 
identifying independent arguments in the welfare function (the extra-welfarist approach), 
which would allow the methods of welfare analysis to survive. Health has been proposed as an 
important independent argument in the welfare function,28 as it would be an obvious measure 
to allow interpersonal comparisons within the health system. Therefore health itself, rather 
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than welfare, can be the objective when looking to evaluate the distribution of health care 
resources. The challenge in recent times has involved the development of a quantifiable and 
commensurate measure of health benefit. The quality adjusted life year (QALY) has evolved as 
a regularly used measure of health benefit, particularly in the UK. It has two primary 
dimensions, quantity and quality of life. A QALY requires quality of life to be anchored on a 
scale of one equal to perfect health, and zero equivalent to death. The scores for quality of life 
are more formally called health related quality of life (HRQL) states, or utility values. One QALY 
is therefore equivalent to one year spent in full health.* 
 








𝑟 = discount rate 
𝑡 = year 
𝑛 = time horizon (years) 
  
 






𝑃𝑉𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑠  = present value of benefits 
𝑃𝑉𝑐𝑜𝑠𝑡𝑠 = present value of costs 
  
Box 2.1: Cost Benefit Analysis 
The valuation of QALYs, or more formally the valuation of defined HRQL states, does not 
commit the evaluation to a narrow concept of utility or welfare. Instead, the use of QALY 
analysis allows health states to be valued, but also allows these values to be determined by 
peoples values and feelings for a particular health state, or by some objective principles.36 
COST EFFECTIVENESS ANALYSIS 
The QALY has increased the use of cost-effectiveness analyses (CEA), where benefits are 
measured in units other than money.15 Costs and benefits are evaluated across competing 
alternatives, to inform the allocation of health care resources. Cost-effectiveness analyses are 
related to cost-minimisation analyses (CMA), where the benefits are assumed equal between 
two or more alternatives, and therefore the solution is to pick the alternative with the lowest 
cost. CEA can incorporate benefits of interest such as life years gained (LYG), disability adjusted 
life years (DALYs), as well as clinical outcomes such as hip fractures avoided. When QALYs are 
used to quantify health benefits, the evaluation is formally called a Cost-Utility Analysis (CUA). 
This label recognises that overall health benefits, like utility, are of value. 
                                                          
*
 1 year of life x 1 perfect health HRQL state = 1 QALY 
3 years of life x 0.4 HRQL state = 1.2 QALYs 
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The major advantage of the QALY and CUA is that it allows a comparison of benefits across 
different treatments and conditions due to the common metric to value health benefits. The 
consistent application of CUA allows interpersonal comparison within a health system. For 
consistency and clarity, from now on only the term cost-effectiveness analysis (CEA) will be 
used, although the assumption is that this is equivalent to cost-utility analysis (CUA), and 
unless specified QALYs will be the metric of health benefits. 
Because a CEA does not provide a direct comparison of the value of the effects and the costs, 
decision rules are required. If comparing two treatments, one may cost more but also provide 
more QALYs. The problem for decision-makers is determining how much extra benefit is 
required to justify the extra expenditure, because there is an opportunity cost associated with 
allocating resources. A cost-effective treatment is one where, given limited resources, its use 
will contribute to the maximisation of health benefits. Traditionally, the output of a CEA is 
reported as a ratio of the difference in costs and effects between two alternatives, the 
incremental cost-effectiveness ratio (ICER), as demonstrated in Box 2.2. 
 





𝑎 = Treatment A 
𝑏 = Treatment B 
𝐶 = Costs 








Box 2.2: Cost Effectiveness Analysis 
The ICER can be interpreted as the cost per unit of effect, as represented in equation [2.4]. For 
decision makers, there are four possible situations when using an ICER, which are presented in 
Table 2.2. 
Table 2.2: Results from a cost-effectiveness analysis (CEA) 
 CEA result ICER  Interpretation Fund new treatment? 
1. + Inc. Cost 
+ Inc. QALYs 
Positive More costly and more effective ? 
2. - Inc. Cost 
- Inc. QALYs 
Positive Less costly and less effective ? 
3. + Inc. Cost 
- Inc. QALYs 
Negative More costly and less effective  
4. - Inc. Cost 
+ Inc. QALYs 




With situations 3 and 4, the solution for decision-makers is very straight forward. However, it 
is clear that a definitive answer cannot be provided based on just an ICER value. The estimates 
of costs and effects are required to ensure dominant (less costly and more effective) 
treatments are adopted and dominated (more costly and less effective) treatments are 
refused. With situations 1 and 2, the magnitude of the ICER will have an impact on whether it 
is viewed as cost-effective. The interpretation of an ICER as the cost per additional unit of 
effect means that the higher the ICER, the more you will have to be willing to pay for that 
additional unit of effectiveness. Formally, a cost-effectiveness threshold (𝜆) is a ceiling for 
which an ICER must be less than for it to be considered cost-effective. The 𝜆 threshold can be 
used as a tool to resolve situations 1 and 2, however 2 is generally rare and often other 
decision rules are considered, such as not accepting treatments which result in a health loss, 
which may also be unethical. In situation 1, an ICER for an option below 𝜆 is considered cost-
effective, or the additional (reduced) effect is at an acceptable cost (saving). 
The true definition of the 𝜆 threshold value has been widely debated in health economics. 
Some have proposed that the 𝜆 threshold is a societal estimate of the willingness to pay for a 
QALY.37 This definition allows an empirical estimate of 𝜆 to be found through either revealed 
preferences or studies with hypothetical games. The major issue with this approach is that a 
societal willingness to pay value for a QALY does not consider the fact that the NHS budget is 
fixed, and decision-makers must consider the opportunity cost of the deployment of 
resources. An exhaustive consideration of the costs and QALYs of all NHS services would allow 
a ranking of all by their cost-effectiveness and a budget to be allocated via a cost-effectiveness 
league table.38 A threshold 𝜆 can be derived from the league table approach; it is the ICER of 
the least cost-effective intervention that is currently funded. This intervention would ideally be 
decommissioned by the NHS if a more cost-effective intervention was developed. This 
approach may be feasible for a small budget-holder with only a small set of activities to 
prioritise, however for the NHS the task of identifying these opportunity costs is likely to be 
impossible. Also, the use of a league table could clearly highlight equity issues, such as 
populations of people having no NHS care. 
To allow economic evaluation to inform health care resource allocation, a pragmatic approach 
has been proposed.39,40  The 𝜆 threshold can be informed empirically by past decisions, or by 
estimates from other public sectors. By using past decisions, a decision-maker can be a 
‘threshold seeker’,40 and analyses can highlight services which should be displaced, with clear 
recommendations for disinvestment. The search for a 𝜆 threshold does highlight a limitation of 
economic evaluation and the identification of optimal allocations of health care resources. The 
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current approaches for the economic evaluation of health resources continue to be 
contentious, and the ongoing research to inform the 𝜆 threshold is of great importance.41 
When an evaluation is of only two competing alternatives, then application of the decision rule 
is usually straight forward. The ICER can be calculated between the two alternatives and the 
standard 𝜆 threshold applied. However, when an economic evaluation considers more than 
two alternatives, the decision rules become more complicated, and the quick interpretation of 
results requires a set procedure for the presentation of results. This procedure, known as an 
incremental analysis, consists of ruling out options which are simply dominated (where a less 
costly and more effective alternative exists), and extendedly dominated (where a combination 
of two alternative options is less costly and more effective). The process for undertaking a full 
incremental analysis is presented in Box 2.3. 
1. Rank options by increasing cost 
2. Eliminate options that are simply dominated – there is a less costly and more effective 
comparator 
3. Eliminate options that are extendedly dominated – there is a combination of two other 
options that are less costly and more effective 
4. Calculate the incremental costs and incremental benefits of each remaining option 
5. Calculate the ICER compared to the next best (non-dominated) alternative 
Box 2.3: Process for undertaking a full incremental analysis 
While this process is routinely undertaken for economic evaluations, and ICERs are the 
standard output for a CEA, the ratio properties of an ICER means that often their 
interpretation can be a challenge, especially when there are many comparators. Therefore to 
avoid the limitations of an ICER, it is common to internalise the 𝜆 threshold decision-rule which 
essentially returns us to a CBA, but does not require the imposition of a welfarist framework. 
The aim is to allow cost-effectiveness to be interpreted by a single figure which is not a ratio. 
The net benefit approach is used, with 𝜆 being used to convert either costs into units of effect, 
or benefits into monetary units. 
The net benefit approach is demonstrated in Box 2.4, with the cost effectiveness threshold 𝜆 
used to convert either costs or benefits into a consistent unit. Using the net benefit approach 








 𝑁𝑒𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =  ∆𝐸 − ∆𝐶 [2.6] 
Where: 
∆𝐸 and ∆𝐶 are in the same units 
Cost Effectiveness Threshold 𝜆  
 
 
 𝑁𝑒𝑡 𝑀𝑜𝑛𝑒𝑡𝑎𝑟𝑦 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠 =  𝜆 ∙ ∆𝐸 − ∆𝐶 [2.7] 
If 𝑁𝑀𝐵 > 0, then cost-effective   
 




If 𝑁𝐻𝐵 > 0, then cost-effective   
Box 2.4: Net Benefit 
DECISION ANALYTIC MODELLING 
Health technology assessment (HTA) is “..a multidisciplinary process to evaluate the social, 
economic, organisational and ethical issues of a health intervention or technology.”* It is the 
framework which underpins health resource allocation decision making. For a CEA to inform 
HTA, the costs and effects of competing alternatives are required. However, the estimation of 
costs and effects requires evidence which in general is not observable. Even where costs and 
effects have been observed, for instance within a clinical trial, the evidence may be limited in 
terms of its generalisability and appropriateness for decision-making. In particular, the 
evidence may be short-term, where long-term implications are important, or a trial may not 
include all relevant comparators (placebo-controlled trials are common). For decision-making 
within a HTA process, trial and observational evidence may form a subset of the evidence 
required; however HTA often requires the synthesis of evidence to estimate the costs and 
effects of a technology in circumstances which often have not been observed. For example, a 
novel cancer therapy may have a short placebo-controlled trial to prove efficacy, however the 
long term implications in clinical practice may have never been observed. 
Decision analytic modelling (DAM) “represents the real world with a series of numbers and 
mathematical and statistical relationships.”42  Decision analysis and DAM in the context of 
economic evaluation uses mathematical models to determine the possible consequences that 
would emerge from the competing alternatives being evaluated. A decision analytic model 
(from now on referred to as a ‘model’) allows the consideration of the costs and effects of a 
range of future consequences, with the likelihood of those consequences also being estimated. 
This allows the calculation of the expected costs and expected effects of each option. The 
expected cost (effect) is the sum of all costs (effect) of each consequence weighted by the 
                                                          
*
 http://www.who.int/medical_devices/assessment/en/ - Accessed June 2015 
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probability of that consequence.43 Brennan and Akehurst (2000) detail five roles and 
applications which modelling has within HTA, which are provided in Box 2.5:42 
1. Extending results (from a single trial) 
2. Combining multiple sources of evidence to answer policy questions 
3. Generalising results from one specific context to others 
4. Modelling to inform research strategy and design 
5. Modelling uncertainties in the knowledge base. 
Box 2.5: Roles and applications of modelling within Health Technology Assessment42 
Modelling has become a key component in HTA and the consideration of the cost-
effectiveness of new treatments. Briggs, Claxton and Sculpher (2007) discuss that the 
increased role of modelling is due to the requirements of economic evaluation. Namely, that 
all relevant evidence is synthesised, all relevant comparators are considered, that an 
evaluation time horizon is appropriately long, and that uncertainty in the evidence is captured 
as decision uncertainty.43 
Many models use a cohort approach, where expected costs and effects are estimated for an 
average person, or a cohort of average persons. The outcomes of the model are therefore 
population estimates. This includes methods such as decision trees, and cohort state-
transition/Markov models.44 These methods are often appropriate for the decision context and 
available evidence, however their shortcomings mean that more advanced individual level 
methods have emerged. The decision-maker is concerned with the expected cost and effect 
per patient, to allow an estimation of the cost-effectiveness of a new treatment across a 
population. However, cohort modelling approaches in general do not allow for variability in 
patients outcomes according to particular characteristics. However, these characteristics may 
contribute to costs and effects. Cohort models are often built which allow cohort sub-groups 
to be tracked through a model, and parameters applied which relate to the particular 
characteristics of the subgroup cohort. However these approaches only partially capture 
patient variability, and may result in very complex models, or many models with different 
subgroup populations evaluated.  
An alternative to cohort model approaches are individual level models (ILMs), where 
individuals with their own characteristics can be simulated in a model and the impact of these 
characteristics on costs and effects can be captured. Also, the complexity of treatment 
pathways and the fact that patient history could have an impact on the future can be more 
easily represented.  
ILMs such as patient-level simulation, discrete event simulation (DES), and agent based models 
estimate individual patient output (cost and effects) which is contingent on individual patient 
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covariates. When the simulation is run across a large number of individual patients, the 
expected cost and effects across the population can be estimated. However, the benefits of 
ILMs are at least partially offset due to the requirement of usually thousands of individual 
patient simulations, meaning that ILMs are usually more computationally expensive when 
compared to cohort decision analytic models. 
 
2.5 NATIONAL LEVEL NHS HEALTH RESOURCE ALLOCATION 
In England, the National Institute for Health and Care Excellence (NICE) was established in 
1999.* It is a HTA decision making organisation and has a mandate from the Department of 
Health to evaluate (appraise) the health benefits and costs of new and established health 
technologies and clinical practice. NICE publishes guidance in six areas, as detailed in Table 2.3. 
Table 2.3: Types of NICE guidance 
NICE Programmes Guidance 
published*  
Remit Cost-effectiveness analyses 
Clinical Guidelines 158 Advisory Existing CEA’s reviewed 
Potential CEA’s prioritised 
New analysis – focussed CUA 
Public Health 57 Advisory Existing CEA’s reviewed 
Potential CEA’s prioritised  




270 Mandatory Existing CEA’s reviewed 




458 Advisory None 
Medical technologies 25 Advisory Existing CEA’s reviewed 




1 Advisory Existing CEA’s reviewed 




16 Advisory Existing CEA’s reviewed 
New analysis – comprehensive 
CUA 
*as of September 2015 – includes replaced guidance.  
CEA = Cost effectiveness analysis. CUA = Cost utility analysis 
                                                          
*




Only NICE Technology Appraisals have a mandatory status, which means that if a positive 
conclusion is reached about the use of a particular health technology in the NHS, then there is 
legal requirement for that technology to be available if considered clinically appropriate by a 
patient’s physician.45 Although NICE Clinical Guidelines are not legally mandated, there is an 
expectation by the Care Quality Commission that NICE Clinical Guidelines provide the basis for 
routine clinical practice.46  
The majority of NICE programmes require a review of relevant economic evaluation literature 
to be undertaken, and where appropriate a development of a new economic evaluation to 
ensure that any guidance developed promotes a cost-effective use of NHS resources. 
Therefore the work of NICE has seen a large increase in economic evaluations for health 
treatments and services, and has also driven the discussion and development of new 
methodologies for economic evaluation. The methods, assumptions and evidence used to 
undertake an economic evaluation for NICE, and similar organisations worldwide, will 
therefore have a direct impact on health resource allocation and patient outcomes. 
For their Technology Appraisals programme, NICE have a “Guide to the Methods of Technology 
Appraisal.”47 This document describes the methods that should be used when submitting 
evidence to NICE, as well as their decision making process. This enables consistency across 
Technology Appraisals, as well as ensuring the methods used are robust and transparent. For 
an economic evaluation being submitted as part of a NICE Technology Appraisal, the methods 
guide prescribes which methods should be used within a ‘reference case’. Important 
components of the reference case include that health effects should be measured using 
QALYs, and that a time horizon is long enough to ensure all future health and effects are 
captured. 
The methods guide also states that if the most plausible ICER for a technology is below 
£20,000 per QALY gained, then it is likely to be recommended for NHS use. If the ICER falls 
between £20,000 to £30,000 per QALY gained, then additional factors will be considered by 
the appraisal committee. These include: the degree of certainty around the ICER, whether 
changes to HRQL have been appropriately captured, if the technology is particularly 
innovative, if the technology is a life-extending treatment at the end of life, and if there are 
aspects of the technology related to non-health objectives of the NHS. Above £30,000 per 
QALY gained, then even stronger arguments with respect to the factors listed above will need 
to be made for a positive recommendation to be passed. 
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Therefore the decision rule used by NICE is predominantly based on cost-effectiveness, 
although there is the ability for the decision-makers (one of four appraisal committees) to 
incorporate their judgement regarding those other specific factors. 
The theoretical construct behind NICE’s decision making approach is that recommending 
technologies under £20,000 - £30,000 per QALY will require the disinvestment of technologies 
that have an ICER above £20,000 - £30,000 per QALY gained. This enables total QALYs to 
increase but with no net cost to the total NHS budget. However, while the appraisal process 
clearly explores the costs and benefits provided by a new technology, the interventions that 
are displaced are unknown. This is a source of criticism for NICE, and some have commented 
that the approach is un-economic, with disinvestment and opportunity cost not explicitly 
accounted for.48–50 However, proponents of NICE highlight that the methodology is grounded 
in extra-welfarism theory, while maintaining a process which is pragmatic and feasible. 
 
2.6 OPERATIONAL RESEARCH 
Operational research (OR) is the discipline of applying advanced analytical methods to help 
make better decisions.* OR is also known as ‘management science’.51 It developed as a 
discipline during the wartime period of the early 20th century to inform decision-making 
regarding military strategy and resourcing, and in the post-war period operational researchers 
moved out into industries such as steel and engineering. OR expanded in academia, as well as 
private and governmental organisations, during the second half of the 20th century.52 The 
increase in computational power during the 1980s and 1990s saw practical applications of OR 
methods in wider fields, and interdisciplinary working across academic fields and organisations 
has been a key characteristic of OR.  
Modern OR is often dichotomised as ‘hard’ OR, which involves quantitative analysis, and ‘soft’ 
OR, which incorporates non-mathematical techniques and problem-structuring methods 
(PSMs).53 Soft OR includes methods for structuring and exploring (often complex) problems, 
and the facilitation of engagement in problem-solving, and is often best considered as 
methods to tackle problems in their own right, as well as being complements to hard OR 
methods.53 The hard OR methods draw upon mathematics, economics and computing for 
theoretical underpinning. This is to be expected, due to OR being developed as a relatively new 
interdisciplinary field that included people with these backgrounds. In particular, areas of 
common interest include optimisation, game theory, production, finance and forecasting. 
                                                          
*
 www.theorsociety.com – Accessed June 2015 
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However, it should be highlighted that often economists and operational researchers have 
different interests, and therefore the fields are distinct. Health economics and health resource 
allocation is an area where the fields of economics and OR have collaborated and combined. 
OR methods have had an important role to play in HTA and economic evaluations. Soft OR 
methods, in particular PSMs and model conceptualisation methods, are used to support the 
development of DAMs for HTA.54 Hard OR methods, such as simulation, have been used to 
provide estimates of long term costs and QALYs for economic evaluations via the development 
of ILMs.44 
Optimisation is the task of making the best decision among various alternatives.55 Optimisation 
is a prominent area in OR, involving analytical and heuristic methods to identify an optimal 
(best) or near-optimal solution for a particular maximisation or minimisation problem. 
Optimisation allows the representation of health resource allocation as a maximisation 
problem. That is, how to maximise population health given a fixed monetary budget and 
competing healthcare programs. Health care resource allocation can be represented in a linear 
programming (LP) formulation, as demonstrated by Stinnett and Paltiel (Box 2.6).56 Linear 
Programming is a form of constrained optimisation where the objective function (the function 
that is to be maximised) is linear. The constraints are that the proportion of each program 𝑖 
can only be between 0 and 1, and the total cost must not exceed the budget 𝐶. 
Maximise: ∑ 𝑥𝑖𝑒𝑖 [2.9] 
Subject to: 0 ≤ 𝑥𝑖 ≤ 1  (for all 𝑖) [2.10] 
 ∑ 𝑥𝑖𝑐𝑖 ≤ 𝐶 [2.11] 
Where: 
𝑒𝑖 and 𝑐𝑖 are the effectiveness and cost of program 𝑖 if fully implemented 
𝐶 is the total available budget 
𝑥𝑖 is the proportion implemented of program 𝑖 
Box 2.6: Linear Programming formulation of health care resource allocation56 
A contested aspect of the linear programming formulation, along with CEA more generally, is 
that implementing only proportions of programs (their divisibility) is not likely to be 
appropriate. Also, the divisibility of programs is related to the assumption of constant returns 
to scale for programs, which is contested most notably by Birch and Gafni.48,57 As a program 
increases in size, it is expected that the output will increase by more than a proportional 
increase in inputs (at least to a certain point), but the linear programming formulation does 
not account for this. Instead, a solution is to formulate the problem as an integer programme 
(IP). This has been presented by Torrance (1972)58 and Birch & Gafni (1992), as illustrated in 
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Box 2.7.59 Constraint [2.13] has been altered from the linear programming formulation so that 
programs can only be fully implemented, and therefore programs are not divisible. 
Maximise: ∑ 𝑥𝑖𝑒𝑖 [2.12] 
Subject to: 𝑥𝑖  ∈  {0,1} [2.13] 
 ∑ 𝑥𝑖𝑐𝑖 ≤ 𝐶 [2.14] 
Box 2.7: Integer Programming formulation of health care resource allocation59 
The IP formulation above is defined in OR as the knapsack problem (which is an IP with just 
one constraint). Given a set of items with a given weight and value, the problem is to 
determine which items to place in a knapsack with a given weight limit as to maximise the 
total value. For health, the constrained optimisation problem is to allocate a fixed budget to 
competing programs, each with their own cost and effectiveness. The problem cannot be 
solved analytically, and therefore mathematical algorithms are developed to solve the 
problem. When mathematical algorithms are required, the assumptions and the size of the 
problem have a direct impact on the ability to reach an optimal answer within a given period 
of time.  
The algorithms used to solve or approximately solve constrained optimisation problems like 
the knapsack problem may also have a role when looking to estimate the appropriate 
sequence of therapies for patients with chronic conditions. The objective is to maximise net 
benefits by selecting treatments from an available set, each with their own cost and health 
benefit.  
There is therefore the potential to apply optimisation methods from OR to address economic 
evaluations which have a very large set of competing alternatives. In the following chapter, the 
treatment sequencing problem for economic evaluations of chronic conditions is introduced. 
In Chapter 6, a systematic review of OR literature to identify optimisation methods which may 
be applicable to the treatment sequencing problem is undertaken. 
 
2.7 CONCLUSIONS 
The use of economic evaluations and cost-effectiveness analyses to inform the allocation of 
scarce health resources has increased in recent years, in particular with the development of 
organisations like NICE. However, these methods are likely to be limited in their ability to 
achieve allocative efficiency in a true economic sense, due to the pragmatic approaches 
required to allow a feasible estimate of the impact of alternative states of the world. Instead, 
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economic evaluation represents a transparent and formally defined set of methods which 
allow an informed attempt at meeting social objectives where government provision of health 
care is required. The use of DAMs and OR methods has increased, to allow the synthesis of 
evidence and the estimation of lifetime costs and QALYs for complex conditions and treatment 
pathways.  
Chapter 1 provided an introduction and brief motivation for this thesis. This current chapter 
provides a theoretical underpinning for the remaining thesis. In particular, that models are 
simplifications of reality, and therefore ‘wrong’, however to allocate health care resources 
fairly and efficiently they are required to better inform decision-makers. 
In the next chapter (Chapter 3), the treatment sequencing problem is formally introduced, and 
the rationale for this thesis is provided. The chapter explores what treatment sequences are, 
when they are used, and why they present a challenge for both developing models and 
undertaking economic evaluations. After this, the following chapter reveals how the treatment 
sequencing problem has not been formally address in rheumatoid arthritis (RA), via a 
systematic review (Chapter 4). A model is then developed for an economic evaluation to 
inform a NICE appraisal of biologic treatments for RA (Chapter 5). A review of OR optimisation 
methods is conducted to identify suitable methods to solve the treatment sequencing problem 
(Chapter 6). A method is selected, implemented and evaluated in Chapter 7, before discussions 
and conclusions are drawn in the final chapter.  
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CHAPTER 3: RATIONALE FOR THIS THESIS 
 
3.1 INTRODUCTION 
The aim of this thesis is to identify a simulation optimisation method which can be applied to 
an economic evaluation of sequential therapies for a chronic condition. The rationale for 
undertaking this research will be described in this chapter. 
In Section 3.2, treatment sequences are defined and the reasons for their use are explored. In 
particular, the conditions in which a treatment sequence may be used are highlighted. In 
Section 3.3, the reasons why treatment sequences represent a unique challenge for economic 
evaluation are introduced. It is demonstrated why a long sequence or large number of 
potential treatments can result in an infeasible number of sequences to compare explicitly. 
In Section 3.4, a consideration of the influence of pharmaceutical markets and the 
development of new technologies is reported. These often compound the difficulties in 
evaluating treatment sequences. 
In Section 3.5, there is a discussion regarding how patient choice may impact on the 
development of guidance for treatment sequences. Section 3.6 draws conclusions. Section 3.7 
and Section 3.8 report the aims and objectives, and the structure of the thesis, respectively. 
 
3.2 TREATMENT SEQUENCES 
A literature search using Google Scholar and PubMed was undertaken, but no agreed 
definition of ‘sequential treatments’ was identified. However, it is frequently used to describe 
medical treatment which may follow or precede other treatments.60–62 For this thesis, 
sequential therapies are defined as “the purposeful use of treatments administered one at a 
time to manage a condition over time”. However, to improve the definition, it should be stated 
that “the sequence is determined a priori”, and so the subsequent treatment or remaining 
sequence are known before a prior therapy is delivered. This is because in clinical practice the 
pool of available treatments will be considered before selecting a first therapy, and potentially 
the order of subsequent therapies. In general, a treatment refers to one particular medical 
drug, however many drugs can be used concomitantly, and so combination drug therapy also 




The definition highlights that at a decision point* a physician and patient may have multiple 
treatments available to them, and therefore have multiple potential sequences of treatment 
to consider. The selection of a sequence is based on considering the set of available 
treatments and all possible sequences.  
An example of the issues which arise in considering sequences of treatments is given by the 
NICE Technology Appraisal of tocilizumab for the treatment of RA.† In this evaluation, 
treatment sequences were widely discussed and considered, because tocilizumab could be 
approved in multiple positions within a treatment sequence. The appraisal focussed on the 
assumptions made by the manufacturer, Roche, regarding the sequence of treatments for 
patients with RA. Alternative assumptions about what may occur both before and after 
tocilizumab treatment had a significant impact on the potential cost-effectiveness of 
tocilizumab treatment compared to conventional DMARDs. 
During the course of the appraisal, the NICE Decision Support Unit (NICE-DSU) was 
commissioned to provide additional evidence for the appraisal committee. In their report to 
the committee, the authors Palmer and Sculpher comment that “…the appropriate use of new 
biologics therapies in RA inevitably involves a consideration of the appropriate sequence of 
therapies given the chronic nature of the condition, the fact that therapies do not typically 
remain efficacious and tolerable on a permanent basis and the availability of a number of 
biologic therapies which are licensed for RA.”63 This statement is found in a small report within 
a complex technology appraisal but contains three primary reasons for why treatment 
sequences are used in clinical practice: 
- Chronicity – a chronic condition is more likely to require treatment with a treatment 
sequence 
- Uncertainty – when the effectiveness of a treatment is limited, and response to a 
treatment cannot be predicted, then a sequence may be used to identify a treatment 
which is effective 
- Competition – if there are many possible treatments available, then sequential therapy 
may be used. 
In the remainder of this section, these reasons for why treatments are used in clinical practice 
will be examined further (Competition is discussed within Section 3.4). Also, some further 
                                                          
*
 A decision point could be a new diagnosis, or the failure (loss of efficacy or an adverse effect) of a 
treatment and a consultation to determine the next therapy 
†
 http://www.nice.org.uk/guidance/ta247 - Accessed June 2015 
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reasons will be considered to determine the key characteristics which are required for 
treatment sequences to be clinically appropriate. 
EFFECTIVENESS 
The effectiveness of a particular treatment is defined as the extent to which “...they achieve 
health improvements in real practice settings.” 64 In clinical practice, the effectiveness of a 
treatment may be determined by a measure of improvement, which may be a measure of 
survival, HRQL, or a surrogate outcome such as a laboratory test for a biomarker. Determining 
effectiveness may be complex because a treatment may have multiple impacts on health. For 
example, a treatment might immediately reduce disease activity, but increase the risk of a 
future undesired health effect. These multiple effects, both benefits and risks, can be 
aggregated to provide a benefit-risk profile for a particular treatment.65 Formally, a benefit-risk 
profile is a “reflection of the overall balance of a treatment’s potential benefits with its 
identified risks as revealed through the safety and efficacy evidence.”* A benefit-risk profile 
could be a formally weighted and quantitative assessment of a treatment, or a qualitative 
judgement. Quantitative benefit-risk assessments are included in the regulatory processes 
undertaken by licensing bodies such as the Food and Drug Administration (FDA) in the USA and 
the European Medicines Agency (EMA). New medical products have to provide evidence to 
ensure that the potential benefits clearly outweigh any risks. Qualitative judgements regarding 
the benefit-risk profile of a treatment are routinely undertaken by a clinician who draws upon 
evidence, experience and clinical expertise, along with considering a patient’s views and 
particular circumstances. 
Many treatments will only have a limited effectiveness, both for chronic and acute conditions. 
In some cases it may be immediately obvious that a treatment has not been effective in 
achieving patient benefit. For some treatments, a consideration of the long-run outcomes is 
required, where any benefit may diminish over time, or negative effects such as adverse 
events may occur. In either case, the clinical decision to switch to another treatment to try to 
achieve health benefits may be made. The limited effectiveness is dependent on both the 
treatment, and also the condition. A person’s condition may become refractory over time, and 
control be lost, or a treatment may provide short term benefit but is not sustained. For chronic 
conditions, where a treatment cannot provide cure, it may be the case that a treatment will 
only be effective for a proportion of a patient’s lifetime.  
The effectiveness of available treatments is one determinant of the likelihood of treatment 
sequences being required. If a treatment is curative, or highly effective, then there is less 
                                                          
*
 http://www.hc-sc.gc.ca/dhp-mps/homologation-licensing/gloss/index-eng.php#b - Accessed June 2015 
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reason to require a sequence of therapies. However, if the treatments available for a particular 
condition are less effective, or a condition is chronic, then a sequence of treatments is more 
likely to be observed. Modern medicine, in particular for chronic conditions, has seen the 
development of long-term treatment plans.66 These plans frequently incorporate a strategy for 
sequence selection to ensure effective long term care. 
UNCERTAINTY 
Often in clinical practice, a clinician is uncertain about the best treatment for a particular 
patient. Treatment sequences recognise the limitations of modern medicines and treatments, 
that there is uncertainty with respect to their effectiveness, and also to their adverse event 
profile. If physicians knew with certainty that a treatment would be effective, or that a 
treatment would definitely cause a serious adverse event, then clinical decision-making would 
be rather easier than it actually is. Sequences emerge because a treatment may work in one 
patient, but in a clinically identical patient the same treatment may not work. One patient may 
not tolerate a treatment, while another can. There is uncertainty about how a patient will 
respond to a particular treatment, and treatment sequences emerge through a process of trial 
and error - persisting when a treatment works and switching if it does not. 
With this uncertainty, sequences are required to achieve clinical goals. These goals may be the 
remission or cure of a condition, the control of a chronic condition, or ensuring that a patient 
remains alive. In all cases, a purposeful decision is made to employ a sequence of treatments 
to account for treatment failure.  
An example of this uncertainty is the use of methotrexate, a disease-modifying anti rheumatic 
drug (DMARD) for the treatment of people with rheumatoid arthritis (RA). For many patients 
with RA, methotrexate is effective at reducing disease activity and improving HRQL.67–70 
However, the mechanism of action for methotrexate is still not fully understood, and for some 
patients methotrexate is not effective.71,72 The uncertainty is a challenge for clinicians who are 
initiating DMARD therapy, because their effectiveness is unpredictable, and the mechanism is 
still unclear. This uncertainty leads to variation in treatment selection, with alternative first line 
treatments being prescribed by clinicians.73 It also leads to variation in the time spent on a 
treatment, with therapies tried and rapidly changed if not immediately successful. This rapid 
switching through alternative therapies naturally leads to list of alternatives to try if a first line 
DMARD fails; a treatment sequence. 
CHRONICITY 
The chronicity of a particular condition increases the likelihood of sequential therapies being 
utilised. If a condition is acute, either the treatment may be curative, or there may only be a 
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short period of time to intervene and so a sequence of treatments will not be used. Acute 
conditions may require follow-up care or support, however the future downstream treatments 
are unrelated to the initial decision-point and so these downstream treatments are not 
formally part of a treatment sequence. It should be noted that this has implications for how 
economic evaluations are conducted and will be discussed further in Section 3.3.  
Where a condition is lifelong and chronic, sequences of treatments are very likely to be 
observed. The emphasis of treatment is on long-term control of the primary condition and its 
impact on a patient’s HRQL. Control (the impact of a treatment on a person’s condition) may 
be specific to symptoms (short term control) or disease activity (long term control). The 
objective of a treatment may be to control acute episodes of symptomatic and active disease 
which may be a characteristic of a chronic condition (e.g. ‘flares’ in RA74 and Crohn’s disease75, 
relapses in Multiple Sclerosis76). The natural history of chronic conditions may be of chronic 
progression, where disease activity increases over time and worsens a patient’s HRQL. 
Alternatively, it may be of a relapsing and remitting nature, where an episode of active disease 
begins and a patient is provided with active treatment. Relapsing-remitting conditions include 
multiple sclerosis and some forms of chronic depression, where there are periods of active and 
inactive disease. Treatments for relapsing-remitting conditions may only have short term 
benefits for the current episode of disease, or they may have long term benefits where they 
reduce the risk or increase the time to a future relapse. Relapsing-remitting conditions may 
lend themselves to sequential treatments more naturally, because a treatment may only 
provide short term disease control and repeated control may not be possible or plausible, and 
so a switch to a different treatment is made when a patient experiences a future episode of 
active disease.  These ‘rhythms’ are important when considering how a decision analytic model 
may be constructed to evaluate the cost-effectiveness of treatments and/or treatment 
sequences.77 
The characteristics and the impact a chronic condition will have on a patients HRQL define the 
treatment plan developed for a patient, and also the use of sequential therapies. Also, a 
condition may not be acute or chronic, but instead have an element of chronicity or long-term 
duration which may lead to the use of sequential therapies to maintain long term disease 
control. 
SWITCHING RULE 
As has been discussed in the previous section, factors including chronicity, effectiveness and 
uncertainty will lead to a decision to purposefully employ a sequence of treatments to manage 
a condition over the long term. The reason for change from one treatment to another is often 
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called the ‘switching rule’. In clinical practice, this may be a clinically observable and 
measurable signal that a patient will receive greater benefit from switching to another 
treatment, as opposed to continuing with the incumbent treatment. Alternatively, it may be 
because a treatment is toxic and the benefit/risk profile has changed. 
In particular, the switching rule is the result of a sequence of treatments being possible. If 
there are no alternative treatments, then the only switch possible is to no treatment, and an 
active treatment will be used for as long as health benefits are realised. If many treatments are 
available, the switching rule may allow a change of treatment after a short period of time or if 
only small benefits occur. This allows alternative treatments to be attempted and rapidly 
changed until one is found to provide significant benefits. 
In recent years, there has been the development of biologic therapies. In contrast to standard 
molecular pharmaceutics, these treatments are an extraction or semisynthesis of a biological 
source. They often look to copy the effect of substances that are produced by a body’s 
immune system. They are highly effective in treating many conditions, but their unique design 
and process for manufacture means they are costly to produce, as well as very profitable for 
manufacturers because generics (formally biosimilars) are harder to produce after patent 
expiry.  
For patients with RA, treatment with biologics is limited to people with severe active RA 
(Disease Activity Score 28 (DAS28) > 5.1). Some biologics have been shown to be effective in 
moderately active RA (3.2 < DAS28 < 5.1), however there is less scope for improvement (i.e. 
fewer QALYs are generated by moving from moderate RA to remission, compared to severe RA 
to remission) and so the use of biologics in moderate RA is less likely to be cost-effective when 
the dose (and therefore treatment cost) is the same. Therefore a switch to a subsequent 
treatment may only occur when disease severity has increased and the patient is back in a 
severe active RA state. Determining an appropriate switching rule is often where cost-
effectiveness analyses and decision-analytic modelling can prove to be very informative. It also 
raises the distinction between individual clinical decision making and decision-making based 
on population health. Clinical decision making is concerned with health improvements for each 
patient who is face to face with the clinician, but population health maximisation requires 
trading off the health gains between individuals to ensure that population health is maximised. 
If a clinician is a budget holder or is very budget aware, an individual clinician may have to 




3.3 TREATMENT SEQUENCES AND ECONOMIC EVALUATION 
The time horizon of a cost-effectiveness analysis should extend far enough into the future to 
capture the major health and economic outcomes – both intended effects and unintended side 
effects and costs.64 By omitting any future consequences, the present value estimated for a 
particular intervention may be biased, and a sub-optimal decision could be made regarding the 
allocation of health resources. Future costs and consequences which do not occur at time zero, 
but at some time in the future, must be taken into account.78 This is to ensure that all costs 
and consequences of choosing one action over another are captured. Future costs and 
consequences will include treatments which were not administered at the primary decision 
point, but are subsequent therapies as part of a sequence.  
An economic evaluation contributes to a particular decision problem. Often for NICE, the 
decision problem is whether or not to recommend a new treatment in a particular patient 
population. For NICE, the decision problem is clearly specified. This decision problem 
determines the focus of the economic evaluation. 
A cost-effectiveness analysis may compare treatment A vs. treatment B at a point in time; 
however it is more appropriate to consider it a comparison of treatment pathway with A vs. 
treatment pathway with B. If the treatment is likely to have long term costs and consequences, 
then a short time horizon is unlikely to be appropriate. More specifically, treatments within a 
sequence will have different effectiveness and treatment duration, meaning that a switch may 
happen sooner or later, and the patients at that point of switch will be different. This means 
the costs and benefits attributable to a downstream sequence of treatments do not just cancel 
out in the comparison. NICE in their Guide to the Methods of Technology Appraisal (2013) 
recommend that “the time horizon should be sufficient to reflect important cost and benefit 
differences between the technologies being compared.”47  
In Figure 3.1, the QALY profile for two treatments, A and B, are illustrated. Treatment A is both 
life enhancing and life extending. The curves represent HRQL over time, with the area under 
the curves the QALYs gained. The area between the two HRQL curves represents the QALYs 
gained by A compared to B. Only by estimating the QALYs up until death (assumed to be where 




Figure 3.1: HRQL profile 
For a chronic condition of a relapsing/remitting nature, the HRQL profile may look different. In 
Figure 3.2, a patient has a relapsing/remitting condition and is treated a sequence of two 
treatments: 
 
Figure 3.2: QALY profile - relapsing/remitting chronic condition 
At point 1 a patient begins a first line treatment which significant and quickly improves their 
HRQL up to point 2. The disease slowly worsens over time while on treatment. At point 3, 
treatment effectiveness is lost and the patients HRQL declines during a relapse of severe 
disease until point 4. At this stage, a treatment switch occurs and an improvement (albeit 
smaller) in HRQL is observed. The condition continues to worsen. The overall trajectory of the 
condition and the overall QALYs that are aggregated across a patient’s lifetime are a function 
of the magnitude of initial response, what happens over the longer term, how long a 
treatment is effective for, and when a patient will die. 
The effectiveness of a downstream treatment is contingent on what has happened as a result 
of previous treatments. The patient may be more or less likely to achieve a response if 
response was obtained on a prior therapy.* The patient may be older, and in turn have more or 
less potential for response. The condition may have caused irreversible changes to a person 
and therefore a subsequent treatment may have less potential for benefit. 
                                                          
*
 A patient may be more likely to respond if they responded to a previous treatment. Alternatively, a 
patient may be less likely to respond to a treatment if the previously responded to a treatment with a 
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In Figure 3.3, three different comparator sequence HRQL profiles (SB) are compared to a 
common sequence HRQL profile (SA). SA is identical in all three scenarios. 
 
Figure 3.3: QALY profiles for comparator sequences 
In Scenario 1, SB has an improved initial response, but faster worsening of HRQL over time. The 
switch to a second treatment sees an improvement in HRQL, but HRQL is below where it would 
be on SA. Although death occurs at the same time, there is a net QALY loss on SB. A model will 
need to capture the full sequence until death to ensure the full impact on QALYs is captured. 
In Scenario 2, SB has an identical initial response, and HRQL declines at the same rate as SA. 
However, the patient remains on treatment for longer before switching. The QALY 
contribution of the second line treatment is identical, but due to occurring at different points 
in the future, the discounting undertaken to account for time preferences and estimate 
present values will result in different estimates of this QALY contribution. Again, a model will 
need to capture the full sequence until death to ensure the full impact on QALYs is captured. 
Although it may be fair to assume a future treatment will provide the same benefits, if 
treatments are initiated at different times then discounting to obtain the present value will 
reduce the QALYs accrued. 
Scenario 3 is the only illustration provided where the second line treatment in SA and SB results 
in identical QALYs, and in an economic evaluation these will cancel out between the two 
comparator sequences. In this case, it would be fair to develop a model which has a time 
horizon up until the end of the first treatment, because an accurate estimation of lifetime 

























purpose of an economic evaluation, there is no incremental difference after the first line 
treatment. 
For any economic evaluation there is a decision point, time zero, where a comparison between 
alternatives is made. Some researchers have called this point the ‘divergence point’ of a 
decision analytic model, because the treatment sequence up until the divergence point is 
identical. An evaluation of sequential therapy requires the movement of the divergence point 
to the first line therapy, so that the consequences of all possible subsequent sequences can be 
estimated and compared. The evaluation of a sequence of treatments is important if there is a 
particular treatment which can be used at multiple points within a sequence. For a model to 
allow an estimation of costs and QALYs of all possible sequences, then a model is required 
which allows treatments to vary along the full length of the sequence. Also, the comparison is 
between alternative sequences of treatments, rather than a head to head comparison 
between one particular treatment against a comparator treatment.  
Figure 3.4 provides a schematic for a decision tree model to evaluate three treatments (A, B 
and C). There are three treatment pathways for the model to enumerate the costs and QALYs. 
 
Figure 3.4: Three treatment decision tree model 
However, if the three treatments (A, B and C) can be used sequentially, once only, and in any 
order, then there are six treatment pathways to be enumerated. This is shown 
diagrammatically in Figure 3.5. 
The additional pathways (branches) add both complexity to the decision analytic model and 
evaluation, and require greater amounts of evidence about the costs and consequences of 
each pathway, and the position of treatments therein. 
As the number of treatments included in the sequence increases, it becomes increasingly 
challenging to know what the true treatment effects are likely to be for every technology in 
every position in the sequence. For example, if treatments have been studied in clinical trials 













these treatments in the sequence may be very different from that observed in the trial. The 
corollary is that, as seen frequently with modelling treatment sequences, there is a danger that 
the model has parameters that are difficult to estimate.  
 
Figure 3.5: Three treatment sequential decision tree model 
To resolve this issue, treatment effect decrements have been used in NICE appraisals.63 These 
use the assumption that a treatment will be less effective, the further down the treatment 
sequence it is used. The effectiveness evidence (often a trial) may provide parameters for a 
particular point in the sequence (e.g. first line). This evidence is used to provide treatment 
effectiveness parameters for the model if used in other places in the sequence (where trial 
data may not exist) and a decrement applied to reduce the effectiveness parameters and 
account for diminished effectiveness. These decrements could potentially be informed by 
external data, potentially from registries, or from expert opinion (including elicitation). 
Observational studies could potentially be used to estimate treatment effects, although the 
limitations of this approach have been widely discussed.79–81 In particular, estimating 
treatment effects from observational studies is likely to be biased because groups of patients 
(e.g. patients on different treatments) will vary systematically in ways related to the outcome 
of interest – unmeasured confounders. These confounders can result in mistaken causal 
inferences and biased estimates of treatment effect unless they are accounted for. 
HOW MANY SEQUENCES? 
The number of sequences to be enumerated in an economic evaluation is dependent on the 
number of comparator treatments, and assumptions about the perspective of the sequence. 































treatment sequence. The perspective of the sequence affects the potential size of an economic 
evaluation and the number of comparators therein. 
Firstly, are the existing treatments within a sequence in a fixed sequential order? An example 
is a treatment only licensed for use after a previous therapy. In this case, there is at least a 
partially fixed sequence of treatments. 
Secondly, is the length of the sequence fixed? If so, the new treatment will replace a therapy in 
the sequence to ensure the length of treatment sequence is fixed. If the sequence is not fixed, 
then it is possible for a new treatment to be an addition into the treatment sequence and the 
resulting sequence is extended. 
Thirdly, are truncated sequences of treatments possible? This means that instead of providing 
a full sequence of active treatments for a patient’s lifetime, a sequence could instead be 
stopped. Therefore the evaluation requires the inclusion of all truncated sequences for 
comparison.  
For hypothetical situations the number of sequences to be evaluated can be calculated, as 
shown in Table 3.1. However, in practice, it is likely that the sequences are more complex. 
Some treatments may have a fixed position, as determined by clinical guidance or their 
licensed indication, and some treatments may have a fixed position relative to other therapies 
(again, determined by clinical guidance or by their licensed indication). 
In Table 3.1, A and B are the two existing treatments, and X is a new treatment. The number of 
possible sequences to evaluate in order to identify an optimal sequence is dependent on the 
perspective of the sequence. If the sequence is ordered, that means A and B must retain their 
order. If the sequence is variable, then all treatments can be in alternative orders. If a new 
treatment can be an addition, then the sequence length will extend. However if the treatment 
is a replacement, the length of the sequence is fixed and an existing treatment is removed. If 
truncated sequences are possible, then all sequences of all possible lengths must be 
estimated. 
With an ordered sequence (either addition or replacement), the number of sequences to 
compare grows linearly with the number of treatments eligible. With a variable sequence, the 
growth is exponential. If truncated sequences are plausible, then every plausible truncated 
variable sequence must be included for evaluation. Suddenly for just eight unique treatments, 
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TREATMENT SEQUENCE OR DOWNSTREAM TREATMENT? 
It must also be noted that treatment sequences are not always the same as downstream 
treatments (often called ‘future costs’). Downstream treatments are the full range of possible 
treatments that may be employed after the use of a particular intervention. These treatments 
may be related to the primary condition, and therefore are conditional on the effectiveness of 
the primary intervention, or they may be unrelated to the primary condition. For example a 
patient with RA may be treated with a DMARD, and a downstream treatment may be a 
biologic DMARD. However some patients with RA may also have depression, and will receive 
unrelated (to RA) downstream treatments for their depression. With most modern health 
services structured around specialist treatment and care, unrelated downstream treatments 
are unlikely to be the primary concern for a physician, however several economists argue that 
all costs incurred, related or not, should be included.82–84  
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However, related downstream treatments are not always the same as a treatment sequence, 
because a sequence implies that the order of the therapies can alter. A downstream treatment 
for the purpose of this thesis is defined as one which cannot change position with another 
treatment. For example, a downstream treatment may be palliative care for a patient, and 
would not be provided prior to an active therapy. Treatment sequences therefore capture 
many of the instances where downstream treatments may occur, however reversibility 
represents a key difference. 
Future related health costs still require inclusion within a model to provide an estimate of the 
cost-effectiveness of a particular treatment or treatment sequence. This is because the 
initiation of that particular treatment (sequence) reflects a decision about a course for the 
patients’ condition, and therefore an evaluation of its cost-effectiveness should include health 
costs that are attributable to the primary treatment. 
 
3.4 PHARMACEUTICAL MARKETS AND TREATMENT SEQUENCES 
The pharmaceutical market continues to expand, in particular for chronic conditions. The 
population of many developing countries is ageing, and novel therapies are being developed 
with improved effectiveness and tolerability. The RA drugs market in 2010 generated an 
estimated $12.7bn,* and is expected to continue increasing. 
In a potentially profitable market, pharmaceutical manufacturers will look to develop novel 
therapies for the improved treatment of a condition. Also, manufacturers will look to develop 
‘me-too’ therapies, and generic equivalents when patent protection expires. These competitor 
products increase therapeutic options for clinicians and patients, and therefore increase the 
potential use of sequences to effectively manage chronic conditions. Also, pharmaceutical 
companies will compete for market share to generate a return for their investment in 
developing the new product. In a condition with many incumbent therapies, a company may 
promote sequential use of their product. This decision to build the therapeutic value 
proposition around a sequence is likely to be made early in the development process so that 
appropriate trials and evidence can be generated for both marketing authorisation and 
reimbursement.  
New treatments with marketing authorisation are often constrained by the earliest they can 
be used (i.e. not before another treatment has been attempted), or by a level of disease 
                                                          
*
 http://www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021 - 
Accessed June 2015 
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severity. Therefore the position of treatment within a sequence is not fully fixed, and there 
may be several potential positions that a drug can be used in clinical practice. If a license is not 
restrictive, a drug could potentially be used in any position in a sequence, and therefore allow 
alternative sequences of treatments to be used in clinical practice. 
The biological DMARD (bDMARD) anti-tumor necrosis factor alpha therapies (TNFa’s) for 
patients with RA are broadly similar. They are targeted at the same cytokine, although their 
mechanism may be different.* Also they may differ through mode of administration, and by 
their effectiveness and adverse event profile. The similarities of newer TNFa therapies to 
existing TNFa therapies means they have been categorised as ‘me-too’ therapies.85,86 The term 
‘me-too’ in general refers to products which have many similarities to a competitor, but have 
enough of a difference to allow them to be marketable as a separate product along with its 
own patent. A me-too product on which research is started after the initial product in the class 
is on the market is likely to be less costly to develop, compared to the novel therapy. Much 
research and development may be conducted to develop an innovative therapy, and then only 
a relatively small amount of research and development is required to alter the original therapy 
and obtain a separate licence. The ‘me-too’ title may be unfair on products which come to 
market only a short time after the novel therapy, because the long process of drug 
development means that they were probably equally innovative during their development but 
just happened to enter the market slightly later. 
Me-too therapies, along with all treatment developments in a particular condition, allow price 
competition between competitors.87 This price competition means that often prices are very 
similar (or identical) for rival products. This adds complexity to evaluating cost-effectiveness, 
because similar cost and similar effects can mean that the results are extremely sensitive to 
evidence, assumptions and uncertainty. The availability of multiple therapies also supports 
physician and patient choice to select a particular drug based on favourable characteristics 
such as mode of administration, particular side-effect profiles, or patient co-morbidities. These 
attributes may not directly affect HRQL, or may only have a small impact, however patients 
may value particular characteristics or they may have an impact on wider wellbeing. 
Alternatively, these characteristics may not have been valued within a QALY framework, but 
revealed preferences have still been elicited via an alternative method.88 
Competition also exists between therapies for positioning in a sequence. Manufacturers will 
look to enhance their profitability, generally by offering long term treatment to as many 
                                                          
*
 Monoclonal antibodies for infliximab, adalimumab, certolizumab pegol and golimumab, or a circulating 
receptor fusion protein such as etanercept 
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patients as possible, which maximises the sales of their particular product. In general this 
means that the earlier the position in the sequence, the more profitable it is for a 
manufacturer, due to the length of time available for active therapy, the size of the patient 
population, and assumption that the patients are likely to have less refractory disease. 
For example, if an incumbent treatment exists for a chronic condition, and a new therapy is 
granted marketing authorisation for use in patients with that condition (with no restriction on 
position), then the decision by that manufacturer is whether to attempt to compete at first 
line, or enter as a second (or later) line therapy. If the evidence generated for market 
authorisation and HTA purposes is focussed on first line use, then the manufacturer may be at 
risk of an unfavourable decision at second line due to less robust evidence. More likely, NICE 
would not make a recommendation either way for second line use if not in the original scope 
or manufacturer’s submission, and it would be up to local level decision-making if 
commissioners wished to fund it. 
The market for second line use may be less profitable (smaller and more refractory patient 
population) but if the entrant therapy is only equivalent (in terms of costs and benefits) 
compared to the incumbent therapy then it may not capture a significant market share at first 
line. This example ignores defensive strategies by the incumbent manufacturer. In this 
example, a me-too therapy may not be appropriate at second line if it has the same 
mechanism of action, because it may not be effective after the first line therapy. However, if a 
new therapy can be effective in second line, then it may prove to be a profitable position for 
that therapy and sequential treatment may expand. 
Over the longer term, once patent protection expires for a branded therapy, generic and 
biosimilar alternatives may be developed and granted a licence.  Like me-too therapies, these 
will increase competition in the market for a condition. Because of the reduced R&D costs for a 
generic product, costs and prices are generally lower, and competition is increased.89 
In all these instances, increased competition may lead to sequential therapies because only 
one therapy can generally be used at a time. There are instances where combination therapies 
are used, such as concomitant methotrexate in RA. Often combination therapies are used to 
combine multiple or complementary mechanism of actions,90 or to minimise drug resistance.91 
Whether a novel therapy, a me-too, or generic equivalent, new pharmaceuticals will increase 
the therapeutic options for patients, and are likely to increase the likelihood of sequential 




3.5 PATIENT CHOICE AND TREATMENT SEQUENCES 
In the UK, the National Health Service (NHS) highlights in the NHS Constitution that ‘choice’ is a 
clear ideology as a component of universal health care.* Patients have the choice of GP 
practice, as well as specific health care. In particular, the NHS supports informed choice, with 
support for patients when making choices, as well as providing information to help people 
participate in healthcare decisions. 
Choice is integral in the treatments of chronic conditions. This is for a number of reasons: 
1. Self-management – often the effective management of chronic conditions requires 
both medical treatment  as well as self-management 
2. Adherence – By allowing patients to be an active participant in decision making, rather 
than a passive recipient, adherence to treatment is improved 
3. Long-term ownership – For long term chronic conditions, people have an increased 
risk of mental health issues. Psychological ownership is the term for people finding 
meaning when they are diagnosed with a chronic illness, and learning to make sense of 
living with a chronic illness. 92 As with the above reasons, choice empowers patients, 
leading to engagement with health services, adherence to medication and the desire 
to improve their health. 
Some of these reasons may have positive implications for cost-effectiveness. Self-management 
and adherence both ensure that the realised benefits of treatment are maximised. However, 
sometimes choice may be promoted but the implications for efficiency and cost-effectiveness 
are less clear. Should NICE promote a choice in treatment when there is no net benefit, or 
when a relatively small net benefit is offset by guidance development and implementation 
costs? 
Sequential therapy is often driven by the requirement of choice – that an effective alternative 
will improve the likelihood of controlling a disease, and therefore improve expected health 
outcomes. However, it is also driven by the desire for choice. Irrespective of potential to 
provide benefit, the cost, or the number of treatments already attempted, there is a strong 
belief that a patient requires active treatment. This could be extended to the extreme, where 
further active treatment may have no additional benefit on top of palliation or supportive care. 
This concept could potentially be the ‘arrow in the quiver’ argument; that there must always 
be a choice between alternative options at any point in time. Benefit may be provided by the 
delivery of care even if the treatment is not effective – the placebo effect. 
                                                          
*
 http://www.nhs.uk/choiceintheNHS/Rightsandpledges/NHSConstitution/Pages/Overview.aspx - 




This chapter has highlighted the clinical reasons for why treatment sequences may be 
observed - effectiveness of a treatment, uncertainty regarding its effectiveness, patient 
variability, chronicity of a condition, and the ability to define a switching rule. The chapter also 
explored how the pharmaceutical market and the desire for healthcare choice may further 
promote the use of treatment sequences. 
This chapter has highlighted several challenges for consideration by a research team when 
undertaking an economic evaluation of sequential therapies for chronic conditions. 
Firstly, when the decision space for an economic evaluation includes treatment sequences, 
then the factorial rate of growth in the number of comparators becomes unfeasible for 
decision analytic models to evaluate every possible sequence. Also, the evidence requirements 
for populating a model with numerous treatment sequences as comparators grow rapidly. Not 
all treatment sequences are likely to be clinically plausible, and so scoping has to determine all 
clinically sensible comparator treatment sequences. Some explicit pre judgement has to be 
applied. 
Secondly, when a model becomes more complex, it can lose face validity.93 It is important that 
decision-makers and clinicians can believe the results of the model, and this can become a 
challenge when models require numerous assumptions or have a large amount of parameter 
uncertainty. 
The validity of a model also comes at the expense of complexity that is required to provide 
estimates of the long term costs and effects due to a treatment sequence. The model requires 
complexity to account for the multiple sources of evidence which need to be incorporated, as 
well as the chosen methodology to account for uncertainty, and the consideration of 
alternative decisions such as switching rules. 
Finally, the incorporation of sequential therapies in an economic evaluation may become 
unfeasible for decision-makers and for researchers. The evidence requirements and model 
development time may not fit in with the timeliness of developing clinical guidance. The 
evaluation may also require clinical evidence which may not be available when early decisions 




3.7 AIMS AND OBJECTIVES 
The primary research question for this PhD thesis is ‘How can economic evaluations of 
sequential therapies for chronic conditions improve health resource allocation decision 
making?’ The PhD uses RA as a case study. 
The aim of this thesis is to test the feasibility of simulation optimisation methods to find an 
optimal or near-optimal sequence of disease modifying treatments for RA in an economic 
evaluation framework. 
The objectives to meet this aim are: 
 To explore the key challenges when undertaking an economic evaluation of sequential 
therapies in chronic conditions 
 To identify any published attempt to estimate the most cost-effective (optimal) 
sequence of treatments for patients with RA 
 To develop a cost-effectiveness model which allows the evaluation of sequential 
disease modifying therapies for RA 
 To review and assess the relative merits of methods of optimising a discrete event 
simulation model for a combinatorial decision problem when an incremental analysis 
of all possible alternative treatment sequences is not feasible. 
 To implement and evaluate an identified method using RA as a case study condition 
 To provide recommendations about the application of the implemented method 
 To provide recommendations for further research. 
 
3.8 STRUCTURE OF THE THESIS 
The first chapter provided an overview of the motivation for this thesis. Chapter 2 explored the 
economic framework for Health Technology Assessment (HTA). This set the scene in terms of 
background theory and the current methodology that are applied for the allocation of finite 
healthcare resources. 
This current chapter provides a rationale for this thesis. It explored why treatment sequences 
are used, and why they represent a challenge for undertaking an economic evaluation. In 
particular, it highlights how an incremental analysis is unlikely to be feasible when a large 
number of sequences are available for comparison. 
The next chapter (Chapter 4) reports a systematic review of economic evaluations for disease 
modifying anti-rheumatic drugs (DMARDs) for RA. The objective of this review is to explore the 
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existing economic evidence for RA, assess the quality of this evidence, report to what extent 
they identify an optimal sequence of treatments, and identify where improved methods for 
economic evaluation may improve decision making in this context. 
Chapter 5 reports the development of a discrete event simulation model for the evaluation of 
treatment sequences in RA. In Chapter 6, a systematic review of relevant simulation 
optimisation methods is reported, which are subsequently applied to the discrete event 
simulation model in Chapter 7. The thesis ends with Chapter 8, and a discussion regarding the 
strengths and limitations of the work undertaken. Recommendations for policy makers and 




CHAPTER 4: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF 
DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) FOR 
RHEUMATOID ARTHRITIS 
 
4.1 CHAPTER OVERVIEW 
The previous chapters have introduced the rationale for this thesis, by exploring why 
sequences of treatments represent a unique challenge when conducting an economic 
evaluation. This chapter contains a systematic review of economic evaluations of DMARDs for 
RA. The review determines the extent to which treatment sequences have been evaluated, 
and the methodological challenges that have arisen when developing a DAM. The review 
provides important information regarding the structure and parameterisation of a DAM 
developed in Chapter 5, and used in Chapter 7 as part of the simulation-optimisation analysis. 
The scope of the systematic review is purposefully broad, enabling all economic evaluations of 
DMARDs for RA to be included, irrespective of if they did or did not model a treatment 
sequence. Only by including the full body of evidence can a conclusion be drawn regarding the 
extent to which treatment sequences have been explicitly modelled and considered, and only 
then can an inference be drawn to whether decision-makers are being provided with evidence 
required to potentially develop an optimal treatment sequence for clinical guidance. 
There are many studies identified that did not formally consider the downstream sequence of 
treatments. While in many ways these studies are less useful for the objectives of the review, 
it is important to determine, where possible, the justification for why the scope of the 
economic evaluation was limited. 
This systematic review was published in a peer-reviewed journal: 
Tosh J, Stevenson M, Akehurst RL. Health Economic Modelling of Treatment Sequences for 
Rheumatoid Arthritis: A Systematic Review. Current Rheumatology Reports (2014). 16:44794 
  
4.2 INTRODUCTION 
This chapter contains a systematic review of economic evaluations undertaken of DMARDs for 
RA. In Section 4.3 the methods of this systematic review are described. In particular, the 
information sources, eligibility criteria, and methods for data extraction and critical appraisal 
are reported. Section 4.4 presents the results of the search, including the characteristics of 
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each identified economic evaluation and a critical appraisal using the Drummond checklist.78 
Also included is a narrative synthesis of the identified studies. This includes the scope of the 
economic evaluation, the extent to which downstream costs, benefits and sequences are 
captured, the modelling methods used and the final health economic results of the 
evaluations. Section 4.5 provides a discussion of the systematic review, and finally Section 4.6 
draws conclusions and implications for the rest of the thesis. 
OBJECTIVES 
The aim of this systematic review is to summarise the existing economic evidence for the use 
of DMARDs in the treatment of RA. The systematic review will assess the strengths and 
limitations of specific economic evaluations which compare DMARDs, and will draw 
generalised conclusions regarding the methodologies currently used to evaluate treatments 
for RA. 
Specifically, the objectives of the review are: 
1. To identify the existing economic evidence for disease modifying therapies for RA, 
and to assess where there are gaps in the existing evidence base. 
2. To assess the health economic evaluation studies, with respect to their objectives 
and the methods used to meet these objectives. 
3. To identify how improvement in the methods of economic evaluation may 
improve decision making regarding the treatment of people with RA. 
The systematic review is reported to the PRISMA standards.95 A completed PRISMA checklist 
can be found in Appendix A.1. The PRISMA criteria are applicable to clinical systematic reviews, 
and so some elements of the checklist are not directly applicable to this review of economic 
evaluations. However, the PRISMA standard provides a useful checklist of items to ensure all 
relevant details pertaining to the review are reported. The review has been registered with the 
International Prospective Register of Systematic Reviews (PROSPERO). 
EXISTING SYSTEMATIC REVIEWS 
Twenty-four existing systematic reviews of economic evaluations undertaken of disease 
modifying therapies for RA have been identified by the searches detailed in Section 4.3.96–119 
These reviews synthesised the general economic evidence, however the focus varied: some 
focussed on particular treatments, some focussed on particular patient populations, and some 
on particular aspects of the methodology and evidence used. For example, Bansback et al. 
(2008) focussed on HRQL in RA economic evaluations,98 and Emery (2004) focussed on DAM 
methods.103 However, none of the reviews focussed explicitly on the methods used to identify 
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and evaluate sequential therapies for patients with RA, although Sullivan et al. (2013) consider 
the economic impact of sequential DMARD treatment.120 Therefore this review will add to the 




Systematic searches of electronic databases were conducted to identify all published economic 
evaluations of DMARDs for RA. Because DMARDs for RA are numerous, using conventional 
methods for a systematic review would require the formulation of numerous search terms for 
each particular DMARD. Because of the significant number of interventions, and therefore 
search terms, a conventional search method could miss relevant interventions and economic 
evaluations. To ensure that the systematic search had high sensitivity (the identification of 
appropriate studies), a search strategy was developed by applying economics related terms to 
a set of clinical terms covering RA and DMARDs. The disease component of the electronic 
search was based on a previously used electronic search strategy for the NICE RA guideline.121 
Database filters to identify economic evaluations were used from the InterTASC Information 
Specialists’ Sub-Group (ISSG) website.* 
A scoping search was undertaking using Google Scholar© to identify keywords for the search 
strategies. These keywords are listed in Table 4.1 and reported in the PICO (Population, 
Intervention, Comparator, Outcome) format. 
Table 4.1: Keywords for systematic review (PICO format) 
Population Rheumatoid Arthritis, RA 
Intervention/Comparator Disease modifying, disease-modifying, DMARD, biologic, therapy, 
treatment, anti-rheumatic, anti rheumatic, TNF, tumor necrosis 
factor alpha, tumour necrosis factor alpha, TNF-alpha, TNF 
inhibitor, TNF blocker, interleukin 1, IL-1, monoclonal antibody, 
costimulation blocker, interleukin 6, IL-6 
Outcomes Economic, economics, cost, cost-effectiveness, cost-utility, cost-
benefit, utility, health related quality of life, quality of life, quality 
adjusted life year, QALY 
 
The search strategies used MeSH terms, including ‘rheumatoid arthritis’ and ‘economics’, and 
text string terms which were combined in the search strategy using Boolean logic. The search 
                                                          
*
 http://www.york.ac.uk/inst/crd/intertasc/index.htm -  Accessed June 2015 
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strategies for all databases are provided in Appendix A.2. The search strategies were designed 
to maximise sensitivity, however this was at the cost of poor specificity (the rejection of 
inappropriate studies). This meant the search returned a large number of inappropriate 
studies, and therefore the review required extensive sifting of the results to filter out the 
appropriate studies. 
INFORMATION SOURCES 
Systematic searches were conducted in ten databases (Table 4.2). Conference abstracts were 
not included, however publications by the authors of any included studies were searched to 
identify any later publications. Reference and citation searching was undertaken on all 
included studies, including any identified reviews of published economic evaluations of 
DMARDs for RA. Published NICE Technology Appraisals and NICE Clinical Guidelines were 
searched to identify any studies not detected in the electronic searches.  
Table 4.2: Systematic review databases 
Database Date* 
BIOSIS (all databases) 
Cochrane Database of Systematic Reviews (CDSR) 
Cochrane Database of Methodological Reviews 
Cochrane Central Register of Controlled Trials (CCRCT) 
Database of Abstracts of Reviews and Effects (DARE) 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
Embase 
MEDLINE 
NHS Economic Evaluations Database (NHSEED) 
Science Citation Index: Web of Science 
1899 – Feb 2013 
All years – Feb 2013 
All years – Feb 2013 
All years – Feb 2013 
All years – Feb 2013 
1994 – Feb 2013 
1974 – Feb 2013 
1945 – Feb 2013 
All years – Feb 2013 
1899 – Feb 2013 
 
All database searches were undertaken on 1st February 2013, and no date restriction was 
applied. No study type or language restrictions were applied to the electronic search. The 
search strategies were reviewed by an information specialist. 
INCLUSION AND EXCLUSION CRITERIA 
The primary objective of the systematic search is to identify any economic evaluations of 
DMARDs for RA. The search was irrespective of any decision-making context or geographical 
location. The eligibility criteria for the systematic review are presented in Table 4.3. 
Studies were included in the review if they reported a comparative economic evaluation (cost-
effectiveness (CEA), cost-utility (CUA) or cost-benefit analysis (CBA)). Cost-consequence 
                                                          
*
 “All years” when a formal start date for the Database is not provided. 
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analyses (CCA) were also included, because the evidence provided in the study can be used 
comparatively even if the comparison has not been made by the authors. Cost-minimisation 
analyses (CMA) were also included. However, economic evaluations where a full comparison 
between two or more alternatives was not conducted were excluded. This is because they do 
not consider an estimate of incremental costs or benefits between treatments. However, 
excluding these (likely rare) studies may ignore potentially relevant studies where the costs or 
benefits of sequential therapies have been estimated. This is a potential limitation of the study 
and will be discussed subsequently. 
Table 4.3: Eligibility criteria 
Inclusion Criteria 
 Economic evaluation including a comparison of costs and health benefits based on 
outcomes data or undertaken using a decision analytic model 
 Economic evaluations of interventions targeting a change to the natural disease profile of 
people with rheumatoid arthritis (i.e. disease-modifying therapies) 
 Studies reporting costs and health outcomes 
Exclusion Criteria 
 Non-comparative/partial economic evaluations 
 Cost analyses/Cost-of-illness/Burden-of-illness studies 
 Methodological papers which do not report economic and health benefit outcomes 
 Commentaries, letters, editorials 
 Conference abstracts 
 Studies which claim cost-effectiveness but with no estimation of costs and effectiveness 
outcomes 
 Economic evaluations of therapies and treatments which do not modify the progression 
of RA 
 Non-English language studies 
 
CRITICAL APPRAISAL AND DATA EXTRACTION 
The identified studies were appraised using the validated and commonly used Drummond 
(2005) ‘Critical appraisal of a published article’ checklist.78 This is a brief checklist and was used 
to appraise the key aspects of each economic evaluation.  
While the checklist aided the extraction of data and appraisal of the quality of studies, it was 
not appropriate to use just a checklist for this particular review. Many systematic reviews of 
economic evaluations attempt to assess the quality and appropriateness of studies which are 
addressing a similar decision problem, and checklists are designed to aid this. For example, a 
systematic review of early treatments in patients with newly-diagnosed RA may be undertaken 
to appraise the relevant published cost-effectiveness evidence in that particular population, 
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and for that particular decision problem. Instead, the objective for this systematic review is to 
examine where studies have addressed or not addressed the sequential aspect of treatment 
for people with RA. Therefore data pertaining to treatment sequences and modelling 
methodology were extracted. Where studies were similar, themes were extracted to 
generalise the approach taken. Where studies were different but the decision context was 
apparently similar (e.g. the patient population or comparator treatments) then the difference 
in methodology was noted. The full data extraction template is provided in Table 4.4. 
The data extracted from identified studies included general details regarding the economic 
evaluation (method, patient population, comparator interventions or sequences, time horizon, 
disease and treatment history, and health economic results). Data were also extracted 
regarding the sequential nature of the treatments for RA and how this was captured in the 
analysis. In particular, whether all relevant comparators were included in the sequence of 
treatments. Where relevant, information regarding the modelling methods used for the 
economic evaluation were extracted, to identify how data sources were used in reflecting the 
costs and benefits of particular treatments, at all points in the evaluated sequence. The 
principal summary measures for the review were the study name and year, country, evaluated 
interventions, time horizon of the study, the type of economic evaluation, the type of decision-





Table 4.4: Data extraction template 
Evaluation information 
Study (name and year)  
Country  
Evaluation type (CEA, CUA, CCA, CMA, CBA)  
Comparators  
Previous treatment history  
Time horizon of analysis  
Analysis method (Trial evaluation, model)  
Basecase results  





Question Yes No Not sure Additional information 
Was a well-defined question posed in an answerable 
form? 
    
Was a comprehensive description of the competing 
alternatives given? 
    
Was there evidence that the programme’s 
effectiveness had been established? 
    
Were all important and relevant costs and 
consequences for each alternative identified? 
    
Were costs and consequences measured accurately in 
appropriate physical units? 
    
Were costs and consequences valued credibly?     
Were costs and consequences adjusted for 
differential timing? 
    
Was an incremental analysis of costs and 
consequences of alternatives performed 
    
Was allowance made for the uncertainty in the 
estimates of costs and consequences? 
    
Did the presentation and discussion of study results 
include all issues of concern to users? 
    
Sequencing information 
If a sequence was evaluated, how many lines?  
Were all relevant treatments included in each sequence?   
Was the methodology used amenable to varying the sequence and 
comparing a full range of alternatives? 
 
 Was an attempt to find an ‘optimal’ sequence undertaken?  
Modelling information 
If the analysis was undertaken using a decision analytic method, what 
method was used? 
 
How was initial treatment response modelled?  
What determined a switch to an alternative therapy?  
How were the costs and effectiveness of subsequent treatments in a 
sequence modelled 
 







From the systematic searching of electronic databases, 8,281 citations were identified 
(Quorum flow-diagram provided in Figure 4.1). After excluding 3,250 duplicate citations 
electronically, the remaining 5,031 citations were screened by their abstract. Of these, 4,913 
abstracts did not meet the inclusion criteria and 118 full papers were retrieved for a full 
inspection. A total of 70 papers were excluded for not meeting the inclusion criteria, and 9 
other papers were identified by reference and citation searches and searching any identified 
systematic reviews. 57 published studies were included in the systematic review. The full 
papers that were excluded, and the reason for exclusion, are provided in Appendix A.3. The 
data extraction tables and Drummond checklist results are provided in Appendix A.4 and 
Appendix A.5, respectively. 
 
Citations from electronic 
searches 
n = 8,281 
Other studies identified 
n = 9 
Excluded – duplicate 
citations 
n = 3,250 
Paper screened by 
abstract 
n = 5,031 
Abstract did not meet 
inclusion criteria 
n = 4,913 
Full paper retrieved for 
inspection 
n = 118 
Full paper did not meet 
inclusion criteria 
n = 70 
Most common reasons 
Review article = 25 
Non-comparative = 14 
No long-term costs = 6 
Non-English = 5 
See Appendix A.3 
Studies included in 
review 
n = 57 
Figure 4.1: Quorum flow diagram 
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CHARACTERISTICS OF THE ECONOMIC EVALUATIONS 
Of the 57 included studies, 43 (75%) were CUAs with QALYs as the unit of health benefit. Nine 
(16%) CEAs were conducted, with three (5%) CCAs, and two (4%) CMAs. Eleven (19%) studies 
were conducted with a UK perspective, and 11 (19%) with a US perspective. The remainder of 
the studies are mainly European (26 (46%)), along with six (11%) studies from Canada, and one 
(2%) study each from India, Japan and Thailand. The results reinforce the belief that QALYs are 
a common generic metric for health benefits when undertaking a CEA,122,123 and while CEAs are 
undertaken world-wide, they are more common in developed countries. The studies are 
summarised in Table 4.5. 
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Table 4.5: Summary of reviewed studies (Table also published in Tosh et al. (2014)94) 
Recent onset RA       
Study, year Country Interventions Time 
horizon 
Type Model type Incremental Cost-effectiveness Ratio (ICER) 
Chen et al. 2006
124
 UK TNFa with or without MTX at first 
line or third line 
Lifetime CUA Individual Level 
Model 
ICERs for ETN, ADA and IFX after multiple cDMARD failure were £24k, 
£30k and £38k per QALY, respectively 
Davies et al. 2009
125
 US MTX vs. ADA+MTX vs. ETN vs. 
IFX+MTX vs. ADA+MTX 
Lifetime CUA Individual Level 
Model 
IFX and ETN extendedly dominated by ADA. ADA+MTX ICER $47k per 
QALY vs. cDMARDs. ADA+MTX then ETN ICER $42k per QALY vs. 
cDMARDs 
Finckh et al. 2009
126
 US Symptomatic therapy vs. MTX vs. 
bDMARDs 
Lifetime CUA Individual Level 
Model 
bDMARDs dominated by cDMARDs. cDMARDs ICER $4k per QALY vs. 
symptomatic therapy 




NL Placebo vs. folic acid vs. folinic acid. 
Adjunct to MTX 
48 weeks CUA Trial analysis Placebo dominates folic acid. Folinic acid dominates placebo 
Kobelt et al. 2002
128
 UK MTX vs. SSZ vs. LEF 10 year CUA Markov model Using Strand et al, LEF dominates MTX. Using Emery et al, MTX 
dominates LEF. Using Smolen et al, LEF dominates SSZ. 
Kobelt et al. 2011
129
 Sweden ETN+MTX vs. MTX 10 year CUA Markov model ETN+MTX ICER is €13k per QALY vs. MTX 




NL MTX+SSZ+Prednisolone vs. SSZ 56 weeks CUA n/a Combo cDMARDs dominates SSZ 
Maetzel et al. 2002
131
 Canada Adding LEF to a cDMARD sequence 5 year CUA Decision tree Adding LEF ICER is Can$71k per QALY vs. cDMARD sequence 




Germany Adding LEF to cDMARD sequences 3 years CUA Decision tree ICER of adding LEF vs. cDMARD sequence is €8k per QALY 




NL Sequential TNFa use 5 years CUA Markov model ICER TNFa €138k per QALY vs. MTX. ICER MTX+LEF €439k per QALY vs. 
MTX 




US MTX vs. bDMARD mono and combos Lifetime CUA Markov model ICERs ranged $63k per QALY for ADA vs. MTX to $409k per QALY for IFX 
vs. MTX. 
Tosh et al. 2011
135
 UK Alternative cDMARD mono and 
combo therapies 
Lifetime CUA Individual Level 
Model 
Mono, Step-up, Parallel, Steroid are all dominated by step-down. 
Intensive ICER £27k per QALY vs. step-down 




NL Comparing  cDMARD combos vs. IFX 
combo therapy 
2 year CUA Trial analysis Initial combo therapy with prednisone is likely to be the most cost-
effective strategy at a WTP per QALY of  <€100k 





NL Step-down cDMARDs vs. SSZ 1 year CUA n/a Combo. cDMARDs dominates SSZ 
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Established RA       
Study, year Country Interventions Time 
horizon 
Type Model type Incremental Cost-effectiveness Ratio (ICER) 




Canada CYA vs. AZA/PEN vs. placebo 1 year CEA Decision tree CYA ICER $11k per patient improved vs. placebo. 




Sweden TNFa with or without MTX vs. 
cDMARDs 
Lifetime CUA Individual level 
Markov model 
For all TNFa strategies, ICERs using ACR50 response criteria are between 
€34k per QALY and €42k per QALY vs. cDMARDs. ADA+MTX likely to be 
the optimal strategy 
Barbieri et al. 2005
140
 UK IFX+MTX vs. MTX 1 year and 
lifetime 
CUA Markov model IFX-MTX ICER is £33k per QALY vs. MTX 
Barton et al. 2004
141
 UK ETN vs. IFX vs. cDMARD sequence Lifetime CUA Individual Level 
Model 
ETN ICER £50k per QALY vs. basecase. IFX ICER £68k per QALY vs. 
basecase. ETN ICER £28k per QALY vs. IFX 
Benucci et al. 2009
142
 Italy ABT with LEF or MTX vs. ETN with 
LEF or MTX 
2 years CUA Observational 
analysis 
ETN+MTX had the lowest CER compared to baseline (non bDMARD tx) - 
€39k per QALY. 
Benucci et al. 2011
143




RTX ICER €15k per QALY vs. consistent disease comparator (6 months). 
ICER €23k in 1 year 




Spain ADA vs. IFX vs. ABT vs. RTX 2 years CEA Unclear Highest effectiveness and lowest CER for ABT. LDAS and RS outcomes 




UK ETN vs. cDMARD sequence Lifetime CUA Individual Level 
Model 
ETN ICER £16k per QALY vs. cDMARDs 




UK TNFa vs. cDMARDs Lifetime CUA Individual Level 
Model 
TNFa ICER is £23k per QALY vs. cDMARDs 
Chiou et al. 2004
147
 US ANA vs. ETN vs. ADA vs. IFX 1 year CUA Decision tree ETN ICER $7k per QALY vs. ANA. ADA and IFX dominated by ETN 
Choi et al. 2000
148
 US cDMARD mono and combo vs. 
bDMARD mono and combo 
6 months CEA Decision tree ETN ICER $42k per ACR20 responder vs. triple cDMARD therapy. 
Choi et al. 2002
149
 US cDMARD mono and combo vs. 
bDMARD mono and combo 
6 months CEA Decision tree ETN ICER $41k per ACR20 responder vs. MTX 




Italy ABT vs. ADA vs. RTX vs. IFX 2 years CEA Unclear Highest effectiveness and lowest CER for ABT. LDAS and RS outcomes 
Clark et al. 2004
151
 UK Adding ANA in a treatment sequence Lifetime CUA Individual Level 
Model 
ANA ICER over £100k per QALY vs. standard care 
Coyle et al. 2006
152







Italy Sequential bDMARD use lifetime CUA Individual Level 
Model 
TCZ dominates replacing ETN or ADA. TCZ ICER €2k per QALY vs. IFX. TCZ 
ICER €17k when added first line. 
Hallinen et al. 2010
154
 Finland Sequential bDMARD use Lifetime CUA Individual level 
Markov model 
RTX dominates ADA, ABT, ETN after TNFa failure. RTX ICER €30k per QALY 
vs. BSC. 




UK Adding ETN and IFX into a cDMARD 
sequence 
Lifetime CUA Individual Level 
Model 
ETN ICER £83k per QALY vs. basecase. IFX ICER £115k per QALY vs. 
basecase. ETN ICER £44k per QALY vs. IFX. 




US GLD vs. MTX vs. bDMARDs 6 months CCA Decision tree Efficacy reflected as costs. GLD = $6k, MTX = $5k, bDMARDs = $9k 




UK RTX+MTX vs. cDMARD sequence lifetime CUA Individual level 
Markov model 
RTX ICER £11k per QALY vs. cDMARDs. With no sequential bDMARD us, 
RTX ICER £14 per QALY vs. cDMARDs. 
Kievit et al. 2009
158
 NL Comparing treatment guidelines 6 months CCA Trial analysis All strategies had an equal cost. All variations to guideline generated 
more responders. 
Kobelt et al. 2003
159
 Sweden,  
UK 
IFX+MTX vs. MTX 10 year CUA Markov model IFX ICER is €3k per QALY vs. MTX in Sweden. £21k per QALY vs. MTX in UK 
Kobelt et al. 2004
160
 Sweden TNFa vs. cDMARDs 1 year CUA Trial analysis TNFa ICER is €43k per QALY vs. previous years' therapy 
Kobelt et al. 2005
161
 Sweden ETN vs. MTX vs. ETN+MTX 2 year/ 10 
year 
CUA Markov model ETN+MTX ICER is €37k per QALY vs. MTX (2 year horizon). 
ETN+MTX ICER is €46k per QALY vs. MTX (109 year horizon) 




Sweden IFX vs. cDMARDs 20 year CUA Markov model IFX ICER €22k per QALY vs. cDMARDs 




Sweden RTX vs. TNFa lifetime CUA Discrete Event 
Simulation 
RTX dominates TNFa 




Canada LEF vs. MTX vs. placebo 1 year CCA n/a MTX dominates LEF and placebo 




UK ADA vs. ETN vs. IFX vs. RTX vs. ABT 
vs. cDMARD sequence 
Lifetime CUA Individual Level 
Model 
RTX dominates ADA, ETN and IFX 
ABT ICER £130k per QALY vs. RTX  
Marra et al. 2007
166
 Canada IFX+MTX vs. MTX 10 years CUA Markov model IFX ICER between $Can32k-70k per QALY vs. MTX. 




Germany Adding RTX+MTX to a sequence Lifetime CUA Individual level 
Markov model 
RTX ICER €24k per QALY vs. TNFa 
Nuijten et al. 2001
168
 NL ETN vs. IFX 1 year CMA Unclear ETN dominates IFX 
Osiri et al. 2007
169
 Thailand Comparing cDMARD strategies 1 year CEA n/a MTX = $2k (per 1 point HAQ change vs. AM). MTX + AM = dominates. 
MTX + SSZ = $625. AM + SSZ = $14k. AM + MTX + SSZ = $1k. LEF = $1k. 
Other DMARDS = $16k 
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Spain IFX+MTX vs. LEF 1 year CMA Unclear LEF dominates IFX+MTX in the CMA 
Russell et al. 2009
171
 Canada Sequential TNFa use 2 years CEA Decision tree 1st bDMARD position: ABT dominates when using both remission and 
LDAS as outcomes. 2nd bDMARD position: ICER $20k per LDAS and $26k 
per remission 
Saraux et al. 2010
172
 France Sequential TNFa use 2 year CEA Unclear Lower costs per 'theoretical expected number of days in remission' with 
ABT after first TNFa compared with RTX. Consistent with remission 
criteria as well. 
Shini et al. 2010
173
 India cDMARD mono and combo therapies 3 months CEA n/a For mono, lowest CER was HCQ. For combo, lowest CER was MTX+HCQ 
Soini et al. 
174
 2012 Finland ADA vs. ETN vs. TCZ Lifetime CUA Individual Level 
Model 
Wholesale prices: TCZ dominates ADA and ETN and ICER €18k per QALY 
vs. MTX. Retail prices TCZ extendedly dominates ADA, ETN and ICER €17k 
per QALY vs. MTX. 
Tanno et al. 2006
175
 Japan Adding ETN to a cDMARD sequence Lifetime CUA Markov model ETN ICER ¥3.5 per QALY vs. standard therapy 




US ABT vs. cDMARDs lifetime CUA Individual Level 
Model 
ABT ICER $45k per QALY vs. cDMARDs 




US ABT+MTX vs. MTX lifetime CUA Microsimulation ABT+MTX ICER $43k per QALY vs. MTX 
Wailoo et al. 2008
178
 US ETA vs. ADA vs. ANA vs. IFX Lifetime CUA Individual Level 
Model 
ANA was the least effective and least costly strategy. ETN, IFX and ADA 
were similar in terms of effectiveness but IFX was more costly.  
Welsing et al. 2004
179
 NL Usual care vs. LEF vs. TNFa vs. 
LEF,TNFa sequences 
5 years CUA Markov model Post-DMARD failure most cost effective position for TNFa, with ICER of 
€163k per QALY vs. usual care. 
Wong et al. 2002
180
 US IFX+MTX vs. MTX Lifetime CUA Markov model IFX ICER is £30k per QALY vs. MTX 




PATIENT POPULATION AND TREATMENTS 
To categorise the patient population and decision point for which a new treatment is being 
considered, a conceptualisation of RA is required. 
The current NICE Clinical Guideline for RA (CG90) defines one subset of the patient population 
as ‘recent-onset’ – where patients have active RA with no prior use of DMARDs.121 It states 
that the objective for health care professionals is to diagnose active RA as soon as possible so 
that DMARD therapy can be initiated within 3 months of the onset of persistent symptoms. 
Once patients have received DMARD therapy, then the guideline categorises patients as having 
‘established’ disease. The studies will be categorised into these two broad groups, with 
subgroups defined where appropriate.  
The NICE Clinical Guideline (CG90) provides a treatment algorithm to determine the 
appropriate strategy of care for a patient in either population (Figure 4.2). The development of 
the NICE Clinical Guideline was constrained by the fact that NICE Technology Appraisals had 
already developed guidance for the use of bDMARDs in patients with RA,181 and therefore this 
guidance was mandatory and the advisory remit of the Clinical Guideline could not alter this.182  
 
Figure 4.2: NICE Clinical Guideline (CG90) - Patient population and treatment algorithm 
(simplified) 
The treatment algorithm highlights that in general the view of decision-makers has been that 
bDMARDs, due to their cost, should only be attempted when two less costly cDMARDs have 
been attempted first. The NICE Clinical Guideline commissioned a de novo CUA to compare 
different combination therapy and monotherapy cDMARD strategies in patients with recent-
onset RA.135 This CUA informed the treatment algorithm which recommends patients with 
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-No DMARD therapy 
ESTABLISHED RA 
-Confirmed diagnosis 
-Active disease  
-Persistent symptoms 
-Prior DMARD therapy 
cDMARDs 
-Combination cDMARD therapy 
where possible, or monotherapy 
cDMARD  
 
cDMARDs and bDMARDs 
-Switch from combination 
cDMARDs to a bDMARD, or from 








recent-onset RA receive combination cDMARD therapy as their first strategy. The downstream 
impact is that non-responders to combination cDMARDs move more quickly to bDMARDs 
when compared to a trial of cDMARDs in sequence. 
For this systematic review, the patient population for each economic evaluation will be 
determined as either recent-onset or established RA. The position of the decision point in the 
economic evaluation will make reference to the standard treatment algorithm, where a recent 
onset population has no prior DMARD treatment, and established RA patients will have 
previously had DMARD treatment. If bDMARDs are evaluated for the use in treating recent 
onset RA patients, then this will be clearly reported. 
The patient population for each economic evaluation is determined by the point in which the 
comparison between alternatives is made. Some researchers call this the divergence point,124 
because a DAM may explicitly model the previous treatment sequence from recent-onset RA, 
however the sequence only differs at the divergence point. For example a model may have an 
identical recent-onset RA sequence of cDMARDs, and then the divergence point occurs where 
there is a comparison of alternative bDMARDs in patients with established RA. Modelling 
upstream treatments (before the divergence point) may be undertaken to allow movement of 
the divergence point, allow alternative patient populations to be generated, or to allow 
screening or diagnostics to be evaluated. 
There are fourteen (25%) studies of DMARD therapy in patients with recent-onset RA.124–137 42 
(74%) of studies are in patients with established RA.138–155,157–180 In one study (1%), it was 
unclear whether the interventions compared were for recent-onset or established RA.156 The 










14 (25%) Chen et al. 2006124, Davies et al. 2009125, Finckh et al. 2009126, 
Hartman et al. 2004127, Kobelt et al. 2002128, Kobelt et al. 2011129, 
Korthals-de Bos et al. 2004130, Maetzel et al. 2002131, Schadlich et 
al. 2005132, Schipper et al. 2011133, Spalding et al. 2006134, Tosh et 
al. 2011135, van den Hout et al. 2009136, Verhoeven et al. 1998137 
Established 
RA 
42(74%) Anis et al. 1996138, Bansback et al. 2005139, Barbieri et al. 2005140, 
Barton et al. 2004141, Benucci et al. 2009142, Benucci et al. 2011143, 
Beresniak et al. 2011144, Brennan et al. 2004145, Brennan et al. 
2007146, Chiou et al. 2004147, Choi et al. 2000148, Choi et al. 2002149, 
Cimmino et al. 2011150, Clark et al. 2004151, Coyle et al. 2006152, 
Diamantopoulos et al. 2012153, Hallinen et al. 2010154, Jobanputra 
et al. 2002155, Kielhorn et al. 2008157, Kievit et al. 2009158, Kobelt et 
al. 2003159, Kobelt et al. 2004160, Kobelt et al. 2005161, Lekander et 
al. 2010162, Lindgren et al. 2009163, Maetzel et al. 2002a164, 
Malottki et al. 2011165, Marra et al. 2007166, Merkesdal et al. 
2010167, Nuijten et al. 2001168, Osiri et al. 2007169, Rubio-Terrés et 
al. 2001170, Russell et al. 2009171, Saraux et al. 2010172, Shini et al. 
2010173, Soini et al. 174. 2012, Tanno et al. 2006175, Vera-Llonch et 
al. 2008176, Vera-Llonch et al. 2008a177, Wailoo et al. 2008178, 
Welsing et al. 2004179, Wong et al. 2002180 
Unclear 1 (1%) Kavanaugh et al. 1996156 
Total 57 (100%)  
 
The studies cover a range of monotherapy and combination therapies utilising both cDMARDs 
and bDMARDs for patients with recent-onset RA. These are summarised in Table 4.7 and Table 
4.8. 
CRITICAL APPRAISAL OF THE ECONOMIC EVIDENCE FOR DMARDS IN RECENT-ONSET RA 
Presented here is a critical appraisal of the economic evaluations conducted which compared 
treatment strategies for patients with recent-onset RA. Fourteen studies were identified in this 
population.124–137  
i) Scope of the economic evaluations in recent-onset RA 
The summary details for all fourteen recent-onset RA economic evaluations are presented in 
Table 4.5. All fourteen studies were CUAs, with benefits quantified using QALYs. Ten (71%) of 
the studies considered the introduction of a particular DMARD to a treatment 
pathway,124,125,127,133,134,137 and four (29%) studies evaluated the adjustment or tapering of a 
treatment strategy.126,131,135,136 The specific treatments evaluated for people with recent-onset 
RA in the identified studies are reported in Table 4.7. 
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Table 4.7: Treatments evaluated for recent-onset RA 









7 Davies et al. 2009125, Finckh et al. 
2009126, Kobelt et al. 2002128, Kobelt et 
al. 2011129, Schipper et al. 2011133, 
Spalding et al. 2006134, Tosh et al. 2011135 




MTX+LEF 1 Schipper et al. 2011133 
MTX+SSZ 1 Tosh et al. 2011135 
MTX+Prednisone 1 Tosh et al. 2011135 
MTX+SSZ+Prednisone 1 Korthals-de Bos et al. 2004130 
Step-up combination 1 Tosh et al. 2011135 
Step-down combination 1 Tosh et al. 2011135 
Intensive combination 1 Tosh et al. 2011135 
Monotherapy 
bDMARDs 
ADA 2 Chen et al. 2006124, Spalding et al. 
2006134 
ETN 3 Chen et al. 2006124, Davies et al. 2009125, 
Spalding et al. 2006134 
Combination 
bDMARDs 
ADA+MTX 3 Chen et al. 2006124, Davies et al. 2009125, 
Spalding et al. 2006134 
ETN+MTX 2 Chen et al. 2006124, Kobelt et al. 2011129 
IFX+MTX 3 Chen et al. 2006124, Davies et al. 2009125, 
Spalding et al. 2006134 
Other cDMARDs 2 Chen et al. 2006124, Schadlich et al. 
2005132 
bDMARDs 2 Finckh et al. 2009126, Schipper et al. 
2011133 
Non-DMARD 1 Finckh et al. 2009126 
Placebo+MTX 1 Hartman et al. 2004127 
Folic Acid+MTX 1 Hartman et al. 2004127 
Folinic Acid+MTX 1 Hartman et al. 2004127 
See glossary for definitions of abbreviations. 
 
The studies were diverse in their treatment considerations, and since 2006 seven of the 
fourteen studies (50%) have evaluated the use of bDMARDs in recent-onset RA.124–
126,129,133,134,136 Prior to 2006, six studies (43%) were published which evaluated the economic 
impact of cDMARDs.127,128,130–132,137 This leaves one (7%) relatively recent study (Tosh et al. 
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(2011))135 evaluating cDMARDs. This suggests that with bDMARDs coming on the market in 
early 2000s, there has understandably been a shift to evaluating their cost-effectiveness, at 
the expense of continuing evidence generation for the use of established and lower cost 
cDMARD treatments. 
The disease severity in the patient population being evaluated was not clearly reported across 
the studies. Kobelt et al. (2011) evaluated ETN+MTX vs. MTX in a severe RA population.129 
Kobelt et al. (2002) was an evaluation of MTX+SSZ vs. LEF in any patient with RA.128 Six (43%) of 
studies were explicitly reported as being in an active RA population.124,127,132,135–137 In the 
remaining six (43%) studies, the patient population and disease severity was not 
reported.125,126,130,131,133,134 
Only five (36%) of the studies had a lifelong time horizon for the economic evaluation.124–
126,134,135 Of these five studies, four of them were evaluations of bDMARDs in recent-onset RA, 
and all four used decision-analytic modelling methods to estimate costs and effects.124–126,134 
This included Chen et al. (2006), a publication of the independent submission made by the 
NICE Technology Appraisal Group based at Birmingham.124 Only Tosh et al. (2011) considered 
the lifetime costs and effects of alternative cDMARD monotherapy and combination therapy 
strategies in recent-onset RA.135 TNFa’s were not considered at this divergence point, due to 
the evaluation being used to inform the NICE Clinical Guideline,121 and the NICE guidance at 
that time published from Technology Appraisals recommending that bDMARDs (specifically, 
TNF-a inhibitors) only be used after treatment failure with at least two cDMARDs. 
Four studies (29%) had a time horizon of no more than 2 years.127,130,136,137 A truncated time 
horizon of this magnitude is likely to omit future costs and benefits that occur between 
alternative treatments, and in particular if a DMARD therapy is assumed to have a disease-
modifying effect on the future course of a chronic condition like RA. Therefore, the short time 
horizon in these studies is likely to lead to biased estimates of cost-effectiveness. 
Ten of the fourteen (71%) studies used DAM methods to estimate expected costs and 
QALYs.124–126,128,129,131,132,134,135 The remaining four studies (29%) were economic evaluations 
alongside clinical trials.127,130,136,137 Prior to 2006, six studies (43%) evaluated the economic 
impact of cDMARDs, with no evaluation having a time horizon of longer than 10 years.127,128,130–
132,137 Three of the six studies (50%) undertook an economic evaluation alongside a clinical 
trial.127,130,137 This partially explains the short time horizon and why downstream implications 
are not fully considered. The extrapolation or modelling of costs and effects may not be the 
primary objective when reporting a clinical trial; however the results of these studies will be of 
limited use for resource allocation decision-making. 
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ii) Downstream costs and effects in recent-onset RA 
In the five studies with a lifelong time horizon for the economic evaluation, only Chen et al. 
(2006) explicitly modelled a downstream sequence of treatments.124 The analysis allowed a 
consideration of multiple positions of bDMARDs within the treatment sequence. However, the 
authors did not attempt to identify an optimal treatment sequence from the available 
treatment set.  
Of the remaining four studies, Tosh et al. (2011) considered alternative cDMARD monotherapy 
and combination therapy strategies in recent-onset RA.135 TNFa’s were not considered at this 
divergence point, due to the evaluation being used to inform the NICE Clinical Guideline, and 
the NICE guidance at that time stating that bDMARDs can only be used after treatment with at 
least two cDMARDs.121 The lifelong time horizon would have allowed the implications of faster 
access to bDMARDs (but using combination rather than sequential monotherapy cDMARDs) to 
be quantified, however the downstream bDMARDs were not explicitly modelled, and instead 
estimates of expected costs and QALYs were added on. Spalding et al. (2006) used a pooled 
estimate of costs and effects to provide evidence of the downstream sequence after 
comparing the first line use of bDMARDs.134 Finckh et al. (2009)  compared symptomatic care 
with MTX and bDMARDs, and did not clearly report how future costs and QALYs after 
treatment failure were estimated.126 Davies et al. (2009) evaluated bDMARDs at first line 
position in an explicit sequence (bDMARD, MTX+HCQ, LEF, GLD, PC), however they did not 
clearly report how evidence was used to determine the cost and QALY impact of these future 
treatments.125 
From the nine studies with a truncated time horizon, five explicitly included a downstream 
sequence of treatments.129,131–133,136 Kobelt et al. (2011) evaluated ETN+MTX vs. MTX over a 10 
year time horizon, with a downstream sequence of two bDMARDs and then progression to a 
standard therapy extrapolation of costs and disease activity.129 Both Maetzel et al. (2002)131 
and Schadlich et al.(2005)132 evaluated the impact of adding LEF to a cDMARD sequence at 
second line, over a five year and three year time horizon, respectively. Neither study evaluated 
the cost-effectiveness of adding LEF at alternative positions in the sequence. Schipper et al. 
(2011) evaluated the cost-effectiveness of allowing sequential bDMARD use in recent-onset 
RA, over a five year time horizon.133 After bDMARD use the model contained a transition to 
combination cDMARDs, however the impact of this on costs and effects was not reported. Van 
den Hout et al. (2009) compared cDMARD monotherapy and combination therapies with initial 
IFX+MTX therapy, over a two year time horizon.136 The analysis was an economic evaluation 
alongside a clinical trial, and after switching treatment in the trial the patient progressed to 
another active therapy. The trial was reported as Intention to Treat (ITT), and so the costs and 
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effects of transition to downstream sequential therapies were included in the economic 
evaluation but only within the trial follow up period. 
Four studies remain with a truncated time horizon and no explicit inclusion of downstream 
costs and effects.127,128,130,137 All four studies are relatively old (1998-2004) and are evaluations 
of cDMARDs. For these treatments, there was less of a focus on future benefits such as disease 
control and joint damage, and more of a focus on a short term reduction in disease activity. 
Three of the four studies were clinical trials,127,130,137 and only Kobelt et al.(2002) used a DAM  
to estimates costs and effects over a 10 year time horizon.128 In their analysis, long term costs 
and effects are derived from an observational study (the Early Rheumatoid Arthritis Study). 
iii) Decision-analytic modelling methods in recent-onset RA 
Ten of the fourteen (71%) studies used DAM methods to determine expected costs and 
QALYs.124–126,128,129,131,132,134,135 Two of the ten models (20%) were a decision tree,131,132 four 
studies (40%) are cohort Markov/State-transition models,128,129,133,134 and four studies (40%) 
are ILMs.124–126,135 
The decision tree model by Maetzel et al. (2002) had a 5 year time horizon and was capable of 
modelling a sequence of six explicit treatments.131 However, this modelling method required 
simplifications which lead to limitations of the final analysis. In particular, only one level of 
treatment response was incorporated (ACR20), with the authors recognising that incorporating 
ACR50 would have allowed the potential superiority of newer DMARDs to be quantified in the 
model. Also, the model only incorporates approximate direct costs over the long term. The 
decision tree model by Schadlich et al. (2005)132 had a 3 year time horizon and was very similar 
to that of Maetzel et al. (2002).131 It also suffered from the same limitations, and additionally 
the fact that it did not account for disease duration or diminished clinical response for 
cDMARDs used at later points in the sequence. 
The four Markov models defined health states and transition probabilities between different 
states. Two defined these health states by HAQ score, one by DAS score, and one simply by 
either being on an active treatment or dead, and with time dependent costs and 
utilities.128,129,133,134 
The four ILMs explicitly modelled sequential treatments.124–126,135 Tosh et al (2011)135 and 
Davies et al. (2009)125 used a regular 6-month time point to update costs and QALYs. This 
represents a simplification of evidence, in particular when events can occur at any time, or 
when regular events (such as treatment re-administration) occur outside of the 6-month cycle. 
Chen et al. (2006)124 and Finckh et al. (2009)126 overcome this limitation by being a time-to-
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event model. The model time is updated when an event occurs which has an impact on costs 
or effects. 
The six older studies evaluating cDMARDs in recent-onset RA were, unsurprisingly, less likely to 
meet the Drummond checklist for assessing the quality of the study.127,128,130–132,137 Only 
Maetzel et al. (2002)131 fully met the Drummond criteria. The other studies in general did not 
have a long enough time horizon to fully capture future costs and benefits,127,128,130,132,137 and 
did not report a fully incremental analysis between alternatives.127,132,137 Probabilistic 
Sensitivity Analysis was not commonly performed, however if detailed and comprehensive 
scenario and one-way sensitivity analyses were performed then it was considered that this was 
an appropriate level of testing for uncertainty. 
Of the eight newer studies, five fully met the Drummond criteria.124–126,135,136 Kobelt et al. 
(2011)129, Schipper et al. (2011)133 and Spalding et al. (2006)134 did not clearly detail the 
evidence to establish the programme’s effectiveness, and the latter two studies did not report 
fully incremental results. 
iv) Health economic results in recent-onset RA 
Seven studies (50%) evaluated the economic impact of cDMARDs in patients with recent-onset 
RA.127,128,130–132,135,137 Three of these studies evaluated combination cDMARD strategies, and all 
three found that a combination of cDMARDs dominated monotherapy cDMARDs.130,135,137 Of 
the remaining four studies, three evaluated LEF monotherapy. Maetzel et al. (2002) estimated 
an ICER for LEF of $Can71,000 per QALY compared to a cDMARD sequence.131  Kobelt et al. 
(2002) concluded that LEF either dominates or is dominated compared to SSZ and MTX 
depending on the clinical evidence used to derive effectiveness.128 Schadlich et al. (2005) 
estimated that adding LEF to a cDMARD sequence generated additional QALYs, with an ICER of 
€8,000 per QALY.132 Hartman et al. (2004) estimated that, adjunct to MTX, folic acid was 
dominated by placebo, and folinic acid dominated placebo.127 
In the seven studies (50%) evaluating the economic impact of bDMARDs in patients with 
recent-onset RA, the general conclusion was that bDMARDs added both costs and benefits to 
cDMARD comparators.124–126,129,133,134,136 However, Finckh et al. (2009) estimated that 
bDMARDs would be dominated by cDMARDs in recent-onset RA.126 Chen et al. (2006),124 
Schipper et al. (2011),133 Spalding et al. (2006),134 and van den Hout et al. (2009)136 concluded 
that the ICERs comparing bDMARDs to cDMARDs are likely to be too high for decision-makers 
to approve. Only Davies et al. (2009),125 with an ICER of $47k per QALY for ADA+MTX vs 
cDMARDs, and Kobelt et al. (2011),129 with an ICER of €13k per QALY for ETN+MTX vs MTX, are 
64 
 
potentially within the threshold for being cost-effective.* Both analyses are for countries (US 
and Sweden respectively) where cost-effectiveness thresholds are not established for health 
resource allocation decision-making. 
Of the fourteen studies, six (43%) reported sensitivity analysis did not significantly alter the 
baseline estimates of cost-effectiveness.128,130,132,133,137,182 It was not possible to clearly identify 
what criteria were used to suggest the results were robust, and whether the sensitivity 
analysis was comprehensive enough.  Eight studies reported significant decision uncertainty, 
with four studies (29%) reporting specific model parameters which lead to decision 
uncertainty. These were the progression rate of HAQ whilst on treatment,124,125  the mapping 
algorithm from HAQ to utility,125 the initial effectiveness,124 and withdrawal rate for cDMARDs, 
125 and the initial change in HAQ score after a treatment response.134 
CRITICAL APPRAISAL OF THE ECONOMIC EVIDENCE FOR DISEASE-MODIFYING THERAPIES IN 
ESTABLISHED RA 
Presented here is a critical appraisal of the economic evidence identified within established 
RA.  42 studies provided economic evidence for treatments of established RA.138–155,157–180 
i) Scope of the economic evaluations of disease-modifying therapies in established RA 
All 42 studies were economic evaluations of DMARD therapies for people with established RA. 
The summary details for all of the established RA economic evaluations are presented in Table 
4.5. 29 of the 42 studies (69%) were CUAs, with effects quantified as QALYs.139–143,145–147,151–
155,157,159–163,165–167,174–180 Nine studies (21%) were CEAs,138,144,148–150,169,171–173 with four using low 
disease activity score (LDAS) or remission as the unit of effect,144,150,171,172 two with ACR70 
weighted response,148,149 and one study apiece using per patient improved,138 HAQ 
improvement,169 and DAS improvement.173 Two studies (1%) were CCAs,158,164 and two studies 
(1%) were CMAs.168,170 The specific treatments evaluated for people with established RA in the 
identified studies are reported in Table 4.8. 
  
                                                          
*
 Assuming a threshold of £30,000 (or €40,000 or $50,000) per QALY.  
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Table 4.8: Treatments evaluated for established RA 
Type Treatment Studies References 
Monotherapy 
cDMARDs 
AZA 1 Shini et al. 2010
173
 
CYA 1 Anis et al. 1996
138
 
GLD 1 Barton et al. 2004
141
 
HCQ 2 Osiri et al. 2007
169
, Shini et al. 2010
173
 
LEF 3 Maetzel et al. 2002a
164
, Rubio-Terrés et al. 2001
170




MTX 10 Barbieri et al. 2005
140
, Choi et al. 2000
148
, Choi et al. 2002
149
, 
Kobelt et al. 2003
159
, Kobelt et al. 2005
161
, Maetzel et al. 
2002a
164
, Marra et al. 2007
166
, Osiri et al. 2007
169
, Shini et al. 
2010
173
, Wong et al. 2002
180
 





AZA+Pen 1 Anis et al. 1996
138
 
HCQ + SSZ 2 Osiri et al. 2007
169
, Shini et al. 2010
173
 
HCQ + SSZ 
+ MTX 
3 Choi et al. 2000
148
, Choi et al. 2002
149





2 Osiri et al. 2007
169
, Shini et al. 2010
173
 
MTX + SSZ 2 Osiri et al. 2007
169
, Shini et al. 2010
173
 
MTX + LEF 1 Shini et al. 2010
173
 
MTX + CYA 2 Choi et al. 2000
148





ABT 6 Beresniak et al. 2011
144
, Cimmino et al. 2011
150
, Hallinen et al. 
2010
154
, Malottki et al. 2011
165
, Russell et al. 2009
171




ADA 11 Bansback et al. 2005
139
, Beresniak et al. 2011
144
, Chiou et al. 
2004
147
, Cimmino et al. 2011
150
, Diamantopoulos et al. 2012
153
, 
Hallinen et al. 2010
154
, Malottki et al. 2011
165
, Russell et al. 
2009
171
, Saraux et al. 2010
172
, Soini et al. 
174




ANA 2 Chiou et al. 2004
147
, Wailoo et al. 2008
178
 
ETN 18 Bansback et al. 2005
139
, Barton et al. 2004
141
, Brennan et al. 
2004
145
, Chiou et al. 2004
147
, Choi et al. 2000
148
, Choi et al. 
2002
149
, Clark et al. 2004
151
, Coyle et al. 2006
152
, 
Diamantopoulos et al. 2012
153
, Hallinen et al. 2010
154
, 
Jobanputra et al. 2002
155
, Kobelt et al. 2005
161
, Malottki et al. 
2011
165
, Nuijten et al. 2001
168
, Russell et al. 2009
171
, Saraux et 
al. 2010
172
, Soini et al. 
174
, 2012 Tanno et al. 2006
175




IFX 13 Barton et al. 2004
141
, Beresniak et al. 2011
144
, Chiou et al. 
2004
147
, Cimmino et al. 2011
150
, Diamantopoulos et al. 2012
153
, 
Hallinen et al. 2010
154
, Jobanputra et al. 2002
155
, Lekander et al. 
2010
162
, Malottki et al. 2011
165
, Nuijten et al. 2001
168
, Russell et 
al. 2009
171
, Saraux et al. 2010
172
, Wailoo et al. 2008
178
 
RTX 7 Benucci et al. 2011
143
, Beresniak et al. 2011
144
, Cimmino et al. 
2011
150
, Hallinen et al. 2010
154







, Saraux et al. 2010
172
 
TCZ 2 Diamantopoulos et al. 2012
153





ABT+LEF 1 Benucci et al. 2009
142
 
ABT+MTX 3 Benucci et al. 2009
142
, Vera-Llonch et al. 2008
176




ADA+MTX 1 Bansback et al. 2005
139
 
ETN+LEF 1 Benucci et al. 2009
142
 
ETN+MTX 5 Bansback et al. 2005
139
, Benucci et al. 2009
142
, Choi et al. 
2000
148
, Choi et al. 2002
149
, Kobelt et al. 2005
161
 
IFX+MTX 7 Bansback et al. 2005
139
, Barbieri et al. 2005
140
, Coyle et al. 
2006
152
, Kobelt et al. 2003
159





, Wong et al. 2002
180
 
RTX+MTX 2 Kielhorn et al. 2008
157
, Merkesdal et al. 2010
167
 
Other cDMARDs 8 Bansback et al. 2005
139
, Brennan et al. 2004
145
, Brennan et al. 
2007
146
, Clark et al. 2004
151
, Osiri et al. 2007
169
, Tanno et al. 
2006
175
, Vera-Llonch et al. 2008
176





4 Benucci et al. 2011
143
, Kobelt et al. 2004
160
, Lekander et al. 
2010
162
, Lindgren et al. 2009
163
 
bDMARDs 4 Brennan et al. 2007
146
, Kobelt et al. 2004
160
, Merkesdal et al. 
2010
167









The studies were diverse in the treatments considered, however only four (9%) studies were 
exclusively for cDMARDs.138,164,169,173 This potentially reflects the development of bDMARD 
therapies in the last 15 years, and their relatively high cost requiring a formal economic 
evaluation to determine if they offer value for money for use in patients with established RA. 
In fourteen (33%) of the 42 studies, the disease severity in the patient population being 
evaluated was not clearly reported.138,141,145,148,149,151,159,160,165,168,169,173,175,178 Eleven (26%) studies 
were reported as being in an active RA patient population.146,155–157,162–164,167,170,179,180 Four (9%) 
studies were in a severe RA patient population,140,152,154,161 leaving thirteen (24%) studies in a 
moderate-severe RA patient population.139,142–144,147,150,153,158,171,172,174,176,177 
Only 19 (45%) of the studies had a lifelong time horizon for the economic evaluation.139–
141,145,146,151,153–155,157,163,165,167,174–178,180 All of these studies used decision-analytic modelling 
methods. None of the cDMARD exclusive studies in established RA had a lifelong time horizon. 
17 (40%) studies had a time horizon of no more than two years.138,142–144,147–150,158,160,164,168–173 
36 (86%) of the 42 studies used DAM methods to determine the expected costs and QALYs.138–
141,144–155,157–159,161–163,165–168,170–172,174–180 This includes prospective studies with a model to 
extrapolate estimates into the longer-term. Of the six remaining studies, five were 
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observational studies,101,142,160,169,173 and one was an economic evaluation alongside a clinical 
trial.164 None of these six studies had a time horizon longer than two years. 
ii) Downstream costs and effects in established RA 
In the 19 studies with a lifelong time horizon for the economic evaluation, 13 (68%) explicitly 
modelled a downstream sequence of treatments.114,139,141,145,146,151,153–155,157,163,165,175 None of 
these studies attempted to estimate the optimal sequence of treatments from the available 
treatment set. 
Bansback et al. (2005) evaluated bDMARDs with or without adjunct MTX vs cDMARDs in 
patients who had already failed on two previous cDMARDs.139 The downstream cDMARD 
sequence was explicitly modelled; however the sequence was fixed for all comparisons. 
Hallinen et al. (2010) compared alternative sequences of bDMARDs after failure on one 
bDMARD.154 
Jobanputra et al. (2002),155 and Barton et al. (2004)141 evaluated ETN and IFX in a cDMARD 
sequence. ETN and IFX were evaluated in three different positions in a sequence of 10 active 
therapies. The same decision analytic model was used by Clark et al. (2004) to evaluate 
anakinra in alternative positions in a cDMARD sequence,151 and by Malottki et al. (2011) to 
evaluate bDMARDs after failure on a previous bDMARD.165 
Brennan et al. (2004) evaluated ETN in a cDMARD sequence.145 ETN was only evaluated in one 
position, after 2 cDMARDs had failed. However, alternative downstream sequences were 
modelled in scenario analyses. This was the same for a latter evaluation by Brennan et al. 
(2007) comparing TNFa’s as a class to a cDMARD sequence.146  Tanno et al. (2006) evaluated 
ETN in a sequence of three cDMARDs over a patient’s lifetime,175 after failure on bucillamine. 
The downstream sequence is likely to be too short and omits other cDMARD options and 
sequential bDMARD use for this patient population. 
Diamantopoulos et al. (2012) compared alternative positions of TCZ in a bDMARD naïve and 
experienced population.153 Kielhorn et al. (2008) evaluated the introduction of RTX+MTX after 
people had failed on two previous bDMARDs.157 The downstream sequence, or position of 
RTX+MTX, was not altered. Lindgren et al. (2009) evaluated the introduction of RTX after 
failure on one previous bDMARD.163 The subsequent sequence of treatments was not 
specified, and was not altered. Merkesdal et al. (2010) evaluated the introduction of RTX after 
failure on one previous bDMARD.167 The subsequent sequence of cDMARDs was not altered, 
and no comparison to other bDMARDs was made. 
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Six studies (72%) had a lifelong time horizon but did not explicitly model the downstream 
treatments.140,174,176–178,180 Barbieri et al (2005) simulated HAQ states with associated costs and 
utilities.140 Soini et al. (2012) modelled progression to best supportive care, and did not clearly 
report how costs and HRQL were estimated.174 Vera-Llonch et al. (2008) used the same model 
for two analyses, and after treatment withdrawal moved onto a linear extrapolation of HAQ 
with mapped estimates of costs and utilities.176,177 Wailoo et al. (2008) also extrapolated HAQ 
after treatment withdrawal.178 Wong et al. (2002) estimated future costs and health effects by 
simulating a worsening of HAQ score via movement of the modelled cohort through Markov 
health states.180 
23 of the 42 studies (55%) in established RA did not have a lifelong time horizon. Of these, only 
six (26%) explicitly modelled a downstream sequence of treatments.144,150,152,171,172,179 The time 
horizon for these studies was no longer than 5 years, and only Coyle et al. (2006) considered 
more than one downstream treatment in the sequence (the other five modelling only a switch 
onto one other active therapy).152 
17 studies remain with a truncated time horizon and no explicit inclusion of downstream costs 
and effects.131,138,142,143,147–149,158–162,166,168–170,173 The justification for omitting long-term future 
costs and effects is not clear in any of the studies. Six studies are either observational 
analyses,101,142,160,169,173 or evaluations alongside a trial,164 and long-term modelling may not 
have been the primary research objective. 
iii) Decision-analytic modelling methods in established RA 
As already mentioned, 36 (86%) of the 42 studies used DAM methods to determine the 
expected costs and QALYs.138–141,144–155,157–159,161–163,165–168,170–172,174–180 Five (14%) of the 36 
models were a decision tree,138,147–149,171 nine (25%) were cohort Markov 
models,140,152,159,161,162,166,175,179,180 and 16 (44%) were individual level models.139,141,145,146,151,153–
155,157,163,165,167,174,176–178 For the remaining six (17%) studies, the method of decision-analytic 
modelling was unclear.144,150,158,168,170,172 
Of the five decision tree models,138,147–149,171 none had a time horizon of over 2 years. Only 
Russell et al. (2009) considered sequential use of therapies.171  Moving onto a second therapy 
occurred after an inadequate response, and the evidence for this was not clearly reported.  
The nine Markov models were also limited in considering the costs and effects of future 
treatments.140,152,159,161,162,166,175,179,180 Only three had a lifelong time horizon,140,175,180 and only 
three considered sequential use of treatments.152,175,179 
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The 16 individual level simulations all had a lifelong time horizon.139,141,145,146,151,153–
155,157,163,165,167,174,176–178 12 of these studies also considered sequential use of therapies in 
patients with established RA.139,141,145,146,151,153,154,157,163,165,167 All 12 determined a treatment 
switch by either a short-term lack of response, or a long-term withdrawal due to a loss of 
efficacy or an adverse event. Initial response was modelled using an ACR response mapped to 
a HAQ improvement in six models.139,145,153,154,157,167 Brennan et al. (2007) modelled initial 
treatment response using the EULAR response categories and mapping the response to EQ-5D 
(or SF-6D) via a multivariate regression.146 
Only 17 of the 42 (40%) met the Drummond checklist for assessing the quality of the 
study.141,145,146,151,154,157,159,162,165–167,175–178,180 The most common reason for not meeting the 
Drummond criteria were: not providing a comprehensive description of the competing 
alternatives;174,179 not providing evidence that the programme’s effectiveness had been 
established;148,155,168,170 not including all important and relevant costs and 
consequences;144,148,150,158,170,179 not measuring costs and consequences appropriately;144,150 not 
undertaking a fully incremental analysis;138,139,144,150,152,153,158,161,168,170–172 not allowing for 
uncertainty;140,147–149,170,172 and not including all issues of interest.138–
140,144,148,150,152,153,155,158,161,168,170–172 
iv) Health economic results in established RA 
The health economic results are provided for each study in Table 4.5. None of the studies 
looked to identify the optimal sequence of treatments from the treatment set included in the 
analysis. 
Four of the 42 studies (10%) were exclusively for cDMARDs in patients with established 
RA.138,164,169,173 In Maetzel et al (2002)164 observed in a one year economic evaluation alongside 
a clinical trial that MTX dominates LEF and placebo, with Osiri et al (2007) also concluding that 
MTX+AM dominates AM, and non-MTX strategies are unlikely to be cost effective.169 Shini et 
al. (2010) performed a CEA with change in HAQ as the unit of health benefit.173 Their study 
suggests that HCQ is the most cost effective monotherapy cDMARD strategy, with MTX+HCQ 
the most cost effective combination strategy. Anis et al. (1996) estimated an ICER of CYA 
therapy of $1,000 per patient improved compared to placebo.138 
19 studies (45%) were non-sequential evaluations of bDMARDs in patients with established 
RA.140,142,143,147–149,158,161,162,166,168,170,174,176–178,180 In general, the studies found that bDMARDs 
were more effective but also more costly compared to cDMARDs in patients with established 
disease. This conclusion was consistent across all studies, irrespective of country, patient 
population or method of evaluation. Six of the 19 studies were decision-analytic models with a 
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lifelong time horizon.140,174,176–178,180 Barbieri et al. (2005)140 and Wong et al. (2002)180 estimated 
an ICER for IFX+MTX vs MTX of £33,000 and £30,000 per QALY, respectively. Likewise, two 
analyses performed by Vera-Llonch et al. (2008) estimated an ICER for ABT+MTX vs MTX of 
$43,000 per QALY and $45,000 per QALY, in a TNFa naïve177 and TNFa experienced176 patient 
population, respectively. 
19 studies (45%) were evaluations of alternative sequences of bDMARDs in patients with 
established RA.139,141,144–146,150–155,157,163,165,167,171,172,175,179 13 of these studies had a lifelong time 
horizon, and as before these studies found sequential bDMARD use to be more effective but 
also more costly.139,141,145,146,151,153–155,157,163,165,167,175  
Four studies evaluated the introduction RTX into a sequence of DMARDs. Hallinen et al. 
(2010),154 Lindgren et al. (2009),163 and Merkesdal et al. (2010)167 concluded that RTX was cost-
effective after TNFa failure compared to TNFa’s. Kielhorn et al. (2008) concluded that RTX after 
two TNFa failures was cost-effective.157 None of the studies considered the optimal position of 
RTX, at the very least by comparing RTX after one or two TNFa failures.* 
Of the nine remaining studies, nearly all were consistent in concluding that bDMARDs were 
likely to be cost effective. The studies by Barton et al. (2004)141 and Jobanputra et al. (2002)155 
were the only studies to conclude that, after two cDMARDs, bDMARDs were unlikely to be cost 
effective compared to further cDMARD treatment. 
There were six studies with an explicitly modelled sequence of downstream treatments, but 
with a truncated time horizon.144,150,152,171,172,179 These studies reported that bDMARDs were 
less likely to be cost effective. The truncated time horizon may therefore omit important 
downstream health benefits from bDMARDs, such as delayed joint erosion or disease 
progression. 
22 of 42 (52%) of studies reported the results were robust when undertaking sensitivity 
analyses.140,141,144,148,150,152–154,157–160,162,163,165,168,170,172,176,177,179,180 As with the similar conclusion 
from the recent-onset RA population, it was not clear what criteria had been used to suggest 
that the results were robust, and whether rigorous enough testing had been performed. Eight 
studies (19%) reported significant uncertainty,139,145–147,149,155,166,174 with six studies (14%) 
reporting specific model parameters which lead to significant sensitivity in the economic 
model. These were the baseline age in the model,139 the standardised mortality ratios,139 the 
algorithm to estimate HRQL,139,146,166 the rate of disease progression,145,146 discounting rates,146 
ACR response rates,147 and cost parameters.149 
                                                          
*





The review identified 57 unique economic evaluations of DMARD therapy for people with RA. 
However, none of the identified studies have considered identifying the most cost effective 
sequence from the full treatment set available. This has therefore led to clinical guidance being 
developed without published economic evidence being available to ensure that health 
resource allocation decisions are fully informed. Where models have been developed that 
consider a lifelong time horizon and downstream treatment sequences, evidence gaps have 
been identified, and evaluations have not fully considered optimising the sequence. These 
evidence gaps include the efficacy of treatments in downstream positions, and the long term 
impact of treatments on costs and HRQL in the future. The review has identified that methods 
have not been consistently applied, which has led to varied estimates of cost-effectiveness and 
uncertainty with respect to the most appropriate analyses to address particular decision 
questions. 
A number of key themes have been identified from this systematic review of economic 
evaluations of disease modifying therapies for rheumatoid arthritis. 
Firstly, the review highlights the significant decision space within rheumatoid arthritis. 
Fourteen economic evaluations were undertaken of therapies within a recent-onset RA 
population, and 42 undertaken within an established RA population. Evaluations were 
undertaken when people have had no prior treatment, up to patients having had cDMARDs 
and two bDMARDs. There are several potential positions for each DMARD therapy, and the 
review identified approximately 30 discrete treatments. Therefore the decision space on a very 
crude level is every potential sequence constructed from that set of 30 treatments.* 
Understandably, the vast decision space and therefore huge number of potential comparators 
led to no study attempting to determine the optimal sequence of therapies. The decision 
space could be broadly divided into recent-onset RA and established RA populations. The 
evaluation by Chen et al. (2006) represents the only attempt from 57 evaluations to determine 
whether bDMARDs should be used in recent-onset or established RA.124 However, the 
evaluation only considers a small subset of all feasible treatment sequences. Therefore the 
review has identified a significant number of constrained or pair-wise evaluations, the majority 
of which did not conduct a fully incremental analysis or discuss the possibility of alternatives 
positions other than the primary analysis. This is not particularly surprising, because each 
                                                          
*
 30! = 265,252,859,812,191,058,636,308,480,000,000. If each sequence took one second to enumerate, 
it would take over 8 years to solve 
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study was undertaken for its own particular decision-making context. The heterogeneity in 
terms of comparators, sequences and methodology reflect both local/national variation and 
also the context in which health economic evaluation is conducted. 
Secondly, the modelling methodology was a significant predictor with respect of the quality of 
the study and the ability to evaluate alternative sequences. Models with a lifelong time 
horizon were more likely to be an individual level simulation, and Markov and decision tree 
models were less likely to evaluate the impact of switching onto another therapy. In all studies, 
the quality of reporting about the impact of future treatments on costs and health benefits 
was varied. Within a short peer-reviewed journal article it is understandable that not every 
detail regarding a model can be fully explained. However, in sensitivity analyses undertaken in 
several studies, the long term progression of disease was shown to be a key parameter that 
determines cost-effectiveness. 
Finally, when downstream treatments were explicitly modelled, the evidence used to 
parameterise this part of the model was not consistent, and also poorly reported. Evidence 
used was often referred to rather than explicitly stated. In several evaluations assumptions of 
equal efficacy between treatments, or potential treatment decrements for later positioning 
within a sequence, was referred to when direct evidence was not identified. However, the 
quantitative or qualitative evidence to support these assumptions was not provided. The 
assumptions used to determine differences in impact of alternative treatments lead to 
significant uncertainties in the evaluations, and also highlighted that when cDMARDs or 
bDMARDs can largely be considered a class, with similar costs and health effects, small 
assumptions can have a significant impact on a treatment’s cost-effectiveness. Therefore it is 
important to identify and synthesise all relevant evidence to inform models, not just at the 
divergence point, but also throughout the complete model pathway. 
As with any systematic review, there are limitations that should be considered. The review 
does not include non-economic evaluations, or purely disease modelling studies. Some studies 
which modelled a sequence of treatments may have been omitted. These studies may have 
provided data regarding modelling methods, but their usefulness would have been limited by 
not being a comparative evaluation, which will determine model structure, evidence and 
assumptions.  
Secondly, there were some aspects of the data extraction which relied on a certain level of 
subjectivity. Where possible, checkbox choices and the Drummond checklist were used to 
ensure bias was minimised. However, when considering particular modelling methodologies 
and the ability of the model to estimate sequences or identify an optimal sequence, the 
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knowledge of the reviewer was required. To minimise bias, the reviewer relied on what was 
reported by the author as fact. Where details were missing, this was noted, rather than 
assuming what had been undertaken. Also the identified systematic reviews of economic 
evaluations in RA were cross-checked when data extraction overlapped. Some of this 
subjectivity could have been accounted for by having multiple reviewers to ensure consistency. 
However, for this PhD it was not feasible. 
Finally, manufacturer’s submissions to organisations such as NICE were not included, because 
full text versions of their reports are not publicly available. These submissions would have 
potentially been a very informative source of evidence regarding some of the published 
studies identified, as well as unpublished models which have been used substantially to inform 
health resource allocation decisions within RA. 
The electronic searches were conducted in February 2013. There is the potential for relevant 
studies to have been published after this date. The review has not been formally updated due 
to time constraints; however non-systematic searches were conducted to ensure that any 
recently published studies would not materially affect the conclusions of this systematic 
review. These searches were performed when the systematic review was published, when it 
contributed to the NICE biologics TA, and when the thesis was finalised in 2015. No major 
papers were identified. 
 
4.6 CONCLUSIONS 
This chapter highlights that treatment sequences represent a challenge when undertaking an 
economic evaluation of DMARDs for people with RA. The methods used to model treatment 
sequences have a significant impact on the final estimates of cost-effectiveness, and these 
methods have not been consistently applied. This has led to varied estimates of cost-
effectiveness, which may potentially alter decisions regarding reimbursement if used in 
practice. The level of reporting of the methods and data used to assess the impact of 
downstream treatments in a sequence was poor, and when downstream treatments have 
been modelled, evidence gaps have been identified. 
This systematic review has demonstrated the significant challenges faced when attempting to 
estimate cost-effectiveness of competing treatment sequences. There is therefore a 
requirement for methods that allows all relevant sequences to be evaluated. The remainder of 
this thesis attempts to address this, by developing a flexible decision-analytic model in Chapter 

















CHAPTER 5: DEVELOPING A HEALTH ECONOMIC MODEL FOR THE NICE 
TECHNOLOGY APPRAISAL OF BIOLOGICS FOR RHEUMATOID ARTHRITIS 
 
5.1 CHAPTER OVERVIEW 
The first three chapters provided the background, context and rationale for this thesis. In 
Chapter 4, a systematic review was undertaken to highlight the extent to which treatment 
sequences have been evaluated in RA, and some of the methodological challenges which have 
arisen in previous attempts to develop decision analytic models for RA economic evaluations. 
This chapter introduces the current NICE Technology Appraisal of biologics for RA in Section 
5.2, and the decision problem is defined in Section 5.3. NICE decided not to appraise 
downstream (post 1 bDMARD) sequences within this appraisal. This has led to the potential for 
a sub-optimal sequence to be recommended. The reasons for this are detailed, and 
subsequently discussed in Section 5.7. 
For the appraisal, a health economic model was developed. The chapter reports the 
conceptualisation of the model in Section 5.4, and highlights how key decisions regarding the 
structure of the model were reached. A discrete event simulation model was developed for 
the appraisal, and this is reported in Section 5.5. The model evaluates three main populations, 
patients with severe RA and no previous DMARD treatment (Population 1), patients with 
severe RA and treatment with two previous DMARDs (Population 2), and patients with 
moderate to severe RA and treatment with two previous DMARDs (Population 3). These 
populations further divided into two, one sub-population with people eligible for 
methotrexate (MTX) therapy, and one sub-population who are not. 
The results of the analysis are reported, and the model finds that the ICER for bDMARD use in 
populations 2 & 3 are over £60,000 per QALY gained compared to a cDMARD treatment 
sequence.* In patients who are ineligible for MTX, the ICERs are higher, at approximately 
£90,000 per QALY gained. bDMARD therapy in Population 1 is unlikely to be cost-effective, 
with ICERs of over £300,000 per QALY gained. 
The key component of the model that significantly affects the estimated ICER is the growth 
model used to estimate HAQ progression whilst on cDMARD therapy. Using a previously used 
                                                          
*
 The original results for the analysis reported in the Assessment Group report – viewable here: 
http://www.nice.org.uk/guidance/gid-tag313/documents/rheumatoid-arthritis-adalimumab-
etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumab-review-assessment-
report2 - Accessed June 2015 
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linear model brings the ICER down to £37,000 per QALY for Population 2 patients who can 
receive MTX. However, this linear model is less valid compared to the latent class growth 
model used within this analysis. 
The results and the ongoing nature of the appraisal are discussed in Section 5.7, before 
conclusions are drawn in Section 5.8. 
 
5.2 INTRODUCTION 
This chapter has two objectives. The first is to report the development of a health economic 
model for the NICE Multiple Technology Appraisal (MTA) of bDMARDs for RA. The second is to 
explain how NICE determined the scope for this appraisal and their rationale for not fully 
evaluating all possible treatment sequences. 
At the start of the PhD, an opportunity arose to develop a Technology Assessment Group 
(TAG) cost effectiveness model for the NICE MTA update (now referred to as the ‘NICE RA 
biologics appraisal’) of bDMARDs in people with moderate and severe RA.* 
With the PhD requiring the development of a flexible health economic model for RA, it was 
decided that developing the model for the NICE RA biologics appraisal would be beneficial to 
the PhD. In particular, the opportunity to engage with the NICE appraisal process for a complex 
chronic condition with treatment sequences would add value to this PhD. 
This chapter is divided into four sections. Section 5.3 explains the decision problem for the 
NICE RA biologics appraisal. Section 5.4 explains the conceptualisation process of the health 
economic model. Sections 5.5 and 5.6 explain how the model was develop, reports the input 
parameters and assumptions used, and provides the results of the analysis. Section 5.7 
presents a discussion before conclusions are drawn in Section 5.8. 
INDEPENDENT ASSESSMENT GROUP 
The University of Sheffield School of Health and Related Research (ScHARR) Technology 
Assessment Group (ScHARR-TAG) are assigned the role of independent assessment group for 
some NICE single technology appraisals (STAs) and MTAs. For both forms of appraisal, ScHARR-
TAG provides a critique of the clinical and cost-effectiveness evidence submitted by sponsor 
organisations, as well as a systematic review of the wider published clinical and cost-
                                                          
*
 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for 
the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic 




effectiveness evidence. For MTAs, a de novo cost effectiveness analysis is submitted by the 
TAG for consideration alongside the sponsor submissions by the NICE Technology Appraisal 
Committee. 
The ScHARR-TAG assessment for this NICE RA biologics appraisal was understandably a large 
and collaborative research project, led by Professor Matt Stevenson, and included a team 
comprised of systematic reviewers, statisticians, information specialists, clinicians, health 
economic modellers and health economists. As a member of the team, my specific role was to 
design, develop and validate the de novo cost effectiveness analysis, and to include the 
systematic review of economic evaluations (from this PhD research). Many parameter values 
used as inputs into the model were identified by other colleagues, which included the 
development of econometric models to estimate certain patient-level parameters. The final 
validation and debugging of the model, running the simulations, and reporting the results, was 
undertaken by Professor Matt Stevenson. 
DMARDS: CONVENTIONAL AND BIOLOGIC 
The disease modifying anti-rheumatic drugs (DMARDs) licensed for RA are numerous. Table 5.1 
provides a list of 16 commonly used DMARDs for RA. They are classified into two groups, 
conventional DMARDS (cDMARDs), and biologic DMARDs (bDMARDs).  
Table 5.1: Disease modifying anti-rheumatic drugs (DMARDs) 


































Conventional DMARDs are in general older and less expensive. They can be used as 
monotherapy treatments, in combinations with each other (double or triple cDMARD therapy), 
or with steroids. Their effectiveness varies, however many patients with RA benefit from their 
use.  
Biologic DMARDs are newer and more expensive. Evidence suggests that bDMARD 
monotherapies are superior to cDMARDs monotherapies.183–185 However, recent evidence 
suggests non-inferiority between triple cDMARD combination therapy and bDMARDs.186 The 
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significant cost of bDMARDs (over £10,000 per annum) is why NICE have been required to 
appraise their clinical and cost-effectiveness. Some bDMARDs are used as monotherapy, and 
some are only licensed for use with concomitant methotrexate (Table 5.3). At present there is 
little evidence to support combination therapies of multiple bDMARDs and their high cost 
would suggest that any clinical use is unlikely. 
 
5.3 DECISION PROBLEM 
As discussed in Chapter 3, a decision problem is where a decision maker is faced with 
competing options. NICE faces a complex decision problem in the treatment of people with RA. 
The fundamental problem is - which treatment(s) to approve for people with a diagnosis of 
RA? The utility function for the outcome of each competing option is the net benefit for each 
competing alternative. However, the chronic nature of RA, the numerous treatments available 
(both cDMARDs and bDMARDs), and the uncertain and limited efficacy of these treatments 
means that another problem emerges – what treatment(s) to approve for patients with RA 
who have failed a DMARD? This decision problem is contingent on the recommendations that 
NICE have made ‘upstream’, because treatments will not be available if they have been used 
previously. 
The decision problem is therefore compounded by the multiple treatment histories that will be 
faced by a rheumatologist. Some patients will have a new diagnosis of RA and no previous 
DMARD treatment, and some will have established RA and have failed on several DMARDs. 
When considering RA, and reflecting on the findings from the previous chapters, there is a 
treatment sequencing issue which leads to another decision problem – what is the optimal 
sequence of treatments for a patient with RA? However, this decision problem is not 
addressed in either this appraisal, or the previous guidance developed by NICE. The systematic 
review in Chapter 4 showed that it has not been addressed by any published cost-effectiveness 
analysis, and exploring this decision problem is an objective of this PhD. 
SCOPE 
The NICE RA biologics appraisal does not attempt to address the fundamental decision 
problems stated above. Instead, the scope is a complex subset of questions which have been 
formed due to the existing NICE guidance which are being reviewed, and the scoping process 
undertaken by NICE to determine the most important questions to be addressed within the 
timescales of the appraisal. 
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The NICE RA biologics appraisal is a review of NICE TA guidance 130, 186, 224, 234, and a part 
review of TA guidance 225 and 247. Table 5.2 outlines these individual pieces of NICE 
guidance. All guidance is for patients with a Disease Activity Score (DAS28) greater than 5.1; 
classified as severe RA by the European League against Rheumatism (EULAR). 
Table 5.2: Technology Appraisals being updated by NICE RA biologics appraisal 
Appraisal Type bDMARDs Guidance 
TA130 MTA Adalimumab, 
etanercept, 
infliximab 
Adalimumab, etanercept and infliximab, in combination 
with methotrexate, recommended in patients with 
active RA who have tried methotrexate and one other 
DMARD. Adalimumab or etanercept can be given as 
monotherapy if intolerant to methotrexate. 
TA186 STA Certolizumab 
pegol 
As per TA130 
TA224 STA Golimumab Suspended – no evidence submitted by manufacturer 
TA234 STA Abatacept As per TA130 
TA225 STA Golimumab As per TA130, and recommended in combination with 
methotrexate in patients who have failed a previous 
TNF inhibitor  
TA247 STA Tocilizumab As per TA130, and recommended in combination with 
methotrexate in patients who have failed a previous 
TNF inhibitor and are contraindicated to, or suffer an 
adverse event from, rituximab. 
MTA = Multiple Technology Appraisal. STA = Single Technology Appraisal 
 
TA195 appraised adalimumab, etanercept, infliximab, rituximab and abatacept after TNF 
inhibitor failure. The recommendation was that rituximab was the preferred treatment in this 
position, and the other treatments were only recommended if the patient was contraindicated 
to, or suffer an adverse event from, rituximab. TA195 was not to be updated within this 
appraisal (for reasons detailed later in this section). Therefore this guidance represented a 
constraint to the sequences which could be evaluated within this appraisal. 
A NICE Clinical Guideline was published in 2009, recommending the use of combination 
cDMARDs* in patients with early active RA.121 However, this is only a recommendation, and is 
not mandatory guidance for the NHS. 
                                                          
*
 Specifically an intensive cDMARD combination which combines three cDMARDs and steroids, as used 





From these seven NICE Technology Appraisals, as well as a NICE Clinical Guideline, a complex 
sequence of treatments has emerged for patients with severe active RA (DAS>5.1). This 
sequences is shown in Figure 5.1. 
 
Figure 5.1: Summary of biologics within NICE TA guidance *†‡ 
 
For the NICE RA Biologics appraisal, the remit of the appraisal was to “appraise the clinical and 
cost effectiveness of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, 
tocilizumab and abatacept within their licensed indications for the treatment of rheumatoid 
arthritis.”§  
The scope was to re-appraise the recommendations made for severe active RA patients in the 
light of new evidence, and also to assess whether the interventions were cost-effective in 
moderate-to-severe active RA patients (DAS28 3.2 - 5.1). All previously appraised bDMARDs 
have a licensed indication which covers both moderate-severe and severe RA patients. In the 
previous NICE TAs, bDMARDs were not approved for use in patients with moderate-to-severe 
RA, only severe RA. Not all bDMARDs are licensed to be used without concomitant 
methotrexate, or prior to the use of methotrexate. The licenses for bDMARDs are summarised 
in Table 5.3. 
                                                          
*
In combination with methotrexate 
†
 If rituximab and MTX is contraindicated or withdrawn due to adverse events then the following can be 
used: adalimumab or etanercept or infliximab or abatacept in combination with MTX; adalimumab or 
etanercept monotherapy TA195 : tocilizumab in combination with MTX TA 247, assuming these have not 
been used previously in the sequence 
‡
 Would not be used if tocilizumab has been used previously in the sequence 
§
 http://guidance.nice.org.uk/TAG/313#keydocs Final Scope – Accessed June 2015 
Intensive cDMARDs 
bDMARD* 
adalimumab or etanercept or infliximab TA130 or certoloizumab pegol TA186 
or golimumab TA225 or tocilizumab TA247 or abatacept TA280 
Ritixumab in combination with methotrexate TA195† 
Tocilizumab in combination with methotrexate TA247‡ 
cDMARD / Palliation 
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The scope was constrained by the fact that post bDMARDs positions were not to be included in 
this appraisal (TA195 is to be reviewed separately at a later date). This means that after a 
bDMARD is used in a sequence, the sequence then follows the existing NICE TA195 guidance. 
This limits the ability for the appraisal to identify and recommend an optimal sequence of 
DMARDs for patients with severe RA. 
There were three reasons why NICE made the decision not to include sequential bDMARD use 
within the scope of the appraisal. Firstly, there was a desire by the manufacturers to see a re-
appraisal of biologics in the moderate-severe active RA population in the light of the original 
rejection by NICE and a maturing of the evidence base. This guided the scoping discussions, 
and placed the focus on this patient population. Secondly, manufacturers were not interested 
in addressing sequential positions of their treatments. If manufacturers identify an optimal 
sequence, it exposes them to the risk of their treatment not being recommended, or being 
‘relegated’ to a less attractive downstream position. Thirdly, NICE believed that the appraisal 
was already complex enough without adding in the sequential biologics question. The scope of 
the appraisal (seven bDMARDs) across multiple patient populations represents the largest 
NICE appraisal to date. 
Table 5.3: Licenses for RA bDMARDs 
Intervention Is the intervention licensed… 
 Prior to the 






For patients with 
moderate to 
severe RA? 
Abatacept      
Adalimumab     
Certolizumab pegol     
Etanercept     
Golimumab     
Infliximab     
Tocilizumab     
 
5.4 MODEL CONCEPTULISATION 
For the de novo cost-effectiveness model developed by the TAG, a conceptual model was 
firstly developed. This process involves translating the decision problem with the aim of 
guiding the development of a mathematical model.54,187 
The conceptualisation of the model for the TAG submission involved understanding the scope 
of the appraisal and making decisions regarding the sequences of treatments to be compared 
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within a cost-utility analysis. It also involved the conceptualisation of a health economic model 
which could estimate the costs and QALYs of each defined DMARD treatment sequence. 
FINAL DECISION PROBLEM 
Having consulted with NICE, the TAG project team made the decision to fix the downstream 
sequence of drugs beyond the first use of bDMARDS. This was for two reasons: firstly to reflect 
the NICE scope for the appraisal, where existing guidance was available for sequential biologics 
(TA195) and was not changeable within the remit of this appraisal, and secondly to reduce the 
workload of the TAG by reducing the number of evaluations required. It avoided the 
undertaking of analyses which would not be considered by the appraisal committee and 
therefore would not have a bearing on the final guidance. 
The TAG defined three patient populations for their report and analyses. 
 Population 1: Adults with severe active RA not previously treated with cDMARDS 
 Population 2: Adults with severe active RA that have been previously treated with 
cDMARDS but not bDMARDS 
 Population 3: Adults with moderate to severe active RA that have been previously 
treated with cDMARDS only (including MTX unless contraindicated or inappropriate) 
Population 1 is patients with severe active RA who are newly diagnosed and have not been 
treated with cDMARDS. Population 2 and 3 follow this point, and are patients who have been 
treated with cDMARDS, but not bDMARDS. Population 2 is severe patients with RA, and 
Population 3 moderate to severe patients with RA. 
These populations were run for two different analyses. One was the comparison of bDMARDS 
in combination with MTX, and one was the comparison of bDMARD monotherapy. Therefore 
across three populations, six baseline analyses were undertaken (Table 5.4). 
Table 5.4: Populations and analyses 




1: Adults with severe active RA not previously treated 
with cDMARDs 
1 2 
2: Adults with severe active RA that have been 
previously treated with cDMARDs but not bDMARDs 
3 4 
3: Adults with moderate to severe active RA that have 
been previously treated with cDMARDs only (including 





For each analysis, a baseline cDMARD treatment sequence was required which represented 
the baseline comparator. Each bDMARD would then be compared to this baseline cDMARD 
sequence, as well as each alternative bDMARD sequence. 
For Population 1, the NICE RA Clinical Guideline recommends combination cDMARDs.121 This 
guidance was based on a cost-effectiveness analysis comparing combination cDMARDs to 
monotherapy cDMARDs.135 Therefore, it was assumed that patients will have had combination 
cDMARDs as first line treatment, and subsequently the comparator cDMARD sequence would 
be sequential monotherapy cDMARD use (specifically called non-biologic therapy (NBT)).  
After first line bDMARD use (the comparison of the interventions in the appraisal) patients 
progress to RTX+MTX and then TCZ+MTX (if not received at first line bDMARD position), as per 
existing NICE guidance. Patients who can receive MTX are eligible to receive TCZ+MTX, which is 
only licensed for use after MTX (Table 5.5). 
For patients who are unable to receive MTX, tocilizumab is not eligible for any sequence, as 
well as abatacept and certolizumab (only licensed for concomitant use with MTX). Intensive 
cDMARD treatment is possible with alternative cDMARD treatments (Table 5.6). 
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Table 5.5: Sequences (patients who could receive MTX) 
Population Treatment sequence (line) 
1
st
 2nd 3rd 4th 5th 6th 7th 
Population 1 MTX Intensive cDMARDs Non-biologic therapy 
MTX Intensive cDMARDs bDMARD + MTX RTX + MTX TCZ + MTX MTX Non-biologic therapy 
MTX Intensive cDMARDs TCZ + MTX RTX + MTX MTX Non-biologic therapy 
bDMARD + MTX
1 
RTX + MTX TCZ + MTX MTX Intensive cDMARDs Non-biologic therapy 
Population 2 & 3 MTX Non-biologic therapy 
bDMARD
2
 + MTX RTX + MTX TCZ + MTX MTX Non-biologic therapy 
TCZ + MTX RTX + MTX MTX Non-biologic therapy 
1




Table 5.6: Sequences (patients who could not receive MTX) 
Population Treatment sequence (line) 
1
st
 2nd 3rd 4th 5th 
Population 1 Intensive cDMARDs cDMARD Non-biologic therapy 





 Intensive cDMARDs cDMARD Non-biologic therapy 





 cDMARD Non-biologic therapy 
1






Table 5.7 to Table 5.10 provide the full sets of sequences evaluated in each analysis. 
Table 5.7: Sequences evaluated for Populations 2 and 3 for those who can receive MTX 
 First line Second line Third line Fourth line Fifth line 
1 MTX NBT    
2 ABT iv+ RTX+ TCZ+ MTX NBT 
3 ABT sc+ RTX+ TCZ+ MTX NBT 
4 ADA+ RTX+ TCZ+ MTX NBT 
5 CTZ+ RTX+ TCZ+ MTX NBT 
6 ETN+ RTX+ TCZ+ MTX NBT 
7 GOL+ RTX+ TCZ+ MTX NBT 
8 IFX+ RTX+ TCZ+ MTX NBT 
9 TCZ+ RTX+ MTX NBT  
‘+’ with MTX 
 
Table 5.8: Sequences evaluated for Populations 2 and 3 for those who cannot receive MTX 
 First line Second line Third line Fourth line 
1 SSZ NBT   
2 ADA ETN SSZ NBT 
3 CTZ ETN SSZ NBT 
4 ETB ADA SSZ NBT 
5 TCZ ETN SSZ NBT 
 
Table 5.9: Sequences evaluated for Population 1 for those who can receive MTX 
 First line Second line Third line Fourth line Fifth line Sixth line 
1 MTX Int CD+ NBT    
2 ETN+ RTX+ TCZ+ MTX Int CD+ NBT 
‘+’ with MTX; Int CD+ = Intensive cDMARDs 
 
Table 5.10: Sequences evaluated for Population 1 for those who cannot receive MTX 
 First line Second line Third line 
1 SSZ NBT  




A conceptual model was developed by the project team, which provided an agreed 
representation of RA, and the treatment of RA, which would be represented mathematically in 
the decision analytic model. 
The conceptual model was developed during project meetings, which included drawing upon 
the team’s experience at developing other health economic models for RA. Time constraints 
meant that the conceptual model was not formally stated or recorded, but there was 
agreement as to the important aspects of the condition and its treatments which would need 
to be captured in the health economic model. 
Rheumatoid arthritis is a chronic autoimmune disease which results in inflammation and 
damage to synovial joints. The conceptual model for the disease focussed on the relapsing-
remitting nature of RA, along with an insidious worsening of disease activity leading to 
irreversible joint damage and permanent disability. Similar to other RA models summarised by 
Madan et al. and Tosh et al., the conceptual model identified three phases of the disease for 
each treatment, which were repeated as the sequence of treatments progressed.188,189 
Phase 1 – Initial response to treatment and improvement in Health Related Quality of Life 
(HRQL) 
Phase 2 – Long-term progression of the disease while on treatment causing a gradual 
worsening of HRQL 
Phase 3 – Loss of efficacy or adverse event causing a worsening of HRQL 
A treatment therefore has the opportunity to improve the long term HRQL of patients with RA 
via the initial response, the progression of disease on treatment, and the time spent on a 
treatment. After a loss of efficacy or adverse event, the treatment is switched to a subsequent 
therapy, and the phases are repeated. 
DISCRETE EVENT SIMULATION 
The decision was made at the conceptualisation stage to develop an individual level simulation 
model for the NICE RA biologics appraisal. Individual level simulation models use probability 
distributions for a set of patient characteristics (e.g. age, gender, disease severity), which can 
be sampled using Monte Carlo methods to simulate an individual patient. Further sampling of 
future events is conducted for each patient, to simulate their disease and the engagement 
with health services, treatments and related events. Each patient simulation allows the 
estimation of lifetime costs and QALYs, and by repeated sampling and simulation of patients, 
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the expected costs and QALYs for the simulated population can be estimated. As discussed in 
Chapter 2, there are benefits to using an individual level model methodology instead of cohort 
model methods, and these benefits were seen as important when looking to develop a lifetime 
model for RA. In particular, it was a priori seen as important to incorporate patient covariates 
throughout the model process, because certain model parameters were dependent on patient 
covariates which when repeatedly sampled would provide an accurate estimate of the 
expected costs and QALYs for the patient population.  
Secondly, a patient level approach was seen as important to allow flexibility in assumptions 
and methods underpinning the analysis, with the expectation that the appraisal committee 
might request alternative analyses, and also the ability to adapt the model to provide 
comparison to the models provided by the manufacturers.  
Finally, the team was confident that the model could be programmed efficiently using 
Microsoft Excel and Visual Basic for Applications (VBA) so that computational time for running 
the patient simulations, probabilistic sensitivity analysis (PSA) and alternative scenarios was 
not excessive. TAGs are limited to Microsoft Excel, TreeAge, WinBugs and R when developing 
cost-effectiveness models for NICE appraisals.190,191 If they wish to use a bespoke simulation 
package (such as Simul8 or Arena) then they are expected to provide licences for each 
stakeholder so that the model can be accessed, which is not feasible. 
It was decided at the conceptualisation stage to develop the patient level health economic 
model using discrete event simulation (DES) methods. A discrete event simulation is often 
called a ‘time to event’ model within health economics. An event is scheduled to occur at a 
particular instance in time, and mark a change of state in the system. For health economic 
modelling, this means that events can occur to a patient (e.g. begin treatment, experience an 
adverse event, disease progresses) which will impact both on their instant costs and HRQL, but 
also on the future competing events which may occur, and when they will occur. A list of all 
possible events is developed, with a time of when each event will occur. The event with the 
shortest time is then selected, and this triggers logic in the model code which updates the 
costs, HRQL and also the list of event times. The process is then repeated until the death event 
occurs and the simulation ends. 
An alternative to DES for a patient level simulation is to use a fixed Markovian time cycle 
(classified by Brennan et al. as simulated patient-level Markov model (SPLMM))44 occurring at 
some arbitrarily time (e.g. 1 month, 6 months, 1 year). The decision between using a DES 
approach compared to a fixed Markovian approach was made by weighing up the advantages 
and disadvantages of the two. These are summarised in Table 5.11. 
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Table 5.11: Discrete vs Markovian patient level simulation 
 Discrete event simulation Fixed Markovian time-cycle 
Advantages Model calculations only occur at 
actual events – potential 
improved efficiency 
Provides a regular time cycle for updating 
costs and QALYs. 
Time to event data more 
accurately incorporated 
Disadvantages Events may frequently occur 
which requires a frequent update 
of the simulation time 
Running the simulation model at time 
cycles when no events are occurring is 
computationally inefficient 
May require manipulation of time-
specific data to fit into time cycle 
 
Due to the size of the appraisal and number of anticipated model simulations and evaluations, 
it was decided to use a DES method to try to minimise the run time. 
 
5.5 MODEL DEVELOPMENT 
MODEL 
The model informed a cost-utility analysis with costs from a NHS and Personal Social Services 
(PSS) perspective, and outcomes measured as QALYs. The model employs a lifetime patient 
time horizon (limited to 101 years), with costs and QALYs discounted at 3.5% per annum as 
recommended by NICE.47 A comprehensive set of sensitivity analyses were undertaken, as well 
as PSA. 
The model estimated a Health Assessment Questionnaire (HAQ) score for the patient at each 
event point because HAQ was used to subsequently estimate costs and a patient’s HRQL. HAQ 
is not a continuous score, but has 25 possible scores from 0-3 at 0.125 intervals. Sampled HAQ 
scores were continuous, and were rounded to a legitimate discrete HAQ score by using the 
inverse relation to their distance from legitimate score and estimating probabilities from which 
to sample from.*  
At the start of the model, a patient was simulated with a baseline age, disease duration, HAQ 
score, Disease Activity Score (DAS), number of DMARDs previously used, and life expectancy. 
                                                          
*
 A non-legitimate HAQ sample of 1.600 has a 20% chance of being rounded to 1.500 and 80% chance of 
being rounded to 1.625, because 1.600 is 80% of the distance between 1.500 and 1.625 
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Their life expectancy was adjusted with a hazard ratio defined by their baseline HAQ to 
account for the reduction life expectancy experienced by people with RA. 
A patient would then begin their first DMARD treatment, with a EULAR response (good, 
moderate or none) estimated at 6 months.* If a good or moderate EULAR response was 
simulated, treatment was continued until a loss of efficacy or adverse event occurred and 
treatment was withdrawn. If no EULAR response occurred, then the treatment would be 
withdrawn. Each EULAR response is associated with a change in a patient’s HAQ score. After 
withdrawal, the patient would lose any gain in HAQ obtained in the first 6 months and would 
switch to the next treatment in the sequence. 
POPULATION 
The model sampled patients who had experienced MTX treatment (Populations 2 & 3) from 
the British Society for Rheumatology Biologics Registry (BSRBR). A multivariate regression 
analysis was undertaken using the patient level data which provided an econometric model 
from which to sample patients with accurately correlated characteristics. Individuals were 
resampled until they met DAS score for the population being modelled (DAS 3.2-5.1 for 
moderate-severe, DAS > 5.1 for severe). This required significant resampling for moderate-
severe DAS patients because they were a minority in the BSRBR dataset.† Multivariate 
sampling was undertaken using the University of Sheffield Centre for Bayesian Statistics in 
Health economics Excel Functions.‡ This allowed the correlation between characteristics to be 
maintained via the variance-covariance matrix from the regression analysis.  
MTX naïve patients (Population 1) were very rarely seen in the BSRBR, due to almost all 
patients on a bDMARD having been previously treated with MTX. Therefore the COMET trial 
was used to sample patient characteristics for population 1.192 Because a covariance matrix 
was not available in the published journal article, the correlation structure between patient 
characteristics could not be maintained. The mean parameters for all Population 1 (COMET 
trial) and Populations 2&3 (BSRBR) are provided in Table 5.12. 
  
                                                          
*
 see latter section – Short Term Response, for further information regarding EULAR response 
†
 The AG was not provided with spate databases for the two patient populations 
‡ http://www.shef.ac.uk/chebs - Accessed June 2015 
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Table 5.12: Population parameters 
Characteristic COMET trial (population 1) BSRBR (populations 2 & 3) 
Mean (unless specified) s.d. Mean (unless specified) s.d. 
Age 51.4 0.6 56.2 12.2 
Proportion female 73% - 76.3% - 
Disease duration 0.8 0.0 13.3 9.6 
DAS 6.5 1.0 6.6 1.0 
Previous DMARDs 0.0 0.0 3.9 1.6 
HAQ 1.7 0.7 2.0 0.6 
Weight 73.11 17.611 73.1 17.6 
1 not reported by COMET so set equal to BSRBR 
 
SIMULATION 
A simulation ‘engine’ was developed for the DES model in Microsoft Excel and Visual Basic for 
Applications (MS VBA). The engine maintained the simulation event list, which contained all 
possible events, and identified the event on the list with the shortest time to occurrence (Time 
to Next Event (TTNE)). Once a next event is identified by the engine, the simulation clock is 
updated and the event occurs, triggering logic code in the model to update costs and QALYs. 
The event also impacts on the time to other events occurring, and therefore each event can 
update the simulation event list. The process of sampling the TTNE is then repeated until the 
next event to occur is death, and the patient simulation is completed. 
The simulation included five competing events: HAQ progression; death; administration of a 
treatment; response to a treatment; and withdrawal from a treatment. More details on each 
event are provided in Table 5.13. 
A logic diagram of the simulation model is provided in Figure 5.2. The diagram shows the 
different events which can occur in the model, and how simulation time and TTNE are used to 




Table 5.13: Simulation event list 
Event List Method of estimating time to event 
Time to HAQ 
change 
Both costs and utility are related to HAQ (and explicitly related in the 
model). Therefore each change in HAQ score is modelled as an explicit 
event. 
Time to death Hazard ratios associated with baseline HAQ scores are used to 
appropriately reduce the sampled life expectancy for each simulated 
patient at model entry. 
Time to 
administration 
The majority of treatments modelled are given in a very frequent 
(continuous) dosing regimen. However, IFX, RTX and TCZ are infrequent 
infusions and therefore their dosing is modelled as an event, to ensure 
accurate costs are calculated in the model. 
Time to response Set for six months until response decision point (good, moderate, none), 
and then large number until next treatment initiated 
Time to withdrawal 
from treatment 
For bDMARDs, uses a statistical model that estimates expected time on 
treatment using patient covariates. 
For cDMARDs, published Weibull distributions are sampled from to 
estimate the time on treatment for different cDMARDs (MTX, 





Figure 5.2: Simulation logic for RA model 
ENTRY: Patient generation 
Set patient characteristics: age, gender, 
disease duration, HAQ, DAS, previous 
DMARDs, age at death, weight 
Patient start 
Set model time = 0 
Mortality HR based on HAQ 
Set adjusted age of death 






Initiate next treatment in sequence 
If treatment is continuous, TTA = large 
number, else TTA set to dosing frequency 
TTR = 6 months 
TTNE = min(TTD, TTR, TTA) 




Update model time 
Update QALYs 
Update Costs  
  
3. Administration 
Update model time 
Set TTD = age of death – model time 
Update costs and QALYs 
Reset TTA 
TTNE = min(TTD, TTR, TTA, TTH) 
Route 1 = Dead, Route 2 = Response, Route 3 = 
Administration, Route 4 = HAQ Progression 
2. Response 
Simulate response (good, 
moderate, none) 
Estimate HAQ change 
Update costs and QALYs 
  
EULAR response 
Good or Moderate None 
Long term treatment phase 
Update model time 
Set TTD = age of death – model time 
Set HAQ change (based on response), 
Update costs and QALYs  
Set TTW (based on response), TTH, TTD 
TTNE = min(TTD, TTA, TTH, TTW) 
Route 1 = Dead, Route 3 = 
Administration, Route 4 = HAQ 
Progression, Route 5 = Withdraw, 5. Withdraw 
Update model time 
Set HAQ rebound 
Update costs and QALYs 
 
4. HAQ Progression 
Update model time 
Set TTD = age of death – model time 
Set HAQ increment 
Update costs and QALYs 
Set TTW, TTH, TTD 
TTNE = min(TTD, TTA, TTH, TTW) 
Route 1 = Dead, Route 3 = 
Administration, Route 4 = HAQ 
Progression, Route 5 = Withdraw 
 
Legend 
TTD = Time to Death, TTR = Time 
to Response, TTA = Time to 
Administration, TTH = Time to 
HAQ change, TTW = Time to 





SHORT TERM RESPONSE 
Short term response was estimated using the EULAR criteria for RA. The EULAR criteria defines 
response based on both the magnitude of a DAS change observed, and also the final DAS score 
(see Table 5.14). It is a response criterion which is used in current NICE guidance for bDMARDs 
in RA and is aligned with UK clinical practice. The DAS is a routinely collected measure in the 
NHS and therefore EULAR response is very easily collected and reported. Alternative response 
criteria include the American College of Rheumatology (ACR) criteria (ACR20/50/70), which is 
not routinely used in the NHS, but is very commonly reported in RA clinical trials. In the 
decision-analytic model, response was assumed to occur during the first six months on 
treatment, which was aligned with the standard time point for observing response in both 
clinical practice and the reviewed clinical trials. 
Table 5.14: EULAR response criteria 
Final DAS28 DAS28 improvement 
> 1.2 > 0.6 and ≤ 1.2 ≤ 0.6 
≤ 3.2 Good Moderate No response 
> 3.2 and ≤ 5.1 Moderate Moderate No response 
> 5.1 Moderate No response No response 
 
The EULAR response probabilities were taken from a network meta-analysis of all included 
clinical trials. Not all reported EULAR response, however all reported ACR response. Where 
EULAR was missing, a model using the US Veterans Affairs Rheumatoid Arthritis (VARA) dataset 
was used to provide an empirical relationship between EULAR response and ACR response. 
This model allowed all ACR trials to be interpreted using the EULAR response criteria, however 
these trials were not combined into one analysis, but evaluated separately. 
The main analysis used the mean EULAR response from all trials (Figure 5.3). Scenario analyses 
included the inclusion of trials which did not meet the strict inclusion criteria, and an analysis 
using the ACR trials. 
A sampled EULAR response in the patient level simulation was converted to an appropriate 
improvement in the patients HAQ score. These changes in HAQ scores were identified from 
the BSRBR. The BSRBR data were restricted to patients who had a full set of baseline 
characteristics, and had at least two measurements of HAQ whilst on bDMARD therapy. This 
resulted in 10,186 included patients, with 2,417 (24%) good EULAR responders, 5,492 (54%) 





Figure 5.3: Mean EULAR response probabilities for comparator treatments (Population 2&3, 
main analysis - all ACR trials) - reproduced from ScHARR Technology Appraisal Report* 
It was assumed that the change in HAQ due to a response would be the same, irrespective of 
treatment, and therefore was applied to cDMARDs as well as bDMARDs. This assumption was 
considered acceptable by the clinical advisors to the project. The change in HAQ score are 
provided in Table 5.15. 
Table 5.15: Mean HAQ improvement by EULAR response - BSRBR dataset 
EULAR response baseline – 6 month HAQ change 
Mean s.e. 
None 0 - 
Moderate -0.317 0.048 
Good -0.672 0.112 
HAQ PROGRESSION – CONVENTIONAL DMARDS 
After the initial 6 month improvement due to a treatment response, those patients who had 
either a good or moderate EULAR response remained on a cDMARD until withdrawal due to an 
adverse event or loss of efficacy. While on treatment, a worsening (progression) of their HAQ 
over time was modelled. 
In many other health economic evaluations of RA therapies, an annual rate of HAQ progression 
is used for patients receiving cDMARDs to account for disease progression. Estimates include 
                                                          
*































0.08 per annum over 5 years,193 0.06 per annum over 3 years,194 and 0.05 per annum over 5 
years.195 However, the challenges with estimating this are well recognised and the clinical 
plausibility is weak, especially for tolerated cDMARDs which can be administered for many 
years.196 In models with a lifetime horizon, it’s common for HAQ with a linear trajectory to 
‘bottom out’ at 3, which is not clinically realistic, and is a health state usually valued as worse 
than death.  
To overcome these limitations, a non-linear growth mixture model was developed by Norton 
et al. using the Early Rheumatoid Arthritis Study (ERAS) inception cohort study (n=1460, 10 
years follow up).197 This model was corroborated using two other datasets.* The growth 
mixture model produced four latent classes of HAQ progression, and the probability of 
membership of each of these classes given the patient descriptors from the DES model. 
Therefore, given the four latent classes, and a patients set of baseline characteristics, the 
expected HAQ at any time point can be estimated. This allowed the growth model to be 
implemented within the DES model. 
The baseline characteristics sampled in the cost-utility model provided the probabilities of 
latent class membership, which when applied to each of the latent classes provided an 
expected HAQ profile for a given patient. This profile was used to estimate the time to a HAQ 
increase over the longer-term. The growth mixture model provided a HAQ profile up to 15 
years. Patients who stayed on a cDMARD for over 15 years were assumed to remain on a 
constant HAQ score (no progressive worsening). 
HAQ PROGRESSION – BIOLOGIC DMARDS 
To estimate the HAQ progression of patients while on a bDMARD treatment, the dataset from 
the BSBRB to estimate the initial HAQ change due to a EULAR response was used. An 
Autoregressive Latent Trajectory (ALT) model was fitted to moderate and good EULAR 
responders.† The model uses baseline patient covariates, including baseline HAQ, to estimate 
both initial HAQ response (6 months) and the longer term progression of a patient’s HAQ in a 
single statistical model. The predictions of HAQ over time, across different EULAR responders 
is provided in Figure 5.4. With no worsening of HAQ observed over the three year time period, 
this assumption was used within the health economic model, for the whole period while on a 
bDMARD therapy. 
                                                          
*
 The Norfolk Arthritis Register (NOAR) and the Early Rheumatoid Arthritis Network (ERAN). 
†
 Full details are provided in the Assessment Group report – viewable here: 
http://www.nice.org.uk/guidance/gid-tag313/documents/rheumatoid-arthritis-adalimumab-
etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumab-review-assessment-





Figure 5.4: Mean HAQ by EULAR response for bDMARD patients 
 
TIME TO TREATMENT WITHDRAWAL 
After the six month response period, patients remain on treatment until they either die or 
withdraw due to a loss of efficacy or adverse event. The BSRBR database was used to estimate 
survival times on treatments, using the dates on which therapies are initiated and ended. 
Separate models were fitted for those patients obtaining good and moderate EULAR responses 
at 6 months. 
A range of parametric survival models were considered, and based on the Akaike information 
criteria (AIC) and Bayesian information criteria (BIC) the generalised gamma distribution was 
selected for moderate EULAR responders, and the log normal distribution for good EULAR 
responders. 
It was assumed that treatment duration would be unaffected by whether or not cDMARDs 
were used prior to bDMARDs. It was also assumed that the treatments included in the BSRBR 
(ETN, IFX, and ABT) would be very similar to the newer bDMARDs being modelled (GOL, TCZ, 
ADA, CTZ). Due to a lack of data regarding duration of treatment for patients receiving 
cDMARDs, it was assumed that the survival duration for each EULAR response category for 
bDMARDs would be applicable to cDMARDs. This may be an unfavourable assumption for 
cDMARDs, which in general are less toxic compared to bDMARDs. 
COSTS 
Direct drug costs were taken from the BNF January 2013 (BNF65). Illustrative costs are 

















Department of Health, which reduces the treatment cost and therefore increases the 
likelihood of a positive recommendation by NICE. These discounts are called a Patient Access 
Scheme. Details regarding the Patient Access Schemes are confidential, and are not applied to 
the treatment costs shown in Table 5.16 for this reason. However, the Patient Access Schemes 
are included in the model and subsequent cost-effectiveness results. 
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Table 5.16: Drug costs for all included treatments 
Treatment Dose regimen Cost per dose
1
 Cost (first 6 months)
2
 Subsequent annual cost 
Abatacept (intravenous) 500 mg below 60 kg, 750 mg between 60-100 kg, 1000 mg above 100 kg; 0, 2 and 4 
weeks then every 4 weeks thereafter 
169.34 (250mg) £6,350.40 £10,886.40 
Abatacept 
(subcutaneous) 
125mg weekly following loading dose 500 mg below 60 kg, 750 mg between 60-100 
kg, 1000 mg above 100 kg. 
169.34 (125mg) £8,796.44 £15,778.48 
Adalimumab 40 mg; every other week £352.14 (40mg) £4,593.45 £9,186.89 
Certolizumab pegol 400 mg per week initially, repeated at weeks 2and 4 weeks followed by a 
maintenance dose of 200 mg every 2 weeks 
£357.50 (200 mg)  £5,440.59 £9,326.73 
Etanercept 50 mg; every week £178.75 (50mg) £4,663.36 £9,326.73 
Golimumab 50 mg below 100 kg, 100 mg above 100 kg, per month £762.97 (50mg) £4,557.82 £9,115.64 
Infliximab
3
 3 mg/kg: 0, 2, 6 then every 8 weeks  £419.62 (100mg) £6,294.30 £8,222.40 
Tocilizumab 8 mg/kg every four weeks 80.38 (80mg) £5,222.40 £11,673.60 
Rituximab
4 
2000mg every 9 months £3,492.60 (2000 mg) £3,492.60 £3,492.60 per dose 
Hydroxycholoroquine
5
 6.5mg/kg per day (max. 400mg per day) £0.17 (400mg) £31.35 £62.70 
Methotrexate 7.5mg per week escalated by 2.5mg per week up to 20mg per week £0.80 (20mg) £19.32 £41.57 
Prednisolone 7.5mg per day £1.07 (7.5mg) £196.25 £392.50 
Sulphasalazine 500mg per day escalated by 500mg per week up to 3000 mg per day £0.79 (3000mg) £131.38  £290.17 
Intensive combination 
DMARD therapy 
Hydroxycholoroquine + methotrexate + prednisolone + sulfasalazine (doses as per 
monotherapy treatments) 
NA  £378.31 £786.94 








Treatment can be daily or weekly. Assumes weight distribution from the BSRBR and choses the least expensive way of meeting the dose requirement. No vial sharing assumed. No PAS schemes 
included. 
2
No administration or monitoring costs included. 
3
Assuming 8 doses in year 1 and 6.5 in subsequent years. 
4
Rituximab provided every 9 months. 
5
Using a BSRBR average weight of 73kg for 
illustration. 
6




As well as direct drug costs, administration costs and monitoring costs were included. Infusions 
were assumed to cost £154, as reported in TA247.198 It was assumed that 10% of subcutaneous 
injections would require administration by a district nurse, costing an average administration 
cost per subcutaneous injection of £2.61. 
Monitoring of treatment toxicity was assumed equal between cDMARDs and bDMARDs. The 
monitoring costs assumed are provided in Table 5.17. 
Table 5.17: Monitoring costs 








Cost £23 £33 £33 £333 £1283 
Methotrexate: pre-treatment 1 1 1 1 1 £170 
Methotrexate: first 6 months 10 0 10 0 10 £1,700 
Monthly monitoring 1 0 1 0 1 £134 
1FBC = Full Blood Count, 2ESR = Erythrocyte Sedimentation Rate 
3NHS Reference Costs 2012. 
 
It is plausible that hospitalisation costs increase as HAQ increases, due to diminished functional 
ability, and damage to joints requiring surgery. Values of the cost per HAQ value were taken 
from the Norfolk Arthritis Register (NOAR), and their number of inpatient hospital stays and joint 
replacement surgeries.* These values are provided in Table 5.18. 
Table 5.18: HAQ related costs 
HAQ score Cost 
0.0 – 0.5 £167.41 
0.5 – 1.0 £102.54 
1.0 – 1.5 £364.68 
1.5 – 2.0 £523.68 
2.0 – 2.5 £1,246.26 
2.5 – 3.0 £2,687.97 
                                                          
*
 http://www.nice.org.uk/guidance/indevelopment/gid-tag313 - data used from Roche submission.  




Utility values were estimated each time a HAQ change was simulated. By taking the time 
between two HAQ changes, the associated utility values were used calculate QALYs via the 
trapezium rule.  
To estimate utility values, a mixture model developed and published by Hernandez et al. was 
used in the DES model, which estimated utility as a function of HAQ, HAQ2, pain, age, age2 and 
gender.199,200  All of these variables were tracked in the discrete event simulation, apart from 
pain. Pain was estimated from an independent model based on HAQ. Many models estimate 
utility from only HAQ, but the evidence from Hernandez et al. shows that pain is a significant 
independent predictor of HRQL.199,200 
Hernandez et al. fitted the mixture model to data from a US observational database with over 
100,000 observations. The model for pain based on HAQ score was developed using the ERAS 
dataset, and over 13,357 observations. The model is quadratic in HAQ, with HAQ and HAQ2 the 
dependent variables to determine pain. 
This two-step approach of calculating pain based on HAQ, and then utility based on HAQ, pain, 
age, involves significant calculations at each HAQ change event. These events can occur 
frequently when HAQ progression rates are high. This is potentially inefficient for the patient 
level simulation. 
UNCERTAINTY 
Parameter uncertainty was quantified using PSA. This involved assigning probability distributions 
to parameters and undertaking Monte Carlo sampling from these. Repeated sampling reduces 
the Monte Carlo error and allows the estimation of the expected costs and QALYs, and also the 
quantification of parameter uncertainty via Cost Effectiveness Acceptability Curves and the 
probability of being cost-effective given a particular ICER threshold. 
As noted above, many parameters were the coefficients from econometric models. Where 
possible, multivariate normal distributions were assumed for correlated parameters, otherwise 
independent normal distributions were assumed  
Costs were known with certainty and therefore not subject to probabilistic sensitivity analysis, 
and the short term effectiveness probabilities from the network meta-analysis were sampled 




Numerous methodological and structural changes were tested using scenario analyses. These 
included using alternative methods to estimate utility values, using EULAR data only (rather than 
including mapped EULAR from ACR trials), various inclusions and exclusions of particular 
heterogeneous trials, and alternative discount rates. 
 
5.6 MODEL RESULTS AND DISCUSSION 
MODEL RUN TIME AND CONVERGENCE 
The model was found to provide relatively stable ICERs at between 3,000-5,000 patient 
simulations (see Figure 5.5). Two tests of 10,000 simulation patients was undertaken, with a 
difference of approximately £1,000 per QALY in the ICERs from the tests. 10,000 patients were 
simulated (taking approximately 1 hour) for the severe population, and 1,000 patients were 
simulated for the moderate-severe population (also taking approximately 1 hour, due to the 
high amount of resampling to identify an eligible patient). For the PSA, 1,000 patients were 
simulated for the severe population, and 100 for the moderate-severe population, and 100 
probabilistic samples were evaluated. This resulted in PSA taking approximately 10 hours to run. 
Undertaking more simulations was not feasible due to the large number of models to run and 
the time constraints of the NICE appraisal. 
 
Figure 5.5: Discounted ICER of bDMARD sequence compared to non bDMARD sequence in 




The full results are published online and for that reason they are not replicated here.* Also it 
should be noted that the appraisal is still ongoing, and therefore the results may change if the 
committee requests changes to the analysis, and future publications from this appraisal may 
have different results. A summary of the deterministic and probabilistic basecase results and key 
scenario analyses is provided in Table 5.19 to Table 5.22. 
The ICER for bDMARD treatment in Population 2 (severe RA) is approximately £60,000 per QALY 
gained. In Population 3 (moderate to severe RA) the ICER increases to over £70,000 per QALY 
gained. If a patient cannot have MTX, then the ICER increases further (Table 5.20), to 
approximately £90,000 per QALY gained. 
The ICER for Population 1 is £300,000 per QALY gained in patients who can receive MTX (Table 
5.21), and £400,000 per QALY gained in patients who cannot receive MTX (Table 5.22). 
The key parameter within the model that significantly affects the estimated ICER is the method 
used to estimate HAQ progression whilst on cDMARD therapy. If a linear progression rate is used 
(as per previous NICE appraisals), then the ICER falls significantly. The ICER for Population 2 in 
patients who can receive MTX falls to approximately £37,000 per QALY gained (Table 5.19). 
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Basecase Scenario analysis 
 RCTs with 
small %age of 
bDMARD prior 
use , adequate 
MTX-history 
RCTs with small 






























EULAR ERAS £61,200 £61,400 No data No data £49,700 £39,500 £62,200 £73,700 £61,700 
Linear £37,900 £36,300 No data No data £32,400 £22,300 £38,300 £46,300 £37,600 
ACR ERAS £62,200 £62,200 £62,600 £68,900 £49,700 £39,500 £62,200 £73,700 £62,700 






EULAR ERAS £75,000 £74,200 No data No data £53,400 £46,600 £78,100 £87,300 £76,800 
Linear £37,500 £36,600 No data No data £31,300 £21,800 £39,300 £48,300 £35,800 
ACR ERAS £77,100 £77,500 £77,300 £79,200 £53,900 £48,300 £79,800 £89,300 £79,000 
Linear £38,000 £36,700 £38,000 £39,200 £30,000 £21,800 £39,100 £46,700 £38,400 











Basecase Scenario analysis 
 RCTs with 
small %age 
of bDMARD 




RCTs with small 































EULAR ERAS £87,600 £89,000 No data No data £71,600 £58,200 £89,100 £107,000 £88,400 
Linear £39,600 £38,000 No data No data £34,800 £24,800 £40,200 £49,200 £39,100 
ACR ERAS £94,800 £93,900 £99,600 £94,700 £79,000 £64,700 £97,200 £117,400 £90,000 






EULAR ERAS £104,800 £108,100 No data No data £74,400 £65,100 £108,700 £121,900 £105,400 
Linear £41,400 £39,300 No data No data £32,800 £23,900 £41,600 £49,700 £41,700 
ACR ERAS £106,400 £107,900 £110,500 £107,900 £77,200 £70,000 £105,900 £120,300 £108,200 
Linear £38,800 £38,500 £38,000 £37,200 £31,100 £23,800 £40,500 £47,100 £39,600 











Baseaase Scenario analysis 
 RCTs with small 
%age of MTX 
prior use 
Malottki mapping 





Impact of AEs 
assumed to be 100-
fold higher 
Relationship between HAQ 










ERAS £308,700 £571,700 £214,800 £185,000 £326,100 £344,800 £295,700 
Linear £296,300 £432,800 £216,400 £192,900 £323,600 £344,700 £296,700 
All numbers rounded to the nearest £100. 
 






Basecase Scenario analysis 
 RCTs with small 
%age of MTX 
prior use 
Malottki mapping 





Impact of AEs 
assumed to be 100-
fold higher 
Relationship between HAQ 










ERAS £414,700 £140,418 £340,500 £295,400 £382,000 £438,700 £404,500 
Linear £378,000 £139,800 £357,700 £291,200 £375,300 £460,000 £408,800 






This chapter reports the development of a health economic model for the NICE MTA of 
bDMARDs for RA. The chapter details the NICE appraisal process and decision problem for this 
particular MTA. It reports how the health economic model was conceptualised and developed, 
before provide the basecase results from the evaluation. 
The MTA continues to be in development. After the first appraisal committee meeting in 
October 2013, the standard NICE process would be to publish draft guidance in the form of an 
Appraisal Consultation Document (ACD). This guidance would be subject to stakeholder 
comments and review, and often the manufacturers and assessment group are requested to 
undertake further analysis. The committee would then meet one or more times to develop the 
final appraisal document (FAD), which provides the final published guidance.  
Instead, an ACD has not yet been published. The ICERs initially reported in the analysis by the 
assessment group (at least £60,000 per QALY for bDMARDs) were above the normal NICE 
threshold. Following these figures through to a natural conclusion would lead to NICE 
reversing their original decision to recommend bDMARD therapies for funding by the NHS. 
Instead, NICE recognised that the key sensitivity in the model estimates was the growth model 
used to estimate HAQ progression in cDMARD treatment sequences. 
The previously used linear method of HAQ progression results in an ICER that is more likely to 
see a positive recommendation, whereas a more methodologically robust method of latent 
class growth models resulted in a much higher ICER. The decision was made by NICE to 
temporarily halt the MTA while they requested further independent analysis regarding the 
cDMARD HAQ progression modelling. 
At this time of writing (May 2015), the second appraisal committee meeting is imminent; 
however the delay has meant that the final guidance cannot be reported in this thesis. 
As reported earlier in the chapter, NICE decided at the scoping stage to not include 
downstream sequential treatments within the decision problem for the MTA. The reasons for 
this decision were that the manufacturers did not request an appraisal which focussed on 
sequential or post-bDMARD use of alternative bDMARDs. Also, the existing size of the MTA 
appraisal meant it was not seen as feasible to include an attempt to optimise the treatment 
sequence. 
This raises fundamental questions about the objective of NICE and their appraisal process. If 
‘partial’ evaluations are being undertaken, then inconsistent and potentially sub-optimal 
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guidance will be published. However, on the other hand, if feasible methods exist to inform an 
optimal or near-optimal treatment sequence, then they have the potential to be utilised within 
an appraisal process and make a significant positive impact to the development of NICE 
guidance and the optimal allocation of finite health care resources. 
This thesis is therefore well placed to identify and evaluate how untried methods of simulation 
optimisation may help inform future NICE appraisals and resource allocation decisions. 
It should be noted that the model is relatively slow to run. It was developed in Microsoft Excel 
and requires a large amount of data manipulation to use the right data and parameters for 
every possible patient population and analysis. From experience, Microsoft Excel is many times 
slower than a bespoke simulation software package to evaluate a DES model. Rebuilding the 
model in a bespoke package is likely to be a worthwhile endeavour due to the significant 
speed-up that would be gained. The slowness of the model meant that precise ICERs were not 
estimated, due to persisting Monte Carlo error (noise) at 1,000 to 10,000 patient simulations. 
Therefore the bDMARDs were treated as a class and incremental analyses comparing specific 
bDMARDs were not seen as being robust. A much faster model would allow the evaluation of 
more patients and a more precise estimate of each sequence’s costs and QALYs. 
 
5.8 CONCLUSIONS 
The chapter has highlighted that the process for guidance development used by NICE allows 
the possibility of sub-optimal treatment sequences to be recommended for NHS funding. 
Methods which allow the evaluation of all potential treatment sequences may have significant 
value for the formulation of guidance based on economic evaluation evidence. However, these 
methods need to be appropriate and feasible within the NICE appraisal process. The following 
two chapters with seek to identify and implement a simulation optimisation method to inform 
an economic evaluation of RA bDMARDs. In Chapter 8, the feasibility of these methods within 





















CHAPTER 6: A CITATION PEARL GROWING SYSTEMATIC REVIEW OF THE 
METHODOLOGICAL LITERATURE 
6.1 CHAPTER OVERVIEW 
This chapter reports a systematic review to identify methods which are relevant for a 
treatment sequencing problem. The chapter begins by framing the treatment sequencing 
problem, and defining it as a combinatorial discrete simulation optimisation problem. By 
formally characterising the properties of the problem, the relevance of the methods identified 
can be judged. The systematic review uses citation pearl growing methods.201 This involves 
identifying key references, and undertaking citation and reference searches to ensure all 
relevant literature are obtained. 
The appropriateness of each identified method is judged by a bespoke framework. The 
development and theoretical basis of each method is reported. The practical applicability of 
each method to the treatment sequencing problem is judged. The search methodology is 
pragmatic, and methods are considered even if not identified in the first instance but become 
known during the process of searching, synthesis and reflection. This is to account for the fact 
that the literature is reported across many academic disciplines. 
The chapter provides a range of potential methods which could be taken forward for 
implementation and evaluation in Chapter 7 and Chapter 8. These methods are broad in 
scope: published in different disciplines and applied to a range of combinatorial problems. 
Many methods have only been recently developed, and therefore the evidence to support 
their use is relatively scant. However, there are methods of genuine promise, and numerous 
routes for further research have been identified. Contrastingly, some methods have been 
established for a long time, in particular methods applicable to general optimisation which 
have shown good performance for simulation optimisation methods. The robustness of these 
methods, including simulated annealing (SA) and genetic algorithms (GA), across a range of 
problem contexts has been proven. 
 
6.2 INTRODUCTION 
This chapter contains a systematic search and review to identify relevant methods for finding 
an optimal or near-optimal sequence of treatments in an economic evaluation using DES. 
Section 6.3 describes the methods used to undertake the systematic review, and Section 6.4 
describes the search strategy to identify relevant studies. Sections 6.5 and 6.6 detail how the 
110 
 
quality of the papers was assessed, how data were extracted and how it was synthesised. The 
results of the search are provided in Section 6.7, and Section 6.8 is a narrative synthesis of the 
identified methods. Section 6.9 provides discussion and conclusions, including the implications 
of this chapter for the remaining thesis.  
PROBLEM DESCRIPTION 
When undertaking a systematic review of methods (in contrast to a systematic review of 
evidence), there must be a clearly defined problem for which the applicability of identified 
methods can be evaluated.  
The problem to be addressed within this thesis is how to find an optimal sequence of 
treatments for a chronic condition when a discrete event simulation is required to evaluate the 
objective function for an economic evaluation. The objective function in this case is the net 
monetary benefit (NMB). Maximising net monetary benefit represents the optimal 
configuration of health care resources (treatments) for a particular condition. Therefore this 
problem can be represented as an optimisation problem, where a configuration of treatments 
is sought that maximises NMB. 




Where 𝑥 ∈ 𝑿 represents a vector of input variables 𝑥 from the potentially feasible solution 
space 𝑿. Therefore 𝑥 is a particular permutation of a sequence of treatments from all 
potentially feasible treatment sequences 𝑿. 𝑔(𝑥) is the objective function, which cannot be 
determined directly (analytically or observed), but instead must be estimated via simulation. In 
the case of an infinite number of simulations, the simulation model provides an estimation of 
the objective function 𝑔(𝑥) : 
𝑔(𝑥) =  𝐸𝜔[𝐺(𝑥, 𝜔)] [6.2] 
The performance measure estimated via the simulation model 𝐺(𝑥, 𝜔) is stochastic, with 𝜔 
the randomness exhibited in each run of the simulation. 
For 𝑁 simulation runs (𝑖), the sample average is: 







This can be used as an approximation of the objective function 𝑔(𝑥), as ?̅?(𝑥) → 𝑔(𝑥) for 
𝑁 →  ∞: 
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By the strong law of large numbers (Billingsley 1995) when 𝑁 is sufficiently large, the sample 
average can approximate the objective value 𝑔(𝑥). 
The problem is specifically a discrete combinatorial optimisation problem -the set of available 
sequences (the feasible solution space) may be very large, but it is discrete and finite. The size 
of the feasible solution space (𝑿) is very complex to formally estimate, given the various rules 
regarding the eligibility of the position of each treatment. However, an upper bound (𝑿max) can 
be derived using the following formula for k-permutations of n objects, where k is the length of 
the sequence (up to a maximum sequence length L) and n is the total number of treatments in 








For 12 treatments† this equates to an upper bound on the feasible solution space (𝑿max) of 
over 10 billion unique solutions. 
As discussed in previous chapters, full enumeration and comparison of every possible solution 
(treatment sequence) is not possible when the decision space is large. Therefore this particular 
decision problem requires a method which can find a good enough solution within a feasible 
amount of time, rather than a method that can search every feasible solution to find a true 
optimum. In this instance, whether a solution is good enough is a judgement to be made by 
the decision maker, however methods can look to ensure that the good enough solution 
cannot be improved upon and therefore increase confidence that it is a true optimum. 
 
6.3 METHODS 
The methods for systematically reviewing published health evidence (for example, health 
economic evidence, or clinical trial evidence) are well established.202 The classical approach to 
information retrieval involves matching a search query with the relevant literature. Increasing 
the sensitivity of the search increases the likelihood of finding relevant literature, but at the 
cost of finding irrelevant literature. Refining the specificity of the search will reject irrelevant 
                                                          
*
 (a selection of k objects from a list of n, where k ≤ n), and where the order of selection matters and 
selections cannot be repeated. 
†
 n = L = 12 
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literature, and by increasing the sensitivity and specificity of the search, strive towards the 
‘impossible ideal’ as shown in Figure 6.1. 
 
Figure 6.1: Classical search model (Levay 2012)* 
Systematic reviews of clinical effectiveness literature compare the results of different clinical 
studies and take into account the quality of each study. The quality is judged using an explicit 
framework (randomisation, blinding, allocation etc).203,204 However, a systematic review of 
methodological literature is different from reviewing published effectiveness evidence.202,205 In 
particular, methodological literature may be published in disparate or unexpected fields, may 
have been applied in one particular problem but may be relevant for another, and may be 
difficult in general to identify. Most importantly, there is no ‘gold standard’ that different 
methods can be compared against, and therefore alternative methods must be judged upon 
other factors, such as their theoretical suitability and their practical suitability. In the book by 
Black, Brazier and Fitzpatrick (1998), two chapters are dedicated to the issue of searching and 
reviewing health services research methods: Edwards et al. (1998); and Hutton and Ashcroft 
(1998).202  
The chapter by Edwards et al. (1998) proposes that the review of methods must be considered 
according to an explicit framework, as would be the case with any systematic review of clinical 
research evidence. Also, the authors propose that any search spans a range of academic 
disciplines. Because a systematic review of methodological literature is influenced by the topic 
of interest, there is no ‘best practice’ set of methods or processes for the review. Instead, 
Edwards et al. (1998) propose that any systematic review of methods should be ‘objective’ and 
                                                          
*





The impossible ideal 
- Find everything 






- Find a lot 







- Find some 
- Sift a reasonable amount 
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that the process by which literature are obtained and synthesised should be methodological 
and explicit.202 
Therefore, a framework for this systematic review of methods has been developed. This 
framework contains three key factors of interest. Firstly, it is important to understand whether 
the method was developed specifically for a simulation optimisation context, and also whether 
it was developed for a discrete and combinatorial problem. If the method is an adaptation of 
an alternative method, then it is important to understand how the method has been adapted. 
Secondly, the theoretical basis of the identified method contains the key assumptions, 
limitations and possible biases associated with the method. Understanding these ensures that 
the method is suitable for application within the problem context. Thirdly, the practical 
applicability of an identified method considers how it performs when used to solve a real-
world problem. Although the review is focussed on methodological papers, any applications of 
a particular method that are identified will help inform the suitability of a method in practice. 
These factors are summarised within the review framework in Table 6.1. 
Table 6.1: Framework for the methods review 
Framework factor Issues to consider 
Development What problem was the method originally developed for? 
Has the method been adapted from its original context? 
Was the method designed to address discrete event simulation (DES) 
optimisation?  
Or is it a general optimisation method that could be suitable for DES? 
Theoretical basis How does the method address optimising a DES with a combinatorial 
problem? 
What assumptions does the method require? 
What are the theoretical limitations of the method? 
What are the potential biases associated with the method? 
Practical 
applicability 
Has the method been used to optimise a DES with a combinatorial problem? 
If so, how did it perform? (Speed, optimality, ease of implementation) 
If not, are there any suggestions to its practical applicability? 
 
The use of a bespoke framework for classifying the results and evidence introduces bias, due 
to there being many different ways to classify information. In particular, subjective issues 
regarding the limitations and biases of an identified method may be challenging to classify and 
summarise, and therefore a framework ‘cannot be completely impartial.’202 In an ideal 
situation, multiple researchers would be employed to identify and classify information using 
the predefined framework. However, in this PhD thesis it was not possible to employ multiple 
researchers to ensure that inter-observer reliability was maintained. 
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6.4 SEARCH STRATEGY 
A systematic review of methodological literature may cover a number of different 
disciplines.202 For a systematic review of discrete event simulation optimisation methods for 
combinatorial problems, it is expected that methods may emerge from operational research, 
computer science, mathematics, and other academic areas. Therefore a systematic search 
much be performed across all potentially relevant disciplines. 
Rather than a systematic review of clinical trials, where each trial must be identified, a 
systematic search of methods must identify all appropriate methods, rather than all published 
instances of each appropriate method. Therefore rather than a global search identifying an 
infeasible amount of potentially relevant studies, an iterative search focussing on citations and 
references was assumed to be valid in this instance. Edwards et al. (1998) refers to this 
approach as ‘theoretical saturation’, where an iterative approach is used due to the unknown 
quantity of relevant literature. In this model of searching, methodological topics tend to 
frequently return a large quantity of theoretical articles, and the marginal benefit of adding 
further articles decreases rapidly beyond a certain point. The model focuses on truncating the 
search when new information is not forthcoming, rather than pursuing every last possible 
reference. The model therefore needs a net that is cast wide across many types of literature, 
to ensure that relevant methods are not missed. 
 While the classical approach to searching is perfectly acceptable for a tightly defined set of 
information, they rely on pre-defined queries which suggest that there is a subset of 
knowledge which can be defined as “all the relevant evidence” (see Figure 6.1). More complex 
queries or evidence searches (including ‘dynamic queries’) allow new questions and answers to 
emerge from the evidence. 
This breaks down the process of searching for evidence, and allows reflection and thinking to 
occur based on the documents retrieved before either varying the next search query, or 
deciding that information saturation has been reached. It is also a pragmatic process, which 
avoids an unmanageable volume of results. 
Citation pearl growing is a method of searching citation indexes to iteratively explore the 
published evidence. It is particularly useful where terminology or indexing to categorise 
evidence varies (perhaps across fields or disciplines), which has significant benefits for 
searching methodological articles.205 Pearl growing is similar to qualitative research methods, 
where key documents (called ‘pearls’) are identified and then references citing these 
documents are also reviewed to assess their relevance. However, as with qualitative research, 
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the method relies on the prior selection of key records to begin the search process. The 
process is also dependent on relevant literature being relatively well cited. 
SEARCH 
A search was designed based on specific terms already identified in the topic area. These terms 
were generated from the title, abstracts and keywords of already identified relevant papers. In 
particular, Andradottir’s (2006) review of simulation optimisation via random search review 
paper,206 and Fu’s (1994) review of simulation optimisation.207 These search terms are shown 
in Table 6.2. The electronic search was conducted in March 2014 within the ISI Web of Science 
(ISI WoS) database. All databases within ISI WoS were searched including the Science Citation 
Index and the Social Science Citation Index. ISI WoS was selected due to its excellent coverage 
across the full spectrum of science, including the social sciences, computer science and 
technology. It is an index of over 5000 journals, 54 million records which span 100 years. 
Table 6.2: Search terms 
Search step Search terms Results 
1 TITLE: (optimi* AND simulation) 8,996 
2 TOPIC=(method* OR approach) 51,549,272 
3 TOPIC =(simulation) 3,505,384 
4 TOPIC=(optimi*) 2,138,034 
5 TOPIC: (discrete OR combinatorial) 824,381 
6 #1 AND #2 AND #3 AND #4 AND #5 462 
7 #6 Refined by: DOCUMENT TYPES=(ARTICLE OR REVIEW OR BOOK) 170 
Timespan = All years 
ISI Web of Science database (all databases) 
Search language = English   
INCLUSION/EXCLUSION CRITERIA 
From the search, abstracts of identified papers were screened before ordering the full-text 
papers of relevant citations. The inclusion and exclusion criteria used for the screening of 
relevant papers are provided in Table 6.3. 
Table 6.3: Inclusion and Exclusion criteria 
Inclusion criteria Exclusion criteria 
- Methodological papers relevant to 
the problem formulation 
- Methodological papers which are 
potentially generalisable 
- Papers applying a method to a 
broadly similar problem  
- Papers describing or implementing a method which 
is not relevant to the problem formulation 
- Conference abstracts or editorials 
- Methods not applicable to a simulation approach to 
estimate the objective function 
- Methods for obtaining a local optima 
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- Statistical methods for small problems, or to inform 
the comparison of simulation output 
- Methods solely for multi-objective problems 
- Naïve methods (enumeration, trial and error) 
 
CITATIONS AND REFERENCES 
The identification of papers from the search was confirmed by searching the references and 
citations of each paper. By searching citations, any future development of methods could be 
identified. By searching the references, it allowed the identification of the methods’ origins, or 
alternative methods. This process allowed the set of pearl papers to be finalised. 
 
6.5 QUALITY ASSESSMENT 
A published criterion for critically appraising the quality of identified methods for this review 
was not identified. Therefore the framework presented in Table 6.1 was used as a quality 
assessment tool. The synthesis of each identified method includes a critical appraisal based on 
the application of this framework. 
 
6.6 DATA EXTRACTION AND SYNTHESIS 
Data extraction for the review was based upon the framework presented in Table 6.1, and is 
provided in Table 6.4. Full evidence tables are contained in Appendix B.4. A narrative review 
methodology was used to synthesise the details of each identified methodology. A narrative 
review provides a discussion and summary of a particular topic, and the review framework was 
used to provide a structure to this narrative synthesis. Where identified methods were broadly 
similar (or a modification) then they were grouped together. 
Table 6.4: Data extraction form 
Reference Details 
Development 
What is the method?  
What problem was the method originally developed for?  
Has the method been adapted from its original context?  
Was the method designed to address discrete event simulation (DES) 
optimisation?  
 




How does the method address optimising a DES with a combinatorial problem?  
How does the method work?  
What assumptions does the method require?  
What are the theoretical limitations of the method?  
What are the potential biases associated with the method?  
Practical applicability 
Has the method been used to optimise a DES with a combinatorial problem?  
If so, how did it perform? (Speed, optimality, ease of implementation)  
If not, are there any suggestions to its practical applicability?  
 
6.7 SEARCH RESULTS 
The initial search of the database identified 170 citations. 84 of these citations were excluded 
immediately for not being a full peer-reviewed journal article, or not being English language. 
Of the remaining 86 citations, 49 were excluded and a full list of citations and reasons for 
exclusion is provided in Appendix B.1. 
37 full articles were retrieved for assessment. 21 were excluded and a full list of articles and 
the reason for exclusion is provided in Appendix B.2. The remaining 16 articles (pearls) were 
included in the review, and a reference and citation search was applied to these articles. 16 
citations/references were of interest and full papers were ordered. Nine of these articles were 
excluded, and full details are provided in Appendix B.3. The seven remaining articles were 
added to the original 16 pearl articles. Four reviews were cross-checked to identify any 
relevant articles that may have been missed by the database search.206–209 No relevant articles 
were identified. The full process of sifting and exclusion is detailed in the QUORUM diagram in 
Figure 6.2. 
In total, 23 papers were identified which either developed or applied a method for a 
combinatorial simulation optimisation problem. The references of the 23 studies included in 




Figure 6.2: QUORUM diagram for methods review 
 
6.8 NARRATIVE SYNTHESIS OF IDENTIFIED METHODS 
This section of the chapter classifies and describes the methods identified. For each method, 
the development, theoretical basis and practical applicability to the treatment sequencing 
problem are described in detail. Methods of most relevance to the treatment sequencing 
problem (i.e. a combinatorial problem with discrete parameters and a large, finite decision 
space which is evaluated using a discrete event simulation model) are the focus of this section, 
because these will potentially be taken forward for implementation in Chapter 7. Identified 
methods which are not deemed to be as relevant are described in less detail. The reasons for 
why they are not deemed to be as relevant or appropriate are clearly specified. 
Papers identified from 
database search 
n=170 
Excluded at initial sift (study type 
and non-English language) 
n=84 
Full abstracts retrieved 
and sifted 
n=86 
Excluded at abstract stage (see 
Appendix B.1 for details) 
n=49 
Full articles retrieved 
and sifted 
n=37 
Excluded at full paper stage (see 




Citations and references sifted 
n=16 
Excluded (see Appendix 
B.3 for details) 
n=9 
Citations and references added 
n=7 
Reviews crosschecked and articles 
identified 
n=0 





Full tables reporting data extraction from all 23 studies are provided within Appendix B.4. 
Many of the studies identified used similar methods. Where the methods used overlap across 
studies, then some studies are discussed in less detail than others to avoid repetition. Also, 
many methods for simulation optimisation are variations or applications of established 
optimisation methods which do not require a simulation model for solution evaluation. The 
papers included within this review are methods specifically for simulation optimisation, 
however much of the development or theoretical basis for these methods may come from 
general optimisation methods. Where required, reference will be made to these. 
OPTIMISATION 
Optimisation is the task of making the best decision among various alternatives.55 An 
introduction to optimisation is provided in chapter Section 2.6, and the treatment sequencing 
problem is defined as an optimisation problem in Section 6.2. The treatment sequencing 
problem can be defined as a discrete optimisation problem, as opposed to a continuous 
optimisation problem, because alternative solutions are determined by discrete variables. The 
problem is also finite in size, because there is a limited, albeit very large, set of available 
treatments, providing a finite limit on the number of feasible sequences. The number of 
feasible solutions is defined as the potentially feasible solution space 𝑿, where each potential 
solution is 𝑥 ∈ 𝑿 
The global optima within a feasible search space is the configuration of each design parameter 
which maximises (or minimises) an objective function. There may be one global optimum, or 
many configurations which are all global optima. Local optima represent the best solution 
within a particular local neighbourhood of potential solutions. Figure 6.3 provides a 
representation of a continuous search space which contains local and global maxima, where 
𝑔(𝑥) is the objective function value of vector of input variables 𝑥 from the potentially feasible 




Figure 6.3: Local and global optima 
LOCAL SEARCH FOR OPTIMISATION 
If the feasible search space is small enough, then a brute force (or exhaustive) search 
algorithm can be used to systematically enumerate all possible solutions, and therefore 
identify the optimal.* 
However, many optimisation problems are combinatorial (including the treatment sequencing 
problem), which means that the feasible space of potential solutions is finite (but often very 
large).210 As the size of the problem increases (in terms of number of input variables), the 
computational difficulty of enumerating each solution increases. These problems are 
computationally hard to solve,† and therefore beyond small-sized problems, full enumeration 
is unlikely to be feasible.211 In this situation, a local search method can be applied to identify a 
good enough solution within a feasible amount of time. 
Local search (LS) involves the movement from solution to solution by applying local changes. 
Specifically, LS looks for a nearby solution which is better or as good as the current solution. 
The algorithm continually makes moves to better solutions until no further improvement can 
be found. The key to the performance of LS is the neighbourhood function which determines 
how to identify a nearby solution. Formally, the neighbourhood function is 𝑁(𝑥), where 𝑥 ∈ 𝑿. 
For a minimisation problem, a solution 𝑥, is a local optimum with respect to the 
neighbourhood function 𝑁, if 𝑓(𝑥) < 𝑓(𝑦) for every 𝑦 in 𝑁(𝑥). Neighbourhood functions are 
often problem specific and the performance of a search can be closely related to the 
specification of the neighbourhood function. 
                                                          
*
 More formally, all optima 
†







LS will find a local optimum, but they are unlikely to find a global optima if local optima are 
present. For example a hill climbing algorithm is a very simple form of LS. The algorithm starts 
with a randomly selected solution. Incremental changes to an element of the current solution 
are made until the change produces a better solution, at which point the new solution is 
accepted. The process is then repeated until no further improvements can be found.  
Because only local optima can be guaranteed, many LS methods incorporate modifications to 
overcome this, which allow them to become global search methods. These modifications 
include repeated local search, which just repeats the LS with numerous starting points, or an 
iterative local search, which allows the algorithm to jump to another point in the search space 
when a local optimum is found. Alternative modifications have focused on the ability to 
randomly allow worsening moves to be accepted, a form of stochastic optimisation (more 
detail in the following sub-section). This allows the algorithm to avoid becoming trapped in a 
local optimum and to continue to seek a global optimum. 
SIMULATION OPTIMISATION 
Simulation optimisation was the most commonly used term to present the use of a simulation 
model to evaluate the objective function for an optimisation problem. Andradottir (2006) 
defines simulation optimisation as “…a special case of stochastic optimization where the 
required objective function values g(x) are estimated via computer simulation, and hence 
involve some noise.”206 
Stochastic optimisation is defined as optimisation of a problem where there is random noise in 
the measurement of the objective function 𝑔(𝑥). Somewhat confusingly, stochastic 
optimisation is also used to define LS algorithms where there is a random (often Monte Carlo) 
choice made in the search direction as the LS algorithm iterates.212 As was explored in the 
previous section. 
Many of the identified simulation optimisation methods identified in this review met both of 
these definitions. They used a simulation model to determine an approximate estimate of 
𝑔(𝑥), and they used a stochastic optimisation process which allowed worsening solutions to 
be accepted during the search.  
Many heuristics and search methods are designed for deterministic optimisation. These are 
general optimisation methods, and may be applied to a problem where there is an analytic 
value of the objective function. For example the distances between cities for a travelling 
salesman problem are known. Therefore the objective function value (the total route distance) 
can be calculated with certainty.  
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When used in a deterministic setting, a stochastic optimisation algorithm will return the 
solution identified with the best performance as the ‘best solution’. However, within 
simulation optimisation, it is common for the best performing solution to be attributed to the 
solution with the best sample mean objective value. Simulation optimisation may therefore 
attribute a wrong best solution, due to stochastic or Monte Carlo error. 
With a large combinatorial search space, it is not possible to guarantee that an identified 
solution is the global optimum. In particular, for a stochastic simulation setting, even if the 
search algorithm does visit the true global optimum, there is no assurance that the algorithm 
will correctly identify this, due to the stochastic nature of the objective function. For this 
reason, simulation optimisation methods often have to balance a search/selection trade-off.213 
If there is a fixed computation budget, how to allocate computing resources between 
searching the feasible space for better solutions, and evaluating the performance of each 
solution (via a computationally expensive simulation model) to ensure the search is sensible 
and results are useful for decision-making purposes? 
Taxonomies of simulation optimisation methods are provided in Appendix B.5. 
METHODOLOGICAL STUDIES AND CATEGORIES 
The papers identified represent a body of literature concerning simulation optimisation of a 
combinatorial problem. Finding key methodological papers within this literature was a difficult 
task, because many methods were first developed for optimisation problems without 
simulation required to evaluated performance, or for continuous optimisation problems which 
were then applied to combinatorial problems. Therefore the literature identified studies which 
either applied established methods, or adapted established methods, as well as novel 
methods. Within this review, the development of each discussed method is detailed, including 
the background to established methods where necessary. However, the focus remains on the 
suitability of all methods to our particular treatment sequencing problem, and the practical 
applicability of each method revealed by the reviewed studies. 
The 23 identified studies can be classified into broad method areas and specific method 
categories. This classification is detailed in Table 6.5. These classifications are used to guide the 
narrative review. Where several identified studies are within one class, the review is much 
more detailed, compared with classes with just one study. This is to ensure that the 
differences in approaches and specific details are emphasised, while minimising repetition and 
unnecessary detail. The review provides detail about the background, development and 
practical applicability for each identified method. Details regarding how each method works 
are provided in Appendix B.6. 
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Table 6.5: Methodological studies and categories 





Random search hill climbing A stochastic optimisation method where neighbourhood solutions are 
selected using a probabilistic method. 
Jacobson el al. (1998)
214
 






Balanced Explorative and Exploitative 
Search 
An adaptive random search method where a switch between local and 
global search is incorporated into the algorithm 
Andradottir el al. (2009)
216
 
Convergent Optimisation via Most-
Promising-Area Stochastic Search  
A random search algorithm with a unique neighbourhood function Hong el al. (2006)
217
 





Simulated annealing A stochastic metaheuristic which mimics the annealing process of a 
crystalline solid. 
 
It accepts worsening random moves with a decreasing probability based on 
cooling the ‘temperature’ parameter 
Ahmed el al. (1997)
219
 
Ahmed el al. (2002)
220
 
Alrefaei el al. (1999)
221
 
Ghiani el al. (2007)
222
 
Haddock el al. (1992)
223
 
Lacksonen el al. (2001)
224
 
Rosen el al. (2005)
225
 
Genetic algorithms Population based metaheuristics using crossover and mutation to replicate 
evolution and natural selection 
 
Ding el al. (2005)
226
 
Jun el al. (2010)
227
 
Korytkowski el al. (2013)
228
 
Lacksonen el al. (2001)
224
 
Yang el al. (2007)
229
 
Tabu search A metaheuristic that forbids movement to recently visited (tabu) solutions Azadeh el al. (2010)
230
 
Yang el al. (2004)
231
 
Ordinal Optimisation A metaheuristic to identify solutions with a high probability of being ‘good 
enough’ 
Ho el al. (2000)
232
 
Nested partitions A metaheuristic where the feasible region is partitioned and searching 
focusses on regions of most promise 
Shi el al. (2000)
233
 
Particle Swarm Optimisation A population based metaheuristic where the direction of movement 
through the search space is influenced by the current best solution 
Kuo el al. (2011)
234
 
Hybrid and other methods Averaging framework for simulated 
annealing 
A variation of simulated annealing which records the performance of 
previous solutions to estimate how much simulation effort is required 
Prudius el al. (2012)
235
 
Empirical stochastic branch-and-bound A hybrid method of nested partitioning and branch and bound. Xu el al. (2013)
236
 




Random search methods are a broad class of optimisation techniques. There is a general 
distinction between two main types of random search – traditional random search, and 
adaptive random search. These two types of methods are used to provide the structure in this 
section of the narrative review. Also, random search methods are the foundation for many of 
the metaheuristic methods which will be reviewed in the subsequent section of this chapter. 
Search results 
Two studies were identified which used a traditional random search method for a 
combinatorial simulation optimisation problem.214,215  Four studies were identified which used 
an adaptive random search method for a combinatorial simulation optimisation problem.216–
218,236  
Traditional Random Search 
Development 
Traditional Random Search (RS) methods were in general developed to solve deterministic 
optimisation problems, where there is no uncertainty in the value of the objective function for 
a given solution.206 In particular, they were developed as a gradient free method, which 
enables use for non-differentiable discrete and continuous problems. Early development 
coincided with the development of computers, and Rastrigin is often attributed with the first 
use of the term ‘random search’.237 
Practical applicability 
Two studies have reported the use of RS for a combinatorial simulation optimisation 
problem.214,215 Jacobson et al. (1998) use RS for a discrete manufacturing process design 
optimisation problem.214 They apply generalised hill climbing algorithms which incorporate 
different random variables to determine the selection of an inferior solution. Each random 
variable has a different mechanism for accepting an inferior solution at a particular iteration, 
and these are provided in Table 6.6). For instance, one algorithm is a local search, where the 
probability of accepting a worse solution is always returned as 0. This is in contrast to the 
Monte Carlo search (often called a random walk). Here, the algorithm will always accept any 
neighbouring solution, irrespective of its performance.  
One of the random search algorithms applied is a simulated annealing metaheuristic. However, 
the details are limited and therefore this method is not formally reviewed here, and simulation 
annealing is reviewed within the metaheuristics section of this review. 
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Table 6.6: Jacobson et al. algorithm formulations214 
Generalised Hill Climbing algorithms Parameter(s) determining the acceptance of an 
inferior solution 
Simulated Annealing −𝑡𝑘ln (𝑢) 
Threshold accepting 𝑄𝑘 
Monte Carlo search 1 
Local search 0 
Weibull accepting −𝑡𝑘(− ln(𝑢))
1/∝ 
Where 𝑡𝑘 is a temperature parameter, ∝ is a shape parameter, 𝑄𝑘 is a threshold constant, 
𝑢 = 𝑈(0,1) uniform variable. More details regarding Simulated Annealing provided in the 
Metaheuristics section  
 
The study incorporated three different neighbourhood rules, which are used to estimate a 
neighbouring solution from a current solution. 
The study found that simulated annealing, threshold accepting and Weibull accepting methods 
all found comparable results which were superior to Monte Carlo search and local search. The 
local search results tended to yield higher variance. The first neighbourhood rule was very 
conservative, and took a large number of iterations before the stopping rule was met. The 
third rule was aggressive and often terminated very quickly. The authors conclude that rule 
two provided an acceptable balance between time taken to run, and the quality of the solution 
found. The study is limited in providing information about convergence and stopping rules, 
along with the computational burden of the problem and efficiency of the algorithms. 
However, they conclude quite positively by stating that these results are a useful and practical 
tool for a complex manufacturing sequencing problem. 
Kamrani et al. (2012) use RS for a business process optimisation problem.215 The problem 
involves finding the most beneficial assignment of tasks to agents. Tasks can be defined as 
critical and non-critical, and assignments of workers to tasks must avoid invalidating a pre-
defined work process. In one formulation of the problem, assignment of any task to any agents 
does not affect the flow of the business process, and the Hungarian algorithm is applied.* In a 
separate formulation of the problem, the assignment of tasks does affect workflow, and a RS 
heuristic is applied to solve this. The RS algorithm is specifically a hill climbing algorithm, where 
any improving move is accepted (irrespective of being the best move in the evaluated 
neighbourhood), and no worsening moves are accepted. 
                                                          
*
 The Hungarian method is an algorithm that solves the assignment problem. It was developed by Harold 
Kuhn in 1955, and is named after two influential Hungarian mathematicians - Kőnig and Egerváry 
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The random search method was applied with three initial solutions. The algorithm reached 
near optima after 80 iterations. The relative deviation for a number of problem sizes is less 
than 0.5% from the analytically proven optimal value. The authors noted that the algorithm 
showed good performance in their problem context, but is not generalisable to combinatorial 
problems outside of assignment problems. This is because it applies rules based on a 
determination between critical and non-critical tasks in the problem. The optimisation process 
is one relatively minor component of the overall study, and therefore specific details are 
relatively brief. 
Adaptive Random Search – Introduction 
Adaptive Random Search (ARS) is a search method which is designed to address the limitations 
of having a fixed neighbourhood structure. In particular, when an algorithm revisits a solution, 
the candidate solutions are drawn from the same neighbourhood. ARS looks to change the 
neighbourhood structure based on information generated during the algorithm process. With 
an ARS, the neighbourhood will in general shrink as information regarding the objective 
function is gathered. In particular, many problems will have a cluster of good solutions within 
an particular area. Algorithms with an adaptive neighbourhood structure will often perform 
better than those with a fixed neighbourhood structure.217 
The method was initially developed for continuous optimisation problems, and research 
involved experimenting with neighbourhood structures (then referred to as ‘variable step 
sizes’) throughout the 1960s and 1970s. Schumer and Steiglitz developed the ‘Adaptive Step-
Size Random Search’,238 which was extended by Kregting and White and their ‘Adaptive 
Directional Random Search’.239 
Search results 
Three studies used an adaptive random search method for a combinatorial simulation 
optimisation problem.216–218 One study developed the Balanced Explorative and Exploitative 
Search (BEES) framework.216 The two remaining studies report the development and 
application of the Convergent Optimisation via Most-Promising-Area Stochastic Search 
(COMPASS) adaptive search method.217,218 
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Adaptive Random Search – Balanced Explorative and Exploitative Search (BEES) 
Development 
The BEES algorithm was developed by Andradottir & Prudius,216 with the aim of providing 
almost surely* convergent random search algorithms which are simple and general enough to 
provide applicability to a range of combinatorial simulation optimisation problems.216 
Practical applicability 
The algorithms have only be applied to test functions, and not to a real world combinatorial 
simulation optimisation problem. The performance of these algorithms appears to be 
promising, and convergence within a finite search space has been proven by the authors under 
certain conditions. A limitation is that the methods all required user-specified tuning 
parameters (for the deterministic, stochastic and adaptive variants of the Adaptive Random 
Search methods), and these parameters require extensive experimentation. 
Adaptive Random Search – Convergent Optimisation via Most Promising Area Stochastic 
Search (COMPASS) 
Development 
Convergent Optimisation via Most-Promising-Area Stochastic Search (COMPASS) is a random 
search algorithm with a unique neighbourhood function. It was developed by Hong & Nelson 
(2006).217 The method is therefore relatively new and unproven, but has already garnered 
interest in the simulation optimisation field.240 
Practical applicability? 
In the original paper by Hong & Nelson (2006), the algorithm was applied to an assemble-to-
order manufacturing problem, and not to a combinatorial simulation optimisation problem.217 
This particular problem uses mixed value decision parameters and therefore is not strictly 
included within the parameters of this systematic review. However, the algorithm showed 
good performance within this particular problem type.  
Huang et al. (2012) applied the COMPASS algorithm to a vehicle allocation problem. The 
application was for the purpose of testing the method, rather than solving a real work 
problem. The problem is to maximise the throughput of vehicles through an intrabay system 
for semiconductor manufacturing. 11 vehicles can be allocated to 10 intrabay systems. As the 
algorithm iterates, the same size for each solution in the visited-solution set is increased. This 
increases the precision of the objective function estimates. From an initial solution, an extra 10 
                                                          
*
 Almost sure convergence implies that the probability of convergence on a target value (the global 
optima) is 1. 
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designs are sampled. The best solution is selected and the algorithm iterates. The algorithm 
converges to the optimal solution after only 30 iterations of the algorithm. 
A limitation of the study is that the feasible space is not constrained, and therefore the 
simulation model is simplistic and not applicable to the real life problem the authors look to 
solve. Also, little information is given about the relative efficiency of the method, against other 
more established search algorithms. 
METAHEURISTICS 
The majority of methods identified fall under the category of metaheuristics. These methods 
are summarised within this section. To define a metaheuristic, a definition of a heuristic is 
required. 
A heuristic is simply a method of finding a solution to a particular problem. They are designed 
for a specific problem type, and exploit the particularities of a problem which enables a more 
efficient search for a solution. A heuristic may require the trading off between the time it takes 
to execute, and the accuracy of the solution found. Heuristics may be compared to exact 
methods. While an exact method may guarantee a proven optimal solution within a finite 
period time, in reality this time may be prohibitively large. Instead, heuristics are developed to 
find a ‘good enough’ solution within a ‘small enough’ period of time.241 
An example of a heuristic is the greedy algorithm, which simply selects the optimal local choice 
at each stage of the algorithm. For example, the classic travelling salesman problem (TSP) 
requires the shortest possible route between a network of cities to be found. Each city must be 
visited exactly once and the route must end where it begins (e.g. a closed loop). A greedy 
algorithm will select the optimal local choice, which in the case of a TSP is the nearest 
unvisited city. Because TSP is an NP-Complete problem*, the optimal solution for a relatively 
small problem is intractable. The greedy algorithm cannot guarantee to find the optimal 
solution, but by finding a ‘good enough’ solution, it is commonly applied in many situations.242  
Metaheuristics are problem-independent techniques which may not guarantee an optimal 
solution. In contrast to heuristics, metaheuristics are not specific to any particular problem. 
Instead, they offer the capacity to be applied to a wide range of problem types. Metaheuristics 
are a higher-level procedure, meaning they ‘…provide a set of guidelines or strategies to 
                                                          
*
 NP-Complete is a computational complexity theory classification for particular decision problems. NP-
Complete problems are both NP and NP-Hard, where NP refers to ‘nondeterministic polynomial time’. A 
particular characteristic of these problems is that no fast solution is known, because as the input size 
increases, the algorithm time required is superpolynomial (for example, exponential).   
129 
 
develop heuristic optimisation algorithms.’241 Metaheuristics are therefore guidelines to follow 
when designing a search method to solve a particular optimisation problem.  
Because metaheuristics look for a good enough solution within a relatively small period of 
time, they are not subject to combinatorial explosion, where the time required for an 
algorithm to find an optimal solution for an NP-hard problem increases exponentially with the 
problem size.  
All metaheuristics can be defined on the basis of five components: 
1. Representation 
2. Evaluation function 
3. Neighbourhood relation 
4. Search process 
5. Mechanism for escaping from local optima 
Representation 
The representation (or encoding) of a particular solution is fundamental to metaheuristic 
methods. Metaheuristics require a solution to be contained as an object within the computer 
program. It must be possible to manipulate the object using the different operators applied by 
the metaheuristic. Binary encoding, integer encoding, and permutation encoding are all 
common representation types for combinatorial problems, with different types being more 
appropriate for particular problems. For example, binary encoding may be more appropriate 
for knapsack and Boolean Satisfiability (SAT) problems, where a decision variable is yes/no, 
include/exclude. Integer encoding may be more appropriate for an assignment problem, 
where the value and order within a solution may represent tasks and resources applied for 
each task. Permutation encoding may be more appropriate for TSP and sequencing problems, 
where the order of elements (cities) is implied in the solution, and each element (city) is 
uniquely represented by an integer. The representation of a solution must retain the ability for 
the metaheuristic to change the solution, but also be coded efficiently. 
Evaluation function 
The evaluation function provides an indication of the quality of alternative solutions, and 
allows better and worse solutions to be distinguished. Many metaheuristics require the 
magnitude of change in competing solutions to be estimated (that is, precise estimates of the 
performance of two solutions to allow an accurate estimate of the difference), but some 
methods can work based on ordinal ranking of solutions (see the Ordinal Optimisation 
section). There may be single or multiple objectives within the optimisation problem which 
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each require evaluation. The evaluation function may be exact, or it may be approximated (e.g. 
approximation models) or estimated (e.g. simulation models). 
Neighbourhood relation 
The neighbourhood is a set of solutions that can be reached by a simple operator (often 
defined the ‘move operator’). If 𝑿 is the solution space, and 𝑥 ∈ 𝑿 a particular solution, then 
the neighbourhood function for 𝑥 ∈ 𝑿 is denoted 𝑁(𝑥). Neighbour solutions are expected to 
provide similar solutions in terms of their performance. However, for discrete problems this is 
rarely the case, and therefore the neighbourhood relation requires particular consideration 
given the problem type and method of representation. 
With a binary representation of a solution, a neighbourhood function may be flipping of one 
bit in the solution array (called a ‘bit flip’). The neighbourhood size is equal to the solution size. 
Representations and common move operators are demonstrated in Table 6.7, along with the 
corresponding neighbourhood size. 
Table 6.7: Neighbourhood size and move operators 
Representation Example Details Neighbourhood size 
Binary representation 10010  00010 Flip one bit in the 
solution vector 
Binary vector of size n, 
neighbourhood size of n 
Integer representation 57664  27664 A discrete value 
replaced by 
another character 
in the set 
If set of size k, and vector 
size n, then 




51432  15432 Swap two 
adjacent 
elements 
Permutation size n, 
neighbourhood size n-1 
Insertion 
operator 
51432  54312 Select an element 
and insert in 
another position 
Permutation size n, 
neighbourhood size n(n-1) 
Exchange 
operator 
51432  51234 Two selected 
elements are 
swapped 
Permutation size n, 
neighbourhood size n-1 
Inversion 
operator 









The search process within a metaheuristic represents the lower-level heuristic (a perturbation) 
chosen to determine a step to a neighbouring solution. Alternative processes include ‘best 
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improvement’, where all neighbouring solutions are evaluated and the step with the best 
improvement (steepest descent/ascent within the neighbourhood) is accepted. Also 
commonly used is a ‘first improvement’ (gradient descent/ascent) process, where 
neighbouring solutions are evaluated and the first solution to offer an improvement is 
accepted. Finally, a random selection process can be used, where any neighbouring solution is 
selected at random, irrespective of if it is an improvement.  
It is important to note that the best improvement search process will find the local minimum, 
but it requires all possible solutions in the neighbourhood to be evaluated before the 
algorithm can iterate to that identified best solution. For a metaheuristic, it is important to 
balance the search process between exploitation of the best solutions found (referred to as 
intensification around a local optima) and exploration of the whole search space 
(diversification). A search process which is extreme in terms of intensification will only accept 
an improving solution, whereas a process extreme in terms of diversification will accept any 
solution.  
Mechanism for escaping from local optima 
There are two broad approaches to avoid an algorithm being trapped within local optima. The 
first is to repeatedly restart the algorithm with alternative starting points/solutions. The 
second is to allow moves to inferior solutions to be accepted. Allowing non-improving moves 
allows the search to escape a local optima, and this is often achieved by introducing a 
stochastic process which allows a non-improving move to be accepted with a given probability; 
and these are therefore a subset of stochastic optimisation methods. A deterministic algorithm 
will always find the same solution with a given starting solution. However, a 
probabilistic/stochastic algorithm may report a different solution from an identical starting 
solution.  
Memory and solutions 
There is a distinction between metaheuristics which require a memory of previously visited 
solutions, and those which only require the current best solution. Tabu search and particle 
swarm optimisation are two methods with a memory based structure to the algorithm, and 
use the memory of previously visited solutions to guide the algorithm through the search 
space. 
Also, in each iteration of a metaheuristic algorithm, there could be a single solution being 
considered, a population of solutions, or a set of local neighbouring solutions. These 
differences have important implications for the success of the algorithm, as well as the 
computational burden. Single solution searches include simulated annealing and tabu search, 
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population searches include genetic algorithms and particle swarm optimisation. Nested 
partitioning is a metaheuristic focussed on searching a current best neighbourhood/set. A 
table of methods classified by their memory structure and search type is provided in Table 6.8. 




No memory Memory 
Single Simulated Annealing, 
Greedy randomised adaptive search procedure 
Iterative local search 
Tabu Search 
Population Genetic and evolutionary algorithms Particle Swarm optimisation 
Ant Colony optimisation 
Set Nested partitioning - 
 
Search results 
Metaheuristics emerged from the search as the predominant class of method for simulation 
optimisation problems. 16 of the 28 (57%) identified studies were metaheuristic methods. Of 
these 16 studies, seven (44%) were simulated annealing methods, and five (31%) were genetic 
and evolutionary algorithms. See Table 6.5 for the full breakdown of studies and method 
types. 
It is important to note that none of the metaheuristic studies identified for simulation 
optimisation of a combinatorial problem were specifically new methods designed especially for 
the problem. In fact, the majority of studies were applications of established metaheuristics, 




The original genetic algorithm as defined by Holland et al. is now known as the simple genetic 
algorithm (SGA).243 Alternative and newer GAs and evolutionary algorithms (EAs) use 
alternative operations within the algorithm, but the concept is broadly similar. The method 
was not specific to simulation optimisation, but was developed as a metaheuristic with broad 
applicability to a range of optimisation problems. Very quickly, GAs became widely researched 




Five studies reported the use of a genetic algorithm for a combinatorial simulation 
optimisation problem.224,226–229 
Ding et al. (2005) apply a genetic algorithm to a supply chain simulation model with a single 
objective.226 Binary encoding was used and elements of the array represented supplier 
utilisation, assignment weight and replenishment level. The algorithm used roulette wheel 
selection and two-point crossover. Fixed probabilities for mutation and crossover were applied 
and an elitist selection strategy incorporated. Two limitations of the approach were that the 
algorithm stopping rule was simply after a predetermined number of iterations (500), and 
penalty factors were used to account for constraints being broken. These constraints were not 
encoded out and therefore represent inefficiency within the algorithm. However, the 
simulation model only took 1 second to run, and therefore the algorithm terminated after a 
few minutes. Convergence was identified after 100 iterations in their particular problem. 
Jun et al. (2010) report a modification to the SGA approach which incorporates an orthogonal 
quantized crossover operator.227 This method was originally designed for continuous 
optimisation, however it is discussed as applicable for combinatorial problems but it is not 
implemented in a simulation optimisation problem, and therefore the methodology proposed 
is theoretical at this stage.  
Korytkowski et al. (2013) apply a genetic algorithm to a dispatching problem, with four 
independent objectives considered.228 Integer encoding was used and a combination of 
roulette wheel and tournament selection applied. Two point crossover and mutation were 
applied with predefined probabilities. Elitist selection was applied and the algorithm stopped 
when the best solution stabilised. The algorithm reached a stop condition after 10.5 hrs 
(~36,000 iterations). For its four criteria of interest, the algorithm converged and the authors 
conclude that a near optimal solution was found after an acceptable time. 
Lacksonen et al. (2001) applied a genetic algorithm (along with three other optimisation 
algorithms) for four buffer-size problems.224 The study therefore provides a useful comparison 
of alternative methods across four different problems. However, because of this, full details 
about the genetic algorithm are not reported. The authors found that the size of the problem 
had a significant effect on the success of all methods (pattern search, simulated annealing, 
simplex method) apart from the genetic algorithm. The other three methods had poor results 
when the problem size increased, however the GA require significantly more replications to 
achieve the better result. The authors suggest that GAs have a clear trade-off between 
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accuracy and speed. Good solutions were generally found after 1000 replications; however this 
is problem-specific. 
Yang et al. (2007) applied an evolutionary algorithm to a parallel-machine scheduling 
problem.229 Real encoding of the solution was used, and roulette wheel with elitism applied for 
selection. Two-point crossover and mutation was undertaken using a predefined probability. 
Stopping criteria was a fixed number of iterations. The algorithm was found to be robust for 
alternative tuning parameters (crossover and mutation rates) and starting populations. 
However, the authors raised concerns about the computational efficiency of the algorithm; the 
algorithm took 2 hours to execute.  
None of the identified studies were concerned with a combinatorial sequencing problem, and 
therefore there was no permutation encoding of the solutions. Along with the encoding of the 
solution, the methods identified required tuning of the crossover and mutation parameters, 
the selection of the starting population, and the rules for terminating the algorithm. These 
user-defined aspects to the method introduce potential biases. However, there is an 
established body of literature outside of simulation-optimisation to ensure the GA is 
developed correctly and these parameters are unlikely to require special attention due to the 
evaluation of the objective function requiring a simulation. 
None of the studies fully consider how constraints and infeasible solutions are accounted for. 
Ding et al. (2005) use penalty functions which are applied to the output of an infeasible 
solution.226 This is an obvious inefficiency and it is likely to be much quicker to encode out 
infeasible solutions rather than simulating a solution and penalising it. 
Across most studies identified, convergence of the algorithm was identified after a few 
hundred iterations of the GA. It is not clear how relevant this may be to the treatment 
sequencing problem, but it provides an indication of the computational burden that GAs 
generally require. Lacksonen et al. (2001) and Yang et al. (2007) both report concerns about 
the efficiency of genetic algorithms.224,229  
The recognised strengths of GAs are that they are a good method for combinatorial problems, 
and the population approach balances exploration and exploitation, generally achieving 
convergence to near optima and avoiding early convergence. User-defined tuning of the 
algorithm is required, but there has been much research outside of simulation-optimisation to 
inform this. 
The limitations identified include the concerns from two studies that the algorithm is slow. 
Also, no study used a permutation representation of the permutation, which is more complex 
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to apply mutation and crossover. In theory, the stochastic nature of a simulation model is likely 
to cause problems to the traditional stochastic selection process such as roulette-wheel. 
Although some authors used tournament selection, it was surprising that there was not more 
discussion regarding this within a simulation-optimisation context. 
Simulated annealing 
Development 
Simulated annealing (SA) is a local search metaheuristic with the capacity to escape from local 
optima. The term ‘simulated annealing’ is an analogy to the process of annealing within 
crystalline solid. A solid is heated and then allowed to very slowly cool so that a crystalline 
structure of superior structural integrity remains.247 The stochastic acceptance mechanism of 
SA is a generalisation of the Metropolis algorithm, which is a method of sampling a Boltzmann 






𝑝(𝛿𝐸) = probability of an increase in energy by 𝛿𝐸 
𝑇= temperature 
𝑘= Boltzmann’s constant (from the law of thermodynamics) 
Box 6.1: Metropolis algorithm 
The Metropolis algorithm requires a control parameter, called the ‘temperature’. SA allows the 
temperature parameter to be slowly cooled as the algorithm iterates, and this cooling rate is a 
key determinant of the success of the SA algorithm. This method was applied to solving 
combinatorial optimisation problems by Kirkpatrick et al. (1983) and Černý et al. (1985).249,250 It 
has now become one of the most widely used metaheuristics in combinatorial optimisation. A 
key development by Belisle (1992) was the development of a generalised SA algorithm which 
contained a heuristic temperature cooling schedule.251 
The method has been mathematically proven to converge on a global optimum, even in multi-
modal, discontinuous and noisy functions. A good discussion and summary of the proofs and 
conditions of convergence can be founded in Henderson et al. (2003).247  
How does it work? 
The original SA algorithm begins with an initial solution, typically determined at random. At 
each iteration of the algorithm a neighbouring solution is selected (either at random or some 
other low level heuristic). If the neighbour is better than or equal to the current solution, it is 
selected as the current best. If the neighbour is worse, then it is selected with a probability 
determined by the difference in objective values between the two competing solutions, and a 
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temperature parameter determined by the current number of algorithm iterations. The 
acceptance criterion is formally stated below in Box 6.2. 




] , if 𝑔(𝑥′) − 𝑔(𝑥) < 0
1, if 𝑔(𝑥′) − 𝑔(𝑥)  ≥ 0
 
Where: 
𝑥′ is a solution in the neighbourhood of 𝑥 
𝑡𝑘 is the temperature parameter at iteration 𝑘 such that: 
𝑡𝑘 > 0 for all 𝑘  
Box 6.2: Simulated Annealing acceptance criterion 
The probability of accepting a worse solution is based on Boltzmann’s law of thermodynamics, 
analogous to the annealing process that underpins the SA methodology. As with annealing, the 
SA algorithm begins with a high temperature (a higher probability of accepting a worsening 
move). This allows the algorithm to move out of local optima, especially in the early iterations. 
As the algorithm iterates, the temperature is gradually reduced based on a cooling schedule. 
This allows the algorithm to gradually focus on an area within the search space where a near 
optimum can be found. 
A recognised advantage of the SA algorithm is the relatively small number of parameters which 
need to be modified (tuned). The initial solution and the neighbouring feasible solution can be 
randomly selected. The two key parameters within the algorithm are the initial temperature, 
and the temperature cooling schedule. The stopping criteria for the algorithm are often based 
on either a maximum number of iterations, or when an improvement is not seen for a number 
of iterations. 
However, the tuning of the temperature value and cooling schedule is absolutely crucial to the 
success of a SA application. A large temperature value evaluates to a probability of one within 
the acceptance criteria for accepting an inferior move – resulting in a random search. 
However, a small temperature value results in a standard local hill climbing algorithm, because 
the probability of accepting an inferior move is zero. Therefore the tuning of this parameter is 
important to ensure a balance between exploration and exploitation. 
Three main cooling schedules have been the focus of much research involving SA – the 
logarithmic, Cauchy and exponential cooling schedules. Proofs are available which show that 
SA will converge to a global optima when the logarithmic cooling schedule is used.252,253 A 
faster cooling schedule was developed by Cauchy, and proven to converge on a global 
optima.254 An even faster exponential schedule has been often used. Attempted proofs 
regarding its convergence are contentious, however there have been strong arguments for its 
convergence when variables are bounded, which supports its use for discrete and finite 
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optimisation problem.255 Although its theoretical capabilities are unproven, the speed of the 
algorithm is often required for efficient computation and therefore it has been applied for 
optimisation or large problems or those with an expensive simulation.  
Practical applicability 
Seven studies reported the use of simulated annealing for a combinatorial simulation 
optimisation problem.219–225 
Ahmed et al. (1997) applied a slightly modified SA method to three multi-echelon repairable 
item inventory systems. The neighbourhood function was defined as the set that could be 
reached via a single perturbation (one change to the solution). The approach deviated from 
the standard SA, in particular by using the White method to determine the initial temperature. 
This involves computing a number of transitions from a starting solution and estimating the 
standard deviation of the objective value. The initial temperature is then set to this value.256 A 
cooling rate of 0.9 was selected based on the theoretical research by Kirkpatrick et al. 
(1983).257 As per the White method, the stopping criterion for the algorithm was based on the 
final temperature value. There was no modification or consideration of the stochastic nature 
of the evaluation function and how that may influence the performance of the SA algorithm. 
Instead, the authors focus on the fact that their particular problem contains stochastic 
constraints within the search space. However, the results from the study suggest a good 
performance of their SA algorithm. They were able to generate analytical solutions to the 
Markovian system that their problem was related to. In all three test cases the SA algorithm 
found results very close to the analytically proven optima. The authors conclude that the 
algorithm was relatively efficient and viable for their simulation run time and problem size. 
Interestingly, they highlight the problem of using the penalty approach to avoid an infeasible 
solution being the selected as near optima by the algorithm. During early configurations, the 
algorithm selected final solutions outside of the feasible region even when using penalty 
functions. Therefore they encoded the neighbourhood function to ensure that only feasibly 
transitions were accepted. 
In another study by the same research group, Ahmed et al. (2002) present a modified SA 
algorithm which incorporates ranking and selection methods to solve discrete stochastic 
optimisation problems.220 This is called Simulated Annealing with a Ranking and Selection 
procedure (SARS). A mathematical proof for near-guaranteed convergence is provided and 
empirical estimates based on an inventory optimisation problem. 
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Ranking and selection (R&S) is a statistical method for selecting the best result from a 
comparison of stochastic simulation results with a specified level of confidence. Often R&S is 
used when a small set of comparisons are reported by a simulation model. However R&S is 
also able to consider, at each iteration of a simulation model, whether the extra unit of 
computation effort is worthwhile. Therefore R&S minimises the computation effort to reach 
this specified level of confidence. This allows a specification of the number of samples required 
to ensure a desired probability of selecting the best alternative, as well as determining when 
alternatives can be designated as inferior and the simulation terminated. For optimisation, this 
is a very useful method if the search algorithm has already identified some good solutions 
because it provides a method of discarding inferior solutions at an early stage of the 
simulation. Traditionally a frequentist procedure, Chick and Inoue (2001) developed R&S 
procedures based on Bayesian expected value of information methods,258 with good results 
shown in several studies.259,260 
Ahmed et al. (2002) prove that by combining R&S with SA, the sequence converges almost 
surely to the optimum as the simulation runs required to evaluate the solution objective goes 
to infinity.220 However, in practice a stopping criterion is required for the algorithm. 
The algorithm was tested within an inventory problem, where an analytical solution was 
provided. Across eight different case test cases, the algorithm found solutions very close to the 
proven analytical solution. Little detail was given to the practical implications of these results 
and the run time required. The simulation used was relatively simplistic to enable comparison 
with an analytical solution. 
Alrefaei et al. (1999) used a SA algorithm to solve a discrete stochastic optimisation problem. 
They modify the algorithm to use a constant temperature, rather than the standard SA 
approach using a decreasing temperature as the algorithm iterates. This allows the search to 
more freely move within the state. They find that under mild conditions the search converges. 
They also modify the approach to treat the most visited state as the current optimum, rather 
than the recorded ‘current best’ solution. The rationale for these changes is not clearly 
provided. They test the performance of their algorithm in two queuing problems and against 
two alternative SA algorithms. They conclude that their algorithm is superior, with better 
solutions identified, but the performance was dependent on tuning a number of parameters 
(temperature and neighbourhood structure in particular). 
Ghiani et al. (2007) use a SA algorithm to solve a discrete stochastic optimisation problem. The 
focus of their study, rather than proving convergence, is the efficient applicability to numerous 
problems and the ability to parallelise (see later) the SA algorithm to ensure a consistently 
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good result is found in a reasonable amount of time. They also incorporate an indifference-
zone R&S procedure, based on the method by Rinott.261 This method requires an ‘indifference 
zone width’ δ parameter, which selects a solution with expected performance within δ units of 
the optimal performance with a confidence level of 1-δ. The procedure requires a reference 
configuration of samples to calculate the sample mean and marginal sample variance (first-
stage). The second stage involves a number of additional samples of this reference 
configuration to calculate the overall sample means. The number of replications allocated to 
each configuration is proportional to the estimated sample variance in the first stage of the 
procedure, as well as the indifference zone width parameter. 
As mentioned previously, R&S procedures are traditionally only relevant to small sized 
problems with full enumeration possible (although computationally expensive) and they 
require a decision-maker to be ‘indifferent to very similar differences’. Within the Ghiani et al. 
(2007) study, the authors have incorporated the Rinott R&S procedure within the SA algorithm 
in an innovative approach to avoid the traditional R&S limitations. 
The algorithm begins with estimating the Rinott procedure for the initial starting feasible 
solution (randomly chosen). The acceptance criteria are then determined by the estimated 
sample mean from the Rinott procedure for the new neighbouring solution. In practice, the 
process requires the interruption of the simulation model to estimate the first stage sample 
statistics, which informs the number of samples required for the second stage. 
Parallelisation (parallel computing) is where an algorithm or computer process is written so 
that many calculations are carried out simultaneously (as opposed to sequentially).262 If a large 
problem is divided into smaller ones, then these smaller problems can be allocated across 
numerous processors (from single computers, to clusters and clouds) and the total problem 
solved much more quickly. However, the concurrent nature of tasks running in parallel 
introduces complexity, and therefore parallel programming is often much more difficult than 
sequential programming.263 Also, the nature of the SA algorithm does not naturally offer up 
parallelisation solutions, because the standard Metropolis algorithm for acceptance 
“…depends on one or more previous states plus one or more random variables. This serial 
nature of SA is an inherent distraction to parallelization.”264 However, some literature outside 
of simulation-optimisation has attempted to develop parallelised versions of SA, with 
acceptable speed-up gains found.265–267 
Within this study, a master-slave single-thread parallelisation process was incorporated, which 
found significant speed-up gains (between ~2 (2 processors) and ~13 (16 processors) times 
faster than a sequential implementation). However, better solutions were not obtained. Multi-
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thread parallelisation process found slightly superior results (less than 3% on average), but 
much longer computation times was required to achieve this relatively small improvement, 
compared to master-slave single-thread parallelisation. The balance between efficiency and 
effectiveness of search algorithms appears to be a major issue within the parallelisation 
literature, as well as the general metaheuristics literature. 
Haddock et al (1992) used simulated annealing to solve a discrete manufacturing process 
problem. The problem size was small (120 combinations) and therefore it was possible to 
enumerate each solution. The authors found that a more expensive process of multi-restarting 
the algorithm was required to achieve a value which is optimal or near optimal. Otherwise, the 
algorithm was sensitive to different tuning parameter values (initial temperature, number of 
iterations at each temperature, final temperature value). The authors found that the SA 
algorithm identified the global optimum after evaluating approximately 30% of the total 120 
input variable combinations. 
The small problem size limit the conclusions of this study in terms of its relevance; however it 
does suggest that SA can be a reliable method to identify a near optimal solution, in particular 
if a multi-restart method is incorporated. 
Lacksonen et al. (2001) applied a SA algorithm (along with three other optimisation algorithms) 
for four buffer-size problems.224 As mentioned in the genetic algorithm subsection, the study 
therefore provides a useful comparison of alternative methods across four different problems. 
The SA algorithm used was simplistic, and may account for its lack of performance compared 
to the genetic algorithm. The cooling schedule had little justification and it was not clear what 
tuning was applied to each parameter. For each problem size, the SA algorithm was found to 
be inferior to the GA, however the GA required almost double the amount of replications to 
solve. The authors explore the possibility that the problems with the SA algorithm arose from 
requiring different cooling schedules and starting points for each solution. It was not clear why 
this was not conducted to provide a fair comparison between each search method. 
Rosen et al. (2005) applied a SA algorithm to solve a discrete manufacturing process problem. 
The algorithm is a modification of the standard Kirkpatrick et al. SA algorithm.257 The authors 
implement both algorithms to provide a comparison, and find that their modified SA algorithm 
identified either equivalent or superior results in all instances, and usually required a similar 
number of simulation runs. Significant was the finding that the new algorithm was easier to 
tune and in general required fewer simulation runs. 
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The modified algorithm incorporated a linear approximation method to identify an area where 
a solution of high quality is likely to be. These linear approximation methods are adaptations of 
the response surface methods by Box and Wilson.268 The assumption made is that other high 
quality solutions could exist in an adjacent neighbourhood, which is explored using SA. 
Repeatedly iterating this two-phase process using different starting solutions is undertaken to 
find a final best solution. 
Tabu search 
Development 
Tabu search was developed by Glover (1989, 1990) to solve combinatorial optimisation 
problems.269,270 The method is an extension to standard local search hill climbing methods, and 
introduces memory to prevent reversing recently accepted moves. Therefore whenever a local 
optimum is encountered, non-improving moves are accepted because previously visited 
solutions recorded in the memory (the tabu-list) are forbidden. 
Since its development in the late 1980s, the method has a reasonably stable history, with only 
minor modifications to the process of the algorithm and the rules regarding memory structure. 
In the first fifteen years from the method’s development, TS has been applied to combinatorial 
optimisation problems in well over 100 published papers.271 
The development of TS was partially motivated by human behaviour. Glover discusses that 
inconsistent behaviour has often be observed even in similar circumstances and the tendency 
to deviate from a course might both be an error but also an unexpected gain.269 The TS does 
not deviate randomly, but instead supposes that there is no point accepting a poor solution 
unless it is to avoid an already investigated area. 
Tabu search is an example of a computational algorithm with adaptive memory. Adaptive 
memory programming is a growing area of research within metaheuristics and an avenue of 
rich potential.272 
Practical applicability 
Two studies have reported the use of TS for a combinatorial simulation optimisation 
problem.230,231 
Azadeh et al. (2010) develop an integrated process of response surface methodology (RSM) 
and TS to optimise a TS to a discrete production system problem.230 A design of experiment 
analysis is undertaken using the RSM to provide a modelled estimate of the search space and 
objective function. The TS is then applied to these modelled estimates, rather than requiring 
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simulation runs to evaluate the objective function for each solution. There are a number of 
limitations to the study which should be noted. Firstly, the problem size is relatively small, and 
the RSM is fitted for 81 (34) observations, which allows enumeration rather than requiring a TS. 
The TS only required 26 replications to converge, and the neighbourhood structure for three 
competing design factors results in six possible neighbours for each solution. It is not fully clear 
how long the simulation model of the production process requires to achieve a steady state 
estimate of the objective function. A useful comparison would have been to see what 
efficiency saving was made by incorporating the RSM model and whether the results with and 
without (just a simulation-optimisation via TS) identified would differ. The RSM invariably adds 
a level of uncertainty and it is not fully detailed how the model was specified and validated. 
The authors conclude that the methods they follow can be applied for all types of discrete 
production system optimisation which is probably over optimistic given the problem size they 
consider. They also conclude that a global optimum is identified, but no proof is provided. 
Yang et al. (2004) attempt to solve a flow shop with multiple processors (FSMP) problem using 
a TS simulation optimisation method. The FSMP problem involves sequencing jobs in a flow 
shop for processing by more than one identical processing machine. This is a commonly 
observed NP-hard problem in manufacturing and operational research. A discrete event 
simulation model is used to evaluate the performance of each solution, with tardiness the 
objective to be minimised. The TS is separated into two methods, TS1 and TS2. TS1 presents 
the basic implementation of TS as proposed by Glover. TS2 incorporates a long-term memory 
structure to inform the restart procedure of the algorithm. Moves from the current solution 
are undertaken using a pairwise-exchange/swap method. This is a commonly used method to 
construct a neighbouring solution in a permutation-represented problem.273 An aspiration 
criterion is applied so that tabu moves are (re)accepted if they are good solutions. Tabu list 
size is based on previous research which suggests that it is an integer between n/3 and 3n/2 
where n is the problem size.274 The search stops after a defined number of iterations, based on 
the problem size and number of possible swaps, n(n-1). 
The search is run for five different problem scenarios. The authors apply a steepest descent 
pairwise interchange (SDPI) heuristic to solve the problem and provide a benchmark solution. 
Both TS1 and TS2 were a superior search, taking a comparable computational time compared 
to SDPI and finding superior solutions in all five scenarios. In three scenarios, TS1 found a 
better solution compared to TS2. The study represents a good implementation of TS for a 
permutation problem. The high speed of the simulation model results in a final solution being 
found by the TS algorithm within 30 minutes, which represents a good method for solving a 
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practical optimisation problem. The authors do not identify any limitations with the TS method 
that they propose. 
Nested partitions 
Development 
Nested Partitions (NP) is a randomised optimisation framework.233,275,276 The method was 
developed to be applicable to both deterministic and stochastic discrete optimisation 
problems. Immediately after development, the method was applied to two combinatorial 
problems, Shi et al. (1999) for a Travelling Salesman Problem, and Olafsson et al. (2000) for a 
Parallel-Machine Flexible-Resource Scheduling problem.276,277 
Practical applicability 
One study has reported the use of Nested Partitions (NP) for a combinatorial simulation 
optimisation problem.233  Shi et al. (2000) use the stochastic nested partitions method to 
optimise a stochastic travelling salesman problem (TSP).233 The problem is stochastic because 
the time between each city is uncertain, and the total time for each route estimated as the 
average time across each replication of the simulation model. Test problems of size 51, 76 and 
101 nodes were used. The percentage over the optimum for the three problems was 2.77%, 
3.12% and 5.38% respectively, which required 300 iterations of the NP algorithm. This 
performance worsened by approximately 10% when variable noise was added to the 
performance measure of the problem. The authors suggest this is a reasonable amount and 
conclude that the algorithm is relatively robust to noise in the simulation. Convergence to a 
near optimum after 300 replications across three relatively large problem sizes is a positive 
result for the relatively new NP method. 
Ordinal optimisation 
Development 
The development of ordinal optimisation (OO) for simulation optimisation arose because 
making a decision to move within the solution space only requires an ordinal comparison 
between two solutions (𝑔(𝑥1) < 𝑔(𝑥2)) . A precise estimate of the difference between two 
solutions is not required. As stated by Deng and Ho (1999), “It is much easier to determine 
‘order’ than ‘value’”.278  These comparisons are the focus of OO, which was developed by Ho et 
al. (1992).279 In particular, when uncertainty is present then the benefit of an ordinal approach 
over a cardinal approach is even more significant. There is an error possible in simulation 
optimisation because a solution chosen as superior could be inferior due to the uncertain 
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estimate of their performance. This error decreases in probability as the difference between 
two comparators increases. 
It has been shown that ordinal comparison methods converge much more quickly compared to 
cardinal estimation, potentially at an exponential rate with respect to the number of algorithm 
iterations.280 The development of these methods was independent of any particular 
metaheuristic. This is because in all metaheuristics, moves are all based on comparisons 
between solutions and therefore the ordinal comparison approach is relevant to all 
metaheuristics. 
Practical applicability 
One study has reported the use of OO for a combinatorial simulation optimisation problem.232  
Ho et al. (2000) use OO for a buffer allocation problem. A stochastic resource allocation 
algorithm is used with ordinal comparison between alternatives applied. The problem was 
fixed so that the optimal solution was analytically possible to find. The algorithm required only 
approximately 20 iterations to converge on the analytical solution. Even when using the worse 
possible allocations as the starting selection, the algorithm very quickly converged. 
However, there are some limitations to note. Firstly, the problem is simplistic and the 
simulation (6 users for 24 buffer slots) would be extremely fast to run. Secondly, very little 
detail is provided regarding the simulation model and the methods used to apply the OO 
algorithm. 
Particle swarm optimisation 
Development 
Particle Swarm Optimisation (PSO) was developed by Eberhart & Kennedy (1995).281 It is a 
population based metaheuristic with candidate solutions (particles) moving through the search 
space via formulae determining their position and velocity. These formulae incorporate 
information regarding the particle’s own best solution, but also the best solutions of other 
particles in the ‘swarm’ which guide each particle towards good positions within the search 
space. 
PSO was developed as a computer algorithm to simulate the movement of organisms, such as 
birds and fish. The algorithms original objective was to simulate the choreography of swarms 
of organisms, which results in synchronous movement. With particles emulating the success of 
neighbouring particles, the algorithm was found to discover optimal regions within high 
dimensional search spaces. The method was refined and simplified when the objective altered 
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and became focussed specifically on the applicability of the particle swarm algorithm for 
optimisation.282 
Practical applicability 
One study has reported the use of PSO for a combinatorial simulation optimisation problem.234 
Kuo et al. (2011) report using a PSO algorithm for an assembly line problem. They modify the 
standard PSO approach by incorporating a mutation operator which alters similar particles 
(Particle Swarm Optimisation algorithm with Mutation based on Similarity – PSOMS). The 
method also incorporates an inertia weight. They also incorporate two genetic algorithms to 
compare against the PSOMS method. Only very limited information about these genetic 
algorithms is provided which is why they are not formally included in the review. A standard 
PSO algorithm was implemented as well. 
The results showed that PSOMS converged fastest and to the best solution when compared to 
PSO and two GAs. However, the success of the algorithm was dependent on the inertia weight 
parameters. Five evaluations were undertaken and the results varied dramatically by the 
inertia weight used. The PSOMS was also very sensitive to the number of particles used. In 
general, the algorithm improved with higher numbers of particles. The results were also 
sensitive to the learning factor parameters and the mutation parameters. On the whole, the 
PSOMS appears to require the tuning of several parameters and therefore the appropriateness 
of the method must be considered.  
HYBRID AND OTHER METHODS 
Not all of the identified methods for a combinatorial simulation optimisation problem can be 
easily classified. Many of the methods that have been reviewed already are themselves 
modifications of existing methods. Often, particular elements from a method are revised or 
used within a different method, to provide a more appropriate solution to a given problem.  
However, the two methods reviewed in this section, averaging for simulated annealing, and 
empirical stochastic branch-and-bound, are truly hybrid methods which look to combine 
heuristic algorithms with statistical methods so that they resolve the unique issues which arise 
when attempting to optimise a simulation model. 
Also included in this section is a discussion regarding hyperheuristic methods. Although 
hyperheuristics methods for simulation optimisation were not found within this review, 
discussion with experts at a National Taught Course Centre in Operational Research (NATCOR) 
metaheuristics course highlighted that hyperheuristics is a field of research which may have 
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potential applicability to our sequencing problem. Therefore a discussion and review of the key 
literature is provided. 
Hybrid methods 
Development 
Prudius et al. (2012) developed an averaging framework for simulated annealing.235 The 
method is a hybrid application of random search methods as well as averaging methods. The 
method is recently developed, however it draws upon the whole spectrum of simulation 
optimisation methods as reviewed within this chapter. 
Xu et al. (2013) developed an empirical stochastic branch-and-bound method for simulation 
optimisation.236 This is a hybrid method which combines nested partitions and stochastic 
branch-and-bound.  
Practical applicability 
Prudius et al. (2012) apply their average framework for simulated annealing method to a 
three-stage buffer allocation problem.235 They do not provide a great deal of information 
about the practical application of their method. The global algorithms incorporating averaging 
perform better than local algorithms, however this is not unexpected. They do identify that 
averaging does not always benefit the algorithm it is applied to. They apply two variants of 
simulated annealing and demonstrated that averaging alone may either help or hurt the 
performance of the algorithm, compared with no averaging. They do find that averaging within 
the algorithm as well as an adaptiveness component to avoid unnecessary simulation does 
appear to be an effective strategy. 
Xu et al. (2013) apply their empirical stochastic branch and bound method to a three-stage 
flow line with finite buffer storage problem. They find that the algorithm converges 
asymptotically to the global optimum, and they empirically show that their method 
outperforms the standard nested partitioning approach. The advantages of the method are 
maximised when the problem is noisy or there are significant interactions between the 
decision variables. Little other information regarding performance was given, due to the study 
being focussed on the methodological development and proof of convergence. 
Hyperheuristics 
The current heuristic approaches for searching and optimisation still tend to focus on bespoke 
systems and solutions, even given their flexibility. In general, these solutions and algorithms 
have been found to be expensive to develop and run. However, despite this they have 
provided successful results for real world problems. 
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Unfortunately, the application of a metaheuristic to a new problem domain (or even a new 
problem instance) still tends to require expert involvement and often an expensive period of 
research. While a metaheuristic may generate good performance in an alternative problem 
instance, it is often observed that an alternative may also generate good or superior 
performance.283,284 
The goal of much current research is to raise the generalisability of search methodologies 
through learning and adaptation so that these methods are applicable across a broad range of 
problems without requiring any human expert intervention. This area is challenging, because 
there is a lack of theoretical understanding of how to build a meta-level intelligent search 
method which is capable of automatically tuning, selecting and generating a search system.285 
A hyperheuristic is a search method or learning mechanism for selecting or generating 
heuristics to solve computationally difficult problems. The hyperheuristic operates on the high-
level search space of heuristics, rather than on the low level search space of solutions. Or more 
simply, a hyperheuristic is optimising the selection of a lower level heuristic, which in turn 
derives a solution for the problem. 
Although a cutting edge area of current research, the origin of hyperheuristics can be traced 
back to the early 1960s.286,287 Recent research has involved the benchmarking of alternative 
hyperheuristics (HyFlex research project), with the AdapHH heuristic showing clear 
superiority.288,289 However, it in itself requires the tuning of approximately 20 parameters. It is 
still not clear if it really offers a generalisable framework for applying heuristics to solve a 
computationally difficult problem. 
The cutting edge nature of hyperheuristics contrasts the more established background of 
metaheuristics, many of which have a proven theoretical basis. For our particular sequencing 
problem, it does not currently seem appropriate to take advantage of hyperheuristics and 
automate the process of heuristic selection. Instead it seems more appropriate to apply one or 
more established metaheuristic methods to attempt to find a good solution and method, and 
then in the future to maybe consider the applicability of a hyperheuristic. 
 
6.9 DISCUSSION AND CONCLUSIONS 
The aim of this chapter was to systematically search published literature to identify relevant 
methods for finding an optimal or near-optimal sequence of treatments in an economic 
evaluation using discrete event simulation. 
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The treatment sequencing problem was formulated as a combinatorial discrete simulation 
optimisation problem. Therefore methods were searched for which were either developed for, 
or addressed, problems of this type. To facilitate this review, a citation pearl growing search 
was undertaken to identify all relevant methods across a disparate area of research. From the 
results of this search, a narrative review and synthesis was undertaken to draw conclusions 
regarding the applicability of each main method type. Methods were assessed using a bespoke 
framework which addressed their theoretical basis, practical applicability, and relevance to the 
treatment sequencing problem.  
The methods identified could be grouped into two broad categories: random search methods; 
and metaheuristic methods. The majority of methods identified were metaheuristics, which 
are generalised methods with the objective of being applicable to a range of problem types. 
This is an attractive property, because they provide a theoretical basic for their applicability, 
and the review found that they have been applied to a wide range of problems. This supports 
their use for a combinatorial discrete simulation optimisation problem, although no instances 
were found where a metaheuristic was found for a problem with a permutation encoding. This 
is most likely to be the superior way to represent the treatment sequencing problem. Little 
evidence was found about the relative performance of each metaheuristic. Lacksonen et al. 
(2001) applied SA and GA algorithms for four buffer-size problems.224 The SA algorithm used 
was simplistic, and may account for its perceived lack of performance compared to the GA. 
Also, the detail provided in the article was limited, and therefore robust conclusions cannot be 
drawn.  
Statistical methods such as metamodeling, adaptive sampling, and approximation, were 
excluded from the review. These methods are concerned with how simulation runs can be 
efficiently ‘selected’, and how superiority can be proven in the presence of noise. These 
methods have been shown to work well in combination with a range of search algorithms, and 
may provide a significant ‘speed up’ to the ability of a search algorithm to identify a near 
optimal solution. However, some of the methods are were only relevant for relatively small 
problems. Additionally, some required a continual evaluation of the output of the simulation 
model while it was simulated.  
Some important trade-offs have been identified, and some methods explicitly provide the 
ability to ‘balance’ these. In particular, there is a trade-off between exploitation and 
exploration – ensuring the global space is searched but also looking for the local optima within 
a particular area. Furthermore, there is a trade-off between the ability to search within the 
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space, and ensuring that precision is obtained in each simulation of a solutions objective 
function. 
Some limitations of the systematic review should be noted. Firstly, the use of a bespoke 
framework is required because there is no gold standard method against which to compare. 
This is open to reporting bias, in particular due to one researcher working on this review. 
However, the use of a framework to assess the relevance and merits of alternative 
methodologies has been recommended in the methodological systematic review literature.202  
Also, the review of methods fell well outside of health economics and the regular area of 
research and expertise – into engineering, computing and mathematics. This may provide the 
potential for errors in interpreting and understanding particular aspects of a method or 
problem. Intensive training was undertaken alongside this PhD research, in particular on 
metaheuristic methods and simulation modelling, to ensure the skills were available to assess 
and apply alternative methods in this area. The objective of the reviews was not to inform the 
theoretical design of a new optimisation method, but to understand existing methods to an 
appropriate level which would allow a judgement regarding their appropriateness to the 
treatment sequencing problem, and subsequently the ability to implement the method using 
the RA DES model. 
Finally, the search was specific to combinatorial and simulation optimisation problems, 
however methods that are not specific to these may still be relevant and applicable. It should 
be noted that very few sequencing or permutation problems were identified, which are of 
particular applicability to the treatment sequencing problem. These problem types have 
particular issues for search algorithms, in particular neighbourhood functions and move 
operators. Further reviewing for approaches to resolve these may be required when selecting, 


















CHAPTER 7: APPLICATION OF SIMULATION OPTIMISATION VIA 
SIMULATED ANNEALING FOR AN ECONOMIC EVALUATION OF 
TREATMENT SEQUENCES FOR RHEUMATOID ARTHRITIS 
 
7.1 CHAPTER OVERVIEW 
This chapter contains the pivotal analysis within this thesis. It draws from Chapter 5, where a 
discrete event simulation (DES) model is developed for estimating the cost-effectiveness of RA 
DMARDs. It also draws from Chapter 6, where a systematic review to identify methods which 
are relevant for the treatment sequencing problem is conducted.  
In this chapter, simulated annealing (SA) with a memory function is the selected methodology 
to enable the simulation optimisation (SO) of the DES model developed in Chapter 5. The 
whole method is referred to as SOSA (Simulation Optimisation via Simulated Annealing). 
The reasons for selecting SA are fully explained, and the methodology is reported for 
transparency. Modifications to the DES model are required to enable it to be operated by the 
simulation optimisation algorithm. Justifications for these modifications are provided and the 
model is validated. 
The SA algorithm is comprehensively ‘tuned’, where key control parameters are altered to 
obtain good performance of the algorithm. The algorithm is then used to identify a good 
solution to the problem, and sensitivity analysis conducted to test the robustness of the 
results. The identified results are considered in terms of their potential implications for health 
resource allocation policy. 




The aim of this chapter is to undertake a simulation optimisation of a DES model, to enable the 
identification of an optimal or near-optimal DMARD treatment sequence for patients with RA. 
Section 7.3 reports the methods of the analysis. This includes a justification for the chosen SO 
method, a SA algorithm with a memory structure. Modifications are required to the existing 
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DES model to enable it to be operated by the SA algorithm, and these are fully reported. The 
SOSA method and the process undertaken to tune its performance are detailed. 
Section 7.4 presents the results of the SOSA analysis, along with sensitivity analyses. Section 




As reviewed and discussed in Chapter 6, simulation-optimisation (SO) methods are concerned 
with finding an optimal or near-optimal solution for a problem when potential solutions are 
evaluated using a simulation model. SO has two unique aspects, compared with standard 
optimisation methods. Firstly, the simulation model may be stochastic, with an uncertain 
estimate of the objective function. Secondly, the simulation model may take a significant 
period of time to evaluate a solution. SO methods must therefore overcome these challenges. 
Rational for Simulation-Optimisation using Simulated Annealing (SOSA) 
On the basis of the review and appraisal reported in Chapter 6, SA has been selected as the 
metaheuristic SO method to address the RA treatment sequencing problem outlined in earlier 
chapters. The rationale for this decision is based on the following four factors. 
1. SA was found to be the most commonly used method in the systematic review 
reported in Chapter 6. Seven of the 28 (25%) of studies identified were studies where 
SA had been applied to a combinatorial SO problem. These studies on the whole 
reported that SA performed well for their particular SO problem. 
2. Only one study has been identified which compares the performance of SA against 
other metaheuristics.224 Lacksonen et al. (2001) found in their case that SA might not 
perform as well as a genetic algorithm (GA), however neither method was extensively 
‘tuned’ (the process of optimising the control parameters of the algorithms). On one 
occasion the SA method found a solution in much fewer replications compared to GA, 
which indicates that no definitive conclusions were found. There are several 
limitations of the Lacksonen et al. (2001) study which are detailed in Chapter 6. 
3. SA is relatively easy to implement and programme, compared with more complex 
metaheuristics like Tabu Search, Particle Swarm and Genetic Algorithms. 
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4. Genetic Algorithm, another potential method, has in general been found to be robust, 
but also very slow to implement and run. Therefore a trade-off between speed and 
precision is required. 
These four factors have led to the decision to select SA as the method to implement. 
Unfortunately the time taken to implement, validate and run multiple SO methods means that 
is it not possible to implement more than one SO method and judge their relative performance 
within this thesis.  
Simulation Optimisation algorithm 
A Simulation Optimisation (SO) algorithm has been developed to allow the simulation 
optimisation of the RA treatment sequencing problem. The algorithm is detailed in Figure 7.1. 
The SO algorithm allows an optimisation algorithm (in this case, a metaheuristic) to evaluate a 
particular potential solution by running a simulation model. The optimisation algorithm then 
considers the performance of that particular potential solution (the output of the simulation 
model) before generating a new potential solution for the simulation model to evaluate, or 
stopping the SO algorithm. 
The algorithm begins by initialising both the simulation model and the optimisation algorithm. 
User-defined parameters govern both parts of the SO algorithm and need to be selected 
before starting the procedure. Also, a patient-level dataset is required for the simulation 
model. This contains patient characteristics as well as probabilistic parameter values. This 
dataset is generated at the start of the SO algorithm and passed to the patient simulation 
model. Alternatively, to ensure consistent results, a previously generated dataset can be 
loaded into the simulation model.  
A starting treatment sequence is then generated (either at random, or a user-defined 
sequence) and this is evaluated by the simulation model. The results from this evaluation (the 
net monetary benefit (NMB) given a specified cost-effectiveness threshold) are then passed to 
the optimisation algorithm (in this case, a simulated annealing metaheuristic algorithm) which 
generates a neighbouring solution and loads this into the simulation model. The process of 
evaluation, results processing, next sequence generation and re-evaluation is fully automated 
once the algorithm is begun. The algorithm stops when a stopping criterion is met. The 









Simul8© is a simulation modelling software package widely used to develop discrete event 
simulation models. In recent years it has been increasingly used to develop patient level 
simulation models for cost-effectiveness analyses.290–293 The advantages of Simul8 for 
developing a patient level simulation model include: being faster than similar models 
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debugging and validation; and possessing a relatively powerful Visual Logic (VL) language 
which allows user defined functions and code to be run when events occur in the model. 
Simul8 was chosen as the software package to implement the RA model because, from 
experience, it is much faster than MS Excel when running similar patient level simulation 
models. However, Simul8 is not routinely supported by NICE for submissions to its NICE 
Technology Appraisal process (because it is a relatively expensive bespoke simulation software 
package) and therefore the original RA model as reported in Chapter 5 was developed in MS 
Excel. It was decided the investment in time to rebuild the model in Simul8 was worthwhile to 
gain a much faster patient level model. 
Modifications from NICE model 
Where possible, the Simul8 version of the NICE model is an exact copy of the original NICE 
model developed in MS Excel. All analysis is in a severe RA population (Population 1 and 2). 
Identical parameters, evidence sources and costs are used (including confidential ‘Patient 
Access Schemes’ which reduce the cost of selected bDMARD treatments). The following 
sections report the particular areas of the current Simul8 model which deviate from the 
original NICE RA model. 
Treatment decrement parameter 
A treatment decrement parameter has been included within the Simul8 model. This parameter 
was not included within the NICE RA model, because of time constraints within the appraisal. 
Treatment decrement parameters have been used in previous NICE RA appraisals to consider 
the impact on the efficacy of a treatment of having several previous failures on treatments of 
the same general class. It is not seen as clinically plausible that the efficacy of a bDMARD after 
no previous bDMARDs is going to be the same as after 3 or 4 previous bDMARDs. Therefore for 
both bDMARDs and cDMARDs, a treatment decrement parameter was incorporated, broadly 
in line with the approach requested by NICE for the TA198 (now TA247) appraisal of TCZ for 
RA.* In this appraisal, the manufacturer undertook trial subgroup analyses specific to TCZ, ETN 
and RTX to adjust the efficacy data used in the economic model (efficacy reported using ACR 
20/50/70 criteria). Their subgroup analysis produced inconsistent results in places, with 
improved efficacy seen in some levels of response, however it was accepted by the NICE 
appraisal committee as being valid in the absence of better data. These data are reported in 
Table 7.1. 
 
                                                          
*
 http://www.nice.org.uk/guidance/ta247 - Accessed June 2015 
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Table 7.1: TA198 Treatment decrement estimates 
Treatment  ACR 20/50/70 (%) 













It has been assumed that after two prior bDMARD or cDMARD treatments in the sequence, the 
decrement is applied. In the basecase, this treatment decrement is set at 10%, and will be 
varied in scenario analyses.  
Meta model and curve-fitting 
The NICE RA patient-level simulation uses the estimated coefficients from three econometric 
models to provide patient-specific model parameters. 
Specifically, these models are: 
- A generalised gamma regression model used to determine the length of treatment for 
a patient with a moderate EULAR treatment response 
- A log-normal regression model used to determine the length of treatment for a patient 
with a good EULAR treatment response 
- An Adjusted Limited Dependent Variable Mixture Model (ALDVMM) use to estimate 
health related utility values (HRUVs). 
Table 7.2 provides the independent (patient specific) variables used throughout the patient 
simulation, which when combined with the estimated coefficients from the models, determine 
time on treatment (given a moderate or good EULAR response) and HRUV. 
In MS Excel, these models can be easily incorporated to obtain a patient level prediction within 
the simulation model, by using Excel’s inbuilt statistical functions (specifically, probability and 
cumulative distribution functions for normal, log-normal and gamma distributions). However, 
within Simul8 these statistical functions are not included. 
From experience, Simul8 provides a significant improvement in simulation speed compared to 
MS Excel, and therefore undertaking a simulation-optimisation process is not likely to be 
feasible just in MS Excel. However, these econometric models represent the best use of 
available evidence to provide patient-level parameters in the simulation model. Therefore, 
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metamodels of these econometric models were constructed to enable their inclusion in the 
Simul8 model. 
Table 7.2: NICE RA econometric models for patient level parameters 
Model Log normal Generalised Gamma ALDVMM 
Dependent variable Time on treatment 
(Good EULAR response) 
Time on treatment  































Method to account 
for uncertainty 
Multivariate normal distributions across all parameters 
 
 
Health Related Utility Value (HRUV) meta model 
For the HRUV econometric model, a pragmatic solution was to fit a meta-model (essentially a 
regression model of a model) to allow the prediction of the dependent variables given specific 
patient characteristics, which can then be easily incorporated into the Simul8 simulation 
model. 
To fit the metamodel, a dataset of the dependent and corresponding independent variables 
from the econometric model was required. Therefore, a dataset was generated using the 
simulation model in Excel, which returned both the dependent and independent variables. A 
dataset of 2000 simulation observations was generated for the utility value and corresponding 
independent variables. For the utility model, the independent variables are simply Age, Age2, 
HAQ, HAQ2. Therefore these independent variables were fitted to the meta model. 
An OLS regression model was therefore fitted with the following functional form: 
𝑈𝑡𝑖𝑙𝑖𝑡𝑦 =  𝛽0 + 𝛽1𝑎𝑔𝑒 + 𝛽2𝑎𝑔𝑒
2 + 𝛽3𝐻𝐴𝑄 + 𝛽4𝐻𝐴𝑄
2 +  [7.1] 




      Source |       SS       df       MS              Number of obs =    2000 
-------------+------------------------------           F(  4,  1995) = 4262.72 
       Model |  41.0386948     4  10.2596737           Prob > F      =  0.0000 
    Residual |  4.80164569  1995   .00240684           R-squared     =  0.8953 
-------------+------------------------------           Adj R-squared =  0.8950 
       Total |  45.8403405  1999  .022931636           Root MSE      =  .04906 
 
------------------------------------------------------------------------------ 
        util |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   -.000971   .0006111    -1.59   0.112    -.0021695    .0002275 
        age2 |   .0000105   5.11e-06     2.05   0.040     4.67e-07    .0000205 
         haq |  -.2041815   .0074534   -27.39   0.000    -.2187988   -.1895643 
        haq2 |  -.0129101   .0024876    -5.19   0.000    -.0177887   -.0080315 
       _cons |   .9100248   .0183569    49.57   0.000     .8740241    .9460255 
------------------------------------------------------------------------------ 
Box 7.1: HRUV meta model regression results 
The residuals showed some slight correlation (Figure 7.2), and alternative functional forms and 
other independent variables (such as a cubic term) may have improved the fit of the model, 
however within the timeframe of the thesis this was not possible. The predicted values 
appeared to fit the data (Figure 7.3). 
 




















Figure 7.3: HRUV meta model regression fit 
Time-on-treatment meta model 
For the two time-on-treatment models, the output from the econometric model was a survivor 
function and corresponding survival curve. The survival function could not be implemented in 
Simul8, and therefore the two curves (good and moderate EULAR response) for a patient with 
mean characteristics from the analysis were digitised to allow a parametric distribution to be 
fitted to the digitised data. This is a commonly conducted method to allow a parametric model 
to be fitted to a published aggregate survival curve. In this case it represented the most 
effective way of incorporating the survival model data into the Simul8 model, however it is at 
the expense of reduced accuracy, in particular because the time-on-treatment parameters are 
now essentially global parameters, rather than being patient specific. 
Parametric distributions were fitted to the data and the distribution parameters optimised by 
minimising the mean squared error using the MS Excel Solver add-in. Log-normal distributions 
were selected for both models (the EULAR Good Response time-on-treatment model is a log-
normal, however the EULAR Moderate Response model is a generalised gamma) and were 























Figure 7.4: Time-on-treatment (Moderate EULAR response) 
 
Figure 7.5: Time-on-treatment (Good EULAR response) 
 
Treatments and decision space size 
As highlighted in the systematic review of economic evaluations in Chapter 4, there is a large 
set of DMARDs for patients with rheumatoid arthritis. 
For this analysis, all potential competing DMARDs currently used regularly in the NHS were 
selected for the pool of treatments from which to derive each treatment sequence. There are 
several cDMARD therapies (leflunomide, aziathaprine, ciclosporin, penicillamine, injectable 
gold) which are less commonly used and have therefore been omitted. This decision was based 
on two factors. Firstly, to ensure that resulting sequences are clinically meaningful and 
appropriate. Secondly, there is less comparative evidence to provide estimates of the relative 
efficacy of these older and less-commonly used treatments compared to more commonly used 





















































The set of treatments within the analysis is provided in Table 7.3. The treatments are grouped 
by their general classification, and include the current licenced indication for each treatment. 
Treatments can either be used first line, after a previous cDMARD, or after a previous bDMARD 
(rituximab).  
Table 7.3: Treatments included in analysis 








































































Best supportive care 
 
BSC X   
 
Therefore there are 14 treatments (including Best Supportive Care (BSC)) in the pool from 
which sequences can be generated and evaluated using the simulation model. There is a 
maximum possible sequence length of 13, due to it not being clinically appropriate to have a 
sequence including both abatacept and subcutaneous abatacept. The size of the decision 
space (S) is very complex to formally estimate given the various rules regarding the potential 
position of each treatment (e.g. ritixumab cannot start a sequence). However, an upper bound 
(Smax) can be derived using the following formula for k-permutations of n objects, where k is 
                                                          
*
 Based on current EMA licensed indication for adult patients with established moderate-severe 
rheumatoid arthritis 
†
 All bDMARDs administered with concomitant MTX 
‡
 TICORA in an intensive combination cDMARD strategy based on the TICORA study and treatment 
protocol. 
§
 Always provided at the end of a sequence of active treatments for symptomatic relief 
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the length of the sequence (up to a maximum sequence length 𝐿) and 𝑛 is the total number of 
















The maximum size of the decision space is provided in Table 7.4. 
Table 7.4: Maximum size of the decision space 
Sequence length (𝒌) Number of sequences (𝑺) 

















 17,160  
 154,440  
 1,235,520  
 8,648,640  
 51,891,840  
 259,459,200  
 1,037,836,800  
 3,113,510,400  
 6,227,020,800 
TOTAL (𝑆𝑚𝑎𝑥) 10,699,776,685 
 
𝑆𝑚𝑎𝑥 is therefore over 10 billion sequences. This is far beyond the capacity of even a highly 
efficient patient level simulation to evaluate within a reasonable period of time, and likely to 
be far larger than any decision space that has been formally evaluated within a health 
economic evaluation. 
Validation 
The Simul8 RA sequence model was carefully and fully validated. The optimisation algorithm 
was programmed in Excel to allow defined sequences to be run as a group, which allows a 
standard fully incremental analysis of competing sequences to be estimated. The paper by 
Tappenden & Chilcott (2014) provides a list of practical procedures to follow when validating a 
health economic model.294 These are reported below in Table 7.5, and represent just the main 
ways in which the model was validated. 
                                                          
*
 (a selection of k objects from a list of n, where k ≤ n), and where the order of selection matters and selections 
cannot be repeated. 
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Table 7.5: Validation tests 
Area of model Test applied 
QALYs calculated 
properly 
If utility is fixed to 1, then total QALYs equal total life years gained 
(LYG) 
Model is valid Set equal efficacy for all treatments – should result in optimal 
treatment sequence in ascending order of cost 
Checked user defined 
formulae and functions 
within Simul8 
Tested externally in MS Excel, and Simul8 ‘stepped into’ when run 
to check intermediate values were correct 
All treatments set to 
the same efficacy 
Each treatment run in a ‘1 treatment’ sequence and tested for equal 
QALYs and as expected total cost 
All treatments set to 
equal efficacy and cost 
Every evaluated sequence has identical costs and QALYs 
Check ‘eligibility’ code Generated 100 random sequences and manually checked the ‘error 
flag’ to ensure ineligible sequences had be correctly identified 
HAQ progression 
modelling 
Simul8 model built with ‘debug code’ so that intermediate values 
over time were output by the model. This allowed a visual debug of 
the progression of HAQ over time 
Model breakpoints Breakpoints were added to the model, so if impossible 
parameters/values or situations occurred, the model would break 
and an error message reported (e.g. negative costs, HAQ outside 
feasible range (0-3), utility over 1 etc. 
 
The external validity of the results was tested by comparing to the original NICE RA model 
Number of patient simulations 
In a patient level simulation model, there is sampling error due to the variability between each 
simulated patient, often called first-order uncertainty.295 For an identical simulated patient, 
there are random events which will occur, meaning one simulated patient may respond to a 
particular treatment (for example), but an identical patient in the next simulation may not. By 
increasing the number of patients simulated, this first-order uncertainty can be reduced, and a 
better estimate of the true NMB can be derived. However, the reduction in uncertainty is at 
the expense of increased computational time. Therefore, identifying the appropriate number 
of patient simulations is of crucial importance. 
When undertaking a cost-effectiveness analysis using a patient simulation model, the current 
recommendation by the NICE Decision Support Unit is to clearly justify the number of patients 
simulated, normally by using a graphical representation of the model output along with an 
estimate of the cumulative mean and its standard error.295 It is also important to ensure that 
the pseudorandom number generator (PNG) used within the simulation has no effect on the 
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results. Many software packages (including Simul8) allow a seed number to be used to 
initialise the PNG. When the same seed number is used, the PNG generates an identical string 
of pseudorandom numbers, which allows a model with the same parameters and seed number 
to generate identical output when run repeatedly. This functionality is useful for debugging a 
simulation model. When changing the PNG seed number and re-running the model, there 
should be negligible discrepancy in the results if sufficient individual patients have been 
simulated. 
For the RA model, the output of interest is the Net Monetary Benefit (NMB). This enables a 
continuous numerical output from the model to act as the estimate of the objective function 
within the optimisation problem. Using an ICER would be problematic, because improving 
solutions cannot always be inferred by an improved (lower ICER) due to its ratio properties, 
and therefore a multi-criteria optimisation method would be required to incorporate cost and 
QALY output. 
When comparing two solutions (sequences), the incremental NMB (iNMB) is simply the 
difference in the estimated NMB of the two solutions. Ideally, the simulation model should 
therefore be run with enough patients to ensure that an accurate estimation of the iNMB can 
be calculated between two similar solutions, and that the standard error of the mean iNMB is 
low enough for it not to affect the results. 
Figure 7.6 to Figure 7.8 provide graphic output of running 50,000 patients in a simulation 
(approximately 4 minutes simulation time for each comparison). This is repeated across three 
sets of different PNG seeds. Reported are the cumulative mean iNMB, its standard error, and 
the 95% confidence interval. The treatment sequences compared were similar*, to ensure 
sufficient numbers of patients were selected to enable an accurate estimate of low values of 
iNMB (or, to rank sequences with similar NMB).  
Each set of figures relates to a particular setting of uncertainty in the model. In Figure 7.6 , the 
model has no probabilistic uncertainty, and uses only point estimates for each of these model 
parameters. Also the patients sampled are all identical, with no heterogeneity. This setting 
therefore corresponds to a deterministic analysis of a particular patient cohort (in this case, 
the mean characteristics of the patient population as taken from the BSRBR study (see earlier 
section). With probabilistic uncertainty accounted for, the estimated iNMB is stable, as is the 
corresponding confidence interval. However, this interval spans 0 in all three random number 
sets, and at 50,000 patients. Therefore the underlying patient variability is such that using 
                                                          
*
 {TICORA, ETN, RTX, TCZ, MTX, BSC} vs {TICORA, CTZ, RTX, TCZ, MTX, BSC} 
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50,000 simulated patients is not sufficient to accurately confirm which sequence has the 
higher NMB, at 95% confidence.  
The model used to generate Figure 7.7 also has no PSA, but patient level heterogeneity is 
reintroduced. With Figure 7.8, the model includes both patient heterogeneity and 
probabilistically sampled parameters. This model therefore is equivalent to the standard 
basecase model.  Also provided in Table 7.7 to Table 7.9 are the results for different numbers 
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Table 7.6: No patient heterogeneity. No PSA (Deterministic) 
Patient 
Simulations 
iNMB: Random Seed Set 1 iNMB: Random Seed Set 2 iNMB: Random Seed Set 3 
Mean SE L95 U95 Mean SE L95 U95 Mean SE L95 U95 
1,000 £2,572 £1,844 -£1,117 £6,260 £1,400 £1,847 -£2,294 £5,094 -£2,468 £1,880 -£6,228 £1,292 
10,000 £992 £584 -£176 £2,160 -£463 £586 -£1,635 £710 £299 £588 -£877 £1,475 
20,000 £860 £412 £36 £1,684 -£74 £414 -£902 £754 £347 £416 -£484 £1,179 
30,000 £542 £336 -£129 £1,214 -£56 £339 -£735 £622 £482 £338 -£195 £1,158 
40,000 £482 £292 -£102 £1,066 £13 £294 -£574 £601 £289 £293 -£298 £875 
50,000 £500 £261 -£21 £1,022 £413 £262 -£111 £938 £344 £262 -£181 £868 
 
Table 7.7: Patient heterogeneity. No PSA 
Patient 
Simulations 
iNMB: Random Seed Set 1 iNMB: Random Seed Set 2 iNMB: Random Seed Set 3 
Mean SE L95 U95 Mean SE L95 U95 Mean SE L95 U95 
1,000 £2,189 £3,005 -£3,820 £8,198 £2,167 £2,882 -£3,597 £7,931 -£2,745 £2,823 -£8,390 £2,900 
10,000 £2,117 £928 £260 £3,974 £1,507 £935 -£363 £3,377 £2,063 £933 £197 £3,929 
20,000 £1,628 £658 £312 £2,943 £1,804 £667 £469 £3,139 £876 £661 -£446 £2,198 
30,000 £1,564 £543 £479 £2,650 £1,840 £546 £747 £2,933 £1,278 £543 £192 £2,364 
40,000 £1,174 £470 £234 £2,114 £2,047 £473 £1,101 £2,994 £903 £469 -£36 £1,841 






Table 7.8: Patient Heterogeneity. PSA (Basecase model) 
Patient 
Simulations 
iNMB: Random Seed Set 1 iNMB: Random Seed Set 2 iNMB: Random Seed Set 3 
Mean SE L95 U95 Mean SE L95 U95 Mean SE L95 U95 
1,000 £1,318 £2,919 -£4,521 £7,157 -£880 £3,077 -£7,033 £5,274 -£948 £3,047 -£7,041 £5,145 
10,000 £2,523 £940 £643 £4,404 £684 £936 -£1,188 £2,557 £2,451 £951 £549 £4,354 
20,000 £2,262 £667 £928 £3,595 £724 £657 -£591 £2,039 £2,249 £670 £909 £3,590 
30,000 £1,898 £545 £808 £2,988 £1,760 £545 £671 £2,849 £1,918 £549 £820 £3,016 
40,000 £1,631 £470 £690 £2,572 £1,998 £472 £1,054 £2,942 £1,817 £473 £871 £2,764 




In Figure 7.6, the standard error is low compared with the mean iNMB, however the 95% 
confidence interval spans zero, which confirms that the patient variability in the model is too 
severe to allow a confident distinction between two very similar sequences. Certolizumab 
pegol and etanercept were specifically chosen as comparator treatments within a fixed 
sequence. Their efficacy and costs are not overly dissimilar, as shown in Table 7.9. The 
downstream sequences after these treatments are identical. 
Table 7.9: Comparing certolizumab pegol to etanercept 
Parameter Certolizumab Etanercept 
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Excluding Patient Access Scheme (PAS) discounts 
 
Adding patient heterogeneity and parameter uncertainty increases the standard error of the 
mean iNMB. It also results in a different estimate of iNMB compared with the deterministic 
results. This justifies the use of a probabilistic patient simulation model, because there is non-
linearity between the input parameters and the NMB output. A further explanation is that, 
when patient heterogeneity is removed, only a female cohort of patients is run (females are 
significantly more likely than men to have RA). Therefore life expectancy and patient level 
predictions which include age (HAQ progression) lead to different results, compared with 
when patient heterogeneity is introduced and men are simulated.  
From 40,000 patient simulations, the standard error is under £500 for all three random 
number sets, compared to an iNMB output of over £1000. The lower 95% confidence intervals 
are all above zero (Table 7.8). It was decided that 40,000 patient was a pragmatic number of 
patients to run. The simulation model takes approximately 3 minutes to run each sequence, 
and the desire is for each optimisation run to take days, rather than months to complete. The 
average standard error (£472) for this comparison will be used as an indicator of ‘indifference’ 
between compared sequences when their iNMB is within 2 standard errors (£944). 
There was not believed to be any significant marginal benefit in running more patient 
simulations, at the expense of significant increases in computational time. For the purposes of 
tuning the algorithm, 2,000 patient simulations was selected as an adequate number for each 
tuning run of the optimisation algorithm, because the accuracy of the model output is less 
important for this objective. This lower number of patient simulations allowed a greater 
degree of tuning to be undertaken given the fixed time available. 
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Linkage to MS Excel 
For the SO algorithm to be fully automated, a data link between the optimisation algorithm 
and the simulation model is required. Treatment sequence information must be passed to the 
patient simulation model, and the evaluated results from the patient simulation model passed 
back to the optimisation algorithm. Within one software package or computing language, this 
linkage would be fully integrated. However, although Simul8 is an ideal software package for 
discrete event simulation, its inbuilt Visual Logic language is not flexible enough to enable 
some of the statistical requirements of the patient simulation model. Also, it is not possible to 
generate and manipulate array variables, which are the ideal variable structure for dealing 
with treatment sequence data and applying the low level heuristics to implement the 
neighbourhood function. 
Therefore, a decision was made to link Simul8 with Microsoft Excel. Excel provides standard 
spreadsheet functions, as well as access to the powerful Visual Basic for Applications (VBA) 
language. Excel can be linked to Simul8 via Windows COM, the interface standard for 
Microsoft software. This allows the full automation and manipulation of a Simul8 model from 
MS Excel, including within an Excel VBA macro. Therefore this allows the required data linkage 
between Excel and Simul8 (see Figure 7.9). An Excel VBA macro can theoretically provide an 
infinite cycle of data flow between Excel and Simul8, which is required for an SO algorithm. 
 
Figure 7.9: COM Interface 
The linkage of two software packages via COM has introduced an element of inefficiency into 
the overall optimisation process. Each time the simulation model is updated with new 
sequence information, it has to be saved, and each time the Excel macro calls the simulation 
model to run, Simul8 has to open the saved simulation model, run the model, save the model 
and shut it down. It has been estimated that this process costs approximately five seconds per 
iteration of the optimisation algorithm. 
























The use of Excel for the optimisation algorithm allows evaluated sequences and their results to 
be stored within a spreadsheet (a cache). Due to common random numbers being used for 
each iteration of the patient simulation model, the repeated simulation of the same treatment 
sequence will result in identical results for the same patients. 
Using a VBA search algorithm, the current sequence can be searched for in this cache to see if 
it has already been evaluated by the simulation model. If it has, then there is no need to run 
the simulation model, and instead the cached result can be inserted. This represents a form of 
‘simulated annealing with memory’, and borrows principles from Tabu search, which is an 
alternative metaheuristic which incorporates memory. Unlike Tabu Search, the memory does 
not guide the search heuristic, but instead is just to avoid inefficient re-evaluation of 
sequences. The cache search heuristic was tested and even when the cache contained 10,000 
evaluated sequences and their results, the cache took under 1 second to search, compared to 
at least 8 seconds to evaluate the sequence in the simulated model (assuming 2000 patient 
simulations). A simple process could be added to turn off the cache search when the cache 
search time was expected to take longer than the evaluation time, but it was not seen as 
necessary in this instance. 
SIMULATED ANNEALING 
Simulated annealing (SA) is a local search algorithm with the capability to escape from a local 
optima.247 It is a probabilistic metaheuristic which is frequently applied to global optimisation 
problems. It is so named due to its analogy to the physical annealing process undertaken by a 
crystalline solid. SA is most commonly applied to discrete optimisation problems, although it 
has the capability to optimise continuous problems. A more complete introduction to SA is 
provided in the methodological review of simulation optimisation methods reported in 
Chapter 6. 
SA requires the decision problem to be encoded in a way which enables the decision space to 
be searched. Common methods of encoding include integer encoding, bit encoding and 
permutation encoding. These are detailed in Chapter 6. For this particular decision problem, 
permutation encoding is the more suitable, because each treatment within a sequence is 
unique and can only be used once only.  
SA requires a neighbourhood function to be designed, which determines the movement of the 
algorithm from one solution to another ‘nearby’ solution. The neighbourhood function is a 
formal statement of what ‘nearby’ means in a problem specific context. The neighbourhood 
function therefore allows the movement of search to evaluate nearby solutions and find local 
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optima. At each iteration of the algorithm, two potential solutions are compared. These are 
the current solution in the algorithm (𝑥), and a newly selected neighbour of the current 
solution (𝑥’)). If the newly selected neighbour is an improvement compared with the current 
solution (𝑔(𝑥′) − 𝑔(𝑥) >  0) then the new solution is accepted and it becomes the current 
solution (𝑥). The algorithm then takes a neighbour from that new solution and repeats the 
process. However, a proportion of non-improving (inferior) solutions are also accepted based 
on an acceptance criterion. The acceptance of inferior solutions allows the possibility of 
escaping local optima. The acceptance criterion is a function of the temperature in the 
algorithm, which is a parameter which decreases in value as the algorithm iterates. The 
probability of accepting an inferior solution 𝑥’ as the next solution is based on the Metropolis 
acceptance criterion, which is reported in Box 7.2: Metropolis acceptance criterion.248 




] , if 𝑔(𝑥′) − 𝑔(𝑥) ≤ 0
1, if 𝑔(𝑥′) − 𝑔(𝑥) >  0
 
𝑡𝑖 is the temperature parameter at iteration 𝑖 such that: 
𝑡𝑖 > 0 for all 𝑖  
Box 7.2: Metropolis acceptance criterion 
Therefore the probability of accepting an inferior solution is a function of the current 
temperature, and the magnitude of the difference between the solutions. The probability 
decreases as the temperature decreases (moving the search from a random search to a local 
search as the algorithm iterates), and the probability increases as the difference between 
solutions decreases. As the algorithm iterates, the temperature is reduced. It can be reduced 
at every iteration (𝑖), or after a fixed number of iterations called a temperature step length (𝑛), 
where 𝑛 > 𝑖. The number of steps that have occurred in the algorithm is step count (𝑘). A 
graphical representation of the relationship between temperature, algorithm iterations and 
steps is provided in Figure 7.10 
 

















𝑛 𝑛 𝑛 𝑛 𝑛 
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The generalised simulated annealing algorithm to maximise a discrete problem is provided in 
Box 7.3, and provides the basis for the applied algorithm. 
Parameters 
Current solution 𝑥 
Simulated estimate of objective function value (NMB) of solution 𝑥  = 𝑔(𝑥)  
Temperature 𝑡 
Best solution 𝑥𝑏𝑒𝑠𝑡  
Iteration 𝑖 
Temperature step count 𝑘 
Cooling function 𝜑(𝑘) 
Length of temperature step  𝑛 
Neighbourhood definition 𝑁 
 
Initialisation 
Initial solution 𝑥0 
Initial Temperature 𝑡0 
Starting iteration 𝑖0 = 𝑖 = 1 




  Randomly select 𝑥′ ∈ 𝑁(𝑥); 
  𝛿 = 𝑔(𝑥′) − 𝑔(𝑥); 
  If 𝛿 > 0 
   𝑥 = 𝑥′; 
  Else  
   If exp (
𝛿
𝑡
) > 𝑟𝑎𝑛𝑑𝑜𝑚(0,1) 
    𝑥 = 𝑥′; 
   Endif 
  Endif 
  If𝑔(𝑥) > 𝑔(𝑥𝑏𝑒𝑠𝑡) 
   𝑥𝑏𝑒𝑠𝑡 = 𝑥; 
  Endif 
                             𝑖 = 𝑖 + 1 
 Until 𝑖 = n 
 Set 𝑡 = 𝜑(𝑘); 
 Set 𝑖 = 1 
Until stopping conditions are met 
Output 𝑥𝑏𝑒𝑠𝑡 as best solution found 
Box 7.3: Simulated annealing algorithm 
It is common for implementations of SA to incorporate a restart process into the algorithm, 
and so this has been incorporated (but is not illustrated in Box 7.3). This allows the algorithm 
to automatically repeat once a stopping criterion has been met.296 This is useful to ensure that 
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the algorithm has converged on the best solution possible within that particular run (with 
multiple restarts) of the algorithm. The restart process normally selects the best solution from 
the prior iteration of the algorithm as the starting solution. This is analogous to the algorithm 
‘reheating’ at a converged solution. Each run of the algorithm, and each consecutive restart of 
the algorithm, is called a ‘round’. After multiple restarts, the overall best solution found is then 
used as a starting point for short local search, to ensure the overall best solution is the local 
optima. For tuning purposes, the algorithm can restart with a randomly generated starting 
solution to provide repeated tests of the performance of a particular tuning parameter. 
Tuning the algorithm 
The algorithm is contingent on the following parameters and components: 
- Initial temperature 𝑡0 
- Cooling function (change in temperature) 𝜑(𝑡) 
- Number of iterations at each temperature level 𝑘 
- The construction of the neighbourhood of the problem 𝑁 
- The rule(s) to determine when the algorithm stops 
The appropriate specification of these parameters of the algorithm can be critical. In general, 
the algorithm is sensitive to all parameters and therefore successfully implementing the 
algorithm is contingent on finding appropriate parameter values. In this case, “success” is 
defined as the SA algorithm finding a good solution within a reasonable amount of time. A 
good solution is defined as having face validity, being a true local optimum, and not being 
improved upon when subjected to multiple restarts of the SA algorithm.  
There are no hard rules which determine how these parameters are selected, and instead one 
relies on the user ‘tuning’ the algorithm to optimise its performance. Historically, 
parameterising an SA algorithm was a process of trial and error alongside low level heuristics 
and experience. However, newer methods have looked to automate the tuning process, and 
even newer hyperheuristic methods allow fully automated tuning of the metaheuristic. This 
includes selecting between SA and alternative metaheuristics. However, these methods are 
beyond the scope of this research problem, in particular because these methods are very 
computationally expensive (hundreds of iterations of the metaheuristic) and for a SO problem 
they are not likely to be feasible. 
Each specification of the algorithm when tuning parameters represents a particular 
experiment. It would be possible to use a factorial design, to ensure that every possible 
combination of tuning parameter values is attempted. However, in this case this is not feasible. 
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Although SA has relatively few parameters compared to other metaheuristics, the range of 
potential parameter values and the time required to run the SO algorithm mean that this level 
of tuning is not feasible. Instead, each parameter will be tuned in turn, and then a full 
validation of the final set of parameter values to ensure the final specification is robust.  
In reality, SA cannot guarantee that the true global optima will be identified within a feasible 
amount of time. However, re-running and restarting the process can build confidence that the 
best potential solution found by the algorithm is in fact the true global optimum. Also, running 
a local search at the end of the algorithm process allows verification that the best potential 
solution at the end of the SA algorithm is in fact at least a local optimum. As tuning is 
conducted, a ‘current best’ solution is likely to emerge. Therefore all references during the 
tuning process to the performance of the algorithm will be made to the ‘current best’ overall 
solution. The frequency in which it is found will be a measure of confidence that it is the true 
global optimum (the best sequence in the decision space), and if a particular specification of 
the algorithm does not perform well, then this judgement is based on its inability to efficiently 
find the ‘current best’. The following sections provide in depth detail about the tuning of each 
component of the algorithm. 
Neighbourhood function 
The definition used for the neighbourhood function is crucial to the efficiency of any SA 
algorithm.247 When designing the neighbourhood function, there are two specific rules which 
must be enforced to guarantee convergence of the algorithm. Firstly, all potential solutions 
must be reachable (in a finite number of steps). Secondly, the neighbourhood must be 
symmetrical, and therefore backwards moves must be possible.  
Much literature is devoted to highlighting how a neighbourhood function is required that 
imposes a smooth topology to the search space. In reality, that means a neighbourhood 
function with small changes to the solution, resulting in a relatively small change in the 
objective function. This also means that there are a large number of possible neighbourhood 
moves (the ‘neighbourhood size’). However, for the RA treatment sequencing problem, any 
change to a solution (for example the addition or removal or a treatment, or swapping the 
position of two treatments) could in reality have a large impact on the objective function. 
Research is ongoing about the size of the neighbourhood (e.g. how many neighbouring 
solutions can be drawn from for a given solution within the decision space).247 While some 
researchers believe a smaller neighbourhood to be favourable,297 others propose that the 
neighbourhood is as large as possible.298 A small neighbourhood means the algorithm takes a 
long time to search through the solution space, whereas a large neighbourhood corresponds 
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to random sampling within the solution space.299 The only area of agreement in this particular 
area of SA research is that the neighbourhood function tends to be a problem-specific issue.247 
For this application of SA, a neighbourhood function was designed based on three possible 
changes (move operators) to the current solution: a treatment addition; a treatment removal; 
and a swap of two selected elements. These operators borrow concepts from the Genetic 
Algorithm literature regarding encoding a permutation problem. The order of the sequence is 
important, as well as the fact that a treatment cannot be used twice. These move operators 
respect those problem-specific conditions, in that they will not invalidate the permutation 
encoding of the problem. The first two change operators were relatively simple to implement. 
A list of unused treatments is maintained by the algorithm. For the treatment addition 
operator, a random treatment from this list is selected and inserted into the sequence at a 
randomly selected position. The downstream treatments all shift down by one position to 
accommodate the new intervention. For the treatment removal operator, a randomly selected 
treatment is removed from the sequence.  
The swap operator was programmed with two options. Firstly, an adjacent pairwise 
interchange operator, with two adjacent treatments within the sequence swapped.  Secondly, 
a random exchange operator, with two randomly selected treatments swapped. Box 7.4 
provides a representation of the move operators for the neighbourhood function. 
When problems can have an infeasible solution (for example, a treatment sequence with a 
treatment in a non-licensed position) then traditionally in optimisation these solutions are 
evaluated and then penalised. This process works well when both the evaluation and 
penalising of a solution can be done in a trivial amount of time. However, in SO, evaluating 
infeasible solutions can be very inefficient, especially when there are numerous rules regarding 
the eligibility of treatment in various positions. Therefore for this problem, VBA code was 
written to check that each sequence generated is eligible and feasible. Each time a sequence is 
generated, or a neighbour sequence generated, the code is run to check that a sequence is 
eligible. If necessary the move operation is re-run until an eligible sequence is generated. The 
eligibility check and re-running of a move operator proved to be many times more efficient 
that running the simulation model, evaluating the solution and penalising an infeasible 
solution.* 
                                                          
*
 Over 50 eligible sequences can be generated per second in MS Excel VBA. A simulation of 40,000 
patients in the Simul8 model took over 2 minutes, with additional time required for data transfer 
between MS Excel and Simul8 for each algorithm iteration. 
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The addition, removal and adjacent pairwise interchange are all competing move operators 
when a neighbouring solution is required in the SA algorithm. Therefore, user defined 
probabilities are required so that the algorithm randomly selects a move operation. When a 
sequence has a length of 1 or 13 (the minimum and maximum possible sequence length) then 
the probability of a treatment addition or removal operator being selected is set to zero (as 
appropriate). 
 1 2 3 4 5   
 GOL IFX MTX TCZ BSC   
Addition        
 GOL IFX MTX TCZ HCQ BSC  
        
 1 2 3 4 5 6  
 GOL IFX MTX TCZ HCQ BSC  
Removal        
 GOL HCQ TCZ IFX BSC   
        
 1 2 3 4 5 6  
 GOL IFX MTX TCZ HCQ BSC  
Adjacent pairwise interchange        
 GOL MTX IFX TCZ HCQ BSC  
        
 1 2 3 4 5 6  
 GOL IFX MTX TCZ HCQ BSC  
Random exchange operator        
 GOL HCQ MTX TCZ IFX BSC  
        
Box 7.4: Neighbourhood move operators 
Three different probability values for the competing move operators were assigned to the 
algorithm and tested. Table 7.10 provides the results of tuning the neighbourhood function.  
Each experiment for tuning was undertaken with a random starting sequence for each round 
(as opposed to using the best sequence identified in a previous round, which is the case for 
generating the final results). The stopping criteria applied were: when 2400 runs were 
completed; when the temperature was below 100; or 50 consecutive solutions were rejected. 
The initial temperature was set at 15,000. A 50 repetition geometric cooling schedule with a 
rate of 0.9 was used to decrease the temperature as the algorithm iterated.* These criteria and 
parameter values were selected based on some rapid experiments to establish settings for an 
initial algorithm that performed well.  
                                                          
*
 Further details regarding these particular cooling schedules is provided later in the chapter. 
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Neighbourhood function experiment 2 (see Table 7.10), with a medium probability of adding 
or removing a treatment to the sequence (20% for each operator) along with an adjacent 
pairwise interchange operator (compared to a random exchange operator), converged on the 
best performing sequence (across all tuning trials) and converged on this solution for each of 
the five rounds. 
This set of neighbourhood function parameters (20% probability of add/remove and a 60% 
probability of an adjacent pairwise interchange) were taken forward when tuning the other 
components of the SA algorithm. 
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Table 7.10: Tuning the neighbourhood function 
Neighbourhood function 1: 5% Addition, 5% Removal, 90% Adjacent pairwise interchange 
Round Sequence (line) NMB* Costs* QALYs* Iteration when 
best solution found 1 2 3 4 5 6 7 8 9 10 11 
1 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1824 
2 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  662 
3 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1550 
4 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  97 
5 MTX SSZ HCQ TICORA GOL RTX CTZ ETN IFX ADA BSC £140,657 £59,034  6.656  1586 
Neighbourhood function 2: 20% Addition, 20% Removal, 60% Adjacent pairwise interchange 
1 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  845 
2 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  796 
3 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  798 
4 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  315 
5 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  813 
Neighbourhood function 3: 40% Addition, 40% Removal, 20% Adjacent pairwise interchange 
1 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1019 
2 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1125 
3 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1148 
4 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1284 
5 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1029 
Neighbourhood function 4: 20% Addition, 20% Removal, 60% Adjacent pairwise interchange 
1 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1096 
2 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1074 
3 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1277 
4 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  1496 
5 MTX SSZ HCQ TICORA BSC       £143,530 £39,106  6.088  499 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution identified by algorithm. bDMARDs in bold 
Algorithm settings: Initial temperature 15,000, 50 repetition schedule and geometric cooling at rate 0.9. Random initial solution for every round. Stop when 2400 





The initial temperature parameter value is of critical importance to the performance of the SA 
algorithm. If the initial temperature is low, then the search may be restricted to the region of 
the search space around the initial starting point, because the algorithm is less likely to escape 
a local optimum. If the initial temperature is too high, the SA algorithm will initially perform a 
‘random walk’, with many inferior solutions accepted. This is inefficient, and it can lead to the 
algorithm terminating early if the total number of algorithm iterations is fixed. 
The initial temperature parameter must be defined so almost any feasible solution is accepted 
during the first run of the algorithm. A priori information regarding the problem and the 
neighbourhood design can inform analytically derived values for the initial temperature. 
However, it is common to use the SA algorithm itself to provide an estimate of an appropriate 
initial temperature parameter value, in particular when information regarding the problem 
and neighbourhood design is difficult to derive. Both methods rely on the concept of an 
‘acceptance ratio’ or ‘acceptance probability’, This is the number of worse solutions accepted 
at a given temperature, divided by the total number of worse solutions proposed by the 
algorithm. An acceptance ratio of 0.8 is suggested by Kirkpatrick, although he highlights that 
this parameter is problem-specific.257 The initial temperature parameter is a highly researched 
and contentious issue and beyond the scope of this thesis, however an alternative acceptance 
ratio of 0.6 will be tested, to see if the initial temperature it derives performs well compared to 
initial temperature derived by the established ratio of 0.8.  
Based on a pre-specified acceptance ratio, two methods for deriving the initial temperature 
are commonly used; the van Laarhoven formulae, and a rapid warm-up algorithm. 
Van Laarhoven formulae 
Van Laarhoven et al. (1988) proposed a formulae to determine the initial temperature  𝑡0, 
where Ξ is the target acceptance ratio, and |∆𝐺𝑚| is the mean absolute change in the objective 
function of every proposed move from a set of iterations, 𝑚 .300 This method of determining 





After running a random search algorithm, the mean change in objective function (NMB) after 
𝑚 = 500 iterations was £4,653. This resulted in estimates of initial temperature of 9,110 from 
a target acceptance ratio of 0.6, and 20,855 from a target acceptance ratio of 0.8 (Table 7.11). 
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Table 7.11: van Laarhoven formulae estimates of initial temperature parameter 




Rapid warm-up algorithm 
An alternative method to the van Laarhoven formula is to start the simulated annealing 
algorithm at a low initial temperature, and periodically increase the temperature until the 
acceptance ratio is met. This was undertaken by setting the initial temperature at 1,000. The 
algorithm then increased the temperature in increments of 1,000 every time the algorithm had 
random drawn 20 inferior potential solutions. Therefore the algorithm begins with a low 
temperature, and therefore a low likelihood of accepting a worse move. As the temperature is 
increased and worse moves begin to be accepted, the probability of accepting a worse move 
increases, until the predefined acceptance ratio target is achieved. 
This was conducted over 10 rounds of the algorithm for both 0.6 and 0.8 acceptance ratio 
targets. The results are provided in Table 7.12. 
Table 7.12: Rapid warm-up algorithm for initial temperature parameter 
 Estimated initial temperature value (T0) 































Maximum = 7,000 
Mean = 5,400 
Maximum = 11,000 
Mean = 9,200 
Temperature increased in steps of 1,000  
20 worse moves required at each temperature iteration 
Each round uses a random initial solution 
 
With an acceptance ratio of 0.6, the estimated initial temperature generated by the rapid 
warm-up algorithm (mean = 5,400) is smaller than the estimated initial temperature from the 
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van Laarhoven formula (9,110). This difference is also found with a higher acceptance ratio of 
0.8, with a mean 𝑡0 of 9,200 estimated by the rapid warm-up algorithm, compared to 20,855 
as estimated by the van Laarhoven formula. 
The algorithm was run with four alternative initial temperatures, which spanned the range of 
temperatures identified via the two methods and two acceptance criteria. The results are 
provided in Table 7.13. The results show that, in this decision problem, the algorithm was not 
sensitive to the alternative initial temperature values. The current best sequence found from 
any tuning run {MTX, SSZ, HCQ, TICORA, BSC} was found by all experiments and on every 
restart. To reduce the computational time required, the lowest value tested (7,000) was taken 
forward for the next stage of algorithm tuning. 
It is common for the initial temperature to be tuned as part of the overall annealing 
component of the algorithm (including the cooling schedule and stopping rule). However, it 
was not feasible to do a full factorial experimental design to tune all possible combinations of 
all parameters, which is a common problem for SA, even though it has relatively few 
parameters. Therefore a decision was made to tune individual components and then test the 
final set of parameters for robustness. With several rounds and full sensitivity analysis 





Table 7.13: Tuning the initial temperature parameter 
Initial temperature T0 = 7,000 (Maximum possible runs per round = 1400) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when best 
solution found 1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  821 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  893 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  640 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1073 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1052 
Initial temperature T0 = 11,000 (Maximum possible runs per round = 2150) 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1029 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  347 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  757 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  575 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  850 
Initial temperature T0 = 15,000 (Maximum possible runs per round = 2400) 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  845 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  796 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  798 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  315 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  813 
Initial temperature T0 = 20,000 (Maximum possible runs per round = 2550) 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  470 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1180 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1393 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1243 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106  6.088  1010 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ 
solution being identified by algorithm. bDMARDs in bold 
Algorithm settings: 50 repetition schedule and geometric cooling at rate 0.9. Random initial solution for every 
round. Stop when temperature < 100 or 50 consecutive solutions rejected. 2000 simulation model runs for tuning. 
 
Cooling schedule 
The strategy for cooling (reducing) the temperature as the algorithm iterates is of critical 
importance. When the temperature is very high, the algorithm operates as a random walk (all 
inferior solutions accepted), and when the temperature is very low, the algorithm operates as 
a local search (only improving solutions accepted). Therefore the rate of cooling acts as formal 
parameter to balance the exploration and exploitation of the search space by the algorithm. 
Many cooling schedules exist for SA. Static cooling schedules are only dependent on globally 
defined parameters and the current number of algorithm iterations and temperature. Five 
commonly used static cooling schedules are provided in Table 7.14.  
The algorithm iterates (𝑖) from 1,…,𝑙 where 𝑙 is a maximum number of iterations. The 
algorithm temperature steps down after a set of iterations, 𝑛. The cooling schedule of the 
algorithm is generally comprised of three parameters: the number of temperature steps, 𝑘, 
the number of iterations, 𝑖, and the temperature change parameter. With these three 
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parameters, the temperature at iteration 𝑖, 𝑡(𝑖), can be estimated. The cooling schedule can 
be dependent or independent of the current temperature parameter. A commonly used 
temperature dependent cooling schedule is a geometric cooling function, where the change in 
temperature is a function of both the temperature in the algorithm, and the temperature 
change parameter. Another commonly used independent cooling schedule is a linear cooling 
function, where the magnitude of the change in temperature is the same at every step, 
irrespective of the current temperature parameter. 
Table 7.14: Static cooling schedules for simulated annealing 
Type Temperature at iteration 𝒊 Temperature change parameter(s) 
Geometric 𝑡(𝑘𝑖) =  𝑡0 ∝
𝑘 0 ≪∝< 1 
Linear 𝑡(𝑘𝑖) =  𝑡0 − 𝜂𝑘 𝜂 > 0 
Lundy and Mees 𝑡(𝑘𝑖) = 𝑡(𝑘) =  𝑡𝑖−1/(1 + 𝛽𝑡𝑖−1) 0 < 𝛽 ≪ 1 
Exponential 
𝑡(𝑘𝑖) =  𝑡0exp (−∝ 𝑡𝑘
1
𝑁) 
0 ≪∝< 1 
𝑁 = Neighbourhood size 
Logarithmic 𝑡(𝑘𝑖) =  
𝑐
log(𝑘 + 𝑑)
 𝑐 ≥ Energy barrier* 
Typically 𝑑 = 1 
Where: 
𝑡(𝑘) is the current temperature at cooling ‘step’ 𝑘 
𝑡(𝑖) is the current temperature at algorithm iteration 𝑖 
𝑡0 is the initial temperature 
*Energy Barrier is the largest possible difference in the objective function between 
neighbouring solutions 
 
A unique one-parameter cooling schedule was proposed by Lundy and Mees, with one 
iteration performed at each temperature step (𝑛 = 1, therefore 𝑘 = 𝑖).302 The temperature is 
reduced according to 𝑡 → 𝑡/(1 + 𝛽𝑡). Exponential and Logarithmic cooling schedules are also 
used, however they require further parameterisation which is specific to the problem and 
neighbourhood function. The logarithmic cooling schedule is analytically proven to converge 
on the true global optima, but only within a very long period of time, and for all purposes is 
not practical. 
More advanced cooling schedules are adaptive, and incorporate learning and feedback from 
the decision space at each temperature level. Reheating of the temperature is sometimes 
incorporated when good solutions are not being found. Our particular implementation of the 
algorithm incorporates a restart procedure once a stopping rule has been met, which is a 




The geometric, linear and Lundy & Mees cooling schedules are all commonly performed and 
well tested for their performance. An appropriate cooling schedule is problem-specific, and so 
tuning is required to identify those which perform well. These three cooling schedules will be 
tested, and if none perform well then the exponential will be tested. 
As can be seen from Figure 7.11, the three selected cooling schedules all offer quite different 
performance when moving through the decision space. Given a fixed number of iterations to 
reach a target temperature, they all move from explorative searching at a high temperature to 
exploitative search at low temperature. The Lundy schedule is aggressive, moving quickly from 
a high temperature down to a relatively low temperature, where it spends a significant 
amount of time as an exploitative search. The Linear schedule is much slower at reducing the 
temperature. The geometric schedule operates in-between the two more extreme schedules. 
The tuning of the cooling schedule will be constrained by the total running time that can be 
afforded for each experiment. The exact number of replications and temperature changes will 
be estimated on this basis, using data from previous tuning experience to identify the expected 
running time. 
 



















Temperature Target (100) Lundy Geometric Linear
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Lundy and Mees cooling schedule 
The Lundy and Mees Cooling Schedule was run with four different Lundy parameter values (β). 
These are reported in Table 7.15. The Lundy parameter values selected for tuning were solved 
for by setting four levels of maximum iterations (between approximately 500 and 2500 
iterations) and estimating the corresponding β.  
Table 7.15: Lundy parameter values 









With 𝑡0= 7,000 and final 𝑡 = 100 
 
 
Figure 7.12: Lundy cooling schedules 
The algorithm was run with each Lundy parameter value. The algorithm was restarted for each 
parameter five times, each time with a randomly generated starting solution. The results are 
provided in Table 7.16. With a smaller Lundy parameter (more iterations) the algorithm does 
not perform particularly well. When the algorithm does not find the best sequence {MTX, SSZ, 
HCQ, TICORA, BSC} it appears to have sorted the early part of the sequence reasonably well, 
with cDMARDs occupying early positions. However, many bDMARDs remain in the latter 





















Lundy 4.0x10-6 Lundy 6.5x10-6 Lundy 1.4x10-5 Lundy 2.0x10-5
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resulting in lower NMB at £30k per QALY compared to the ‘cDMARD only’ sequence that is 
currently the best sequence identified. 
However, with the largest Lundy parameter tested (2.0x10-5), the algorithm performs well, 
finding the best solution (from all tuning experiments) in all five rounds. The results are 
surprising, and suggest that performance is not linear in the cooling schedules control 
parameter. Instead, it may be the case that this particular parameter value has found a 
particular ‘sweet spot’ in the decision space and neighbourhood function which allows the 
algorithm to extremely quickly find the best solution (between just 129 and 180 iterations).  
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Table 7.16: Lundy cooling schedule 
Lundy Parameter 4.0x10
-6 
(Maximum possible runs per round = 2500) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when 
best solution found 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106  6.088  271 
2 MTX SSZ HCQ TICORA GOL RTX CTZ TCZ ABT ETN ADA IFX BSC £141,337 £59,717  6.702  508 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106  6.088  361 
4 MTX SSZ HCQ TICORA ADA ETN CTZ RTX ABTS TCZ BSC   £139,715 £59,874  6.653  438 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106  6.088  277 
Lundy Parameter 6.5x10
-6 
(Maximum possible runs per round = 1517) 
1 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  248 
2 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  107 
3 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  148 
4 SSZ MTX TICORA HCQ ADA RTX IFX ETN ABTS GOL TCZ BSC   £136,518 £61,739 6.609  117 
5 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  169 
Lundy Parameter 1.4x10
-5 
(Maximum possible runs per round = 705) 
1 MTX SSZ HCQ TICORA BSC               £143,530 £39,106 6.088  141 
2 MTX HCQ TICORA SSZ ADA IFX RTX CTZ BSC       £137,444 £61,153    6.620  73 
3 MTX HCQ GOL RTX ADA ETN CTZ TCZ TICORA SSZ BSC   £128,255 £77,899     6.872  300 
4 MTX SSZ HCQ TICORA BSC               £143,530 £39,106     6.088  178 
5 MTX HCQ TICORA SSZ CTZ RTX ETN ADA ABTS BSC     £139,026 £59,325 6.612  260 
Lundy Parameter 2.0x10
-5 
(Maximum possible runs per round = 493) 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  180 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  129 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  166 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  119 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  161 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold 
Algorithm settings: Initial temperature 7000, 1 repetition schedule. Random initial solution for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive 




Linear cooling schedule 
The algorithm was run with four alternative parameter settings for a linear cooling schedule. 
The two parameters for this cooling schedule (the number of repetitions at each cooling step, 
and the size of the change in temperature at each step) were estimated by setting an upper 
(2800) and lower (700) bound on the maximum number of iterations at each round. These 
values were selected based on the time required to run each algorithm, subject to the total 
time available for algorithm tuning. 
A simple 2x2 experimental design was established, with number of repetitions either 50 or 
100, and size of the decrement in temperature either 250 or 500. The corresponding cooling 
schedules are shown graphically in Figure 7.13. 
The results are provided below in Table 7.17. The algorithm performed well across all four 
experiments, with 18 out of 20 rounds in total finding the current best sequence. The 
algorithm found the current best sequence in both experiments where the repetition 
parameter was set to 100, and was not sensitive in this case to the size of the temperature 
decrement. With 100 repetitions and a temperature change decrement of 500, the algorithm 
found the current best at all five independent rounds, and the maximum number of iterations 
of 1400 per restart is relatively efficient. 
 





















Linear 100/250 Linear 100/500 Linear 50/250 Linear 50/500
192 
 
Table 7.17: Linear cooling schedule 
Linear Cooling: 100 Repetitions per step. 250 Decrement per step. (Maximum possible iterations per round = 2800) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  634 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1237 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  326 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1344 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1337 
Linear Cooling: 100 Repetitions per step. 500 Decrement per step. (Maximum possible iterations per round = 1400) 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  893 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1246 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  881 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1340 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1261 
Linear Cooling: 50 Repetitions per step. 250 Decrement per step. (Maximum possible iterations per round = 1400) 
1 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  893 
2 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  1246 
3 MTX SSZ HCQ TICORA ADA RTX IFX ETN ABT CTZ GOL BSC   £139,580 £60,277  6.662  881 
4 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106  6.088  1340 
5 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106  6.088  1261 
Linear Cooling: 50 Repetitions per step. 500 Decrement per step. (Maximum possible iterations per round = 700) 
1 HCQ MTX TICORA SSZ ADA BSC        £138,612 £52,699  6.377  517 
2 MTX SSZ HCQ TICORA BSC          £143,530 £39,106  6.088  486 
3 MTX SSZ HCQ TICORA BSC          £143,530 £39,106  6.088  693 
4 MTX SSZ HCQ TICORA BSC          £143,530 £39,106  6.088  470 
5 MTX SSZ HCQ TICORA BSC          £143,530 £39,106  6.088  575 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold 
Algorithm settings: Initial temperature 7000. Random initial solution for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive solutions rejected. 




Geometric cooling schedule 
The algorithm was run with four alternative parameter settings for a geometric cooling 
schedule. The first settings (50 repetitions and 0.9 cooling rate) were the initial settings for the 
tuning of the neighbourhood function. Three alternative experiments were established, with 
two levels for the repetition schedule (50 or 25), and a cooling rate of between 0.80 and 0.95. 
This resulted in a maximum number of algorithm iterations of between 1000 and 2075 (see 
Table 7.18).  
Table 7.18: Geometric cooling parameters 














This range of cooling rate has been well established as a sensible range for a geometric cooling 
function in general.247 The resulting cooling schedules are shown graphically in Figure 7.14. The 
50/0.9 schedules and 25/0.95 schedules are very similar in terms of resulting rate of change in 
the temperature parameter. 
 
Figure 7.14: Geometric cooling schedule 
The results are provided below in Table 7.19: Geometric cooling schedule. The algorithm 
performed well across all four experiments, with 17 out of 20 restarts finding the current best 
sequence. However, there are counterintuitive results which should be highlighted. Firstly, 



















Geometric 50/0.9 Geometric 25/0.95
Geometric 50/0.85 Geometric 50/0.8
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step repetitions (25 compared to 50). This result is similar to that found with the Lundy 
algorithm, where the more aggressive algorithm achieved greater success. 
The algorithm also found that when comparing the two similar schedules (50/0.9 and 25/0.95), 




Table 7.19: Geometric cooling schedule 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.9 (Maximum possible runs per round = 2050) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  821 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  893 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  640 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1073 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1052 
Geometric Cooling: 25 Repetitions per step. Cooling rate 0.95 (Maximum possible runs per round = 2075) 
1 HCQ MTX SSZ TICORA BSC         £143,321 £39,315 6.088  234 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  1106 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  399 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  887 
5 SSZ MTX HCQ TICORA BSC         £143,523 £39,114 6.088  487 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.85 (Maximum possible runs per round = 1350) 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  473 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  562 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  227 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  505 
5 MTX SSZ HCQ TICORA GOL ABTS CTZ ETN ADA IFX RTX TCZ BSC £141,984 £59,813 6.727  899 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.80 (Maximum possible runs per round = 1200) 
1 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  543 
2 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  366 
3 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  767 
4 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  383 
5 MTX SSZ HCQ TICORA BSC         £143,530 £39,106 6.088  287 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold  
Algorithm settings: Initial temperature 7000. Random initial solution for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive solutions 




In Table 7.20, each chosen cooling schedule for each method is run with 10 random restarts. 
The Lundy cooling schedule finds the current best solution in six out of ten attempts, but is 
also relatively quick at finding these solutions (within 300 iterations). On the other hand, the 
Linear cooling schedule performs similarly, but is much slower (maximum number of iterations 
per restart is 1400). The Geometric cooling schedule is the best performing, in this particular 
experiment. It finds the current best solution in seven out of ten restarts, and is faster than the 
linear schedule, but slower than the Lundy schedule. 
Similar results were found when using the current best solution for each restart. Each schedule 
performed well, and identified the current best well within ten restarts. These results are 
presented in Table 7.21. 
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Table 7.20: Final tuning - random starting solution for each round 
Lundy Parameter 2.0x10-5 (Maximum possible runs per round = 493) 
Round Sequence (line) NMB* Costs* QALYs
* 
Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 MTX SSZ HCQ ETN RTX TICORA ABTS TCZ ADA IFX GOL CTZ BSC £136,969 £66,605 6.786 131 
2 SSZ HCQ TICORA TCZ RTX GOL CTZ IFX ETN MTX ADA ABTS BSC £130,555 £72,455 6.767 181 
3 MTX SSZ TICORA ABT CTZ ADA HCQ IFX BSC         £133,987 £66,842 6.694 174 
4 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  228 
5 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  170 
6 MTX SSZ HCQ TICORA CTZ IFX GOL BSC           £139,997 £58,243 6.608 101 
7 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  119 
8 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  87 
9 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  237 
10 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  109 
Linear Cooling: 100 Repetitions per step. 500 Decrement per step. (Maximum possible runs per round = 1400) 
1 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  339 
2 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  908 
3 MTX SSZ HCQ BSC            £141,133 £34,748 5.862 27 
4 SSZ HCQ TICORA BSC            £141,304 £39,870 6.039 572 
5 MTX SSZ HCQ TICORA CTZ BSC        £142,545 £49,168 6.390 1236 
6 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  908 
7 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  996 
8 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  1049 
9 HCQ SSZ MTX TICORA BSC          £143,317 £39,319 6.088 247 
10 MTX SSZ HCQ TICORA BSC          £143,530 £39,106 6.088  1226 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.80 (Maximum possible runs per round = 1200) 
1 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  748 
2 SSZ MTX HCQ TICORA ETN CTZ GOL IFX ADA RTX TCZ ABT BSC £139,686 £60,567 6.675 609 
3 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  538 
4 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  262 
5 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  249 
6 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  464 
7 HCQ MTX TICORA SSZ CTZ BSC               £141,849 £50,742 6.420 301 
8 MTX SSZ HCQ TICORA CTZ GOL ETN RTX ADA TCZ ABTS IFX BSC £141,212 £59,772 6.699 564 
9 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  494 
10 MTX SSZ HCQ TICORA BSC                 £143,530 £39,106 6.088  334 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm settings: Initial temperature 7000. 




Table 7.21: Final tuning - current best solution for each round 
Lundy Parameter 2.0x10-5 (Maximum possible runs per round = 493) 
Round Sequence (line) NMB* Costs*  QALYs* Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 
1 MTX SSZ HCQ TICORA CTZ GOL RTX ADA IFX BSC £139.748 £59,705 6.648  153 
2 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  110 
3 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
4 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
5 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
6 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
7 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
8 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
9 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
10 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
Linear Cooling: 100 Repetitions per step. 500 Decrement per step. (Maximum possible runs per round = 1400) 
1 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  69 
2 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
3 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
4 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
5 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
6 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
7 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
8 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
9 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
10 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.80 (Maximum possible runs per round = 1200) 
1 MTX SSZ TICORA BSC       £141,619 £39,555 6.039  430 
2 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  208 
3 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
4 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
5 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
6 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
7 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
8 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
9 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
10 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm 
settings: Initial temperature 7000. Previous best solution for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive solutions rejected. 2000 




The Lundy cooling schedule continued to show good performance compared with the linear 
and geometric cooling schedules. All three converged to the same optima and the Lundy 
schedule was faster than the Geometric schedule at finding this optima. The Lundy cooling 
schedule was run one more time under the same conditions to confirm its performance. On 
this occasion it converged on the best-identified optima in the first restart, and after just 97 
iterations (see Table 7.22). 
Table 7.22: Final test of Lundy cooling schedule 
Lundy Parameter 2.0x10
-5 
(Maximum possible runs per round = 493) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution 
found 
1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  97 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
6 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
7 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
8 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
9 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
10 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution 
being identified by algorithm. bDMARDs in bold. Algorithm settings: Initial temperature 7000. Previous best solution 
for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive solutions rejected. 2000 
simulation model runs for tuning. 
 
Efficiency of the algorithm 
The Lundy (2.0x10-5) algorithm was taken forward to conduct the basecase analysis. Tuning 
experiments were conducted to attempt to improve the efficiency of the algorithm. 
The algorithm will continue to iterate indefinitely until a stopping criterion is met. The 
implemented algorithm contains three stopping rules, which can each be independently 
activated: 
1. Maximum number of algorithm iterations 
2. Minimum temperature value 
3. Maximum consecutive rejected solutions 
Stopping rule 1 acts as an overall control on the algorithm and is always active. Stopping rules 
2 and 3 avoid inefficient running of the algorithm when stuck at a local optimum. When the 
temperature is zero or very near to zero, then the algorithm is performing a local search. 
When the algorithm is rejecting every consecutive neighbouring solution, then it is a signal that 
the algorithm has converged on a solution. 
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At the end of the optimisation process, including every restart, the algorithm has been 
designed to perform a short local search (temperature = 0, iterations = 100) to check that the 
best identified solution across all restarts is likely to be the true local optimum. 
Tuning was conducted on stopping rule 3, the maximum consecutive number of rejected 
solutions. This was conducted to improve the overall efficiency of the algorithm while 
attempting to minimise any reduction in its performance. 
Table 7.24 to Table 7.26 report the effect of reducing the number of consecutive failed 
attempts. From 50 to 15, there is no noticeable effect on the total number of iterations run per 
round. The results from the algorithm are consistent. 
When reducing the number of consecutive failed attempts to 10 (Table 7.26), the algorithm 
continues to perform well, however it only requires approximately half the total number of 
iterations (see Table 7.23).  Reducing this again to five (Table 7.26) has an impact on the 
performance of the algorithm (in two attempts, the algorithm required four and two rounds 
respectively, before finding the current best solution). The improved efficiency from 10 to 5 
maximum consecutive failed attempts is at a cost of the reduced performance in the 
algorithm. For this reason, 10 consecutive failed attempts was selected as an appropriate 
stopping rule to avoid inefficient running of the algorithm. This decision was based on there 
not being any obvious increase in the rounds required to find the current best (3 rounds), but 
it also offered a significant decrease in the total number of iterations required (from 4448 to 
2723).  
Table 7.23: Tuning the maximum number of consecutive failed attempts 
Maximum number of 
consecutive failed 
attempts 
Round when current 
best solution 
identified 
Iteration when best 
solution identified 
































Table 7.24: Maximum consecutive failed attempts (50 - 30) 
Maximum consecutive failed attempts = 50 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 
Total Iterations 
1 2 3 4 5 6 7 8 9 10 11 12 
1 MTX SSZ HCQ TICORA GOL ADA RTX ETN TCZ ABTS CTZ BSC £139.969 £60,369 6.678 453 493 
2 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  180 493 
3 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
4 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
6 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
7 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
8 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
9 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
10 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
Maximum consecutive failed attempts = 40  
1 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  347 493 
2 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
3 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
4 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
6 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
7 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
8 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
9 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
10 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
Maximum consecutive failed attempts = 30  
1 MTX HCQ TICORA GOL SSZ RTX ABT BSC     £135,523 £63,120 6.621 84 221 
2 MTX SSZ HCQ TICORA ADA RTX BSC      £140,912 £54,953 6.529 381 493 
3 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  77 493 
4 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
6 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
7 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
8 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
9 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
10 MTX SSZ HCQ TICORA BSC        £143,530 £39,106 6.088  1 493 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm settings: Initial temperature 7000. Previous 




Table 7.25: Maximum consecutive failed attempts (20 and 15) 
Maximum consecutive failed attempts = 20 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 
Total Iterations 
1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  170 493 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
6 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
7 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
8 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
9 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
10 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
Maximum consecutive failed attempts = 15  
1 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  363 493 
2 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
3 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 388 
4 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
6 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
7 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
8 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 390 
9 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 493 
10 MTX SSZ HCQ TICORA BSC £143,530 £39,106 6.088  1 219 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by 
algorithm. bDMARDs in bold . Algorithm settings: Initial temperature 7000. Previous best solution for every round. Stop when maximum 
runs completed (temperature < 100). 2000 simulation model runs for tuning. Lundy Parameter 2.0x10
-5 
(Maximum possible runs per 




Table 7.26: Maximum consecutive failed attempts (10 and 5) 
Maximum consecutive failed attempts = 10 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 
Total 
Iterations 1 2 3 4 5 6 7 8 9 10 
1 MTX TICORA ADA RTX GOL SSZ IFX HCQ ABT BSC £127,682 £76,127 6.794  61 104 
2 HCQ MTX SSZ TICORA GOL RTX ETN BSC   £143,530 £39,106 6.088  101 113 
3 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  196 272 
4 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 493 
5 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 164 
6 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 387 
7 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 274 
8 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 343 
9 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 329 
10 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 244 
Maximum consecutive failed attempts = 5 
1 MTX SSZ HCQ ABTS ADA GOL BSC    £134,989 £66,785 6.726 39 56 
2 MTX SSZ TICORA HCQ ABTS GOL ADA RTX BSC  £136,215 £61,828 6.601 5 59 
3 MTX SSZ HCQ TICORA CTZ BSC     £142,545 £49,168 6.390 41 66 
4 MTX SSZ HCQ TICORA CTZ BSC     £142,545 £49,168 6.390 1 74 
5 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  58 79 
6 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 142 
7 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 9 
8 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 40 
9 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 22 
10 MTX SSZ HCQ TICORA BSC      £143,530 £39,106 6.088  1 99 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm 
settings: Initial temperature 7000. Previous best solution for every round. Stop when maximum runs completed (temperature < 100). 2000 simulation model runs for tuning. Lundy 
Parameter 2.0x10
-5 






The basecase analysis was run with the tuned parameter settings for the SA algorithm. These 
were the Lundy cooling schedule with a parameter of 2.0x10-5, an initial temperature of 7,000 
and the algorithm stopping after 10 consecutive rejected solutions or a temperature less than 
100. The algorithm was run for 10 rounds with the best solution identified used at the initial 
solution for each restart. The results of the basecase analysis are provided in Table 7.27, along 
with the final parameter values. 40,000 patient simulations were run for each iteration of the 
algorithm, and the maximum possible number of iterations for each restart of the algorithm 
was 493. The algorithm converged on the current best solution during the first round after just 
188 iterations. Nine subsequent rounds of the algorithm did not find any improvement. 
The current best solution is exclusively a cDMARD sequence, given a willingness to pay of 
£30,000 per QALY gained. The best sequence found is {MTX, SSZ, HCQ, TICORA, BSC}. This 
sequence is consistent with the best sequence found in any of the tuning experiments. 
Therefore it is likely to be the global optima, although it is not possible to be certain. 
Table 7.27: Basecase results 
Basecase analysis 






Iterations 1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 188 291 
2 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 183 
3 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 60 
4 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 362 
5 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 493 
6 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 261 
7 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 166 
8 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 264 
9 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 173 
9 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 180 
END MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 100 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current 
best’ solution being identified by algorithm. bDMARDs in bold. Algorithm settings: Initial temperature 
7,000. Previous best solution for every round. Stop when maximum runs completed (temperature < 100) 
or 10 consecutive solutions rejected. 40,000 simulation model runs for tuning. Lundy cooling schedule 
with parameter 2.0x10
-5 
(Maximum possible runs per restart = 493) 
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2,433 total iterations of the algorithm were performed until the algorithm terminated.* From 
rounds 2 to 10, a better solution was not identified, however the algorithm still iterated 
(between 60 and 493 times) due to accepting worse solutions at high temperatures. The final 
‘end run’ local search was conducted (100 iterations) after 10 rounds, and confirmed the 
current best solution was a local optima. 
For every potential solution evaluated by the simulation optimisation algorithm, the NMB was 
stored within a cache. Therefore the final cache can be ranked in order of performance to 
identify the potential solutions that were close to the current best solution found. This was 
undertaken and the results for the top 20 solutions reported. This ranked top 20 of the cache 
is displayed in Table 7.28. The top 18 are highlighted in green, because their own performance 
falls within 2 estimated standard errors of the current best solution, indicating that there may 
be indifference between these solutions due to the patient level variance. The top 20 solutions 
are all composed of purely cDMARD sequences. In fact, all bar two sequences are within the 
neighbourhood of the current best, because they can all be reached by one of the three 
neighbourhood operators.  
  
                                                          
*
 This required ~15 hours on a Windows 64-bit PC with i5 Quad Core @ 2.00GHZ and 8GB RAM 
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Sequence (line) NMB* Costs* QALYs* 
1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 
2 SSZ MTX HCQ TICORA BSC £141,816 £38,368 6.006 
3 MTX HCQ SSZ TICORA BSC £141,752 £38,433 6.006 
4 SSZ HCQ MTX TICORA BSC £141,740 £38,445 6.006 
5 HCQ MTX SSZ TICORA BSC £141,609 £38,575 6.006 
6 HCQ SSZ MTX TICORA BSC £141,605 £38,579 6.006 
7 MTX SSZ TICORA HCQ BSC £140,342 £39,604 5.998 
8 SSZ MTX TICORA HCQ BSC £140,334 £39,612 5.998 
9 MTX HCQ TICORA SSZ BSC £140,214 £39,732 5.998 
10 SSZ HCQ TICORA MTX BSC £140,199 £39,747 5.998 
11 MTX SSZ HCQ BSC  £140,152 £34,586 5.825 
12 SSZ MTX HCQ BSC  £140,145 £34,594 5.825 
13 MTX HCQ SSZ BSC  £140,080 £34,658 5.825 
14 HCQ MTX TICORA SSZ BSC £140,070 £39,876 5.998 
15 SSZ HCQ MTX BSC  £140,068 £34,670 5.825 
16 HCQ SSZ TICORA MTX BSC £140,062 £39,884 5.998 
17 HCQ MTX SSZ BSC  £139,937 £34,801 5.825 
18 HCQ SSZ MTX BSC  £139,933 £34,805 5.825 
19 MTX TICORA SSZ HCQ BSC £138,136 £43,095 6.041 
20 SSZ TICORA MTX HCQ BSC £138,123 £43,108 6.041 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Algorithm settings: Initial 
temperature 7000. Previous best solution for every round. Stop when maximum runs completed 
(temperature < 100) or 50 consecutive solutions rejected. 40000 simulation model runs for tuning. 
Lundy Parameter 2.0x10
-5 
(Maximum possible runs per restart = 493). Highlighted green if within 2 
standard errors (£944) of best identified sequence 
 
SCENARIO ANALYSIS 
Alternative cost-effectiveness thresholds (λ) 
By varying lambda (the cost-effectiveness threshold), the net monetary benefit of each 
sequence will change, ceteris paribus. 
When lambda is zero, cost-minimisation is assumed, because any benefits are not valued at all. 
When lambda is very large, the decision problem tends towards benefit-maximisation, because 
the monetary value of any benefit dwarfs any costs associated with each sequence. 
When using the net monetary benefit framework for an economic evaluation, it is important to 
test the results and explore how they are affected by varying lambda, especially when the ICER 
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between comparators may fall very close to lambda (and therefore the incremental NMB will 
be very close), because a decision-maker’s belief about ‘true lambda’ may be very important 
when determining the true optimal solution. For NICE, their cost-effectiveness threshold is 
defined as £20,000 - £30,000 per QALY gained, and there are instances where technologies can 
be approved with an ICER above £30,000 per QALY gained. Therefore a single defined lambda 
is not available for the purposes of NICE. Therefore scenario analysis with alternative values of 
lambda is important. Scenario analysis was performed with lambda values of £0, £20,000, 
£50,000, £100,000 and £1,000,000. 
Table 7.29 provides the scenario analysis results for lambda values of £0, £20,000 and £50,000 
per QALY. The cost minimising (lambda of £0 per QALY) strategy was ‘do nothing’, with the 
optimal sequence purely best supportive care. At lambda of £20,000 per QALY, the results 
were consistent with the basecase analysis (lambda of £30,000 per QALY) with the best 
sequence found being {MTX, SSZ, HCQ, BSC}. When lambda is increased to £50,000 per QALY, 
bDMARDs contribute to the best identified sequence, but only after all cDMARD treatments 
have been used. The best sequence is {SSZ, HCQ, MTX, TICORA, CTZ, RTX, ETN, ADA, ABTS, 
GOL, BSC}. 
Table 7.30 provides the scenario analysis results for lambda values of £100,000 and £1,000,000 
per QALY. At £100,000 per QALY, first line use of bDMARDs contribute to the optimal 
treatment sequence. The best sequence identified is {ADA, RTX, MTX, SSZ, HCQ, TICORA, ABTS, 
ETN, CTZ, GOL, IFX, TCZ, BSC}. At £1,000,000 per QALY, the results are identical to £100,000. 
The best sequence identified is {ADA, RTX, MTX, SSZ, HCQ, TICORA, ABTS, ETN, CTZ, GOL, IFX, 
TCZ, BSC} 
It should be noted that the algorithm was not tuned for these much larger estimates of the 
objective function (NMB). Therefore it is not surprising that the algorithm appears to perform 
less well when undertaking these scenario analyses with a high lambda. The same solution is 
identified at £100,000 per QALY and at £1,000,000 per QALY, but the algorithm appears to 
require more rounds before the best solution is identified, at least compared to the basecase 
analysis and the scenarios conducted with lower lambda values. 
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Table 7.29: Scenario analysis - Lambda values £0, £20,000, £50,000 
Lambda £0 per QALY (Cost-Minimisation) 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 11 
1 BSC           -£22,995 £22,995 4.502 205 
2 BSC           -£22,995 £22,995 4.502 1 
. . . 
               
10 BSC           -£22,995 £22,995 4.502 1 
END BSC           -£22,995 £22,995 4.502 1 
Lambda £20,000 per QALY 
1 MTX SSZ HCQ BSC        £81,906 £34,586 5.825 35 
2 MTX SSZ HCQ BSC        £81,906 £34,586 5.825 1 
. . . 
               
10 MTX SSZ HCQ BSC        £81,906 £34,586 5.825 1 
END MTX SSZ HCQ BSC        £81,906 £34,586 5.825 1 
Lambda £50,000 per QALY 
1 SSZ MTX HCQ TICORA ETN ADA RTX IFX GOL BSC   £264,592 £61,950 6.531 87 
2 MTX SSZ HCQ TICORA CTZ RTX ETN BSC       £266,383 £57,491 6.477 138 
3 MTX SSZ HCQ TICORA CTZ RTX ETN BSC       £266,383 £57,491 6.477 1 
4 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 162 
5 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 1 
6 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 1 
7 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 1 
8 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 1 
9 MTX SSZ HCQ TICORA ABTS RTX ADA CTZ ETN BSC   £266,516 £60,074 6.532 1 
10 SSZ HCQ MTX TICORA CTZ RTX ETN ADA ABTS GOL BSC £266,832 £59,746 6.532 276 
END SSZ HCQ MTX TICORA CTZ RTX ETN ADA ABTS GOL BSC £266,832 £59,746 6.532 1 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm settings: Initial 
temperature 7000. Previous best solution for every round. Stop when maximum runs completed (temperature < 100) or 50 consecutive solutions rejected. 40,000 simulation model. 
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Table 7.30: Scenario analysis - Lambda values £100,000, £1,000,000 
Lambda £100,000 per QALY 
Round Sequence (line) NMB* Costs* QALYs* Iteration when  
best solution found 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 ADA RTX SSZ MTX HCQ CTZ TICORA ABTS ETN GOL IFX BSC  £614,106 £112,587 7.267 426 
2 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 227 
3 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 1 
4 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 1 
5 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 1 
6 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 1 
7 ADA RTX SSZ MTX HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,214 £111,885 7.261 1 
8 ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 3 
9 ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 1 
10 ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 1 
END ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 1 
Lambda £1,000,000 per QALY 
1 ADA ETN TCZ GOL CTZ RTX MTX ABTS TICORA IFX SSZ HCQ BSC £7,300,822 £148,251 7.449  321 
2 ADA RTX ETN GOL CTZ TCZ IFX TICORA MTX ABTS SSZ HCQ BSC £7,302,991 £133,829 7.437  185 
3 ADA RTX ETN GOL CTZ TCZ IFX TICORA MTX ABTS SSZ HCQ BSC £7,302,991 £133,829 7.437  1 
. . .              
 
   
10 ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 1 
END ADA RTX MTX SSZ HCQ TICORA ABTS ETN CTZ GOL IFX TCZ BSC £614,216 £111,883 7.261 1 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. bDMARDs in bold . Algorithm settings: Initial 




Alternative treatment decrement values 
A treatment decrement parameter affects the effectiveness of the treatment within a 
sequence. It is applied to any cDMARD treatment where two prior cDMARDs are used, and 
also to any bDMARD treatment where two prior bDMARDs have been used. In the basecase 
analysis, the parameter is set at 10%. Once two prior (cDMARD or bDMARDs) have been used 
in the treatment sequence, the probability of treatment response is reduced by multiplying the 
probability of response by 1-10%. By varying the treatment decrement parameter, the 
downstream efficacy of treatments can be altered, to reflect diminished efficacy when similar 
treatments have already been attempted (classified by cDMARD or bDMARD status). 
Scenario analyses were conducted with the treatment decrement parameter set at 0%, 20%, 
30% and 40%, compared to the basecase value of 10%. 
This analysis found that the best sequence found identical to that found in the basecase 
analysis when the treatment decrement parameter was varied in all instances. (Table 7.31).  
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Table 7.31: Scenario analysis - treatment decrement values 
Treatment Decrement = 0% 
Round Sequence (line) NMB  Costs* QALYs* Iteration when  
best solution found 1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £142,913 £40,314 6.108 120 
2 MTX SSZ HCQ TICORA BSC £142,913 £40,314 6.108 1 
. . . 
         
10 MTX SSZ HCQ TICORA BSC £142,913 £40,314 6.108 1 
END MTX SSZ HCQ TICORA BSC £142,913 £40,314 6.108 1 
Treatment Decrement = 20% 
1 MTX SSZ HCQ TICORA BSC £139,471 £36,074 5.852 179 
2 MTX SSZ HCQ TICORA BSC £139,471 £36,074 5.852 1 
. . . 
         
10 MTX SSZ HCQ TICORA BSC £139,471 £36,074 5.852 1 
END MTX SSZ HCQ TICORA BSC £139,471 £36,074 5.852 1 
Treatment Decrement = 30% 
1 MTX SSZ HCQ TICORA BSC £138,588 £34,552 5.771 311 
2 MTX SSZ HCQ TICORA BSC £138,588 £34,552 5.771 1 
. . . 
         
10 MTX SSZ HCQ TICORA BSC £138,588 £34,552 5.771 1 
END MTX SSZ HCQ TICORA BSC £138,588 £34,552 5.771 1 
Treatment Decrement = 40% 
1 MTX SSZ HCQ TICORA BSC £138,217 £34,390 5.754 171 
2 MTX SSZ HCQ TICORA BSC £138,217 £34,390 5.754 1 
. . . 
         
10 MTX SSZ HCQ TICORA BSC £138,217 £34,390 5.754 1 
END MTX SSZ HCQ TICORA BSC £138,217 £34,390 5.754 1 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ solution being identified by algorithm. 
bDMARDs in bold . Algorithm settings: Initial temperature 7000. Previous best solution for every round. Stop when maximum runs completed (temperature < 
100) or 50 consecutive solutions rejected. 40,000 simulation model. 
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Alternative cooling schedules 
The final scenario analysis involved running the SA algorithm using the linear and geometric 
cooling schedules. These cooling schedules were run using the tuned parameters estimated in 
the tuning process (see Table 7.20 and Table 7.21). The results are reported in Table 7.32. 
Table 7.32: Scenario analysis - alternative cooling schedules 
Geometric Cooling: 50 Repetitions per step. Cooling rate 0.80 (Maximum possible runs per round = 1200) 





Iterations 1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 615 1001 
2 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 693 
3 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 874 
4 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 671 
5 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 961 
6 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 828 
7 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 350 
8 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 746 
9 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 540 
10 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 549 
END MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 100 
Linear Cooling: 100 Repetitions per step. 500 Decrement per step. (Maximum possible runs per round = 1400) 
1 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 971 1400 
2 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1301 
3 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
4 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
5 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
6 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
7 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
8 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
9 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
10 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 1400 
END MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 1 100 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. Green shading for ‘current best’ 
solution being identified by algorithm. bDMARDs in bold. Algorithm settings: Initial temperature 7,000. Previous 
best solution for every round. Stop when maximum runs completed (temperature < 100) or 10 consecutive 
solutions rejected. 40,000 simulation model runs  
 
The best found sequence was consistent with that identified in the basecase analysis, 
irrespective of which cooling schedule was use. However, the basecase cooling schedule 
(Lundy) was much more efficient. The geometric and linear cooling schedules took 6,312 and 
14,001 iterations, respectively, compared with the basecase analysis which took 2,433. 
OPTIMAL CDMARD-ONLY TREATMENT SEQUENCE 
The patient simulation model was run without the optimisation procedure, enabling a subset 
of user-specified cDMARD treatment sequences to be run. The total number of sequences 
which only include cDMARD treatments is 65 (see Table 7.33). All 65 sequences were run in 
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the simulation model to identify the optimal cDMARD-only treatment sequence, and the 
results are presented in Table 7.33. MTX, HCQ and SSZ have identical efficacy*, which is why 
many sequences generate identical total QALY estimates. Unsurprisingly, these results 
mirrored the basecase analysis, with an optimal sequence of {MTX, SSZ, HCQ, TICORA, BSC}. 
The top six solutions are within two standard errors of the apparent optimal solution {MTX, 
SSZ, HCQ, TICORA, BSC}, and are highlighted in green. 
The most effective set of sequences {TICORA, cDMARD, BSC} (solutions 43-48 in Table 7.33) 
were also the most costly. From this analysis, some conclusions can be drawn. Firstly, at a 
lambda threshold of £30,000 per QALY, an intensive strategy (TICORA) of combination 
DMARDs may not be cost effective as first line treatment. Also, if treatments are assumed to 
have equal efficacy and licensed indication (as with MTX, SSZ and HCQ) then it is logical that 
treatments are prescribed in ascending order of treatment cost.  
  
                                                          
*
 They are identical in terms of initial treatment response, length of time spent on treatment, and their 
impact on HAQ progression over time.  
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Table 7.33: Optimisation of cDMARD treatment sequence 
Sequence 
(ranked by NMB) 
Line NMB* Costs* QALYs* 
1 2 3 4 5 
1 MTX SSZ HCQ TICORA BSC £141,824 £38,361 6.006 
2 SSZ MTX HCQ TICORA BSC £141,816 £38,368 6.006 
3 MTX HCQ SSZ TICORA BSC £141,752 £38,433 6.006 
4 SSZ HCQ MTX TICORA BSC £141,740 £38,445 6.006 
5 HCQ MTX SSZ TICORA BSC £141,609 £38,575 6.006 
6 HCQ SSZ MTX TICORA BSC £141,605 £38,579 6.006 
7 MTX SSZ TICORA HCQ BSC £140,342 £39,604 5.998 
8 SSZ MTX TICORA HCQ BSC £140,334 £39,612 5.998 
9 MTX HCQ TICORA SSZ BSC £140,214 £39,732 5.998 
10 SSZ HCQ TICORA MTX BSC £140,199 £39,747 5.998 
11 MTX SSZ HCQ BSC 
 
£140,152 £34,586 5.825 
12 SSZ MTX HCQ BSC 
 
£140,145 £34,594 5.825 
13 MTX HCQ SSZ BSC 
 
£140,080 £34,658 5.825 
14 HCQ MTX TICORA SSZ BSC £140,070 £39,876 5.998 
15 SSZ HCQ MTX BSC 
 
£140,068 £34,670 5.825 
16 HCQ SSZ TICORA MTX BSC £140,062 £39,884 5.998 
17 HCQ MTX SSZ BSC 
 
£139,937 £34,801 5.825 
18 HCQ SSZ MTX BSC 
 
£139,933 £34,805 5.825 
19 MTX TICORA SSZ HCQ BSC £138,136 £43,095 6.041 
20 SSZ TICORA MTX HCQ BSC £138,123 £43,108 6.041 
21 MTX TICORA HCQ SSZ BSC £138,095 £43,136 6.041 
22 SSZ TICORA HCQ MTX BSC £138,079 £43,152 6.041 
23 HCQ TICORA MTX SSZ BSC £137,855 £43,376 6.041 
24 HCQ TICORA SSZ MTX BSC £137,852 £43,379 6.041 
25 MTX SSZ TICORA BSC 
 
£137,672 £38,370 5.868 
26 SSZ MTX TICORA BSC 
 
£137,664 £38,377 5.868 
27 MTX HCQ TICORA BSC 
 
£137,387 £38,655 5.868 
28 SSZ HCQ TICORA BSC 
 
£137,360 £38,681 5.868 
29 HCQ MTX TICORA BSC 
 
£137,243 £38,798 5.868 
30 HCQ SSZ TICORA BSC 
 
£137,224 £38,817 5.868 
31 MTX SSZ BSC 
  
£136,339 £32,686 5.634 
32 SSZ MTX BSC 
  
£136,332 £32,694 5.634 
33 MTX HCQ BSC 
  
£136,053 £32,972 5.634 
34 SSZ HCQ BSC 
  
£136,027 £32,999 5.634 
35 HCQ MTX BSC 
  
£135,911 £33,114 5.634 
36 HCQ SSZ BSC 
  
£135,892 £33,133 5.634 
37 MTX TICORA SSZ BSC 
 
£135,646 £41,894 5.918 
38 SSZ TICORA MTX BSC 
 
£135,633 £41,907 5.918 
39 MTX TICORA HCQ BSC 
 
£135,453 £42,086 5.918 
40 SSZ TICORA HCQ BSC 
 
£135,427 £42,113 5.918 
41 HCQ TICORA MTX BSC 
 
£135,213 £42,326 5.918 
42 HCQ TICORA SSZ BSC 
 
£135,200 £42,340 5.918 
43 TICORA MTX SSZ HCQ BSC £134,294 £47,885 6.073 
44 TICORA SSZ MTX HCQ BSC £134,290 £47,889 6.073 
45 TICORA MTX HCQ SSZ BSC £134,252 £47,927 6.073 
46 TICORA SSZ HCQ MTX BSC £134,245 £47,934 6.073 
47 TICORA HCQ MTX SSZ BSC £134,177 £48,002 6.073 
48 TICORA HCQ SSZ MTX BSC £134,175 £48,005 6.073 
49 MTX TICORA BSC 
  
£132,292 £40,465 5.759 
50 SSZ TICORA BSC 
  
£132,266 £40,491 5.759 
51 HCQ TICORA BSC 
  
£131,845 £40,912 5.759 
52 TICORA MTX SSZ BSC 
 
£131,437 £46,703 5.938 
53 TICORA SSZ MTX BSC 
 
£131,432 £46,707 5.938 
54 TICORA MTX HCQ BSC 
 
£131,232 £46,907 5.938 
55 TICORA SSZ HCQ BSC 
 
£131,214 £46,926 5.938 
56 TICORA HCQ MTX BSC 
 
£131,157 £46,982 5.938 
57 TICORA HCQ SSZ BSC 
 
£131,143 £46,996 5.938 
58 MTX BSC 
   
£127,929 £29,661 5.253 
59 SSZ BSC 
   
£127,902 £29,687 5.253 
60 TICORA MTX BSC 
  
£127,678 £45,125 5.760 
61 TICORA SSZ BSC 
  
£127,660 £45,143 5.760 
62 HCQ BSC 
   
£127,483 £30,107 5.253 
63 TICORA HCQ BSC 
  
£127,385 £45,418 5.760 
64 TICORA BSC 
   
£121,357 £42,091 5.448 
65 BSC 
    
£112,062 £22,995 4.502 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY.  




COMPARISON TO NICE MTA APPRAISAL OF RA BIOLOGICS 
The simulation model was run using the treatment sequences evaluated in the NICE MTA 
appraisal of RA bDMARDs (Severe RA patients, Population 1 and 2). 12 sequences were 
evaluated; one cDMARD comparator sequence {MTX, TICORA, BSC}; eight third-line bDMARD 
sequences {MTX, TICORA, bDMARD 1, RTX 2, bDMARD2*, BSC}, and three first line bDMARD 
sequences {bDMARD1, RTX, TCZ, MTX, TICORA, BSC}. 
The full results are presented in Table 7.34. At a lambda threshold of £30,000 per QALY gained, 
the optimal sequence was the cDMARD comparator sequence. bDMARD sequences were not 
cost-effective, at both first line and third line use. The cDMARD comparator sequence was 
both the least costly and least effective. The bDMARD sequences provided additional benefits 
in terms of QALYs, but at too high a cost. 
Table 7.34: Comparison to NICE MTA appraisal of RA biologics 
Sequence 
Line NMB* Costs* QALYs* ICER 
1 2 3 4 5 6 7 
cDMARD comparator sequence 
1 TICORA MTX BSC 
  
  £127,678 £45,125 5.760 - 
Third line bDMARD sequences 
2 TICORA ABT RTX TCZ MTX BSC  £105,055 £99,095 6.805 £51,646
1
 
3 TICORA ABTS RTX TCZ MTX BSC  £105,658 £99,782 6.848 £50,236
1
 
4 TICORA ADA RTX TCZ MTX BSC  £105,086 £99,874 6.832 £51,072
1
 
5 TICORA CTZ RTX TCZ MTX BSC  £107,156 £96,994 6.805 £49,635
1
 
6 TICORA ETN RTX TCZ MTX BSC  £104,527 £100,733 6.842 £51,394
1
 
7 TICORA GOL RTX TCZ MTX BSC  £104,647 £99,773 6.814 £51,848
1
 
8 TICORA IFX RTX TCZ MTX BSC  £99,160 £100,550 6.657 £61,789
1
 
9 TICORA TCZ RTX MTX BSC   £119,853 £95,277 7.171 £55,911
1
 
Current NICE recommended treatment sequence 
10 MTX TICORA ADA RTX TCZ SSZ BSC £120,777 £77,043 6.594 - 
First line bDMARD sequence  
11 ADA RTX TCZ MTX BSC   £93,074 £120,136 7.107 £84,002
2
 
*Costs (£) and QALYs discounted at 3.5%. NMB valued at £30,000 per QALY. 
1
Compared to sequence 1 
 
2
Compared to sequence 10 
 
The use of bDMARDs in third-line had an ICER of between £49,635 and £61,789 per QALY 
gained compared to cDMARDs only. The range was dependent on the particular bDMARD 
therapy used. These results are slightly lower than the original results estimated in the NICE RA 
MTA assessment group analysis. The basecase ICER using the original model was £56,000 per 
QALY gained for third line bDMARD therapy compared to cDMARDs only. 
The use of bDMARDs in first line had an ICER of £84,002 per QALY gained compared a 
treatment sequence reflecting NICE guidance. These results are slightly lower than the original 
                                                          
*
 Where relevant 
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results estimated in the NICE RA MTA assessment group analysis. The range was dependent on 
the particular bDMARD therapy used. The basecase ICER using the original model was £98,000 
per QALY gained for first line bDMARD therapy compared a treatment sequence reflecting 
NICE guidance. 
Unfortunately the full NICE MTA results, in terms of absolute costs and QALYs, cannot be 
reported due to being Commercial in Confidence. 
The deviation between the two analyses could come from several different sources: 
1. The modifications undertaken (see page 155) within the Simul8 model may have 
significantly altered the results. Using metamodels and incorporating a treatment decrement 
parameter will undoubtedly alter the results slightly. 
2. An error in either version of the model, which given the size and complexity of the 
models does remain a possibility 
3. Slight different sequences of treatments being modelled – the SOSA analysis model 
was amended slightly to match the NICE MTA sequences evaluated 
4. Slightly different patient populations – this analysis used the treatment naïve 
(Population 1) data for the patient population, and then models cDMARD use until bDMARDs 
(Population 2/3 in the MTA), and these patients may be different to those sampled in 
Population 2/3 used in the MTA. 
Both models were fully validated, and the NICE MTA model underwent a full external peer-
review. Therefore it is important to highlight that the software package used, and therefore 
the methods used to develop the model and simulate lifetime costs and QALYs may have an 
impact on the validity of the final results. It should also be noted that the objective of this 
analysis was not to replicate the NICE MTA model, but instead to provide a model which would 
enable the implementation of the simulation optimisation method, and therefore the 
deviation between the two sets of results does not detract from meeting this objective. 
COMPARISON TO EXISTING NICE GUIDANCE 
The existing NICE clinical pathway for patients with severe RA was detailed in Figure 5.1. After 
two cDMARDs, patients can receive a bDMARD. After this bDMARD, patients can receive RTX, 
and then TCZ. If a patient is contraindicated to RTX, then an alternative bDMARD can be used. 
The model was run with the 21 sequences possible from this current NICE guidance pathway. It 
was assumed, for simplicity, that people are eligible for RTX treatment. The first line treatment 
was either TICORA, or two sequential cDMARD therapies before bDMARDs. If the first line 
treatment was TICORA, then Sequences 8-14 assume that cDMARDs are not used after 
217 
 
bDMARD treatment, and Sequences 15-21 assume that the remaining cDMARDs are used after 
bDMARD treatment. 
The best sequence identified from the basecase simulation optimisation {MTX, SSZ, HCQ, 
TICORA, BSC} was run as a comparator (Sequence 22). This was undertaken to see if the new 
sequence identified was superior, and whether it was more efficacious than current NICE 
guidance. 
Table 7.35 presents the results from this analysis. The best sequence in terms of maximising 
NMB remains the sequences found in the basecase simulation optimisation {MTX, SSZ, HCQ, 
TICORA, BSC}. 
However, this sequence is both less costly and less efficacious when compared with the NICE 
guidance pathway. In these sequences, bDMARDs are used from third line position in the 
sequence. The addition of bDMARDs increases the lifetime QALYs provided by the treatment 
sequence. These sequences are also much more costly. Using {MTX, SSZ} as the first line 
treatment in the sequence is superior compared to using TICORA. This reinforces earlier 
findings (Table 7.28). 
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Table 7.35: NICE guidance comparison 
Sequences 
 
Line NMB* Costs* QALYs* 
1 2 3 4 5 6 7 8 
“MTX, SSZ” first line NICE sequence 
1 MTX SSZ ADA RTX TCZ TICORA HCQ BSC £123,629 £75,467 6.637 
2 MTX SSZ ETN RTX TCZ TICORA HCQ BSC £123,182 £76,521 6.657 
3 MTX SSZ IFX RTX TCZ TICORA HCQ BSC £122,018 £76,652 6.622 
4 MTX SSZ CTZ RTX TCZ TICORA HCQ BSC £125,364 £73,346 6.624 
5 MTX SSZ GOL RTX TCZ TICORA HCQ BSC £123,799 £75,246 6.635 
6 MTX SSZ ABT RTX TCZ TICORA HCQ BSC £123,105 £75,562 6.622 
7 MTX SSZ ABTS RTX TCZ TICORA HCQ BSC £123,446 £75,648 6.636 
TICORA first line NICE sequence(no post-biologics cDMARDs) 
8 TICORA ADA RTX TCZ BSC    £104,275 £99,266 6.786 
9 TICORA ETN RTX TCZ BSC    £102,993 £100,690 6.789 
10 TICORA IFX RTX TCZ BSC    £102,826 £100,085 6.764 
11 TICORA CTZ RTX TCZ BSC    £105,439 £96,768 6.740 
12 TICORA GOL RTX TCZ BSC    £104,999 £98,838 6.795 
13 TICORA ABT RTX TCZ BSC    £103,996 £98,761 6.759 
14 TICORA ABTS RTX TCZ BSC    £104,144 £99,210 6.778 
TICORA first line NICE sequence(including post-biologics cDMARDs) 
15 TICORA ADA RTX TCZ MTX SSZ HCQ BSC £105,897 £100,240 6.871 
16 TICORA ETN RTX TCZ MTX SSZ HCQ BSC £105,301 £101,415 6.891 
17 TICORA IFX RTX TCZ MTX SSZ HCQ BSC £104,949 £101,039 6.866 
18 TICORA CTZ RTX TCZ MTX SSZ HCQ BSC £107,269 £97,717 6.833 
19 TICORA GOL RTX TCZ MTX SSZ HCQ BSC £106,004 £100,032 6.868 
20 TICORA ABT RTX TCZ MTX SSZ HCQ BSC £105,661 £99,880 6.851 
21 TICORA ABTS RTX TCZ MTX SSZ HCQ BSC £106,022 £100,297 6.877 
Best sequence from simulation optimisation 
22 MTX SSZ HCQ TICORA BSC    £141,824 £38,361 6.006 




7.5 DISCUSSION AND CONCLUSIONS 
The aim of this chapter was to undertake a simulation optimisation of a discrete event 
simulation model, to enable the identification of an optimal or near-optimal DMARD 
treatment sequence for patients with RA. 
SA with a memory function was selected as the simulation optimisation method to be 
implemented. Modifications to the DES model were required to enable the simulation 
optimisation algorithm to run. The SA algorithm required tuning of control parameters to 
enable it to function properly. The best solution found (across all simulations, as well as in the 
basecase analysis) was a CDMARD-exclusive sequence of {MTX, SSZ, HCQ, BSC}. For the 
basecase analysis, the algorithm was relatively quick to complete, requiring about 15hrs to 
run, and evaluating over 2,400 potential solutions. 
The best solution found was robust when the treatment decrement parameter was varied. The 
best solution found was also robust when a cost effectiveness threshold of £20,000 per QALY 
was assumed. At a threshold of £50,000 per QALY, the best sequence found included 
bDMARDs after four previous cDMARD treatments. First line bDMARD use was found to be 
potentially optimal when the threshold was increased to £100,000 per QALY. 
Compared to the NICE RA MTA model developed in Excel, the results using this model were 
found to be slightly different. This will be discussed further in the following paragraphs. Finally, 
the best sequence found was compared to the existing set of sequences recommended in the 
NICE guidance for RA. It was found that the best sequence identified {MTX, SSZ, HCQ, BSC} was 
optimal compared to NICE guidance, in that NMB would be increased. However, this increase 
in NMB was at the cost of a reduction in total QALYs.  
There are several limitations which require further consideration. 
Firstly, the Simul8 model is slightly different to the original model developed in Excel. 
Modifications were required to enable it to be developed in Simul8. The significant speedup 
offered by Simul8 came at a potential cost because the econometric models used to provide 
patient level parameters could not be properly incorporated. This represents a limitation of 
Simul8, but it also highlights the general trade-off between precision and speed, when 
developing a complex computer model. 
The difference in the results is highlighted in Table 7.34. These differences may come from the 
modifications made to the Simul8 model, as discussed. However, it could be that an error 
remains within the analysis, either in the Simul8 model for this thesis or the Excel model for 
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the RA MTA appraisal. Both models were validated but there always remains a risk of an 
unidentified error within a model. 
Secondly, the patient level variability within the model was such that a definitive statement 
about superiority between two very similar sequence was not possible. To account for this, the 
standard error of the best found sequence was used to illustrate which nearby solutions may 
be within a level of tolerance (twice an estimated standard error). In all cases, the results 
found to be within this margin of tolerance were very similar to that found to be the best. 
However, as reviewed in Chapter 6, there is a large body of methodological literature that 
looks to inform how to compare and rank the output of noisy simulation models. Due to 
limited time, it was not possible to investigate how these methods could be applied to the 
treatment sequencing problem, however this remains an area for further research. 
The SA algorithm required tuning to enable good performance. Trial and error was used across 
some control parameters, and simple factorial design across others, to enable experimentation 
of different control parameters. Ideally, a full factorial set of experiments would have been 
conducted to obtain the optimal setting for the algorithm, however this was not feasible. In 
reality, designing and tuning an optimisation algorithm such as a metaheurstic itself represents 
an optimisation problem. Hyperheuristic methods (see Section 6.8) enable the automation of 
this tuning process; however they require a very efficient simulation model for their use in a 
simulation optimisation problem. Also there remains the possibility of algorithm parameters 
which would enable the algorithm to perform better. Repeated tuning experiments was 
undertaken to build confidence that it was a change in a parameter which affected 
performance, rather than chance. However, it does remain possible that the final set of tuned 
parameters were found by chance, and that superior parameter settings exist. 
The algorithm appears to have performed well, given its simplicity compared to much more 
advanced SA implementations. Relatively simple static cooling schedules were evaluated and 
the SA algorithm uses a simple restart procedure to provide the algorithm with the best 
chance of escaping a local optima in the early rounds. The memory cache of previously 
evaluated solutions enabled a significant speed-up and should be considered in future. While 
the cooling schedules and SA algorithm performed well, more advanced schedules, such as 
dynamic schedules, and more advanced algorithms, including reheating procedures and 
adaptive neighbourhood functions could have improved performance even more. 
While the algorithm performed well in the basecase, when the lambda threshold was 
increased to a point where there was a large change in the NMB objective values being 
evaluated, then the algorithm performed less well. This was likely to occur because the 
221 
 
algorithm was not tuned for objective values of this particular magnitude. This is an important 
implication for health economic evaluation. Using a NMB framework allows the problem to be 
characterised as a simple maximisation problem, but the NMB for any solution is dependent 
on the lambda value used to monetise benefits. Therefore further tuning may be required if a 
set of lambda values are to be fully evaluated.  
The SO procedure utilises a link between Excel (the optimisation process) and Simul8 (the 
simulation model) to enable neighbouring sequences to be selected (implemented in Excel 
VBA) and then passed to Simul8 via Microsoft COM. This is potentially an area of inefficiency 
for the SO procedure. Also, the way the link was implemented meant that the number of 
simulation runs had to be predefined. That is, every run of the SO algorithm had a predefined 
number of patient simulations in the Simul8 model. Therefore it was not possible to attempt 
ordinal optimisation, or a statistical method which reduces the simulations required for 
solutions which are clearly inferior. This is a limitation of the approach taken, mainly due to 
current computing expertise, and also the fact that health economic models are normally 
developed in a package which enables a level of user interface. Executable models written in a 
true programming language may have offered significant speed up, as well as the possibility to 
test alternative SO methods, but it was not possible in this case. 
Finally, it was not possible within these timescales to implement an alternative metaheuristic 
method. For example, it would have been valuable to implement GA and compare its 
performance to SA. In the review in Chapter 6, only one study compared GA and SA in a 
combinatorial simulation optimisation problem. It would have added to the body of evidence 
to implement another metaheuristic and compare their performance. GA’s are harder to 
implement, and require more tuning due to having a greater number of user control 
parameters. The limited evidence from Lacksonen et al. (2001) is that GA’s offer greater 
performance but at the expense of longer running time.224 Therefore it was decided to try to 
implement one method but with as full an experimentation and tuning as possible, rather than 
implement two methods but with less time for tuning and experimentation. The comparative 
evidence would have been less robust, compared to the evidence found in this chapter which 
broadly supports SA and its use for SO. SA has been found to be efficient at reaching what 
appears to be a global optima of the problem. The method was relatively straightforward to 
implement, although the modifications required to rebuild the model in Simul8 may have 
made the final results less robust. The SA algorithm also requires more tuning to ensure that 





















CHAPTER 8: DISCUSSIONS, RECOMMENDATIONS AND CONCLUSIONS 
 
8.1 CHAPTER OVERVIEW 
This chapter provides a discussion of the research presented within this thesis. It highlights the 
contribution of this work within the context of other related research. It also provides 
recommendations for further research, before drawing conclusions. 
Section 8.2 presents the contribution of this work in the context of other research. Section 8.3 
considers the strengths and limitations of this research. Section 8.4 presents recommendations 
for further research. Finally, Section 8.5 draws conclusions about the overall value and impact 
of this research. 
 
8.2 CONTRIBUTION OF THIS WORK IN THE CONTEXT OF OTHER 
RESEARCH 
Since beginning this PhD at the start of 2012, there have been several key publications and 
further advances in research related to this area. 
Firstly, Tappenden et al. published a Whole Disease Modelling (WDM) methodological 
framework and an application of this framework.292,303 This WDM framework is a system-level 
approach to health economic modelling which captures the whole system of disease and 
treatment pathway within one consistent mathematical infrastructure. It allows the 
incorporation of multiple decision points, and the full quantification in terms of costs and 
QALYs of downstream consequences. An innovative aspect of the WDM framework is that it 
allows multiple decision points to be evaluated. Within the context of colorectal cancer, 
Tappenden et al. were able to evaluate screening, surgery, and metastatic treatment across 
the full pathway of cancer diagnosis and treatment.292 
The DES model developed for implementing simulation optimisation for the RA treatment 
sequencing problem is consistent with the principles of the WDM framework. A whole disease 
model is required for a full treatment sequence to be evaluated. The full consequences of 
alternative treatment sequences have been captured, and alternative options at every decision 
point (e.g. first line, second line, third line therapy) have been formally evaluated in the RA 
simulation optimisation analysis.  
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While the framework was not formally applied when developing either the NICE RA model or 
the Simul8 model, our research adds value to the WDM research by highlighting the 
importance of a consistent model which allows the evaluation of all possible decision points in 
a patient’s pathway. Piecemeal models and partial economic evaluations are likely to lead to 
sub-optimal decisions if downstream consequences are omitted. 
The application of a simulation optimisation extends the WDM framework. Rather than a 
process of identifying key decision questions and using a whole disease model to evaluate each 
decision question, all possible questions can be considered as an optimisation problem – how 
do we optimise the complete treatment pathway for a particular population? Although our 
context has been treatment sequencing, it would not be unfeasible to incorporate alternative 
policy decisions about diagnosis and treatment, such as optimising screening intervals and 
population selection, and optimising treatment switching rules. 
Secondly, there is an ongoing PhD on a similar topic by a post graduate student at ScHARR. 
Their research is specific to hypertension treatment, and applies metaheuristic methods to a 
health economic model. There has not been dialogue between the two PhD candidates while 
research has been ongoing. The PhD topics were developed in very separate contexts and had 
separate supervisory teams. However, it will be of great interest to consider the final outputs 
of both PhDs to see where conclusions are similar and where differences are found. 
Thirdly, a relevant paper was identified during the latter stages of this thesis. Brailsford et al. 
(2006) report the application an ant colony optimisation (ACO) model to identify optimal 
screening policies for diabetic retinopathy.304 It is not clear why this paper was not identified 
during the systematic review of simulation optimisation methods in Chapter 6. As such, this 
highlights a limitation of the search process used in the review.  
ACO is a population-based stochastic optimisation method. When a combinatorial problem can 
be demonstrated through a graph, such as the travelling salesman problem, then ACO can be 
applied to find the optimal route or path through the graph. 
Brailsford et al. used a previously published simulation based ACO method (S-ACO) for their 
analysis.305,306 The method used by Brailsford et al. is particularly interesting due to the 
dynamic process utilised. The development of a solution for evaluation (a particular screening 
programme) is guided by the simulation and ACO process in one model. This is different to an 
optimisation algorithm generating a solution, and then passing that solution to a simulation 
model for evaluation. The authors report that the method worked well and their results have 
225 
 
face validity. In particular, they maximise cost-effectiveness (identify the strategy with the 
lowest cost per year of sight saved), and also report the most effective screening strategy. 
It is a weakness of this thesis that this research was not identified earlier and considered in the 
systematic review. ACO appears to be a promising method, and further research within a 
health economic evaluation context would be of significant value. 
Finally, in 2013 NICE updated their Guide to the Methods of Technology Appraisal.47 I was an 
invited expert to provide a briefing paper and attend a working party meeting during this 
process (before this PhD began).* NICE had found that treatment sequences had caused issues 
for the development of guidance. My briefing paper regarding treatment sequences and 
downstream costs was considered by the working party. It highlighted that sequences should 
be considered, explores the key issues when modelling sequences, and identifies the key 
primary and sensitivity analyses which should be reported. This particular topic, as well as 
others, was influential in a modification to the Guide to the Methods of Technology Appraisal, 
which clarified that at the scoping stage, potentially relevant comparators should not be 
eliminated. Treatment sequences continue to represent a challenge for decision-makers and 
health economists. It is hoped that this thesis has provided a significant insight into the 
problem, and provides a potential method which can be applied. 
 
8.3 STRENGTHS AND LIMITATIONS OF THIS RESEARCH 
The rationale for undertaking this research is grounded by a systematic review (Chapter 3) 
which identifies how current methods have led to differing estimates of cost-effectiveness, 
and potentially sub-optimal decisions, with respect to RA sequences of treatments. 
The systematic review reported in Chapter 4 is comprehensive. All major databases were 
searched with no date limit applied and across all possible disease modifying treatments. 57 
studies and fully appraising them using the validated Drummond checklist.78 Systematic 
reviews are regarded as the most robust of all study design types, within evidence based 
medicine.† Although this particular review concerned health economic evaluations, rather than 
randomised controlled trials, it is still a transparent and robust synthesis of the totality of 
health economic evidence pertaining to RA treatment. 
                                                          
*
  http://www.nicedsu.org.uk/NICE-Methods-Guide-updates(1985333).htm – Accessed June 2015 
†
  http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ - 
Accessed June 2015 
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The systematic review was validated by cross-checking other reviews of RA health economic 
literature, including a systematic review also concerned with health economic evaluations for 
RA treatment sequences.120 The conclusions found across these similar reviews were 
consistent, adding to its validity. The chapter was also peer-reviewed and published in an 
international RA journal.94 
The research in this thesis is further underpinned by another systematic review (Chapter 6). 
This pearl growing systematic review uses innovative searching methods to identify methods 
of potential applicability to the treatment sequencing problem. As before, a systematic review 
is robust due to its validated and transparent methodology. In this case, the search and review 
was conducted across a range of academic disciplines. The applicability of each identified 
method was judged using a bespoke framework. This was reported with full transparency 
(extraction tables provided in Appendix B.4), to avoid bias.  
The breath of search may have meant that meant that some studies of relevance were missed. 
This is known to be true for the Brailsford et al. diabetic retinopathy study, and related 
research using Ant Colony Optimisation methods.304 It may have been beneficial to involve 
experts within the area of simulation optimisation to ensure that relevant methods and studies 
had been identified; however this was not feasible within the time available. 
The review sought to identify relevant methods, irrespective of the academic field they were 
developed in or applied. This included fields such as engineering, computing and mathematics. 
As such, there may be bias and errors in the interpretation of particular aspects of the method 
or optimisation problem. To minimise the risk of this, intensive training was undertaken 
alongside this PhD research. Courses offered by the OR Society and the National Taught Course 
Centre in Operational Research (NATCOR) were attended. Courses focussed on stochastic 
modelling, metaheuristics, optimisation and simulation modelling. Skills were developed to 
ensure that alternative methods could be assessed and applied to the RA treatment 
sequencing problem. 
The review of methods was specific to combinatorial problems and focussed on simulation 
optimisation methods. Therefore non-combinatorial problems were not included, although 
potentially they could work for a treatment sequencing problem. Also, statistical methods of 
sample approximation, and metamodeling/emulation were not included within this review. 
These could provide a solution to the treatment sequencing problem, but a decision was made 
to focus on metaheuristic methods due to the significant amount of current research that has 
been applied to combinatorial simulation optimisation problems. 
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Both systematic reviews would have benefitted from a second reviewer to validate and cross-
check data extraction and data appraisal. This approach is standard practice in regular health 
research and systematic reviewing, but not feasible for a PhD project. 
The timing of this PhD was ideal, because it enabled involvement with the NICE re-appraisal of 
biologics for RA. This enabled a model to be developed for the NICE appraisal and a separate 
model based on this to be developed for the PhD. The NICE MTA model was developed as a 
collaborative effort, involving health economists, statisticians, systematic reviews and 
modellers. This meant that the final model used the most appropriate evidence, and avoided 
simplifications which would have been inevitable if conducted by just one person. The model 
development process and team were carefully constructed so that I retained overall 
responsibility for the final model. However, much of the evidence synthesis used with in the 
model is the result of other people’s work. This reflects the reality of health economic model 
development, which is almost always a collaborative process. PhD’s are normally the 
endeavour of one person and sometimes this can act as a constraint. However, good timing 
and an accommodating team within ScHARR enabled my PhD to benefit from a much more 
comprehensive model, and I was able to engage with the NICE appraisal process and further 
understand the NICE process (scoping, appraisal, guidance development). 
The research would have benefitted from the experience of using the simulation optimisation 
methodology within a real world decision-making context. This was not possible during this 
PhD. However, with the SOSA method providing positive results, it is hoped to engage with 
upcoming NICE appraisals, in RA and in other chronic conditions, where flexible simulation 
modelling methods and optimisation methods can potentially be applied. 
A weakness is that a comparative evaluation of simulated annealing and an alternative 
optimisation method was not possible. It would have been ideal to implement alternative 
methods (for example, a genetic algorithm) and explore whether one particular method is 
superior. However, it was not feasible to undertake this within the PhD. Programming, tuning 
and evaluating one simulation optimisation method was a substantial undertaking, even 
though simulated annealing is often seen as a relatively straight forward algorithm to 
implement (compared with population based and adaptive metaheuristics methods). Also, the 
value of a comparison of two or more methods is limited due to their performance often being 
problem-specific. Finding that one method is superior to another in one problem context may 
not be useful if the converse is true in an alternative problem context. Therefore further 
studies of alternative methods within alternative problem contexts are of value. The evidence 
found within the systematic review of methods (Chapter 5) did not report a clear finding as to 
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which method is potentially best for a combinatorial simulation optimisation problem. 
Therefore this unanswered question is wider than just health economic evaluation, but a 
question for simulation optimisation as a discipline. 
The SOSA methodology would have been improved if it was possible to incorporate the 
precision of the estimated objective value into the algorithm’s decision to run a set of patients. 
For example, some SO methods allow the decision about whether to run more simulations to 
be determined by the expected estimate of the objective function and its variance. Therefore 
solutions which are clearly inferior are only run for a small number of patient simulations, but 
solutions which are very close, or potentially an improving solution are run for a large number 
of patient simulations. This could have improved the accuracy of the results, due to simulation 
time being focussed on good solutions and improving the precision of the estimate of 
performance, however it was not feasible due to the software used. Simul8 has limits on the 
dimensions of its data and it is unable to easily and efficiently move large data in and out of 
Excel. Also, the number of patients run had to be determined a priori using the COM interface, 
and was therefore the same for every evaluation. Using an alternative software package, or a 
programming language, would have got around this limitation, but this was not feasible. 
SOSA is limited by the software package or language it is implemented in. If using a bespoke 
simulation package such as Simul8 or Arena, then the complexity of the optimisation algorithm 
is limited to the bespoke programming language in each package (Visual Logic for Simul8, and 
a limited Visual Basic interface for Arena). Simul8 was chosen over Arena due to user 
familiarity, as well as being routinely used in our academic department; however it may be 
that it is feasible to program the simulation model and optimisation process within an Arena 
model. Further investigation and dialogue with OR simulation community may resolve this. 
The alternative to using a bespoke simulation package is to develop the simulation model and 
optimisation process within a particular programming language (C++, Java, Fortran, R etc.), the 
benefit may be increased performance, but the downside is that often programmed models 
are less visual for decision making purposes, which are significant limitations when considering 
the NICE appraisal process and the fact that the stakeholders and independent assessment 
groups must be able to externally validate and critique the model.  
Simul8 and Arena both have an optimisation software package associated with them 
(OptQuest), however this package is bespoke, black box and requires the full Professional 
version. It is not clear exactly what algorithm and process is being applied, although the 
documentation reports that composite search algorithm is used combining ‘tabu search, 
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scatter search, integer programming and neural networks’.* Using a black box bespoke 
optimisation software package is less suitable for academic purposes, although it may well 
deliver good performance in practice. 
A final strength of this research is that the generalisability and robustness of SA continues to 
be reinforced. The algorithm remains relatively simple and easy to implement, but has good 
performance across a range of simulation and non-simulation optimisation problems. Applying 
it to a treatment sequencing problem is yet another unique problem instance where it has 
performed well. There remain several other possibilities for optimisation within a health 
economic evaluation context and SA would appear to be a potential solution. 
8.4 RECOMMENDATIONS FOR FURTHER RESEARCH 
This thesis represents a single attempt to apply SOSA to the RA treatment sequencing 
problem. Therefore remains several unresolved methodological issues regarding SOSA which 
require further research. 
FURTHER EVALUATION 
Repeated evaluation would generate greater evidence regarding the appropriateness and 
feasibility of using simulation optimisation for DES models in a health economic evaluation 
context. Within simulated annealing, there are alternative neighbourhood functions, cooling 
schedules and algorithm methodologies which could provide better results and greater 
efficiency. The algorithm applied is relatively simplistic, and a significant improvement in using 
SA for the RA treatment sequencing problem could be made by applying more cutting edge SA 
methods. 
Outside of SA, there remain other metaheuristics which may offer greater performance. GAs 
have been shown to perform well for combinatorial SO problems, but there remain questions 
regarding their efficiency. Brailsford et al. found that ACO performed well for their diabetic 
retinopathy screening optimisation problem. Further evaluation with these alternative 
methodologies is required. 
FURTHER GENERALISABILITY 
This research focussed on an application of SOSA for a treatment sequencing problem in RA. 
There are other clinical conditions where treatment sequencing issues remain, and where sub-
optimal sequences of treatments may be used, both from a clinical and health economic 
viewpoint. These conditions include depression, hypertension, epilepsy and other chronic 
conditions. Also, wider than just clinical areas, the new advances in personalised medicine and 
                                                          
*
 http://goo.gl/0B8wM9 - OptQuest documentation - Accessed June 2015 
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gene therapy open up possibilities for SOSA to be applied to individualised patient treatment 
pathways, including adaptive treatment decisions which involve patient characteristics and 
rapid simulation of future costs and benefits.  
If SOSA is used in other clinical areas and problem contexts, then further evaluation should be 
undertaken. Qualitative research involving health economists could provide further evidence 
regarding the feasibility of SOSA within the particular decision context within which it is being 
applied.  Also, more broadly, qualitative research involving decision-makers would help 
understand more fully the contexts in which SOSA may and may not be helpful. 
PILOT STUDY WITH A DECISION-MAKING CONTEXT 
The application of SOSA within a real-life decision-making context would be very valuable. The 
current window of time afforded to model development and evaluation within a NICE MTA is 
already very tight. It is unlikely that SOSA could be undertaken within this current window. The 
implementation, tuning and evaluation took the best part of 1 year to complete, and that was 
with an existing model structure to use, albeit in a separate platform. There may be ways to 
significantly reduce the time required to undertake SO. Computer code was written from 
scratch for this analysis; however components could be reused in the future (see Code in 
Appendix D). If further evaluations of alternative SO methods are undertaken then less tuning 
may be required as confidence in the performance of alternative metaheuristics grows. 
Efficiently coded DES models could theoretically be used with a hyperheuristic, which would 
remove a great deal of bespoke coding and algorithm development. Simulation methods 
continue to advance, along with computing power, which will enable more complex models to 
be evaluated more quickly. 
The SO process could be brought forward in the NICE decision-making context, and instead of 
being used for optimisation, it could be used as a method to ‘seek’ decision problems and 
contexts which may or may not be most important for evaluation. For example, the results 
show from our evaluation that first line bDMARD use is not cost-effective. This could have 
been identified at the scoping stage and not taken forward for full evaluation. An existing 
model would be required, but it would enable NICE to avoid evaluating decision problems with 
a high likelihood of an intervention not being cost-effective. Where quite different sequences 
are identified to have very similar NMB, then a much more robust evaluation and comparison 
between those two (or more) sequences could be conducted.* 
                                                          
*
 for example, a non-bDMARD sequence has similar estimated NMB to a bDMARD sequence 
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Instead the results can be used to identify the iNMB between ‘good sequences’ and highlight 
where further evaluations (including many more patient simulations) should focus to gain 
more confidence in the optimality of a particular sequence. 
Making a definitive decision to recommend one treatment sequence over another when the 
iNMB between them is very small is unlikely to happen. Monte Carlo error leads to a risk that a 
wrong decision is made in reality, and even if the right decision is made, the net gain is very 
small. There may be numerous reasons for why a decision maker may decide to avoid making a 
distinction between closely performing alternative sequences. These include: pharmaceutical 
competition; patient choice; clinical choice; benefits not captured within the QALY; and the 
continued generation of clinical evidence. Also, it is likely to suggest overconfidence in the DES 
model that underpins the analysis, and a metaheuristic cannot guarantee the optimal solution, 
just a near-optimal solution with varying degrees of confidence. 
  
8.5 CONCLUSIONS 
The aim of this research was to test the feasibility of simulation optimisation methods to find 
an optimal or near-optimal sequence of disease modifying treatments for RA in an economic 
evaluation framework. The thesis has looked to explore why treatment sequences are used 
and why they present a challenge for economic evaluation, and reviewed economic 
evaluations in RA to identify why sequences have not been fully considered. The thesis then 
framed the treatment sequencing problem as an optimisation problem, and reviewed 
simulation optimisation methods and assessed their appropriateness and feasibility for 
addressing the treatment sequencing problem. Finally, the thesis contains an implementation 
of SOSA, and considers its real world applicability within a health economic evaluation context. 
The review of economic evaluations in Chapter 4 reaffirmed a prior belief, that existing 
analyses have not sought an optimal treatment sequence in RA. Coupled with NICE 
undertaking numerous partial evaluations and appraisals, there is a significant risk that sub-
optimal guidance has been developed for RA. This concern could pass through to other chronic 
conditions where treatment sequences are common. 
SOSA has been identified and applied, which represents a novel use of a methodology from 
another field, and its application to a health economic evaluation problem is unique. SOSA has 
shown promise as a potential method for resolving treatment sequencing health economic 
evaluation problems, where a simulation model is computationally expensive, and the number 
of alternative competing solutions is large. 
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The implementation of SOSA found that the best solution found by the analysis generates 
greater net monetary benefit that the current sequence recommended by NICE. However, the 
sequence identified is more cost-effective, but at reduced total QALYs. While plausible and 
economically valid, it is unlikely to see implementation by NICE. Identifiable patients would 
suffered reduced health benefits while unidentifiable patients would benefit. 
When this research began, there was an absence of literature informing the development of 
health economic models for treatment sequencing problems. As such, there was variability in 
the approaches used to model treatment sequences.94 The research undertaken has 
attempted to fill this void, and reduce this variability, by drawing across academic disciplines 
and applying and evaluating a methodology which has not previously been attempted. 
 Overall, the aims and objectives of this thesis have been achieved. The research represents a 
novel and innovative addition to the body of methodological research that underpins health 
economic evaluation. There is scope for further research; however this thesis represents a 
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APPENDIX A: RA ECONOMIC EVALUATION SYSTEMATIC REVIEW 
APPENDIX A.1: PRISMA CHECKLIST 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  43 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  
45 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  43 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
46 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including 
registration number.  
n/a 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as 




Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and 
date last searched.  
46 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  256 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  46 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
47 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  47 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), 
and how this information is to be used in any data synthesis.  
47 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  47 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2
) for each meta-analysis.  n/a 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  n/a 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
50 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  52 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  58 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
n/a 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
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Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  n/a 
DISCUSSION  
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
71 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  71 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  71 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  1 
 





APPENDIX A.2: SEARCH STRATEGIES 
Database Search Strategy 
BIOSIS (WoK) all 
databases 
1. Topic=(rheumatoid arthritis) 
2. Topic=((disease modifying or disease-modifying or DMARD* or biologic* or therap* or treatment* or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor 
alpha or tumour necrosis factor alpha or TNF-alpha or TNF inhibitor* or TNF blocker* or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or 
interleukin 6 or IL-6)) 
3. Topic=((methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab* or golimumab or anakinra or rituximab or abatacept or tocilizumab)) 
4. Title=((economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or value for money or budget*)) 
5. #2 OR #3 
6. #1 AND #4 AND #5 
Cochrane Database of 
Systematic Reviews 
(CDSR), The Cochrane 
database of methodology 
reviews, Cochrane 
Central Register of 
Controlled Trials (CCRCT), 
Database of Abstracts of 
Reviews of Effects (DARE) 
1. MeSH descriptor Arthritis, Rheumatoid explode all trees 
2. (disease modifying or disease-modifying or DMARD* or biologic* or therap* or treatment* or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor alpha or 
tumour necrosis factor alpha or TNF-alpha or TNF inhibitor* or TNF blocker* or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or interleukin 6 or 
IL-6):ti,ab,kw 
3. (methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab* or golimumab or anakinra or rituximab or abatacept or 
tocilizumab):ti,ab,kw 
4. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or value for money or budget*):ti,ab,kw 
5. (#2 OR #3) 
6. (#1 AND #4 AND #5) 
CINAHL 1. (MH "Arthritis, Rheumatoid") 
2. TI (disease modifying or disease-modifying or DMARD* or biologic* or therap* or treatment* or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor alpha 
or tumour necrosis factor alpha or TNF-alpha or TNF inhibitor* or TNF blocker* or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or interleukin 6 
or IL-6) OR AB (disease modifying or disease-modifying or DMARD* or biologic* or therap* or treatment* or anti-rheumatic or anti rheumatic or TNF or tumor necrosis 
factor alpha or tumour necrosis factor alpha or TNF-alpha or TNF inhibitor* or TNF blocker* or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or 
interleukin 6 or IL-6) 
3. TI (methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab* or golimumab or anakinra or rituximab or abatacept or tocilizumab) OR 
AB (methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold of minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab* or golimumab or anakinra or rituximab or abatacept or tocilizumab) 




5. TI (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or value for money or budget*) OR AB 
(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or value for money or budget*) 
6. S2 OR S3 
7. S4 OR S5 
8. S1 AND S6 AND S7 
EMBASE 1. exp arthritis, rheumatoid/ 
2. (disease modifying or disease-modifying or DMARD$ or biologic$ or therap$ or treatment$ or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor alpha or 
tumour necrosis factor alpha or TNF-alpha or TNF inhibitor$ or TNF blocker$ or interleukin 1 or IL-1 or monoclonal antibod$ or costimulation blocker$ or interleukin 6 or 
IL-6).tw. 
3. (methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab$ or golimumab or anakinra or rituximab or abatacept or tocilizumab).tw. 
4. Economics/ 
5. exp "Costs and Cost Analysis"/ 
6. Economics, Dental/ 
7. exp Economics, Hospital/ 
8. economics, medical/ 
9. economics, nursing/ 
10. economics, pharmaceutical/ 
11. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab. 
12. (expenditure$ not energy).ti,ab. 
13. value for money.ti,ab. 
14. budget$.ti,ab. 
15. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  
16. ((energy or oxygen) adj cost).ti,ab. 
17. (metabolic adj cost).ti,ab. 
18. ((energy or oxygen) adj expenditure).ti,ab. 
19. 16 or 17 or 18 
20. 15 not 19 
21. letter.pt. 
22. editorial.pt. 
23. historical article.pt. 
24. 21 or 22 or 23 
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25. 20 not 24 
26. Animals/ 
27. Humans/ 
28. 26 not (26 and 27) 
29. 25 not 28 
30. 2 or 3 
31. 1 and 29 and 30 
MEDLINE(R) In-Process & 
Other Non-Indexed 
Citations and Ovid 
MEDLINE(R) 
1. exp arthritis, rheumatoid/ 
2. (disease modifying or disease-modifying or DMARD$ or biologic$ or therap$ or treatment$ or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor alpha or 
tumour necrosis factor alpha or TNF-alpha or TNF inhibitor$ or TNF blocker$ or interleukin 1 or IL-1 or monoclonal antibod$ or costimulation blocker$ or interleukin 6 or 
IL-6).tw. 
3. (methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab$ or golimumab or anakinra or rituximab or abatacept or tocilizumab).tw. 
4. Economics/ 
5. exp "Costs and Cost Analysis"/ 
6. Economics, Dental/ 
7. exp Economics, Hospital/ 
8. economics, medical/ 
9. economics, nursing/ 
10. economics, pharmaceutical/ 
11. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab. 
12. (expenditure$ not energy).ti,ab. 
13. value for money.ti,ab. 
14. budget$.ti,ab. 
15. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  
16. ((energy or oxygen) adj cost).ti,ab. 
17. (metabolic adj cost).ti,ab. 
18. ((energy or oxygen) adj expenditure).ti,ab. 
19. 16 or 17 or 18 
20. 15 not 19 
21. letter.pt. 
22. editorial.pt. 
23. historical article.pt. 
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24. 21 or 22 or 23 
25. 20 not 24 
26. Animals/ 
27. Humans/ 
28. 26 not (26 and 27) 
29. 25 not 28 
30. 2 or 3 
31. 1 and 29 and 30 
NHSEED/HTA MeSH DESCRIPTOR arthritis, rheumatoid EXPLODE ALL TREES IN NHSEED,HTA 
SCI WoK 1. Topic=(rheumatoid arthritis) 
2. Topic=((disease modifying or disease-modifying or DMARD* or biologic* or therap* or treatment* or anti-rheumatic or anti rheumatic or TNF or tumor necrosis factor 
alpha or tumour necrosis factor alpha or TNF-alpha or TNF inhibitor* or TNF blocker* or interleukin 1 or IL-1 or monoclonal antibod* or costimulation blocker* or 
interleukin 6 or IL-6)) 
3. Topic=((methotrexate or sulfasalazine or leflunomide or hydroxychloroquine or chloroquine or gold or minocycline or azathioprine or ciclosporin or cyclosporine or 
penicillamine or cyclophosphamide or etanercept or infliximab or adalimumab or certolizumab* or golimumab or anakinra or rituximab or abatacept or tocilizumab)) 
4. Topic=((economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or value for money or budget*)) 
5. #2 OR #3 




APPENDIX A.3: EXCLUDED ARTICLES 
Reference Reason for exclusion 
Agarwal, Sukhpreet V. and Tiwari, Pramil Treatment and monitoring costs in rheumatoid arthritis: Preliminary results from an Indian setting Indian Journal of Pharmaceutical 
Sciences 2007, 69(2):226-231. 
Not a comparative 
analysis 
Agnew-Blais, J. C., Coblyn, J. S., Katz, J. N., Anderson, R. J., Mehta, J., and Solomon, D. H. Measuring quality of care for rheumatic diseases using an electronic medical record 
Annals of the Rheumatic Diseases 2009, 68(5):May 
No long-term 
evaluation 
Allaart, C. F., Breedveld, F. C., and Dijkmans, B. A. C. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt Study Journal of Rheumatology 2-11-2007, 34:25-
33. 
No long term costs 
Anderson, R. B., Needleman, R. D., Gatter, R. A., Andrews, R. P., and Scarola, J. A. Patient outcome following inpatient vs outpatient treatment of rheumatoid arthritis 
Journal of Rheumatology 1988, 15(4):556-560. 
No treatment specific 
long term evaluation 
Andrews, G., Simonella, L., Lapsley, H., Sanderson, K., and March, L. Evidence-based medicine is affordable: The cost-effectiveness of current compared with optimal 
treatment in rheumatoid and osteoarthritis Journal of Rheumatology 2006, 33(4):671-680. 
Not a comparative 
analysis 
Anon. Patients with rheumatoid arthritis survive longer if treated with methotrexate Pharmaceutical Journal 2002, 268(7192):06 News article 
Anon. Treatment of rheumatoid arthritis: unknown long-term effects. [Review] [71 refs] Prescrire International 2001, 10(52):55-61. Article 
Arce-Salinas, C. A., Vargas, J., Ivanova, E., and Villasenor-Ovies, P. Estimation of rheumatoid arthritis (RA) treatment costs in Mexico. Comparison between biologic agents 
and the ticora strategy using a markov's model Journal of Rheumatology 2006, 33(2):422-422. 
Abstract 
ArizaAriza, R., MestanzaPeralta, M., and Cardiel, M. H. Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center Clinical and 
Experimental Rheumatology 1997, 15(1):75-78. 
No long term costs 
Arshad, A. and Sulaiman, W. Optimizing the use of traditional DMARD in RA: 2781Getting the most out of what we can afford! APLAR Journal of Rheumatology 2007, 
10(1):April 
Review 
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., Proudlove, C., Kennedy, T., Moots, R., Williamson, P., and Dickson, R. Rituximab for the 
treatment of rheumatoid arthritis Health technology assessment (Winchester, England) 2009, 13(pp 23-29):Sep 
NICE ERG report 
Bansback, N. J., Regier, D. A., Ara, R., Brennan, A., Shojania, K., Esdaile, J. M., Anis, A. H., and Marra, C. A. An overview of economic evaluations for drugs used in rheumatoid 
arthritis - Focus on tumour necrosis factor-alpha antagonists Drugs 2005, 65(4):473-496. 
Review 
Bansback, N., Ara, R., Karnon, J., and Anis, A. Economic evaluations in rheumatoid arthritis Pharmacoeconomics 2008, 26(5):395-408. Review 
Bansback, N., Brennan, A., and Anis, A. H. A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis Expert Review of Pharmacoeconomics and 
Outcomes Research 2005, 5(5):October 
Review 
Bansback, N., Marra, C. A., Finckh, A., and Anis, A. The economics of treatment in early rheumatoid arthritis Best Practice and Research: Clinical Rheumatology 2009, 
23(1):February 
Review 
Bansback, N., and Marra, C. A. Now That We Know What's BeSt, What Is Good Value for the Money? Arthritis & Rheumatism-Arthritis Care & Research 2009, 61(3):289-290. Editorial 
Bansback, Nick, Marra, Carlo A., Finckh, Axel, and Anis, Aslam The economics of treatment in early rheumatoid arthritis Best practice & research.Clinical rheumatology 2009, 
23(1):83-92. 
No de novo analysis 
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Barra, L., Pope, J. E., and Payne, M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness 
based on number needed to treat to improve health assessment questionnaire (Provisional abstract) Journal of Rheumatology 2009, 36:1421-1428. 
Not a comparative 
analysis 
Benucci, M., Saviola, G., Manfredi, M., Sarzi-Puttini, P., and Atzeni, F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A 
systematic review literature International journal of rheumatology 2011, 2011 
Review 
Beresniak, Ariel, Gossec, Laure, Goupille, Philippe, Saraux, Alain, Bamberger, Marion, Bregman, Bruno, and Dupont, Danielle Direct Cost-Modeling of Rheumatoid Arthritis 
According to Disease Activity Categories in France Journal of Rheumatology 2011, 38(3):439-445. 
No long term costs 
Blomqvist, P., Feltelius, N., Ekbom, A., and Klareskog, L. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions Journal of Rheumatology 
2000, 27(5):1171-1177. 
No long term costs 
Boonen, A. and Severens, J. L. Evaluating Treatment Strategies in Patients with Early Rheumatoid Arthritis: Merging Modeling Theory with Clinical Practice Journal of 
Rheumatology 2011, 38(8):1538-1540. 
Editorial 
Bullano, M. F., McNeeley, B. J., Yu, Y. F., Quimbo, R., Burawski, L. P., Yu, E. B., and Woolley, J. M. Health economics. Comparison of costs associated with the use of 
etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis Managed care interface 2006, 19(9):47-53. 
No long term costs 
Colombo, G., Muzio, A., and Longhi, A. Economic evaluation of Infliximab (Remicade) vs Etanercept (Enbrel) in the treatment of rheumatoid arthritis Farmeconomia e 
Percorsi Terapeutici 2003, 4(2):77-86. 
Not in English 
Crespo, Carlos, Brosa, Max, Galvan, Jordi, Carbonell, Jordi, Maymo, Jordi, Marenco, Jose Luis, Del Pino-Montes, Javier, Alonso, Alberto, and Rodriguez, Carlos 
[Pharmacoeconomic analysis of Metoject() in the treatment of rheumatoid arthritis in Spain] Reumatologia clinica 2010, 6(4):203-211. 
Not in English 
Doan, Q. V., Chiou, C. F., and Dubois, R. W. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the 
management of rheumatoid arthritis Journal of managed care pharmacy : JMCP 2006, 12(7):Sep 
Review 
Drummond, M. Pharmacoeconomics: friend or foe? Annals of the Rheumatic Diseases 2006, 65 Suppl 3:iii44-iii47. No de novo analysis 
Emery, P. Review of health economics modelling in rheumatoid arthritis Pharmacoeconomics 2004, 22(2):55-69. Review 
Ferraz, M. B., Maetzel, A., and Bombardier, C. A summary of economic evaluations published in the field of rheumatology and related disciplines Arthritis and Rheumatism 
1997, 40(9):1587-1593. 
Review 
Finckh, A., Bansback, N., and Liang, M. H. Cost-effectiveness of biologics in early rheumatoid arthritis Annals of Internal Medicine 2-3-2010, 152(5):333-334. Letter 
Fleurence, Rachael and Spackman, Eldon Cost-effectiveness of biologic agents for treatment of autoimmune disorders: Structured review of the literature Journal of 
Rheumatology 2006, 33(11):2124-2131. 
Review 
Fries, J. F. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis Annals of the Rheumatic Diseases 1999, 58:86-89. Review 
Gabriel, S. E., Coyle, D., and Moreland, L. W. A clinical and economic review of disease-modifying antirheumatic drugs Pharmacoeconomics 2001, 19(7):715-728. Review 
Gabriel, S. E., Crowson, C. S., Luthra, H. S., Wagner, J. L., and O'Fallon, W. M. Modeling the lifetime costs of rheumatoid arthritis Journal of Rheumatology 1999, 26(6):1269-
1274. 
Not a comparative 
analysis 
Gabrielle, Pham, Ba', Machado, M. +, Ieraci, Luciano, Witteman, William, Bombardier, Claire, and Krahn, Murray Cost-effectiveness of biologic response modifiers compared 
to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review Arthritis Care & Research (2151464X) 2011, 63(1):65-78. 
Review 
Hoving, J., Bartelds, G., Sluiter, J., Sadiraj, K., Groot, I., Lems, W., Dijkmans, B. A. C., Wijbrandts, C. A., Tak, P. P., Nurmohamed, M. T., Voskuyl, A. E., and Frings-Dresen, M. H. 
W. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and 




partial economic evaluation Scandinavian Journal of Rheumatology 2009, 38(4):246-250. 
Hulsemann, J. L., Ruof, J., Zeidler, H., and Mittendorf, T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study' Rheumatology International 
2006, 26(8):704-711. 
No long term costs 
Kavanaugh, A. The pharmacoeconomics of newer therapeutics for rheumatic diseases Rheumatic Disease Clinics of North America 2006, 32(1):45-+. Review 
Kobelt, G. and Joensson, B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments European Journal of Health Economics 2008, 
8:S95-S106. 
Review 
Kobelt, G., Jonsson, L., Lindgren, P., Young, A., and Eberhardt, K. Modeling the progression of rheumatoid arthritis - A two-country model to estimate costs and 
consequences of rheumatoid arthritis Arthritis and Rheumatism 2002, 46(9):2310-2319. 
Not a comparative 
analysis 
Kobelt, G., Lindgren, P., and Geborek, P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data 
Scandinavian Journal of Rheumatology 2009, 38(6):409-418. 
Not a comparative 
analysis 
Kobelt, G., Lindgren, P., Lindroth, Y., Jacobson, L., and Eberhardt, K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis 
Rheumatology 2005, 44(9):1169-1175. 
Not a comparative 
analysis 
Laas, K., Peltomaa, R., Kautiainen, H., Puolakka, K., and Leirisalo-Repo, M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during 
infliximab treatment Annals of the Rheumatic Diseases 2006, 65(7):924-928. 
Not a comparative 
analysis 
Lyseng-Williams, K. A. and Foster, R. H. Infliximab - A pharmacoeconomic review of its use in rheumatoid arthritis Pharmacoeconomics 2004, 22(2):107-132. Review 
Lyseng-Williamson, K. A. and Plosker, G. L. Etanercept - A pharmacoeconomic review of its use in rheumatoid arthritis Pharmacoeconomics 2004, 22(16):1071-1095. Review 
Maetzel, A. Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary The Journal 
of rheumatology.Supplement 2005, 72(pp 51-53):Jan 
Review 
Maetzel, A., Ferraz, M. B., and Bombardier, C. A review of cost effectiveness analyses in rheumatology and related disciplines Current Opinion in Rheumatology 1998, 
10(2):1998 
Review 
McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., Hill, R., Jones, A., Mota, R. Mujica, and Walley, T. Adalimumab, etanercept and infliximab for the 
treatment of ankylosing spondylitis: A systematic review and economic evaluation Health Technology Assessment 2007, 11(28):IX-+. 
Not Rheumatoid 
Arthritis 
Merkesdal, S. and Ruof, J. Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis Zeitschrift fur Rheumatologie 2002, 61:29-
32. 
Not in English 
Merkesdal, S., Ruof, J., Mittendorf, T., and Zeidler, H. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis Expert Opinion on 
Pharmacotherapy 2004, 5(9):1881-1886. 
Review 
Nurmohamed, M. T. and Dijkmans, B. A. C. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis 
Drugs 2005, 65(5):661-694. 
Review 
Ostrov, B., Robbins, L., Ferriss, J., Newman, E., Maclary, S., Ayoub, W., Harrington, T., and Perruquet, J. Improved tolerance and cost-effectiveness of subcutaneous vs oral 
methotrexate in rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) Arthritis and Rheumatism 1998, 41(9 SUPPL.):S75 
Abstract 
Prashker, M. J. and Meenan, R. F. The Total Costs of Drug-Therapy for Rheumatoid-Arthritis - A Model-Based on Costs of Drug, Monitoring, and Toxicity Arthritis and 
Rheumatism 1995, 38(3):318-325. 
Cost analysis 
Ruchlin, H. S., Elkin, E. B., and Paget, S. A. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis Arthritis Care and Research 1997, 10(6):413-421. Review 
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Sany, J., Cohen, J. D., Combescure, C., Bozonnat, M. C., Roch-Bras, F., Lafon, G., and Daures, J. P. Medico-economic evaluation of infliximab in rheumatoid arthritis--
prospective French study of a cohort of 635 patients monitored for two years Rheumatology (Oxford, England) 2009, 48(10):Oct 
Not a comparative 
analysis 
Schadlich, P. K., Zeidler, H., Zink, A., Gromnica-Ihle, E., Schneider, M., Straub, C., Brecht, J. G., and Huppertz, E. Contribution of leflunomide to the cost effectiveness of 
sequential DMARD therapy of rheumatoid arthritis in Germany Zeitschrift fur Rheumatologie 2004, 63(1):61-77. 
Not in English 
Schoels, Monika, Wong, John, Scott, David L., Zink, Angela, Richards, Pamela, Landewe, Robert, Smolen, Josef S., and Aletaha, Daniel Economic aspects of treatment options 
in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis Annals of the Rheumatic 
Diseases 2010, 69(6):995-1003. 
Review 
Schulze-Koops, H., Deeg, M., Runge, C., Volmer, T., and Brecht, J. Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and 
etanercept based on the TEMPO Study Zeitschrift fur Rheumatologie 2009, 68(10):836-841. 
Not in English 
Suarez-Almazor, M. E., Ortiz, Z., Lopez-Olivo, M., Moffett, M., Pak, C., Skidmore, B., Kimmel, B., Kallen, M., and Cox, V. Long-term clinical and cost-effectiveness of infliximab 
and etanercept for rheumatoid arthritis 2007 
Summary report 
Suka, M. and Yoshida, K. Cost effectiveness of leflunomide in the treatment of rheumatoid arthritis in Japan Expert Review of Pharmacoeconomics and Outcomes Research 
2004, 4(6):December 
Not a comparative 
analysis 
Tella, M. N., Feinglass, J., and Chang, R. W. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002 Current Opinion in 
Rheumatology 2003, 15(2):127-131. 
Review 
van den Hout, W. B., Goekoop-Ruiterman, Y. P., Allaart, C. F., Vries-Bouwstra, J. K., Hazes, J. M., Kerstens, P. J., Van, Zeben D., Hulsmans, H. M., De Jonge-Bok, J. M., De 
Sonnaville, P. B., Dijkmans, B. A., and Breedveld, F. C. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis and 
Rheumatism (Arthritis Care and Research) 2009, 61(3):291-299. 
Duplicate citation 
van der Velde, G., Pham, B., Machado, M., Ieraci, L., Witteman, W., Bombardier, C., and Krahn, M. Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-
Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review Arthritis Care & Research 2011, 63(1):65-78. 
Duplicate citation 
van, der, V, Pham, B., Machado, M., Ieraci, L., Witteman, W., Bombardier, C., and Krahn, M. Cost-effectiveness of biologic response modifiers compared to disease-
modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. [Review] Arthritis Care & Research 2011, 63(1):65-78. 
Review 
Verhoeven, A., Bibo, J., Boers, M., Engel, G., Schouten, H., and van der Linden, S. Combination of step-down steroids, methotrexate, and sulphasalazine is cost-effective 
compared to sulphasalazine alone in early rheumatoid arthritis British Journal of Rheumatology 1997, 36(SUPPL. 1):181 
Abstract 
Virkki, L., Konttinen, Y., Peltomaa, R., Suontama, K., Saario, R., Immonen, K., Jantti, J., Tuomiranta, T., Nykanen, P., Hameenkorpi, R., Heikkila, S., Isomaki, P., and Nordstrom, 
D. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice Clinical and Experimental Rheumatology 2008, 26(6):1059-1066. 
Not a comparative 
analysis 
Walsh, C., Minnock, P., Slattery, C., Kennedy, N., Pang, F., Veale, D., Bresnihan, B., and FitzGerald, O. Quality of life and economic impact of switching from established 
infliximab therapy to adalimumab in patients with rheumatoid arthritis Rheumatology 2007, 46(7):1148-1152. 
Not a comparative 
analysis 
Welsing, P. M. J., Severens, J. L., and Laan, R. F. J. M. Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result Rheumatology 
2003, 42(12):1574-1575. 
Letter 
Welsing, Paco M., Severens, Johan L., Hartman, Margriet, van Gestel, Anke M., van Riel, Piet L., and Laan, Roland F. The initial validation of a Markov model for the economic 
evaluation of (New) treatments for rheumatoid arthritis Pharmacoeconomics 2006, 24(10):1011-1020. 
Not a comparative 
analysis 
Wong, J. B. Cost-effectiveness of anti-tumor necrosis factor agents Clinical and Experimental Rheumatology 2004, 22(5):S65-S70. Article 
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APPENDIX A.4: DATA EXTRACTION 
Name Sequencing information Modelling information 
 If a sequence 
was evaluated, 










to vary the 
sequence and 




attempt to find 
a truly 'optimal 
' sequence 
undertaken? 









a switch to an 
alternative 
therapy? 
How were the costs 
and effectiveness of 
subsequent 





available for a 






 1 Unclear N No Decision tree Functional 
index 
improvement 













Yes No Individual level 
Markov model 
ACR response 






loss of efficacy or 
an AE 
For sequential 
DMARDs, efficacy is 







 1 No Markov model. 
Unlikely 






 Up to 11 Potentially Potentially No Individual 
Sampling Model 
HAQ score Probability of 
early withdrawal 
and time to later 
withdrawal 
Modelled explicitly.  Not clear 
Benucci  2009
142
 1 No. Infliximab 
not included 
No No Observational 
analysis 
HAQ score n/a observational data n/a 
Benucci  2011
143
 1 No No No Observational 
analysis 







2 No. IFX not 
included in 
second line. 








Unclear Remission or 
LDAS 








within model time 
horizon and 
comparators. No 
future projections of 
costs and benefits 
Assumed same 





4 No Potentially No Individual 
Sampling Model 





loss of efficacy or 
an AE 
Explicitly Data were 
available. 
Assumed class 






6 lines Potentially, 
however 
sequential use 


























Potentially No Individual 
Sampling Model 
HAQ score Probability of 
early withdrawal 
and time to later 
withdrawal 
Modelled explicitly.  Not clear 
Chiou  2004
147
 1 No No No Decision tree ACR response n/a n/a n/a 
Choi  2000
148
 n/a n/a n/a n/a Decision tree ACR response n/a n/a n/a 
Choi  2002
149







2 No. IFX not 
included in 
second line. 








Unclear Remission or 
LDAS 








within model time 
horizon and 
comparators. No 
future projections of 
costs and benefits 
Assumed same 




 Up to 11 Potentially Potentially No Individual 
Sampling Model 
HAQ score Probability of 
early withdrawal 
and time to later 
withdrawal 
Modelled explicitly.  Not clear 
Coyle  2006
152
 6 No No No Markov model ACR Response Stopping for AE or 
stopping for lack 
of benefit 
Trial data or 
simulated 
Assumed the 




 5 (unique) No. No 
combination 
DMARDs for 
early RA. No 
full 
comparators 
Potentially yes No Individual 
Sampling Model 
ACR50 Withdrawal for AE 
or inefficacy 





5 (with 6 for one 
sensitivity 
analysis) 
Yes Potentially No Individual 
Sampling Model 
ACR response 
to HAQ change 
withdrawal rates 
or non-response 

























Using trial evidence, 
although 
downstream past 3 




 Up to 4 Potentially Yes Potentially No Individual level 
Markov model 
ACR response 
to HAQ change 
withdrawal rates 
or non-response 












Up to 11 Potentially Potentially No Individual 
Sampling Model 
HAQ score Probability of 
early withdrawal 
and time to later 
withdrawal 










6 base case, 7 SA Maybe Y N Individual level 
Markov model 
ACR response 
to HAQ change 
withdrawal rates 
or non-response 






















DAS28 response and 




 1 No No No Markov model Observational 





Observational data n/a 
Kobelt  2003
159
 1 No No No Markov model EQ-5D n/a n/a n/a 
Kobelt  2004
160
 1 No No No Trial analysis EQ-5D n/a n/a n/a 
Kobelt  2005
161
 1 No. No 
comparison to 
other aTNFs 




n/a n/a n/a 
Kobelt  2011
129
 3 (maybe more) 
not clear 
No Potentially No Markov model Remission Trial 
discontinuation 




















Open ended No Potentially No Discrete Event 
Simulation 
HAQ score Treatment 
withdrawal rate 
taken from trial 
data 
Assumed same as 
previous line for RTX 
sequence (i.e. RTX 
has no impact on 
treatment 
effectiveness). For 
TNF data provided 
on 2nd and 3rd line 
from registry but not 

















6 No. No 
sequential 
biologic use 
Potentially No Individual 
Sampling Model 
HAQ score Probability of 
early withdrawal 
and time to later 
withdrawal 
Modelled explicitly.  Not clear 
Marra  2007
166





6 Potentially Yes No Individual level 
Markov model 
ACR response 
to HAQ change 
LoE or AE Trial data adjusted 
crudely 






 1 Potentially No No Unclear n/a n/a n/a n/a 
Osiri  2007
169










 3 No. Abatacept 
not considered 








From trial data n/a 
Saraux  2010
172
 2 No Yes No Unclear DAS Not achieving 
remission 





6 No No No Markov model DAS Not achieving 
remission 
Registry data 2nd line aTNF 






1 Maybe. Wide 
choice of 
DMARDs 
No No n/a n/a n/a n/a n/a 
Shini  2010
173












Yes No Individual 
Sampling Model 














 2012 2 No No No Markov model HAQ score Transition 
probabilities for 
toxicity and loss 
of efficacy 
Pooled estimate of 
















to just SSZ) 
Tanno  2006
175
 3 (biologics 
merged) 
No Potentially No Individual 
Sampling Model 
ACR response Short term 
withdrawal for 
non-response. 
Bolted-on costs and 
QALYs 










 8 (in one 
strategy) 
Potentially yes Trial based 
evaluation 
No Trial analysis DAS DAS > 2.4 Trial Trial 




1 No Unclear No Individual 
Sampling Model 
ACR response 
or HAQ change 





1 No Unclear No Microsimulation ACR response 
or HAQ change 














Potentially yes No Individual 
Sampling Model 
ACR response 
to HAQ change 





 3 at most No No No Markov model Not clear Not clear Trial data n/a 
Welsing  2004
179




APPENDIX A.5: DRUMMOND CHECKLIST 
 Drummond Checklist (Y=Yes, N=No, C=Can’t tell, n/a=Not applicable) 























































made for the 
uncertainty in 
the estimates 














 Y Y C Y Y Y N N Y N 
Bansback  2005
139
 Y Y Y Y Y Y Y N Y N 
Barbieri  2005
140
 Y Y Y Y Y Y Y Y N N 
Barton  2004
141
 Y Y Y Y Y Y Y Y Y Y 
Benucci  2009
142
 Y Y Y N N N N N N N 
Benucci  2011
143
 Y N N C C C N Y N N 
Beresniak  2011
144
 Y Y Y N N Y C N Y N 
Brennan  2004
145
 Y Y Y Y Y Y Y Y Y Y 
Brennan  2007
146
 Y Y Y Y Y Y Y Y Y Y 
Chen  2006
124
 Y Y Y Y Y Y Y Y Y Y 
Chiou  2004
147
 Y Y Y Y Y Y n/a Y N Y 
Choi  2000
148
 Y Y N N Y Y n/a Y N N 
Choi  2002
149
 Y Y Y Y Y Y n/a Y N Y 
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 1 2 3 4 5 6 7 8 9 10 
Cimmino  2011
150
 Y Y Y N N Y C N Y N 
Clark  2004
151
 Y Y Y Y Y Y Y Y Y Y 
Coyle  2006
152
 Y Y Y Y Y Y Y N Y N 
Davies  2009
125
 Y Y Y Y Y Y Y Y Y Y 
Diamantopoulos  2012
153
 Y Y Y Y Y Y Y N Y N 
Finckh  2009
126
 Y Y Y Y Y Y Y Y Y Y 
Hallinen  2010
154
 Y Y Y Y Y Y Y Y Y Y 
Hartman  2004
127
 Y Y Y N Y Y N N Y Y 
Jobanputra  2002
155
 Y Y N Y Y Y Y Y Y N 
Kavanaugh  1996
156
 Y N Y Y Y Y N N Y N 
Kielhorn  2008
157
 Y Y Y Y Y Y Y Y Y Y 
Kievit  2009
158
 Y Y Y N Y Y N N Y N 
Kobelt  2002
128
 Y Y Y N Y Y Y Y Y Y 
Kobelt  2003
159
 Y Y Y Y Y Y Y Y Y Y 
Kobelt  2004
160
 Y N C Y Y Y Y Y Y N 
Kobelt  2005
161
 Y Y Y Y Y Y Y N Y N 
Kobelt  2011
129
 Y Y N Y Y Y Y Y Y Y 
Korthals-de Bos  2004
130
 Y Y N N Y Y n/a Y Y N 
Lekander  2010
162
 Y Y Y Y Y Y Y Y Y Y 
Lindgren  2009
163
 Y Y Y Y Y Y Y Y Y Y 
Maetzel  2002
131
 Y Y Y Y Y Y Y Y Y Y 
Maetzel  2002a
164
 Y Y Y Y Y Y Y N Y N 
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 1 2 3 4 5 6 7 8 9 10 
Malottki  2011
165
 Y Y Y Y Y Y Y Y Y Y 
Marra  2007
166
 Y Y Y Y Y Y Y Y Y Y 
Merkesdal  2010
167
 Y Y Y Y Y Y Y Y Y Y 
Nuijten  2001
168
 Y Y N Y Y Y Y N Y N 
Osiri  2007
169
 Y Y N N Y Y n/a N N N 
Rubio-Terrés  2001
170
 Y Y N N Y Y n/a N N N 
Russell  2009
171
 Y Y C Y Y Y C N Y N 
Saraux  2010
172
 Y Y Y Y Y Y C N N N 
Schadlich  2005
132
 Y Y Y N Y Y N N Y Y 
Schipper  2011
133
 Y Y N Y N Y Y N Y N 
Shini  2010
173
 Y Y N N N Y N N N N 
Soini  2012
174
 Y N Y Y Y Y Y Y Y Y 
Spalding  2006
134
 Y Y N Y Y Y Y N N N 
Tanno  2006
175
 Y Y Y Y Y Y Y Y Y Y 
Tosh  2011
135
 Y Y Y Y Y Y Y Y Y Y 
van den Hout  2009
136
 Y Y Y Y Y Y Y Y Y Y 
Vera-Llonch  2008
176
 Y Y Y Y Y Y Y Y Y Y 
Vera-Llonch  2008a
177
 Y Y Y Y Y Y Y Y Y Y 
Verhoeven  1998
137
 Y Y Y N Y Y n/a N Y Y 
Wailoo  2008
178
 Y Y Y Y Y Y Y Y Y Y 
Welsing  2004
179
 Y N Y N Y Y Y Y Y Y 
Wong  2002
180
 Y Y Y Y Y Y Y Y Y Y 
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APPENDIX B: METHODOLOGICAL REVIEW 
APPENDIX B.1: ARTICLES EXCLUDED AT INITIAL SIFT STAGE 
 Reference Reason for exclusion 
1 Ali M, Vukovic V, Sahir MH, Fontanella G. Energy analysis of chilled water system configurations using simulation-based optimization. Energy and Buildings. 
2013;59:111-22. 
Unrelated problem type 
2 Almeder C, Preusser M, Hartl RF. Simulation and optimization of supply chains: alternative or complementary approaches? Or Spectrum. 2009;31(1):95-119. Unrelated problem type (mixed 
integer) 
3 Arena C, Mazzola MR, Scordo G. A simulation/optimization model for selecting infrastructure alternatives in complex water resource systems. Water Science 
and Technology. 2010;61(12):3050-60. 
Not a combinatorial problem 
4 Azadeh A, Moghaddam M, Asadzadeh SM, Negahban A. An integrated fuzzy simulation-fuzzy data envelopment analysis algorithm for job-shop layout 
optimization: The case of injection process with ambiguous data. European Journal of Operational Research. 2011;214(3):768-79. 
Unrelated problem type – 
production efficiency 
5 Bachelet B, Yon L. Model enhancement: Improving theoretical optimization with simulation. Simulation Modelling Practice and Theory. 2007;15(6):703-15. Not optimisation of a simulation 
model 
6 Bhatnagar S, Mishra VK, Hemachandra N. Stochastic Algorithms for Discrete Parameter Simulation Optimization. Ieee Transactions on Automation Science 
and Engineering. 2011;8(4):780-93. 
Looking to optimise the 
performance of a simulation 
7 Chen Y, Mockus L, Orcun S, Reklaitis GV. Simulation-optimization approach to clinical trial supply chain management with demand scenario forecast. 
Computers & Chemical Engineering. 2012;40:82-96. 
Not a combinatorial problem 
8 Fu MC. Optimization for simulation: Theory vs. practice. Informs Journal on Computing. 2002;14(3):192-215. Not a combinatorial problem 
9 Fu Z, Mo J, Chen L, Chen W. Using genetic algorithm-back propagation neural network prediction and finite-element model simulation to optimize the 
process of multiple-step incremental air-bending forming of sheet metal. Materials & Design. 2010;31(1):267-77. 
Not a combinatorial problem 
10 Geyik F, Dosdogru AT. Process plan and part routing optimization in a dynamic flexible job shop scheduling environment: an optimization via simulation 
approach. Neural Computing & Applications. 2013;23(6):1631-41. 
Not a combinatorial problem 
11 Gosavi A, Ozkaya E, Kahraman AF. Simulation optimization for revenue management of airlines with cancellations and overbooking. Or Spectrum. 
2007;29(1):21-38. 
Not a combinatorial problem 
12 Gulyanitskii LF, Koshlai LB, Sergienko IV. CONVERGENCE OF A SIMULATION METHOD FOR SOLUTION OF COMBINATORIAL OPTIMIZATION PROBLEMS. 
Cybernetics and Systems Analysis. 1993;29(3):445-9. 
Not concerned with stochastic/ 
simulation based problem 
13 Gupta A, Evans GW, Heragu SS. Simulation and optimization modeling for drive-through mass vaccination - A generalized approach. Simulation Modelling 
Practice and Theory. 2013;37:99-106. 
Only an application of a ‘off the 
shelf’ solution 
14 Hong JH, Seo K-M, Kim TG. Simulation-based optimization for design parameter exploration in hybrid system: a defense system example. Simulation-
Transactions of the Society for Modeling and Simulation International. 2013;89(3):362-80. 




15 Horng S-C, Lin S-Y, Lee H, Chen C-H. Memetic Algorithm for Real-Time Combinatorial Stochastic Simulation Optimization Problems With Performance 
Analysis. Ieee Transactions on Cybernetics. 2013;43(5):1495-509. 
Off-line and on-line problem 
16 Huang Y, Li YP, Chen X, Bao AM, Zhou M. Simulation-based optimization method for water resources management in Tarim River Basin, China. In: Yang Z, 
Chen B, editors. International Conference on Ecological Informatics and Ecosystem Conservation. Procedia Environmental Sciences. 22010. p. 1451-60. 
Not a combinatorial problem 
17 Iassinovski S, Artiba A, Bachelet V, Riane F. Integration of simulation and optimization for solving complex decision making problems. International Journal of 
Production Economics. 2003;85(1):3-10. 
Not specific for combinatorial 
problems 
18 Jeong KY. Conceptual frame for development of optimized simulation-based scheduling systems. Expert Systems with Applications. 2000;18(4):299-306. Not a combinatorial problem 
19 Keskin BB, Melouk SH, Meyer IL. A simulation-optimization approach for integrated sourcing and inventory decisions. Computers & Operations Research. 
2010;37(9):1648-61. 
Not a combinatorial problem 
20 Kleijnen JPC, Rubinstein RY. Optimization and sensitivity analysis of computer simulation models by the score function method. European Journal of 
Operational Research. 1996;88(3):413-27. 
Not a combinatorial problem 
21 Klemmt A, Horn S, Weigert G, Wolter K-J. Simulation-based optimization vs. mathematical programming: A hybrid approach for optimizing scheduling 
problems. Robotics and Computer-Integrated Manufacturing. 2009;25(6):917-25. 
Not a combinatorial problem 
22 Latorre J-I, Jimenez E. Simulation-based optimization of discrete event systems with alternative structural configurations using distributed computation and 
the Petri net paradigm. Simulation-Transactions of the Society for Modeling and Simulation International. 2013;89(11):1310-34. 
A method for parallel 
programming for DES 
optimisation 
23 Li J, Sava A, Xie X. Simulation-Based Discrete Optimization of Stochastic Discrete Event Systems Subject to Non Closed-Form Constraints. Ieee Transactions on 
Automatic Control. 2009;54(12):2900-4. 
Not a combinatorial problem 
24 Lu M, Lam H-C, Dai F. Resource-constrained critical path analysis based on discrete event simulation and particle swarm optimization. Automation in 
Construction. 2008;17(6):670-81. 
Not a combinatorial problem 
25 Lu M, Wu D-p, Zhang J-p. A particle swarm optimization-based approach to tackling simulation optimization of stochastic, large-scale and complex systems. 
In: Yeung DS, Liu ZQ, Wang XZ, Yan H, editors. Advances in Machine Learning and Cybernetics. Lecture Notes in Artificial Intelligence. 39302006. p. 528-37. 
Not a combinatorial problem 
26 Mahdavi I, Shirazi B, Sahebjamnia N. Development of a simulation-based optimisation for controlling operation allocation and material handling equipment 
selection in FMS. International Journal of Production Research. 2011;49(23):6981-7005. 
Multi-objective optimisation 
27 Mardan N, Klahr R. Combining optimisation and simulation in an energy systems analysis of a Swedish iron foundry. Energy. 2012;44(1):410-9. Not relevant 
28 Marseguerra M, Zio E, Podofillini L. Condition-based maintenance optimization by means of genetic algorithms and Monte Carlo simulation. Reliability 
Engineering & System Safety. 2002;77(2):151-65. 
Not a combinatorial problem 
29 Matott LS, Tolson BA, Asadzadeh M. A benchmarking framework for simulation-based optimization of environmental models. Environmental Modelling & 
Software. 2012;35:19-30. 
Not a combinatorial problem 
30 Medaglia AL, Fang SC, Nuttle HLW. Fuzzy controlled simulation optimization. Fuzzy Sets and Systems. 2002;127(1):65-84. Not identifying optimal or near-
optimal solutions 
31 Mele FD, Guillen G, Espuna A, Puigjaner L. A simulation-based optimization framework for parameter optimization of supply-chain networks. Industrial & 
Engineering Chemistry Research. 2006;45(9):3133-48. 
Not a combinatorial problem 
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32 Napalkova L, Merkuryeva G. MULTI-OBJECTIVE STOCHASTIC SIMULATION-BASED OPTIMISATION APPLIED TO SUPPLY CHAIN PLANNING. Technological and 
Economic Development of Economy. 2012;18(1):132-48. 
Multi-objective optimisation 
33 Narciso M, Piera MA, Guasch A. A Methodology for Solving Logistic Optimization Problems through Simulation. Simulation-Transactions of the Society for 
Modeling and Simulation International. 2010;86(5-6):369-89. 
Not relevant 
34 Nielsen AL, Hilwig H, Kissoon N, Teelucksingh S. Discrete event simulation as a tool in optimization of a professional complex adaptive system. In: Andersen 
SK, Klein GO, Schulz S, Aarts J, Mazzoleni MC, editors. Ehealth Beyond the Horizon - Get It There. Studies in Health Technology and Informatics. 1362008. p. 
247-52. 
Simple optimisation via 
enumeration 
35 Park C, Telci IT, Kim S-H, Aral MM. Designing an optimal water quality monitoring network for river systems using constrained discrete optimization via 
simulation. Engineering Optimization. 2014;46(1):107-29. 
Not a combinatorial problem 
36 Ramwadhdoebe S, Buskens E, Sakkers RJB, Stahl JE. A tutorial on discrete-event simulation for health policy design and decision making: Optimizing pediatric 
ultrasound screening for hip dysplasia as an illustration. Health Policy. 2009;93(2-3):143-50. 
Not a combinatorial problem 
37 Rosen SL, Harmonosky CM, Traband MT. A simulation optimization method that considers uncertainty and multiple performance measures. European Journal 
of Operational Research. 2007;181(1):315-30. 
Multi-objective optimisation 
38 Roux O, Jamali MA, Kadi DA, Chatelet E. Development of simulation and optimization platform to analyse maintenance policies performances for 
manufacturing systems. International Journal of Computer Integrated Manufacturing. 2008;21(4):407-14. 
Not relevant 
39 Rubinstein RY. Optimization of computer simulation models with rare events. European Journal of Operational Research. 1997;99(1):89-112. Not a combinatorial problem 
40 Salama A, Nehring M, Greberg J. Operating value optimisation using simulation and mixed integer programming. International Journal of Mining Reclamation 
and Environment. 2014;28(1):25-46. 
Not a combinatorial problem 
41 Sanchez D, Amodeo L, Prins C. Meta-heuristic Approaches for Multi-objective Simulation-based Optimization in Supply Chain Inventory Management. In: 
Benyoucef L, Grabot B, editors. Artificial Intelligence Techniques for Networked Manufacturing Enterprises Management. Springer Series in Advanced 
Manufacturing2010. p. 249-69. 
Multi-objective optimisation 
42 Waanders BGvB, Carnes BR. Optimization under adaptive error control for finite element based simulations. Computational Mechanics. 2011;47(1):49-63. Not relevant 
43 Wu F, Dantan J-Y, Etienne A, Siadat A, Martin P. Improved algorithm for tolerance allocation based on Monte Carlo simulation and discrete optimization. 
Computers & Industrial Engineering. 2009;56(4):1402-13. 
Not a combinatorial problem 
44 Yang T. An evolutionary simulation-optimization approach in solving parallel-machine scheduling problems - A case study. Computers & Industrial 
Engineering. 2009;56(3):1126-36. 
Not a combinatorial problem 
45 Yang Y, Blum RS. Sensor Placement in Gaussian Random Field Via Discrete Simulation Optimization. Ieee Signal Processing Letters. 2008;15:729-32. Not a combinatorial problem 
46 Yeo IY, Guldmann JM. Global spatial optimization with hydrological systems simulation: application to land-use allocation and peak runoff minimization. 
Hydrology and Earth System Sciences. 2010;14(2):325-38. 
Not a combinatorial problem 
47 Yoo T, Cho H, Yuecesan E. Web Services-Based Parallel Replicated Discrete Event Simulation for Large-Scale Simulation Optimization. Simulation-Transactions 
of the Society for Modeling and Simulation International. 2009;85(7):461-75. 
Not relevant 
48 Zamora-Cristales R, Boston K, Sessions J, Murphy G. Stochastic simulation and optimization of mobile chipping and transport of forest biomass from harvest 
residues. Silva Fennica. 2013;47(5). 
Not a combinatorial problem 
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49 Zhang R, Chiang W-C, Wu C. Investigating the impact of operational variables on manufacturing cost by simulation optimization. International Journal of 
Production Economics. 2014;147:634-46. 




APPENDIX B.2: ARTICLES EXCLUDED AT FULL PAPER STAGE 
 Reference Reason for exclusion 
1 Abspoel SJ, Etman LFP, Vervoort J, van Rooij RA, Schoofs AJG, Rooda JE. Simulation based optimization of stochastic systems with integer design 
variables by sequential multipoint linear approximation. Structural and Multidisciplinary Optimization. 2001;22(2):125-38. 
Statistical method of approximation 
2 Alkhamis TM, Ahmed MA. Sequential stochastic comparison algorithm for simulation optimization. Engineering Optimization. 2004;36(5):513-24. Statistical method for comparison of 
results 
3 Andradottir S. An Overview of Simulation Optimization via Random Search. Simulation. 2006;13:617-31. Review paper 
4 Azimi P. SIMSUM1: A GENERAL OPTIMISATION VIA SIMULATION APPROACH FOR 0-1 PROGRAMMING MODELS. International Journal of Simulation 
Modelling. 2012;11(3):150-64. 
Not optimisation of a simulation model 
5 Barton RR, Ivey JS. Nelder-Mead simplex modifications for simulation optimization. Management Science. 1996;42(7):954-73. Direct search method, and not specific for 
combinatorial problems 
6 Barton RR, Meckesheimer M. Metamodel-Based Simulation Optimization. Simulation. 2006;13:535-74. Meta-model methods for continuous, not 
combinatorial problems 
7 Chang X, Dong M, Yang D. Multi-objective real-time dispatching for integrated delivery in a Fab using GA based simulation optimization. Journal of 
Manufacturing Systems. 2013;32(4):741-51. 
Multi-objective optimisation 
8 Fu MC, Healy KJ. Techniques for optimization via simulation: An experimental study on an (s,S) inventory system. Iie Transactions. 1997;29(3):191-9. Not a combinatorial problem 
9 Ho, Yu-Chi, R_S Sreenivas, and P. Vakili. "Ordinal optimization of DEDS." Discrete event dynamic systems 2.1 (1992): 61-88. Not optimisation of a simulation model 
10 Hurrion RD. An example of simulation optimisation using a neural network metamodel: finding the optimum number of kanbans in a manufacturing 
system. Journal of the Operational Research Society. 1997;48(11):1105-12. 
Metamodel method 
11 Jia Q-S. An Adaptive Sampling Algorithm for Simulation-Based Optimization With Descriptive Complexity Preference. Ieee Transactions on 
Automation Science and Engineering. 2011;8(4):720-31. 
Sampling strategy for search 
12 Koulouriotis DE, Xanthopoulos AS, Tourassis VD. Simulation optimisation of pull control policies for serial manufacturing lines and assembly 
manufacturing systems using genetic algorithms. International Journal of Production Research. 2010;48(10):2887-912. 
Not a combinatorial problem 
13 Martins MSR, Fuchs SC, Pando LU, Lueders R, Delgado MR. PSO with path relinking for resource allocation using simulation optimization. Computers 
& Industrial Engineering. 2013;65(2):322-30. 
Not a combinatorial problem 
14 Miranda AK, Del Castillo E. Robust parameter design optimization of simulation experiments using stochastic perturbation methods. Journal of the 
Operational Research Society. 2011;62(1):198-205. 
Robust parameter design methods. Not 
optimisation of a simulation 
15 Pan Y, Zhou M, Chen Z. SIMULATION-BASED OPTIMIZATION FOR RESOURCE ALLOCATION AT THIRD-PARTY LOGISTICS SYSTEMS. International 
Journal of Industrial Engineering-Theory Applications and Practice. 2012;19(2):101-15. 
Not accessible 
16 Pinho AFd, Montevechi JAB, Marins FAS, Costa RFdS, Miranda RdC, Friend JD. Evaluation of a proposed optimization method for discrete-event 
simulation models. Pesquisa Operacional. 2012;32(3):543-60. 
Only reporting a black box solver 
17 Pichitlamken J, Nelson BL, Hong LJ. A sequential procedure for neighborhood selection-of-the-best in optimization via simulation. European Journal Sampling strategy for search 
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of Operational Research. 2006;173(1):283-98. 
18 Smew W, Young P, Geraghty J. SUPPLY CHAIN ANALYSIS USING SIMULATION, GAUSSIAN PROCESS MODELLING AND OPTIMISATION. International 
Journal of Simulation Modelling. 2013;12(3):178-89. 
Not a combinatorial problem 
19 Subramanian D, Pekny JF, Reklaitis GV, Blau GE. Simulation-optimization framework for stochastic optimization of R&D pipeline management. Aiche 
Journal. 2003;49(1):96-112. 
Not a combinatorial problem 
20 Swisher JR, Hyden PD, Jacobson SH, Schruben LW. A survey of recent advances in discrete input parameter discrete-event simulation optimization. 
Iie Transactions. 2004;36(6):591-600. 
Review paper 
21 Yoo T, Cho H, Yuecesan E. Hybrid algorithm for discrete event simulation based supply chain optimization. Expert Systems with Applications. 
2010;37(3):2354-61. 
Not a combinatorial problem 
 
APPENDIX B.3: ARTICLES EXCLUDED AT CITATION/REFERENCE REVIEW STAGE 
 Reference Reason for exclusion 
1 Andradottir S. A method for discrete stochastic optimization. Management Science 1995;41(12):1946}61. Not a combinatorial problem 
2 D. Costa, E.A. Silver, Tabu search when noise is present: An illustration in the context of cause and effect analysis, Journal of Heuristics 4 (1998) 5–23. Not of a simulation model 
3 Guo Yet al (2006) SimOpt: a new simulation optimization system based virtual simulation for manufacturing system. Simul Model Pract Theory 14:577–585 Computer engineering of an 
algorithm / program 
4 Kleijnen, Jack PC, Wim van Beers, and Inneke van Nieuwenhuyse. "Constrained optimization in expensive simulation: Novel approach." European Journal of 
Operational Research 202.1 (2010): 164-174. 
Use of black box optimiser 
5 Nemhauser, G.L.; Wolsey, L.A. 1988: Integer and combinatorial optimization. New York: John Wiley & Sons Not of a simulation model 
6 Spinellis, D.D. and Papadopoulos, C.T., 2000. A simulated annealing approach for buffer allocation in reliable production lines. Annals of Operations 
Research, 93, 373–384. 
Not of a simulation model 
7 Sriver, Todd A. Pattern search ranking and selection algorithms for mixed-variable optimization of stochastic systems. AIR FORCE INST OF TECH WRIGHT-
PATTERSON AFB OH SCHOOL OF ENGINEERING AND MANAGEMENT, 2004. 
Not of a simulation model 
8 Zeng, Q.,&Yang,Z.(2009).Integrating simulation and optimization to schedule loading operations in container terminals. Computers & Operations 
Research,36, 1935–1944 
Not a combinatorial problem 
9 Zhang H, Li H (2004) Simulation-based optimization for dynamic resource allocation. Autom Constr 13:409–420 Dynamic modelling 
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APPENDIX B.4: REFERENCES FOR INCLUDED STUDIES 
 Reference 
1 Ahmed MA, Alkhamis TM, Hasan M. Optimizing discrete stochastic systems using simulated annealing 
and simulation. Computers & Industrial Engineering. 1997;32(4):823-36. 
2 Ahmed MA, Alkhamis TM. Simulation-based optimization using simulated annealing with ranking and 
selection. Computers & Operations Research. 2002;29(4):387-402. 
3 M.H. Alrefaei, S. Andradoittir, A simulated annealing algorithm with constant temperature for 
discrete stochastic optimization, Management Science 45 (1999) 748–764. 
4 Andradottir S, Prudius AA. Balanced Explorative and Exploitative Search with Estimation for 
Simulation Optimization. Informs Journal on Computing. 2009;21(2):193-208. 
5 Azadeh A, Maghsoudi A. Optimization of production systems through integration of computer 
simulation, design of experiment, and Tabu search: the case of a large steelmaking workshop. 
International Journal of Advanced Manufacturing Technology. 2010;48(5-8):785-800. 
6 Ding HW, Benyoucef L, Xie XL. A simulation optimization methodology for supplier selection problem. 
International Journal of Computer Integrated Manufacturing. 2005;18(2-3):210-24. 
7 Ghiani G, Legato P, Musmanno R, Vocaturo F. A combined procedure for discrete simulation-
optimization problems based on the simulated annealing framework. Computational Optimization 
and Applications. 2007;38(1):133-45. 
8 Haddock J, Mittenthal J. Simulation optimization using simulated annealing. Computers and Industrial 
Engineering 1992;20(4):87}395. 
9 Ho YC, Cassandras CG, Chen CH, Dai L. Ordinal optimisation and simulation. Journal of the 
Operational Research Society. 2000;51(4):490-500. 
10 Hong, L. Jeff, and Barry L. Nelson. "Discrete optimization via simulation using COMPASS." Operations 
Research 54.1 (2006): 115-129. 
11 Huang C-J, Chang K-H, Lin JT. Optimal vehicle allocation for an Automated Materials Handling System 
using simulation optimisation. International Journal of Production Research. 2012;50(20):5734-46. 
12 Jacobson SH, Sullivan KA, Johnson AW. Discrete manufacturing process design optimization using 
computer simulation and generalized hill climbing algorithms. Engineering Optimization. 
1998;31(2):247-60. 
13 Jun Z, Yu-An T, Xue-Lan Z, Jun L. An improved dynamic structure-based neural networks 
determination approaches to simulation optimization problems. Neural Computing & Applications. 
2010;19(6):883-901. 
14 Kamrani F, Ayani R, Moradi F. A framework for simulation-based optimization of business process 
models. Simulation-Transactions of the Society for Modeling and Simulation International. 
2012;88(7):852-69. 
15 Korytkowski P, Wisniewski T, Rymaszewski S. An evolutionary simulation-based optimization 
approach for dispatching scheduling. Simulation Modelling Practice and Theory. 2013;35:69-85. 
16 Kuo, R. J., and C. Y. Yang. "Simulation optimization using particle swarm optimization algorithm with 
application to assembly line design." Applied Soft Computing 11.1 (2011): 605-613. 
17 Lacksonen, T., Empirical comparison of search algorithms for discrete event simulation. Computers & 
Industrial Engineering, 2001, 40, 133–148. 
18 Prudius AA, Andradottir S. Averaging frameworks for simulation optimization with applications to 
simulated annealing. Naval Research Logistics. 2012;59(6):411-29. 
19 Rosen SL, Harmonosky CM. An improved simulated annealing simulation optimization method for 
discrete parameter stochastic systems. Computers & Operations Research. 2005;32(2):343-58. 
20 L. Shi, S. Olafsson, Nested partitions method for stochastic optimization, Methodology and 
Computing in Applied Probability 2(3) (2000) 271–291. 
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21 Xu WL, Nelson BL. Empirical stochastic branch-and-bound for optimization via simulation. Iie 
Transactions. 2013;45(7):685-98. 
22 Yang T, Kuo Y, Chang I. Tabu-search simulation optimization approach for flow-shop scheduling with 
multiple processors - a case study. International Journal of Production Research. 2004;42(19):4015-
30. 
23 Yang T, Fu H-P, Yang K-Y. An evolutionary-simulation approach for the optimization of multi-constant 
work-in-process strategy - A case study. International Journal of Production Economics. 
2007;107(1):104-14. 
 
APPENDIX B.5: TAXONOMIES OF SIMULATION OPTIMISATION 
Numerous simulation optimisation methods exist for the identification of local optima, including 
approximation,307 response surface methods (RSM),308,309 and ranking and selection.310 A 
taxonomy of local and global simulation optimisation methods is provided in Figure AB.1. A 
comprehensive review of local simulation optimisation methods is provided by Fu et al. in 1994 
and 2002.207,311 
Identified in this review was the contribution that LS methods had made to the development of 
global search methods. In particular, many global methods use LS algorithms to identify local 
optima before moving to another area within the search space. Therefore these local search 
methods will be considered where relevant within the results of this review. 
 
Figure AB.1: Local/Global taxonomy of simulation optimisation methods 
Optimisation problems can also be classified by function argument variables that the problem 
contains. In fact, this step is crucial in determining an appropriate method for an optimisation 
problem, since many optimisation algorithms and solutions are specifically tailored for a type of 
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problem. Even methods which promote the ability to work across a range of problem types may 
still perform better or worse in particular instances. 
Optimisation problems with variables that take values from a discrete set are discrete problems, 
with a discrete input state space. Optimisation problems with variables that can take any real 
value, either finite or infinite, are continuous optimisation problems. Often, although not always, 
continuous problems are easier to solve, because the smoothness of the objective function 
means the function can be used to determine information about solutions within a 
neighbourhood. Often methods estimate derivatives to determine movements towards an 
optima. Some problems may have a mixture of both discrete and continuous variables – called 
mixed state optimisation problems. 
This classification of the treatment sequencing problem allows several methods applicable only 
to continuous state spaces to be ruled out. These include derivative based approaches including 
gradient based and hessian based methods via standard calculus, and derivative free approaches 
for continuous problems, including the Nelder-Mead simplex method,312 and standard 
applications of Particle Swarm Optimisation.313 
Many continuous optimisation methods rely on the ability to continue moving in a favourable 
direction. In a discrete search space, the concept of ‘direction’ may not have any significant 
meaning. Therefore the theory that underpins many methods may be distinct to either discrete 
or continuous optimisation, however some methods have proven successful across both state 
space types. The exact methods contained in this taxonomy are global methods for small (or 
simple) optimisation problems. These are methods which will guarantee to final a global optima. 
Therefore they are only relevant for relatively small problems. Examples of these methods 
include exhaustive and implicit enumeration, Branch and Bound,314 Dantzig’s simplex method,315 
and column generation.316 For large or more complex problems, particular features of the 
problem may guarantee to find a global optimum, however due to the size of the problem (or 
the computational complexity of the problem) this may require a long time to execute.  
A taxonomy of simulation optimisation methods grouped by the state space they apply to is 




Figure AB.2: State space taxonomy of simulation optimisation methods 
SIMULATION OPTIMISATION 
MIXED STATE SPACE DISCRETE STATE SPACE 






















































APPENDIX B.6: HOW THE METHODS WORK 
Traditional Random Search 
Random search (RS) is a stochastic optimisation procedure, with a probabilistic (or random) 
procedure determining which neighbouring solutions are selected during the iteration. The 
general structure of RS for simulation optimisation involves a defined sampling strategy for the 
selection of neighbouring solutions. These solutions are evaluated, the best solution selected, 
and the algorithm iterates to a new point in the search space. The sampling strategy is often a 
key component of the algorithm. A generic RS algorithm is provided in Table AB.1.206 
The number of sample solutions at iteration 𝑛 is given by 𝑀𝑛, and is a parameter of the 
sampling strategy. There are no other user-defined (tuning) parameters required for this 
algorithm. The generic RS algorithm does not include a stopping criterion, because RS 
literature has shown that the sequence will converge asymptotically on the global 
optima (𝑥𝑛 → 𝑥
∗ for 𝑛 → ∞). However, in practice stopping rules are applied to ensure the RS 
algorithm terminates in a finite period of time.206 
Table AB.1: Traditional random search algorithm for simulation optimisation (Adapted from 
Andradottir (2006))206 
Step Process Details 
0 Initialise Choose initial sampling strategy 𝑆1 and set iteration count n = 1 
1 Sample Select 𝑥𝑛
(1)
, … , 𝑥𝑛
(𝑀𝑛) ∈ 𝑿 according to the sampling strategy 𝑆𝑛 
2 Simulate Estimate 𝑔(𝑥𝑛
(𝑖)), for 𝑖 = 1, … , 𝑀𝑛, using the simulation model 
3 Update Select optimal solution 𝑥𝑛
∗ , update 𝑆𝑛+1, n = n+1, Go to Step 1 
𝑀𝑛 is the number of sample solutions at iteration 𝑛 
 
Adaptive Random Search – Balanced Explorative and Exploitative Search (BEES) 
The concept underpinning the adaptive random search method is that there is an optimal 
point where each random search method should switch from the exploration of the global 
search space, to an exploitation of the local search space. The authors, Andradottir & 
Prudius,216 present two variations of their methodological framework. Deterministic 
optimisation using randomised search (R-BEES) uses a probability sampled from a uniform 
distribution to switch the algorithm between either a local or global search. Stochastic 
optimisation using randomised search (R-BEES with estimation = R-BEESE) is applicable for 
stochastic problems, and also uses a probabilistic switch between local and global search. 
The authors also present adaptive variations of the two methods. These require tracking the 
change in the optimal solution and the distance between the two optimal solutions. The 
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algorithm switches from local to global if the change in optimal solution is small (suggesting a 
local optimum nearby). A switch from global to local can happen when a promising region is 
found (a small improvement) or if a large improvement is found in a short distance (to focus on 
that area). 
Adaptive Random Search – Convergent Optimisation via Most Promising Area Stochastic 
Search (COMPASS) 
Initially, the most promising area identified is the whole feasible search space. At every 
iteration of the algorithm, a small number of simulation runs are undertaken of a sample of 
solutions. All visited solutions are collected into a set, and full simulations are undertaken as 
assigned by the simulation-allocation rule (SAR) for each solution within the set. As the 
algorithm proceeds, the set enlarges and more runs are required for each solution. The sample 
average of each solution therefore updates iteratively. As the sample becomes sufficiently 
large, the algorithm can select the best performing solution. 
For each iteration, the algorithm selects the best current solution, and the most-promising 
area is defined as the set of feasible solutions that are at least as close to the current best as 
they are to other visited solutions. Therefore as more solutions are sampled, the most-
promising area shrinks in size. 
Genetic algorithms 
Genetic algorithms are a population-based metaheuristic, with a pool of potential solutions 
maintained in the algorithm. They mimic the process of natural evaluation and use concepts of 
natural selection and genetic inheritance to navigate the search space.317 Each potential 
solution is represented as a chromosome with each decision variable (often called an element) 
a gene. This representation type naturally leads GAs to be a popular method for combinatorial 
problems. 
There are two key operations within the GA which evolve the pool of potential solutions – 
crossover and mutation. Crossover is the operation of taking parent solutions from the 
population, and generating offspring with a ‘crossed over’ set of chromosomes (see Box AB.1). 
Mutation is the altering of each gene independently via a specified probability (the mutation 
rate - see Box AB.2). 
Evolutionary algorithms are related to genetic algorithms, but they only include offspring 




    Crossover   
        
Parent 1 0 0 0 0 0 0  
        
Parent 2 1 1 1 1 1 1  
        
        
Offspring 1 0 0 0 1 1 1  
        
Offspring 2 1 1 1 0 0 0  
       
Box AB.1: One point crossover 
        
Offspring 1 0 0 0 1 1 1  
        
Offspring 2 1 1 1 0 0 0  
        
        
Offspring 1 Mutated 0 1 0 0 0 1  
        
Offspring 2 Mutated 0 1 1 1 0 1  
        
Box AB.2: Mutation 
The SGA has a simple iterative process to replace the whole population with the offspring 
generated by crossover and mutation: 
1. Select parents for the mating pool (size of mating pool = population size) 
2. Shuffle the mating pool 
3. Select a set of parents from the mating pool. For each consecutive pair apply crossover 
with a defined probability, otherwise copy parents. This requires two parents and 
results in two offspring. 
4. For each offspring apply mutation (for a binary representation - bit-flip with a defined 
probability independently for each bit) 
5. Replace the set of parents with the resulting offspring and return to mating pool. 
Even more so than other metaheuristic methods, the representation of the solution is crucial 
for genetic algorithms. This is because the newer and more complex crossover and mutation 
operators are directly informed by the representation type. The SGA was represented by a bit 
array (binary representation). However, as already discussed, binary representation is only 
suitable for a subset of combinatorial optimisation problems. 
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Permutation representation as already discussed is more appropriate for ordering and 
sequencing problems (e.g. TSP, sequencing problem), and the RA treatment sequencing 
problem. However, permutation representation introduces challenges for genetic algorithms 
and standard crossover and mutation operations. This is because the order and the adjacency 
of elements within the solution sequence are crucial.318 Normal crossover and mutation 
operators lead to inadmissible solutions, and therefore at least two elements/genes within the 
chromosome must be changed to ensure a valid solution. This increases the neighbourhood 
size for the GA. 
Four common mutation operators for permutation representation and provided below (Box 
AB.3, with details on their ability to retain order and adjacency information within the 
chromosome. 
Like mutation, normal crossover operations will often result in inadmissible solutions. 
Therefore a large number of specialised operators have been devised which focus on 
combining order and adjacency information from the two parents. These include order one 
crossover, partially mapped crossover, cycle crossover, edge recombination and multi-parent 
recombination.319 
Within a genetic algorithm, there are two points where selection of solutions occurs. Firstly, 
when selecting from the current population which solutions are going to take part in mating 
(parent selection). Secondly, when selecting which parents and offspring go into the next 
generation (survivor selection). 
1. Insert mutation  
 1 2 3 4 5 6  1 2 5 3 4 6  
Select two values, move second to follow first and shift rest to accommodate. This method 
preserves most order and adjacency information. 
 
2. Swap mutation 
 1 2 3 4 5 6  1 5 3 4 2 6  
Pick two values and swap. Preserves most adjacency information but disruptive to order. 
 
3. Inversion mutation  
 1 2 3 4 5 6  1 5 4 3 2 6  
Pick two values and invert substring between them. Preserved most adjacency information 
but disruptive to order. 
 
4. Scramble Mutation 
 1 2 3 4 5 6  1 4 3 5 2 6  
Select a subset and randomly rearrange. Disruptive to order and adjacency. 
Box AB.3: Mutation operators 
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Traditionally, fitness-proportionate selection has been a commonly applied method, including 
roulette-wheel algorithms and Baker’s stochastic universal sampling (SUS) algorithm.320 
However, these can be problematic if a highly fit member dominates the population and can 
lead to premature convergence. Also, when a population is very similar in terms of fitness, the 
selection pressure of the algorithm can drop and convergence does not occur.321,322 Selection 
pressure is the informal term within the evolutionary algorithm literature to reflect the 
balance between exploration and exploitation. Some authors quantify selection pressure as 
the ratio of maximum to average fitness within the population.323 
Rank based selection is a potential solution to the limitations of fitness-proportionate 
selection, and is based on relative rather than absolute fitness. This is a common way to 
maintain selection pressure within the algorithm. However, a sorting overhead is imposed on 
the algorithm when this is introduced. Tournament selection is similar, with a subset of 
solutions randomly selected from the pool and the best solution then selected as a parent. The 
size of the subset (tournament) is a user-defined parameter and the selection pressure is 
highly sensitive to the tournament size.324 
For survivor selection, there are two general methods: age based selection where the oldest is 
deleted, and fitness based selection. However, two special cases have been introduced and 
widely used - Elitism (always keep the best solution), and GENITOR (GENetic ImplemaTOR - 
always delete the worst solution).325 Elitism means that the fitness of the best solution in the 
population never deteriorates as the algorithm iterates. The ability of a GA to asymptotically 
converge has been found to rely on elitism, and several studies have shown that algorithms 
with elitism converge faster than those without.326,327 
If there are constraints to the problem, then genetic algorithms can incorporate penalties to 
the objective function.328 However, it is much preferable to encode out any infeasible 
solutions, rather than evaluate and then apply a subsequent penalty.329 
Tabu search 
Tabu search (TS) is a local search method with a flexible memory structure. Unlike branch and 
bound (rigid memory structure) and simulated annealing (no memory structure), TS has a 
short-term memory structure to avoid moving back to a recently visited solution (tabu moves). 
TS has the same foundations as an ordinary local or neighbourhood search. Each vector of 
decision variables from the feasible space 𝑥 ∈ 𝐗 has an associated neighbourhood 𝐍(𝑥) ⊂ 𝐗 
and each neighbouring solution 𝑥′ ∈ 𝐍(𝑥) is reached from 𝑥 via a move operation. 
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Unlike genetic algorithms and simulated annealing, which are probabilistic/stochastic search 
methods, TS accepts non-improving solutions deterministically by guiding a steepest-
descent/ascent hill-climbing heuristic based on the best neighbouring non-tabu solution. 
However, for problem where 𝐍(𝑥) is large or each element of 𝐍(𝑥) is computationally costly 
to retrieve, the steepest descent method may be impractical. Therefore any improving move 
can be selected as a relaxation to the algorithm. 
The decision regarding the evaluation (and subsequent selection) of a solution is called the 
‘candidate list strategy’ and is an important component of the TS method. In particular, the 
relevance of choosing a good solution is magnified when looking to move out of a local 
optimum (where a descent method would normally terminate). At this point, the method 
requires the selection of the best non-improving solution.272 
If the best neighbouring solution (descent) heuristic is relaxed to avoid evaluating every 
possible move in a current neighbourhood, then it needs to be the case that neighbours are 
identified which are meaningful for the particular problem. Candidate lists are methods to 
isolate good candidate moves from the current neighbourhood. Candidate moves use an 
intelligent process, rather than random or naïve processes.330 It allows a reduction in the 
number of evaluations conducted and allows the problem structure to be exploited (called 
‘context related rules’ in Glover & Laguna (1997).272,330 
Examples of candidate list strategies include the ‘elite candidate list strategies’, which records 
the best moves encountered and then implement this list of moves for each solution. 
‘Aspiration plus strategy’ is an adaptive method of only implementing moves which currently 
have proved to improve a solution by a given threshold level. More detail regarding these 
strategies is provided in Rangaswamy et al (1998).330 It should be noted that candidate list 
strategies are memory based methods, in keeping with the general paradigm of TS. The 
memory that is used to record recently visited (tabu) solutions is called the Tabu list. This list is 
typically short term, and therefore updated with each move. Diversification within the 
algorithm can be encouraged by increasing the length of the tabu list (tenure), or using a 
dynamic tabu list structure. 
Nested partitions 
The underlying concept of the algorithm is to systematically partition the feasible region into 
subregions, evaluate the potential of each subregion, and then focus on the most promising 




More formally, a promising region at iteration 𝑘, 𝜎(𝑘), is defined, and the initial state of the 
algorithm contains no knowledge regarding the most promising region, 𝜎(0) = 𝑿. At the 𝑘-th 
iteration of the algorithm, a region 𝜎(𝑘) ⊆ 𝑿 is considered the most promising. The most 
promising region is partitioned into 𝑀 subsets which cover the entire best region, and the 
remaining surrounding region 𝑿/𝜎(𝑘) is aggregated into one partition. At each iteration, 
𝑀 + 1 subsets are generated and each region is randomly sampled to estimate a set of 
solutions. The next most promising region is the subset with the best sampled value. If the 
surrounding region is the most promising, then the algorithm backtracks. The new most 
promising region is partitioned and sampled which generates a sequence of set partitions, with 
each partition nested within the last. 
A stochastic version of the method is developed by Shi et al. (2000) where the only 
modification from the original algorithm is the way the optimum is estimated. This 
modification is required to ensure convergence with stochastic problems. Specifically, the best 
solution is the most frequently visited region (the region most often in the most-promising 
region).  
The NP method is particularly robust for simulation optimisation, because nested partition is a 
set-based method with a stochastic move operation. Like genetic algorithms, this stochastic 
move appears to make it relatively insensitive to the noise from the simulation model.331 
To improve the nested partition method, a modification by Olafsson (2004) was made to 
introduce a statistical selection mechanism to guide the search, which acts as a control to the 
noise in the algorithm. A first phase to the algorithm undertakes a small sample of the 
performance variance in each region. This also allows very poor regions to be screened. Then 
based on the initial samples a second phase of sampling is conducted to ensure that the 
correct selection of a region is made, using an indifference zone selection procedure with a 
specified minimum probability.332  
Ordinal optimisation 
In ordinal optimisation (OO), the objective is relaxed from finding the optimal solution to 
finding a subset of ‘good enough’ solutions. This is also known as ‘goal softening’. The authors 
make it clear that this is a retreat from a hard method to a soft method, but it is necessary 
within the context of simulation optimisation. Exact optimisation may just be too 
computationally expensive for many simulation optimisation problems. The shift from cardinal 
to ordinal optimisation methods means looking to maximise the alignment probability of 
alternative solutions – that is, the probability that competing solutions are ranked correctly.  
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The aim of the OO algorithm is to find a subset of the search space 𝑮 which is ‘good enough’. 
In traditional optimisation, the subset 𝑮 is a solution, the optimum (or an optima). However in 
OO the subset 𝑮 is a set of solutions. The OO algorithm uses a selected subset 𝑺 of the search 
space, which again is a set of solutions. In traditional optimisation, 𝑺 is also a single solution, 
with the aim of 𝑺 = 𝑮, so that the selected solution is the optium. However in ordinal 
optimisation, the objective is that 𝑮 intersects 𝑺 above a user defined alignment probability 
(e.g. 95%) , 𝑘. This alignment probability, 𝑃𝑟𝑜𝑏[|𝑮 ∩ 𝑺| ≥ 𝑘], is the probability that there are 𝑘 
truly good enough designs within 𝑺. 
An important component of the method is the Ordered Performance Curve (OPC). This simply 
ranks the designs from a sample of the search space in order of their performance. Lau et al. 
(1997) identify four general types of OPC, as denoted in Figure AB.3.333 
The procedure for OO is simple: 
1. Using a uniform and random sampling method, sample 𝑵 designs 
2. Estimate the performance of these 𝑵 designs (using a crude fast model if required) 
3. Estimate the OPC type and the noise level within the model used for Step 2. The user 
specifies the size of the good enough set and the required alignment level 𝑘 (e.g. 95%) 
4. Calculate the s value (the initial size of subset 𝑺) based on Ho et al. (2008) tables (data 
from step 3).334 
5. Select the top s designs of 𝑵 and specify as the selected set 𝑺. 
6. This top set contains at least k truly good enough designs with probability no less than 
95% 
The OO method introduces a tolerance to the imprecise estimates determined by a stochastic 
simulation model because the goal has been softened and the user has a high confidence in 
obtaining a ‘good enough’ design from a selected set. OO is a method itself, but the idea of 
ordinal comparison can be integrated into alternative search algorithms to provide a much 




Figure AB.3: Types of Ordered Performance Curve (Lau et al (1997))333 
 
Particle swarm optimisation 
Particle swarm optimisation (PSO) is a population based method. The algorithm is initialised 
with a population of random particles (representing different solutions) and each generation 
of the algorithm sees an updating of the particles, which allows a search for the optima. 
Each particle (𝑖𝑑) records its previous best position (𝑃𝑏𝑒𝑠𝑡𝑖𝑑) and has a velocity with which the 
particle travels within the multi-dimensional search space (𝑥 ∈ 𝑿). At each iteration, the 
particle with the best fitness (𝐺) and the position vector of the current particle are combined 
to adjust the velocity. That new updated velocity is then used to compute the new position for 
the particle. Global best and local best alternatives are possible when looking to influence the 
direction of the swarm. Two tuning parameters (c1 and c2) determine the relative influence of 
the social and cognition components (learning factors) of the algorithm. With these, the 
following updating rule is applied within the algorithm: 
𝑣𝑖𝑑
𝑛𝑒𝑤 = 𝑣𝑖𝑑





The maximum velocity is traditionally constrained, which controls the ability of the algorithm 
to explore the search space. However, an inertia component has been added to provide a 
better balance of exploration and exploitation, and this has rendered maximum velocity 
redundant.335 At first, the inertia weight was a constant parameter, however a decreasing rate 
for the inertia parameter was found to have more potential. This is because the higher weight 
293 
 
enables great exploitation as the beginning to find a good area, and the smaller weight 
towards the end has the ability to search the local area. 
Averaging framework for simulated annealing 
The averaging framework for simulated annealing, as developed by Prudius et al. (2012), is 
adaptive, and uses the information gathered at previous iterations of the algorithm to 
determine the amount of simulation effort required.235 Averaging is used to provide estimates 
of the objective values based on the average of all previously visited solutions. 
The authors present a random search variant of the method which incorporates a point-based 
movement. This allows the random search to iterate between different points within the 
feasible space, and is particularly applicable to discrete optimisation problems. The authors 
find that the random search method is globally convergent under mild conditions, and do not 
explore any potential limitations of the method. 
Empirical stochastic branch and bound 
The empirical stochastic branch-and-bound method, as developed by Xu et al. (2013), is a 
combination of nested partitioning and branch and bound. It uses the partitioning structure of 
stochastic branch and bound to determine subregions of the search space. However, it uses 
bounds based on the performance of sampled solutions, as per the nested partitions 
method.233 These bounds are determined by maintaining a set of feasible solutions, as well as 
a set of all solutions. It simulates solutions within the set of feasible solutions and computes 
the bounds using their estimated performance. In the next iteration, a subset of solutions from 
the current partition is sampled. The method is memory intensive due to the overhead 
required to retain and refine the partition structure. The assumptions regarding bounding are 
key, because they provide the guarantee for convergence. Also, there are four tuning 





APPENDIX B.4: DATA EXTRACTION TABLES 




What is the method? Simulated annealing with ranking and selection 
What problem was the method originally 
developed for? 
Solving a discrete stochastic optimisation problem 
Has the method been adapted from its original 
context? 
The method combines simulated annealing and ranking and selection procedures. 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
No, it adapts general optimisation methods for use with a  DES 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
That simulated annealing (SA) has been successfully applied to solve a wide range of combinatorial optimisation problems. Ranking and selection 
(RS) procedures are statistical methods designed to solve discrete stochastic optimisation problems. 
 
Combining the two approaches resolves the limitations of each individual approach. 
 
The method shows that the configuration that has been visited most often in the first m iterations converges almost surely to a globally optimum 
solution.  
How does the method work In each iteration of the algorithm, two neighbouring configurations are compared using RS. This procedure explicitly sets the sample size (run 
length), so to guarantee that the probability of selecting the best configuration is suitably large. 
 
1. Obtain initial solution and temperature 
2. Choose neighbour candidate based on probability distribution 
3. Move to selected candidate 
4. Update temperature and repeat 
What assumptions does the method require? The method resembles original SA (it accepts worse neighbouring configurations, with an acceptance probability which tends to zero). 
 
This therefore requires a ’generating probability function’ for each candidate solution points. 
What are the theoretical limitations of the 
method? 





Original SA only guaranteed to converge in probability. 
What are the potential biases associated with 
the method? 
None identified by the authors. Standard SA biases (initial temperature, temperature length, cooling rate, final temperature) 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – an inventory system example. This was a standard infinite horizon single item periodic review inventory model with zero lead times. An (s,S) 
policy for linear costs – order placed when inventory below s, and order is the difference between S and the inventory position. At each period an 
order can be placed for any positive quantity of stock. The objective is to minimise the long-run average cost function per period. By varying s and 
S. The model is developed with exponential demands, so that an analytical solution is possible.  
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Little information given. The method converges almost surely to a global optimal position. Results are very close to analytical solutions in all cases. 
If not, are there any suggestions to its practical 
applicability? 
I think by forcing simplistic assumptions (exponential demand) you are simplifying the search space. 




What is the method? Simulated annealing 
What problem was the method originally 
developed for? 
Solving a discrete stochastic optimisation problem 
Has the method been adapted from its original 
context? 
They have used Simulated Annealing. They have adapted the rejection/acceptance criteria for stochastic constraints. Normally SA uses a penalty 
system for constraints, but this can result in an “optimal” result being infeasible. Therefore an adaptation to the SA algorithm is used which only 
accepts feasible transitions. 
How does the method work Initialise the user-defined settings (intial temp, temp length, cooling rate, final temp) 
 
Standard SA methods with only feasible transitions accepted 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
No, it adapts general SA for use with a  DES 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
That simulated annealing (SA) has been successfully applied to solve a wide range of combinatorial optimisation problems. Acceptance/rejection is 
based on the expected output of the simulation model. Rejection/acceptance is modified to take into consideration stochastic system constraints. 
The method also includes control variate as a variance reduction technique. 
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How does the method work Standard SA method, with a couple of modifications:  
1. SA algorithm only accepts feasible transitions 
2. Neighbourhood based on a single perturbation 
3. Controlled probability for uphill perturbation move 
What assumptions does the method require? None 
What are the theoretical limitations of the 
method? 
SA tends to need an accurate evaluation of the objective function values. 
Only allows single neighbour perturbation. Inefficient? 
 
What are the potential biases associated with 
the method? 
Standard SA biases (initial temperature, temperature length, cooling rate, final temperature) 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
1. Classical machine repair problem 
2. Two-echelon repairable item provisioning system 
3. Multi-echelon repairable item provisioning system  
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
For 1, the algorithm found the analytical solution. For 2, the algorithm almost found the analytical solution. For 3, not analytical solution is possible 
– it was tested against a greedy algorithm with the same number of iterations. The proposed algorithm was superior for all 6 cases of Test 3. No 
further details 
If not, are there any suggestions to its practical 
applicability? 
 




What is the method? Modified simulated annealing 
What problem was the method originally 
developed for? 
Discrete stochastic optimisation 
Has the method been adapted from its original 
context? 
The method differs from the original simulated annealing algorithm by using a constant (rather than decreasing) temperature 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
No 
Theoretical basis 
How does the method address optimising a DES Because rapidly decreasing temperatures reduce the algorithm time, but the convergence of the algorithm is not guaranteed. The higher the 
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with a combinatorial problem? temperature value, the greater the chance of accepting a worse move (hill climbing move).  
How does the method work It is a simple modification of the standard SA method. 
 
The method also modifies the criteria to evaluate the optimal solution. Firstly by using the number of visits made to different states, and secondly 
to use the state that has the best average estimated value. 
What assumptions does the method require? Standard SA assumptions 
What are the theoretical limitations of the 
method? 
The paper provides a proof of almost-sure convergence. 
What are the potential biases associated with 
the method? 
Standard SA biases 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Discrete queuing systems 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Compared against GM-GP and FH SA algorithms (using decreasing annealing schedule), the modified algorithms perform well. However, the 
performance depends on the choice of temperature, neighbourhood, and the number of estimated function values from each iteration. However, 
the algorithm does not show great sensitivity to the initial temperature. Better overall performance in comparison, with better overall optimal 
solutions estimated. 
If not, are there any suggestions to its practical 
applicability? 
No 




What is the method? Balanced Explorative and Exploitative Search with Estimation (BEESE) for simulation optimisation 
What problem was the method originally 
developed for? 
Simulation optimisation 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
No 
Theoretical basis 
How does the method address optimising a DES The method is a framework which balances exploration for a global search with exploitation for a local search. The advantage is that its 
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with a combinatorial problem? numerically efficient when applied to solve problems with little known structure 
How does the method work The concept underpinning the method is that there’s an optimal switch point from exploration to exploitation. 
 
Deterministic optimisation using R-BEES has a simple probability assigned which is sampled using a uniform distribution to switch between 
searching either the global space or the local space. 
 
Stochastic optimisation using R-BEESE, with a probability parameter sampled to switch between the current optimal solution and sampling as 
before. 
 
Adaptive variations of the two methods are possible. These require tracking of the change in optimal solution, and the distance between the top 
two optimal solutions. The algorithm switches from local to global if the change in optimal solution is small (suggest near local optima). If making 
good progress, the local search is maintained. A switch from global to local can happen when a promising region is found (small improvement) or 
large improvement with a short distance (suggesting a focus on the local area). 
What assumptions does the method require? None, the method is a framework to guide the development of search algorithms which more formally consider the balance between exploration 
and exploitation 
What are the theoretical limitations of the 
method? 
None (see above) 
What are the potential biases associated with 
the method? 
The method requires user-specified algorithms which deterministically, stochastically or adaptively switch the algorithm between local and global 
search. These are open to bias. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
No 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
 
If not, are there any suggestions to its practical 
applicability? 
 
Azadeh A, Maghsoudi A. Optimization of production systems through integration of computer simulation, design of experiment, and Tabu search: the case of a large steelmaking workshop. 




What is the method? A combination of design of experiment and Tabu search 
What problem was the method originally 
developed for? 
A discrete production system with discrete decision making parameters 
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Has the method been adapted from its original 
context? 
Both design of experiment, and Tabu search, are established simulation and global metaheuristic optimisation methods. 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
It uses a metaheurstic method (Tabu search) to optimise the fitted metamodel. This limits the simulations required by fitting a regression model 
using parameter sets determined by the DOE. The Tabu search is then used to optimise this regression function. 
How does the method work 1. Formulate problem 
2. Simulation verification and validation 
3. Simulated output and parameters 
4. Use ANOVA and RSM to establish a design of experiments 
5. Fit a polynomial order regression (Least Squares) 
6. Identify efficient parameters 
7. Undertake a Tabu search 
What assumptions does the method require? Assumptions regarding the functional form of the fitted regression model 
What are the theoretical limitations of the 
method? 
Tabu searches are memory intensive. 
 
What are the potential biases associated with 
the method? 
Regression model determinant on the simulation data – appropriate design required 
 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes a discrete production system with discrete decision making parameters. 
 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
It claims a global optimum was identified but it’s not fully clear how that’s proven in this case.  
If not, are there any suggestions to its practical 
applicability? 
The method was only tested for 4 factors (converters, slag pockets, mixers, blastfurnaces), which only required 81 experiments to be run. 




What is the method? Genetic algorithm 




Has the method been adapted from its original 
context? 
Genetic algorithms have been used in numerous optimisation problems. 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
The method allows the encoding of design points as chromosomes. Design points are explicitly discrete in a combinatorial problem, and therefore 
the methodology is naturally aligned with our problem. 
 
GA’s used to search large, non-linear search spaces where expert knowledge is lacking or difficult to encode and where traditional optimization 
techniques fall short. 
How does the method work 1. Initialise parameters for GA optimizer and sim model 
2. Create initial population 
3. Check feasibility of each network, and repair if not feasible (this allows ‘bad genes’ to be removed and only feasible networks evaluated) 
4. Create and run DES for each individual 
5. Calculated the fitness of each individual according to the fitness definition 
6. Select individuals for mating 
7. Mate individuals to produce offspring 
8. Check stopping criteria 
What assumptions does the method require?  GA’s work with a population of individual strings (chromosomes). Each string represents a possible solution. In practice, each position in the 
chromosome may take on one fof a finite set of values. Each chromosome is assigned a fitness values according to the result of the simulation. 
Highly fit chromosomes survive more frequently and are given more opportunities to reproduce. 
 
Therefore for realistic problems, GA can often find good(near optimal) solutions in a relatively short search period 
What are the theoretical limitations of the 
method? 
Not sure at present. None discussed 
What are the potential biases associated with 
the method? 
GA’s require user input in key ways: 
1. How constraints/legal solutions are managed 
2. How fitness is evaluated 
3. How mutation and reproductions occurs 
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4. Stopping criteria 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a supply chain simulation model is used. A binary string is used, with segments of the string representing supplier utilisation, assignment 
weight, and replenishment level. 
 
Maximum GA generations set at 500, and each population contains 20 individuals. Roulette wheel selection used, with two-point crossover. Fixed 
probabilities for mutation and crossover. An elitist strategy is used to preserve the best individuals. 
 
A penalty factor is used to avoid ‘missed demands’ – constraint on system 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Each simulation takes less than one second. 
The algorithm converges quickly (within 100 generations – so a couple of minutes).  
If not, are there any suggestions to its practical 
applicability? 
The case study illustrates the applicability of the methods. The simulation model is coded efficiently which allows a rapid evaluation. 
 
There could have been greater evaluation of the performance by altering user-defined parameters of the algorithm. Little is said about these 
fundamental assumptions. 





What is the method? Simulated Annealing 
What problem was the method originally 
developed for? 
Optimising a discrete stochastic problem 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
It uses Simulated Annealing, combined with a statistical procedure for comparing solutions.  
How does the method work Standard SA methodology with a Rinott Procedure to compare the current solution and neighbour by using ‘Indifference Zone Ranking and 
Selection’ = SARP 
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What assumptions does the method require? The Rinott Procedure requires the definition of an indifference zone width, and a confidence level. An objective function gap of less than the 
indifference zone width is considered negligible. In the first iteration of the algorithm, independent replications from a reference configurations 
are taken to estimate the sample mean and marginal sample variance, and subsequently solve the Rinott integral. 
What are the theoretical limitations of the 
method? 
None reported in the paper. In theory, standard SA limitations 
What are the potential biases associated with 
the method? 
None reported in the paper. In theory, standard SA biases 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
No, only test problems 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
- 
If not, are there any suggestions to its practical 
applicability? 
- 




What is the method? Simulated annealing 
What problem was the method originally 
developed for? 
Standard optimisation 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
Standard SA 
How does the method work Uses traditional methods for SA. No changes identified  
What assumptions does the method require? The method resembles original SA (it accepts worse neighbouring configurations, with an acceptance probability which tends to zero). 
 
This therefore requires a ’generating probability function’ for each candidate solution points. 
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What are the theoretical limitations of the 
method? 
SA tends to need an accurate evaluation of the objective function values, and RS tends to only be efficient when the number of alternatives are 
small. 
 
Original SA only guaranteed to converge in probability. 
What are the potential biases associated with 
the method? 
None identified by the authors. Standard SA biases (initial temperature, temperature length, cooling rate, final temperature) 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
A simple simulation model is used but due to age of the study it is unlikely to be relevant (1992) 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
 
If not, are there any suggestions to its practical 
applicability? 
 





What is the method? Ordinal optimisation 
What problem was the method originally 
developed for? 
Optimisation of a complex stochastic simulation model 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
Rather than requiring the computations to make a precise estimate of each compared design (which converges slowly), this method of ordinal 
comparison can converge exponentially fast. Also the method uses goal softening to ease the computational burden. 
 
The key concepts are that order converges exponentially fast, compared to value converging at a much slower rate. It is easier to estimate whether 




Also, goal softening eases the computational burden of finding the optimum 
How does the method work The method assumes that the performance measures are nromall distributed. The optimisation problem can then be reduced to determining 
whether the difference in the means is positive or negative.  
 
The method is then to draw independent samples of the compared solutions, and estimate the indifference amount (e.g. the amount of overlap 
between the distributions of the two compared soltuions). Then as the algorithm iterates the simulation will finally produce an estimate of the 
ordinal difference between the two solutions which is below a defined level of tolerance (the indifference amount).  
 
The method also promotes the use of variance reduction techniques (e.g. common random numbers) to reduce the variance in the comparison 
What assumptions does the method require? Normality in the distribution in the uncertainty of the output function 
What are the theoretical limitations of the 
method? 
None noted by the authors 
What are the potential biases associated with 
the method? 
Normality. The use of an indifference amount causes the possibility to arise that the wrong solution is selected. The concept behind this goal 
softening approach is that if the solutions are very close, then it doesn’t matter if the wrong solution is selected. This implies an explicit bias. It is 
for the decision maker to determine whether it is acceptable. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a queuing system with N parallel servers. Buffer allocation problem. 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Very fast convergence to the proven optimum. Little discussion about how easy it is to implement. 
If not, are there any suggestions to its practical 
applicability? 
This was a very hypothetical simulation with a proven analytical solution.  




What is the method? COMPASS 
What problem was the method originally 
developed for? 
The optimisation of discrete simulation models 
Has the method been adapted from its original 
context? 
 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could Yes 
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be suitable for DES? 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
It is a random research-based algorithm with a unique neighbourhood structure, termed ‘the most promising area’. It is defined at each iteration 
to help the algorithm focus on a subset of the decision space that is of potential so to reduce the required simulation runs.  
How does the method work Initially, the most promising area is the whole decision space. At every iteration samples of a couple of solutions are made. All visited solutions are 
collected in a set, and proper runs are assigned by the simulation-allocation rule (SAR) for each solution in the set. As the algorithm proceeds, the 
set enlarges and more runs required for each solution. The sample average of each solution in the set is updated iteratively. As the sample 
becomes sufficiently large, the sample average approaches truth, and the algorithm can correctly select the solution that truly has best 
performance. 
 
For each iteration, the algorithm selects the best current solution, and the most-promising area is defined as the set of feasible solutions that are 
at least as close to the current best as they are to other visited solutions. Therefore as more solutions are sampled the most-promising area shrinks 
in size. 
What assumptions does the method require? 1. It requires that the sample mean of the simulation is a good estimator. If the simulation is independent and identically distributed, then 
strong law of large numbers applies. 
2. The SAR guarantees a converge because the most promising area shrinks in size 
What are the theoretical limitations of the 
method? 
Well the method requires a stored set of solutions and require continue recalculation of sample means and variance – likely to be memory 
intensive. 
 
What are the potential biases associated with 
the method? 
None stated explicitly 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
No 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
 
If not, are there any suggestions to its practical 
applicability? 
 





What is the method? An implementation of the ‘Convergent Optimisation via Most-Promising-Area Stochastic Search’ COMPASS method of Hong and Nelson (2004) 
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What problem was the method originally 
developed for? 
The optimisation of discrete simulation models 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
It is a random research-based algorithm with a unique neighbourhood structure, termed ‘the most promising area’. It is defined at each iteration 
to help the algorithm focus on a subset of the decision space that is of potential so to reduce the required simulation runs.  
How does the method work Initially, the most promising area is the whole decision space. At every iteration samples of a couple of solutions are made. All visited solutions are 
collected in a set, and proper runs are assigned by the simulation-allocation rule (SAR) for each solution in the set. As the algorithm proceeds, the 
set enlarges and more runs required for each solution. The sample average of each solution in the set is updated iteratively. As the sample 
becomes sufficiently large, the sample average approaches truth, and the algorithm can correctly select the solution that truly has best 
performance. 
 
For each iteration, the algorithm selects the best current spoultion, and the most-promising area is defined as the set of feasible solutions that are 
at least as close to the current best as they are to other visited solutions. Therefore as more solutions are sampled the most-promising area shrinks 
in size. 
What assumptions does the method require? 3. It requires that the sample mean of the simulation is a good estimator. If the simulation is independent and identically distributed, then 
strong law of large numbers applies. 
4. The SAR guarantees a converge because the most promising area shrinks in size 
What are the theoretical limitations of the 
method? 
Well the method requires a stored set of solutions and require continue recalculation of sample means and variance – likely to be memory 
intensive. 
 
What are the potential biases associated with 
the method? 
None stated explicitly 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a vehicle allocation problem.  
If so, how did it perform? (Speed, optimality, It is not clear from the example if a near optimal result is found, the model does not seem to converge after only 30 iterations, however it does 
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ease of implementation) show continual improvement in the objective function 
If not, are there any suggestions to its practical 
applicability? 
None stated in the paper.  





What is the method? The whole class of stochastic generalised hill climbing methods for discrete manufacturing design optimisation problems 
What problem was the method originally 
developed for? 
For discrete manufacturing design optimisation problems 
Has the method been adapted from its original 
context? 
The paper is an overview and application of several GHC algorithms 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
 
How does the method work The paper presents a generalised framework for ‘generalised hill climbing’ methods. These retain the best visited solution and allow the visiting of 
many inferior designs to search for a globally optimal design. 
 
Simulated annealing, threshold accepting, tabu search, monte carlo search, local search and Weibull accepting are all variations of GHC. 
What assumptions does the method require? Penalties are applied to infeasible solutions or broken constraints 
What are the theoretical limitations of the 
method? 
The paper doesn’t discuss these 
What are the potential biases associated with 
the method? 
The paper doesn’t discuss these 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 




A neighbourhood selection process that balances conservatism with aggression was superior. 
If not, are there any suggestions to its practical 
applicability? 
None 





What is the method? The method is a hybrid approach using an improved ‘orthogonal genetic algorithm with quantization (OGA/Q)’ evolutionary algorithm combined 
with a neural network determination approach. 
What problem was the method originally 
developed for? 
Simulation optimisation 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
The method uses OGA/Q to solve the simulation optimisation problem. At the same time, dynamic structure-based neural networks are applied to 
learn and replace the known simulation model as an auxiliary method to solve the problem. 
How does the method work 1. Start with the generation counter to zero 
2. Set initial configurations for the simulator (population initialization) 
3. Evaluate fitness of all initial configurations in population by running simulations (population evaluation) 
4. Increase generation counter 
5. Generate the next simulator configurations by the optimization algorithm, which uses performance measures and search techniques to 
decide on these configurations (population recombination) 
6. Evaluate the new obtained configurations by simulations (population evaluation) 
7. Test for termination criterion (number of generations, fitness) and stop or go back to 4. 
What assumptions does the method require? Evolutionary algorithms avoid the shortcomings of SO methods – in particular, sensitivity to local extrema, limitations in addressing problems with 
mixed numerical and no-numerical variables or high computational load.  
What are the theoretical limitations of the 
method? 
EA’s are in general quite slow. The proposed method (Orthogonal genetic algorithm with quantization (OGA/Q) designs a new method for 
generating good initial populations and a new crossover operator. 





Has the method been used to optimise a DES 
with a combinatorial problem? 
No – just test examples 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
The proposed determination approach based on OGA/Q for the DSNN (dynamic structure-based neural network) can find optimal or close-to 
optimal solutions quickly. The number of evaluations was drastically reduced. Numerous evaluations replaced by the evaluation of trained DSNNs. 
Although NN training is time-consuming, its training frequency is small. 
If not, are there any suggestions to its practical 
applicability? 
No 





What is the method? The method(s) involve combining the Hungarian algorithm with a hill climbing heuristic method. 
What problem was the method originally 
developed for? 
Optimizing a business process model with the objective of finding the most beneficial assignment of tasks to agents. Where assignments of tasks to 
agents do not affect the flow of the business process, a Hungarian algorithm is applied. Where assignments of tasks to agents DO affect the 
workflow, depending on who performs them – then the heuristic method is applied to large problem. 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes in this case 
Or is it a general optimisation method that could 
be suitable for DES? 
These are general methods that have been combined 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
Because there are scenarios where the assignment combinations may change the probabilities that govern the path of the workflow – this means 
that there is not a unique ‘value added’ matrix. Instead, different assignments result in different matrices. 
How does the method work The method overcomes this by distinguishing between tasks whose assignment may affect the flow of the process, and other tasks. These are 
called critical and non-critical tasks. 
 
Depending on the size of the problem, either the optimal or near-optimal solution can be identified. 
 
The method employs the Hungarian algorithm to find the optimal assignment for non-critical tasks, which minimises the complexity of the 
algorithm. A heuristic method used in the algorithm (similar to hill climbing) is used to find the near optimal solution for the critical tasks.  
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What assumptions does the method require? That you can clearly distinguish between critical and non-critical tasks. 
 
What are the theoretical limitations of the 
method? 
The Hungarian algorithm has a time complexity of O(m3), where m is the number of tasks. Little mention is given to the appropriateness of a hill-
climbing method for the heuristic. 
 
What are the potential biases associated with 
the method? 
None explicitly stated. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
The random search method was applied with three initial solutions. The algorithm reached a near optima after 80 iterations. The relative deviation 
for a number of problem sizes is less than 0.5% from the optimal value 
 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
 
If not, are there any suggestions to its practical 
applicability? 
 




What is the method? Genetic algorithm with modified genetic operations (selection and crossover) 
What problem was the method originally 
developed for? 
GA’s have been used routinely for optimisation, including combinatorial simulation optimisation 
 
Has the method been adapted from its original 
context? 
Yes – the modification of (regularly modified) selection and crossover rules 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
The method described is a very standard application of a GA.  
How does the method work  
What assumptions does the method require? Pre-experiments were conducted to established the correct size of the initial population (trade off between speed and avoiding premature 
convergence). Selection process was modified, with firstly a proportionate selection) draw from an unjust roulette wheel), and then a tournament 
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to avoid losing the best genetic material. The algorithm also applied an elitist strategy, so the chromosomes with the best fitness go into the next 
population. 
 
Crossover was two-point. 
 
Mutation probability set at 0.05 
 
Stop condition was when the best solution stays within a range (E) for a given population size. 
What are the theoretical limitations of the 
method? 
Generic GA limitations 
What are the potential biases associated with 
the method? 
The fact that GA’s in general require a lot of ‘tinkering’ to set up. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – an offset printing problem. Discrete parameters requiring a DES to evaluate 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
The algorithm reached a stop condition after 10.5 hrs (36k replications). For all 4 criteria it converged and found, after an acceptable time, a near 
optimal result.  
If not, are there any suggestions to its practical 
applicability? 
None noted 




What is the method? Particle Swarm Optimisation 
What problem was the method originally 
developed for? 
Simulation optimisation (assembly line design) 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES Particle Swarm Optimisation) PSO has many similarities to evolutionary methods such as genetic algorithms. The method uses the simulation 
312 
 
with a combinatorial problem? system as the fitness function for the algorithm.  
 
PSO does not have an evolutionary operator in the algorithm (unlike GA). Therefore there is no crossover or mutation.  
 
However, this method in this study uses a modification of PSO which incorporates mutation based on similarity (PSOMS). The concept is based on 
similarity between the specific particle and the current global best particle in the swarm. The collectivity is used to randomly mutate the position 
of all the particles so to maintain diversity in the space. 
 
In PSO, the potential solutions (particles) move through the search space by following the currently optimum particles. 
How does the method work There are three global variables which are tracked: 
1. The target value or condition 
2. The global best value indicating which particle’s data is currently the closest to the target value or condition 
3. Stopping value which indicates when the algorithm should stop 
 
Each particle consists of: 
1. Data that represents a possible solution 
2. A velocity value which indicates how much that possible solution can be changed 
3. A personal best value indicating the closest the particle’s data has come to the target 
 
All these data are combined in an updating procedure to inform a new set of velocities for the particles. 
What assumptions does the method require? Not clearly explained 
What are the theoretical limitations of the 
method? 
Not clearly explained. PSO has a strong theoretical background however 
What are the potential biases associated with 
the method? 
Number of particles, weight, number of epochs, inertia rate, rate of mutation. These are all user defined parameters 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – an assembly line design problem 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
It was fully validated and tested in a good comprehensive study. There were 30 tests conducted. PSO has better regional searching ability and 
required approximately 150 iterations to achieve satisfactory convergence results. It was compared to GA’s and the PSOMS was found to have the 
best problem-solving effect.  








What is the method? Four methods are tested in an empirical study: 
1. Genetic algorithm 
2. Pattern search 
3. Simulated annealing 
4. Simplex method 
What problem was the method originally 
developed for? 
These were tested on two integer problems – standard buffer problem, and distribution models. 
Has the method been adapted from its original 
context? 
No – the algorithms appear to be implementations of standard algorithms 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
See other papers for each method 
How does the method work See other papers for each method 
What assumptions does the method require? The methods required coding of all parameters as integers. A decision regarding the initial solution is required for the SA, pattern search. Simplex 
requires N+1 initial solutions for N variables. 
What are the theoretical limitations of the 
method? 
Pattern search and simplex are local search techniques using one-at a time direct search. 
 
However, SA and GA are global search techniques.  
What are the potential biases associated with 
the method? 
SA and GA require tuning of several parameters (see other papers) 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Problem size had a significant effect on the accuracy on all methods apart from GA. The other three methods had poor results when the problem 
size grew. However, GA required significantly more replications to achieve the better results. 
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If not, are there any suggestions to its practical 
applicability? 
Clear trade-off between accuracy and speed. However, although the GA is slow, it is robust and found good results for all factors tested. Good 
solutions with the GA were usually found within 1000 replications. 




What is the method? Adaptive random search 
What problem was the method originally 
developed for? 
General optimisation methods 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
No 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
The method is adaptive, so it used information gathered at previous iterations to decide on how much simulation effort is expended in the current 
iteration. Also, averaging is used  
How does the method work The method is a random search. Also presented is a random search method using point-based methods, where there is iterative movement 
between points within the feasible region. 
What assumptions does the method require? The method is fundamentally an adaptation of established search methods which uses the feedback of information from previous iterations to 
determine the next iteration. 
What are the theoretical limitations of the 
method? 
The methods are only globally convergent under mild conditions 
What are the potential biases associated with 
the method? 
None mentioned in the paper 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes. Not a fully combinatorial problem but a discrete three-stage buffer allocation problem using a discrete event simulation model. 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Not much information is provided for this. The global algorithms perform better than the local algorithms, but they also show that averaging alone 
isn’t necessarily beneficial. The numerical examples involving two variants of SA demonstrated that averaging alone may either help or hurt 
performance relative to no averaging. But that averaging together with adaptiveness in expending simulation effort appears to be effective. 









What is the method? SA based simulation optimisation method  
What problem was the method originally 
developed for? 
developed to improve the performance of SA for discrete variable simulation optimisation 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
No 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes – Simulated Annealing 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
Simulated Annealing has an established based for discrete parameters simulation optimisation when there is a large solution space. The method 
has two phases. The first phase is a search process using linear approximations. Phase two is an exploration of a small subset of the feasible region 
around the phase 1 solution to locate a solution of possible higher quality. 
 
Therefore Phase 1 is possible local optima solutions, and SA works well for phase 2 because it has the ability to move away from a local optima. 
 
The technique of constructing linear model approximations and searching along the direction of improvement related to the linear model is similar 
to response surface methods. This method is a modification of RSM because it is applicable to discrete decision space. 
How does the method work The main concept is to search out different high quality local optima. Starting points are generated in all areas of the feasible region, but not 
generated within a close area of the final phase 2 solution (which would trigger convergence at an already found solution. 
What assumptions does the method require? The model assumes that if a solution is of high quality, that other high quality solutions could exist in adjacent and nearby neighbourhoods and 
therefore these are searched. 
What are the theoretical limitations of the 
method? 
 
What are the potential biases associated with 
the method? 
As with any SA method, tuning is required to established the algorithm. Also a user defined termination criteria. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes 
If so, how did it perform? (Speed, optimality, It required substantially fewer (~17%) simulation runs to optimise.  
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ease of implementation) 
If not, are there any suggestions to its practical 
applicability? 
None. However, a positive is that it allows better control over the convergence rate of the algorithm by varying the number of searches 
completed. It can be used as either a quick local optima method, or a more thorough method to find a global optima with high probability. 




What is the method? Nested partitions 
What problem was the method originally 
developed for? 
Simulation optimisation 
Has the method been adapted from its original 
context? 
No 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes – optimisation of discrete stochastic problems 
Or is it a general optimisation method that could 
be suitable for DES? 
No 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
Nested partitions is a global sampling strategy for optimisation of a large but finite space which is constantly adapted via the partitioning of the 
search space. 
 
The NP method naturally suits parallelisation, which is a benefit for computation. 
 
It naturally combines global and local search  
How does the method work? At each iteration of the algorithm, we assume there is a sub-region of the search space which is the ‘most promising’. This most promising region is 
partitioned into subregions and the entire surrounding region is aggregated into one region. Therefore at each iteration a disjoint subset of the 
feasible region is searched. Each region is sampled using a random sampling scheme and a ‘promising index’ is calculated for each region. 
 
The promising indices are used to compare all regions and identify the most promising for the next iteration. 
 
If one subregion is best, then it becomes the most promising region 
 
If the surrounding region is best, a region of less depth than the current region = most promising 
 
The portioning and sampling is repeated 
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What assumptions does the method require? Each point in the region must have a positive probability of being selected to ensure convergence 
What are the theoretical limitations of the 
method? 
None explored in this paper 
What are the potential biases associated with 
the method? 
There are 5 important considerations: 
1. How to partition the search space 
2. How to obtain sampled points 
3. How to select a ‘promising index’ 
4. How to backtrack 
5. How to select the initial region of most promise 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a stochastic Travelling Salesman Problem 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Performance is relatively good for large problems. 
If not, are there any suggestions to its practical 
applicability? 
The convergence and efficiency of the NP method relies on partitioning being performed such that good solutions are clustered in a particular sub 
region. If this holds – the method works well. 




What is the method? The method is empirical stochastic branch and bound (ESB&B).  
What problem was the method originally 
developed for? 
‘large scale complicated stochastic optimisation’ 
Has the method been adapted from its original 
context? 
Yes 
Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
It’s a combination of nested partitioning and branch and bound 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
 





The algorithm bounds as per NP by maintaining a set of feasible solutions. It also maintains a set of all solutions. It simulates solutions within the 
set of feasible solutions and computes the bounds using their estimated performance. In the next iteration, it allocates a subset of solutions to be 
sampled from the current partition. At each iteration, the best estimated performance is the current best solution  
What assumptions does the method require? Not fully clear 
What are the theoretical limitations of the 
method? 
There is an overhead needed to retain and refine a larger partition structure. 
What are the potential biases associated with 
the method? 
The bounding assumptions are key – these provide the ‘convergence estimators’. 
 
Sampling and simulation can be balanced by the adjusting of four parameters: 
1. Number of samples for current best region 
2. Number of samples for other regions 
3. Initial number of simulations for new samples 
4. Incremental number of simulations for re-sampled solutions 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a three-stage flow line with finite buffer storage. 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Converges asymptotically to the global optimum. Shows that ESB&B outperforms nested partitioning in general. Advantages are maximised when 
the problem is noisy or significant interactions between decision variables. Normal probability based sample allocation scheme offers the most 
potential 
If not, are there any suggestions to its practical 
applicability? 
 





What is the method? Tabu search simulation optimisation 
What problem was the method originally 
developed for? 
TS is a local search-based optimisation method that has been successfully applied to solve many difficult combinatorial optimisation problems 
Has the method been adapted from its original 
context? 
Not really – it seems a fairly straight forward implementation of TS to a DES model 
Was the method designed to address discrete 




Or is it a general optimisation method that could 
be suitable for DES? 
Yes 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
There isn’t a great deal of discussion regarding the influence of a DES evaluating the objective. Only that there needs to be a balance between 
precision and efficiency. 
How does the method work Initial solution using a heuristic approach. Then a move is initiated (pair-wise exchange/swap) is often used as a move to construct a 
neighbourhood solution in a permutation-type problem (glover 1995). The neighbourhood size has an impact on the process for selecting a 
neighbour (e.g. searching whole neighbourhood for best solution may not be feasible). 
The TS algorithm searches for non-tabu moves except if it’s exhausted all non-tabu options and cannot improve. If the best search result from the 
tabu list outperforms the best solution, then the aspiration criterion overrules the tabu rule. 
 
A long-term memory structure of intensification and diversification are used to generate the initial search sequence and restart the TS procedure.  
What assumptions does the method require? An assumption for the Tabu tenure size. This determins the tabu list for the recent past (preventing the search from repeating moves). 
What are the theoretical limitations of the 
method? 
Tabu searches are memory intensive. 
 
What are the potential biases associated with 
the method? 
No real discussion. There are many assumptions regarding the memory and neighbourhood selection that can lead to bias, but not discussed. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – flow shop problem 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
The solution is significantly better than that found by a simple descent algorithm. Also in most instances it’s quicker. 
If not, are there any suggestions to its practical 
applicability? 
No 





What is the method? Evolutionary algorithm (using just mutation) 
What problem was the method originally 
developed for? 
For a simulation optimisation 
Has the method been adapted from its original 
context? 
Yes – from the original EA methods 
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Was the method designed to address discrete 
event simulation (DES) optimisation?  
Yes 
Or is it a general optimisation method that could 
be suitable for DES? 
Yes – it’s an adaptation of EAs 
Theoretical basis 
How does the method address optimising a DES 
with a combinatorial problem? 
The method requires an appropriate coding of the solution. 
How does the method work The method uses a vector to code the chromosomes. A population of solutions is generated, and roulette wheel is used for selection (not clear if 
elitism contained). Recombination is conducted via two randomly selecting two intersecting points and the ranges between the two points are 
exchanged. 
 
Mutation is via the exchange of two randomly chosen genes 
What assumptions does the method require? Little – the EA appears fairly robust to the problem type 
What are the theoretical limitations of the 
method? 
None discussed 
What are the potential biases associated with 
the method? 
None discussed. In particular, regarding the appropriate number of evaluations, and the number of algorithm runs and stopping rule. 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
Yes – a parallel-machine scheduling problem 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
Reported as effective and robust. However, the computational efficiency was a concern as the problem size increased. 
If not, are there any suggestions to its practical 
applicability? 
Only the computational efficiency. The heuristic could potentially be more efficient which would allow problems of a greater size to be solved 
Practical applicability 
Has the method been used to optimise a DES 
with a combinatorial problem? 
 
If so, how did it perform? (Speed, optimality, 
ease of implementation) 
 





APPENDIX C: SIMUL8 MODEL 




APPENDIX C.2: FULL MODEL CODE 
SIMUL8 Documentation for: C:\Users\User\Google 
Drive\FELLOWSHIP\MODEL\model8.s8 at time 16/05/2015 
11:48:39 Version: 21.0.0.3122 
----------------------------------------------------------------------------------------- 
 
Created by: Jon Tosh 
Last opened by: Jon Tosh 
 
****************************************************** 
General Simulation Information 
------------------------------ 
 
  Warm Up Time: 0   Results Collection Time: 2000 (Minutes) 
  Start of day: 540 Length of day: 480 ,   Days per week: 5 
  Current Random Stream Set: 2 
  Travel Time between objects: automatically set up 




  s_mod 
    Named Distribution 
      Distribution Detail: 
        Log Normal 4.85656 2.98837 1.41979 0.56665 
  s_good 
    Named Distribution 
      Distribution Detail: 
        Log Normal 9.97923 5.72325 2.15832 0.53326 
 
Labels 
  tta 
    (Number) 
  haq 
    (Number) 
  ttd 
    (Number) 
  t 
    (Number) 
  ttw 
    (Number) 
  tth 
    (Number) 
  router 
    (Number) 
  tc1 
    (Number) 
  tc2 
    (Number) 
  dCost 
    (Number) 
  Cost 
    (Number) 
  timex 
    (Number) 
  tx 
    (Text) 
  tx_cost 
    (Number) 
  tx_count 
    (Number) 
  tx_tta 
    (Number) 
  ID 
    (Number) 
  ttr 
    (Number) 
  t_p 
    (Number) 
  tx_class 
    (Text) 
  admin_count 
    (Number) 
  u2 
    (Number) 
  lhaq 
    (Number) 
  c_age 
    (Number) 
  u1 
    (Number) 
  tq1 
    (Number) 
  b_age 
    (Number) 
  tq2 
    (Number) 
  prog_count 
    (Number) 
  hhaq 
    (Number) 
  QALY 
    (Number) 
  dQALY 
    (Number) 
  age_death 
    (Number) 
  loop_count 
    (Number) 
  tx_discrete 
    (Number) 
  tx_response 
    (Text) 
  t_haq 
    (Number) 
  c_dmards 
    (Number) 
  tx_r_t 
    (Number) 
  tx_good 
    (Number) 
  tx_w_t 
    (Number) 
  response_rand 
    (Number) 
  tx_s_t 
    (Number) 
  c_bdmards 
    (Number) 
  tx_mod 
    (Number) 
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  loop_check 
    (Number) 
  t_haq_entry 
    (Number) 
  response_cost 
    (Number) 
  tx_s_haq 
    (Number) 
  tx_r_haq 
    (Number) 
  pre_response_haq 
    (Number) 
  gainhaq 
    (Number) 
  tx_w_haq 
    (Number) 
  failed2dmards 
    (Number) 
  t_dec 
    (Number) 
  b_dd 
    (Number) 
  LYG 
    (Number) 
  b_sex 
    (Number) 
  tx_weight 
    (Number) 
  phaq 
    (Number) 
  age_onset 
    (Number) 
  c_dd 
    (Number) 
  eular_mod 
    (Number) 
  b_haq 
    (Number) 
  dead_tx 
    (Number) 
  dLYG 
    (Number) 
  bio_prog_mod_s 
    (Number) 
  bio_prog_mod_i_age 
    (Number) 
  bio_prog_mod_i 
    (Number) 
  bio_prog_mod_i_pgen 
    (Number) 
  bio_prog_mod_i_dd 
    (Number) 
  bio_prog_mod_i_das 
    (Number) 
  bio_prog_mod_i_dmards 
    (Number) 
  bio_prog_mod_s_age 
    (Number) 
  bio_prog_mod_s_pgen 
    (Number) 
  bio_prog_mod_s_dd 
    (Number) 
  bio_prog_mod_s_das 
    (Number) 
  bio_prog_mod_s_dmards 
    (Number) 
  eular_good 
    (Number) 
  bio_prog_good_s_age 
    (Number) 
  bio_prog_good_i_age 
    (Number) 
  bio_prog_good_i 
    (Number) 
  bio_prog_good_s 
    (Number) 
  bio_prog_good_i_pgen 
    (Number) 
  bio_prog_good_i_dd 
    (Number) 
  bio_prog_good_i_das 
    (Number) 
  bio_prog_good_i_dmards 
    (Number) 
  bio_prog_good_s_pgen 
    (Number) 
  bio_prog_good_s_dd 
    (Number) 
  bio_prog_good_s_das 
    (Number) 
  bio_prog_good_s_dmards 
    (Number) 
  i_d_qaly 
    (Number) 
  b_das 
    (Number) 
  b_weight 
    (Number) 
  b_dmards 
    (Number) 
  entry_t_p 
    (Number) 
  eular_none 
    (Number) 
  i_d_cost 
    (Number) 
  dead_flag 
    (Number) 
  bio_prog_mod_xt5 
    (Number) 
  bio_prog_good_xt5 
    (Number) 
  bio_prog_good_xt2 
    (Number) 
  bio_prog_good_rho2 
    (Number) 
  bio_prog_mod_xt2 
    (Number) 
  bio_prog_mod_rho2 
    (Number) 
  bio_prog_mod_xt3 
    (Number) 
  bio_prog_mod_rho3 
    (Number) 
  bio_prog_mod_xt4 
    (Number) 
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  bio_prog_mod_rho4 
    (Number) 
  bio_prog_mod_rho5 
    (Number) 
  bio_prog_good_rho5 
    (Number) 
  bio_prog_good_xt3 
    (Number) 
  bio_prog_good_rho4 
    (Number) 
  bio_prog_good_xt4 
    (Number) 
  bio_prog_good_rho3 
    (Number) 
  bio_prog_good_rho1 
    (Number) 
  bio_prog_mod_rho1 
    (Number) 
  bio_prog_mod_rho6 
    (Number) 
  bio_prog_good_rho6 
    (Number) 
  r_tx 
    (Number) 
  debug1 
    (Number) 
  tx_c 
    (Number) 
  c_das 
    (Number) 
  tx_resp 
    (Text) 
  s_first_mod_g_age 
    (Number) 
  s_first_mod_g_age2 
    (Number) 
  s_first_mod_g_pgen 
    (Number) 
  s_first_mod_g_dd 
    (Number) 
  s_first_mod_g_dd2 
    (Number) 
  s_first_mod_g_das 
    (Number) 
  s_first_mod_g_dmards 
    (Number) 
  s_first_mod_g_haq 
    (Number) 
  s_first_mod_g_cons 
    (Number) 
  s_first_mod_g_lnsig 
    (Number) 
  s_first_mod_g_kappa 
    (Number) 
  s_first_mod_g_sigma 
    (Number) 
  s_first_good_ln_age 
    (Number) 
  s_first_good_ln_age2 
    (Number) 
  s_first_good_ln_pgen 
    (Number) 
  s_first_good_ln_dd 
    (Number) 
  s_first_good_ln_dd2 
    (Number) 
  s_first_good_ln_das 
    (Number) 
  s_first_good_ln_dmards 
    (Number) 
  s_first_good_ln_haq 
    (Number) 
  s_first_good_ln_cons 
    (Number) 
  s_first_good_ln_lnsig 
    (Number) 
  s_first_good_ln_sigma 
    (Number) 
  loopexit 
    (Number) 
  temp_haq 
    (Number) 
  testg 
    (Number) 
  tx1 
    (Text) 
  tx2 
    (Text) 
  tx3 
    (Text) 
  tx4 
    (Text) 
  tx5 
    (Text) 
  tx6 
    (Text) 
  tx7 
    (Text) 
  tx8 
    (Text) 
  tx9 
    (Text) 
  tx10 
    (Text) 
  tx11 
    (Text) 
  tx12 
    (Text) 
  tx13 
    (Text) 
  tx14 
    (Text) 
  loopcount 
    (Number) 
  block 
    (Number) 
  trip 
    (Number) 
 
Images 
  Default Image Entry 
    Width: 32  Height: 32 
    Transparent Color: 12945930 
  Default Image Queue 
    Width: 32  Height: 32 
    Transparent Color: 12748546 
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  Default Image Activity 
    Width: 32  Height: 32 
    Transparent Color: 12946445 
  Default Image Exit 
    Width: 32  Height: 32 
    Transparent Color: 13078035 
  Default Image Resource 
    Width: 32  Height: 32 
    Transparent Color: 12880393 
  Default Image Conveyor 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Tank 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Rotz 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Process 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Loader 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Vehicle 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image Component 
    Width: 32  Height: 32 
    Transparent Color: 255 
  Default Image 3D Light 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Default Image 3D Object 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
  Redb 
    Width: 8  Height: 8 
    Transparent Color: 16777215 
  Image   2 
    Width: 32  Height: 32 
    Transparent Color: 16777215 
 
SIMUL8 Windows and Sub Processs 
------------------------------- 
    Open 
    Icon Location  X:960 Y:585 W:32 H:32 
    Window Location  X:0 Y:1174 W:1902 H:960 
    Color 16777215 
 
Work Item Types 
--------------- 
  Main Work Item Type 
    Image: Redb 
    Length 1 
    Attached Labels: 
      ID 
      LYG 
      dLYG 
      Cost 
      dCost 
      QALY 
      dQALY 
      b_age 
      b_sex 
      b_dd 
      b_haq 
      b_das 
      b_dmards 
      b_weight 
      age_death 
      tx_count 
      timex 
      ttd 
      tta 
      ttw 
      tth 
      ttr 
      prog_count 
      haq 
      lhaq 
      temp_haq 
      hhaq 
      t 
      tx_s_haq 
      loopexit 
      router 
      dead_tx 
      dead_flag 
      r_tx 
      c_age 
      c_dd 
      s_first_mod_g_age 
      s_first_mod_g_age2 
      s_first_mod_g_pgen 
      s_first_mod_g_dd 
      s_first_mod_g_dd2 
      s_first_mod_g_das 
      s_first_mod_g_dmards 
      s_first_mod_g_haq 
      s_first_mod_g_cons 
      s_first_mod_g_lnsig 
      s_first_mod_g_kappa 
      s_first_mod_g_sigma 
      s_first_good_ln_age 
      s_first_good_ln_age2 
      s_first_good_ln_pgen 
      s_first_good_ln_dd 
      s_first_good_ln_dd2 
      s_first_good_ln_das 
      s_first_good_ln_dmards 
      s_first_good_ln_haq 
      s_first_good_ln_cons 
      s_first_good_ln_lnsig 
      s_first_good_ln_sigma 
      c_dmards 
      testg 
      tx 
      tx_class 
      tx_discrete 
      tx_weight 
      response_cost 
      tx_cost 
      tc2 
      tc1 
      i_d_cost 
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      i_d_qaly 
      bio_prog_mod_i 
      bio_prog_mod_s 
      bio_prog_mod_i_age 
      bio_prog_mod_i_pgen 
      bio_prog_mod_i_dd 
      bio_prog_mod_i_das 
      bio_prog_mod_i_dmards 
      bio_prog_mod_s_age 
      bio_prog_mod_s_pgen 
      bio_prog_mod_s_dd 
      bio_prog_mod_s_das 
      bio_prog_mod_s_dmards 
      bio_prog_mod_rho1 
      bio_prog_mod_xt2 
      bio_prog_mod_rho2 
      bio_prog_mod_xt3 
      bio_prog_mod_rho3 
      bio_prog_mod_xt4 
      bio_prog_mod_rho4 
      bio_prog_mod_xt5 
      bio_prog_mod_rho5 
      bio_prog_mod_rho6 
      bio_prog_good_i 
      bio_prog_good_s 
      bio_prog_good_i_age 
      bio_prog_good_i_pgen 
      bio_prog_good_i_dd 
      bio_prog_good_i_das 
      bio_prog_good_i_dmards 
      bio_prog_good_s_age 
      bio_prog_good_s_pgen 
      bio_prog_good_s_dd 
      bio_prog_good_s_das 
      bio_prog_good_s_dmards 
      bio_prog_good_rho1 
      bio_prog_good_xt2 
      bio_prog_good_rho2 
      bio_prog_good_xt3 
      bio_prog_good_rho3 
      bio_prog_good_xt4 
      bio_prog_good_rho4 
      bio_prog_good_xt5 
      bio_prog_good_rho5 
      bio_prog_good_rho6 
      tx_tta 
      admin_count 
      tq2 
      u2 
      tq1 
      u1 
      tx_c 
      tx_mod 
      tx_good 
      response_rand 
      tx_response 
      tx_r_t 
      tx_w_t 
      c_das 
      tx_resp 
      phaq 
      age_onset 
      failed2dmards 
      t_p 
      tx_s_t 
      tx_r_haq 
      tx_w_haq 
      eular_none 
      eular_mod 
      eular_good 
      pre_response_haq 
      gainhaq 
      debug1 
      t_haq_entry 
      t_haq 
      entry_t_p 
      loop_check 
      loop_count 
      c_bdmards 
      t_dec 






  Start 
    Model Entry 
    ----------- 
      Display Parameters 4 
      X:30 Y:145 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Work Item Type: Main Work Item Type 
    Inter-arrival time 
      Distribution Detail: 
        Fixed 0.00001 0 0 0 
      Route Out Objects 
        Treatment Start 
    On Label Action Visual Logic: 
      VL SECTION: Model Entry Entry Logic ,  LOCALDATA: 
u:[NUMBER] ,  q:[NUMBER] ,  S:[NUMBER] 
        'Set Results labels = 0 
        '(These capture the output for each patient) 
        SET LYG  =  0 
        SET dLYG  =  0 
        SET Cost  =  0 
        SET dCost  =  0 
        SET QALY  =  0 
        SET dQALY  =  0 
        (Disabled) SET trip  =  0 
        'HAQout is a record of HAQ progression data for the last 
person to be simulated. At the start of each patient run, this sheet 
is cleared first. 
        Clear Sheet Area    haqout[2,2] ,  200 ,  200 
        'Set instantaneous discounting parameters 
        SET i_d_cost  =  LOG[1+d_cost] 
        SET i_d_qaly  =  LOG[1+d_qaly] 
        'Set timers (timex is for loops, t = time in model, tc1 and tq1 
are 'increment' timestamps for discrete QALY and cost calcs) 
        SET timex  =  0 
        SET t  =  0 
        SET tc1  =  t 
        SET tq1  =  t 
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        'SET any random numbers to be used so not resampled every 
time 
        SET r_tx  =  RANDOM[0] 
        'Set the break code so that the model stops once the sim_nbr 
set of patients have been run 
        IF Model Entry.Arrived Count  =  sim_nbr 
          SET Model Entry.Interarrival Time  =  large_nbr 
        'Set patient characteristics at baseline 
        SET b_age  =  data[2,4+ID] 
        SET b_sex  =  data[3,4+ID] 
        SET b_dd  =  data[4,4+ID] 
        SET b_haq  =  data[5,4+ID] 
        SET b_das  =  data[6,4+ID] 
        SET b_weight  =  data[8,4+ID] 
        SET age_death  =  data[9,4+ID] 
        SET ttd  =  age_death-b_age 
        IF [b_age-b_dd]  <  1 
          SET age_onset  =  1 
        ELSE 
          SET age_onset  =  b_age-b_dd 
        SET haq  =  b_haq 
        'HAQadjust forces the HAQ value to be an eligible discrete 
HAQ score 
        CALL haqadjust 
        'Set the current patient characteristics (currently equal to 
baseline) 
        SET c_age  =  b_age 
        SET c_dd  =  b_dd 
        SET c_dmards  =  b_dmards 
        SET c_bdmards  =  0 
        SET failed2dmards  =  0 
        'SET initial Utility 
        SET u1  =  
[[[[0.91002]+[haq*NEG[0.20418]]]+[[haq^2]*NEG[0.01291]]]+[c_a
ge*NEG[0.00097]]]+[[c_age^2]*NEG[0.00001]] 
        'debug option 
        (Disabled) SET u1  =  1 
        'Set the treatment counter 
        SET tx_count  =  0 
        'Set Biologic progression model parameters 
        SET bio_prog_mod_i  =  data[37,4+ID] 
        SET bio_prog_mod_s  =  data[38,4+ID] 
        SET bio_prog_mod_i_age  =  data[39,4+ID] 
        SET bio_prog_mod_i_pgen  =  data[40,4+ID] 
        SET bio_prog_mod_i_dd  =  data[41,4+ID] 
        SET bio_prog_mod_i_das  =  data[42,4+ID] 
        SET bio_prog_mod_i_dmards  =  data[43,4+ID] 
        SET bio_prog_mod_s_age  =  data[44,4+ID] 
        SET bio_prog_mod_s_pgen  =  data[45,4+ID] 
        SET bio_prog_mod_s_dd  =  data[46,4+ID] 
        SET bio_prog_mod_s_das  =  data[47,4+ID] 
        SET bio_prog_mod_s_dmards  =  data[48,4+ID] 
        SET bio_prog_mod_rho1  =  data[49,4+ID] 
        SET bio_prog_mod_xt2  =  data[50,4+ID] 
        SET bio_prog_mod_rho2  =  data[51,4+ID] 
        SET bio_prog_mod_xt3  =  data[52,4+ID] 
        SET bio_prog_mod_rho3  =  data[53,4+ID] 
        SET bio_prog_mod_xt4  =  data[54,4+ID] 
        SET bio_prog_mod_rho4  =  data[55,4+ID] 
        SET bio_prog_mod_xt5  =  data[56,4+ID] 
        SET bio_prog_mod_rho5  =  data[57,4+ID] 
        SET bio_prog_mod_rho6  =  data[58,4+ID] 
        SET bio_prog_good_i  =  data[59,4+ID] 
        SET bio_prog_good_s  =  data[60,4+ID] 
        SET bio_prog_good_i_age  =  data[61,4+ID] 
        SET bio_prog_good_i_pgen  =  data[62,4+ID] 
        SET bio_prog_good_i_dd  =  data[63,4+ID] 
        SET bio_prog_good_i_das  =  data[64,4+ID] 
        SET bio_prog_good_i_dmards  =  data[65,4+ID] 
        SET bio_prog_good_s_age  =  data[66,4+ID] 
        SET bio_prog_good_s_pgen  =  data[67,4+ID] 
        SET bio_prog_good_s_dd  =  data[68,4+ID] 
        SET bio_prog_good_s_das  =  data[69,4+ID] 
        SET bio_prog_good_s_dmards  =  data[70,4+ID] 
        SET bio_prog_good_rho1  =  data[71,4+ID] 
        SET bio_prog_good_xt2  =  data[72,4+ID] 
        SET bio_prog_good_rho2  =  data[73,4+ID] 
        SET bio_prog_good_xt3  =  data[74,4+ID] 
        SET bio_prog_good_rho3  =  data[75,4+ID] 
        SET bio_prog_good_xt4  =  data[76,4+ID] 
        SET bio_prog_good_rho4  =  data[77,4+ID] 
        SET bio_prog_good_xt5  =  data[78,4+ID] 
        SET bio_prog_good_rho5  =  data[79,4+ID] 
        SET bio_prog_good_rho6  =  data[80,4+ID] 
        'Set EULAR HAQ response changes 
        SET eular_none  =  data[81,4+ID] 
        SET eular_mod  =  data[82,4+ID] 
        SET eular_good  =  data[83,4+ID] 
        SET t_dec  =  seq[7,2] 
    Label Actions 
      ID 
      Unique 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Treatment Router 
    ---------------- 
      Display Parameters 4 
      X:231 Y:145 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Response Administration 
          Treatment Start 
      Require resources before collecting any work items 
    Routing Out 
      Label 
      On label: router 
      Preference only 
        Route Out Objects 
          Response 
          Dead 
          Response Administration 
      Release resources as soon as task complete 
    Operation Time 
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      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Treatment Router Work Complete Logic ,  
LOCALDATA: u:[NUMBER] ,  q:[NUMBER] ,  S:[NUMBER] 
        'debug option 
        (Disabled) SET tx_discrete  =  0 
        IF ttd  =  1 
          SET ttd  =  ttd 
        'SET MODEL COSTS HERE (HAQ RELATED AND DISCRETE 
TREATMENT) 
        CALL haqcost 
        SET timex  =  0 
        SET admin_count  =  admin_count+1 
        IF admin_count  =  1 
          IF tx_discrete  =  1 
            SET tta  =  0 
        CALL min_response 
        SET t  =  t+timex 
        IF router  =  1 
          SET ttd  =  ttd-ttr 
          SET tta  =  tta-ttr 
          IF tx_discrete  =  0 
            CALL cresponsecost 
        IF router  =  2 
          CALL haqcost 
          SET dead_tx  =  tx_count 
          SET dead_flag  =  1 
          SET ttd  =  0 
        IF router  =  3 
          SET ttd  =  ttd-tta 
          SET ttr  =  ttr-tta 
        IF t  >  [age_death-b_age] 
          SET t  =  t 
        (Disabled) SET tx_discrete  =  seq[4,tx_count+1] 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Response 
    -------- 
      Display Parameters 4 
      X:314 Y:144 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Treatment Router 
      Require resources before collecting any work items 
    Routing Out 
      Label 
      On label: router 
      Preference only 
        Route Out Objects 
          Withdraw 
          Maintenance Router 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Response Work Complete Logic 
        (Disabled) CALL qaly 
        'set timers (t_p is the timer index for cDMARD progression) 
        SET t_p  =  0.5 
        SET tth  =  0.5 
        SET pre_response_haq  =  haq 
        SET response_rand  =  RANDOM[0] 
        IF tx_class  =  "PALLIATIVE CARE" 
          SET router  =  2 
          SET tx_response  =  "PALLIATIVE CARE" 
          SET ttw  =  large_nbr 
        ELSE 
          IF response_rand  <  [1-tx_good]-tx_mod 
            SET router  =  1 
            SET tx_response  =  "NONE" 
            SET haq  =  haq+eular_none 
          ELSE IF response_rand  >  1-tx_good 
            SET router  =  2 
            SET tx_response  =  "GOOD" 
            SET ttw  =  SAMPLE["Lognormal,9.979226,5.723247"] 
            SET haq  =  haq+eular_good 
            CALL haqadjust 
          ELSE 
            SET router  =  2 
            SET tx_response  =  "MOD" 
            SET ttw  =  SAMPLE["lognormal,4.856564,2.988371"] 
            SET haq  =  haq+eular_mod 
            CALL haqadjust 
        'set trackers and output values 
        SET tx_r_haq  =  haq 
        SET gainhaq  =  pre_response_haq-haq 
        SET tx_r_t  =  t 
        SET haqout[3,3*tx_count]  =  tx_r_haq 
        SET haqout[2,3*tx_count]  =  tx_r_t 
        SET haqout[6,3*tx_count]  =  tx_response 
        CALL qaly 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  End 
    Model End 
    --------- 
      Display Parameters 4 
      X:561 Y:279 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
      Input Objects 
        Dead 
      Financial Information 
        Per Unit: 100 
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      Carbon Emissions Information 
        Per Unit: 100 
   
  Activity 
    Dead 
    ---- 
      Display Parameters 4 
      X:396 Y:279 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Treatment Router 
          Maintenance Router 
      Require resources before collecting any work items 
    Routing Out 
      Circulate 
      Preference only 
        Route Out Objects 
          Model End 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Dead Work Complete Logic ,  LOCALDATA: 
tester:[NUMBER] 
        (Disabled) SET tx_count  =  tx_count+1 
        CALL qaly 
        SET t  =  t 
        SET ttd  =  ttd 
        SET tester  =  age_death-b_age 
        SET age_death  =  age_death 
                SET tx_s_t  =  tx_s_t 
        SET tx_r_t  =  tx_r_t 
        SET tx_w_t  =  tx_w_t 
        SET tx_r_t  =  999 
                IF tx_w_t  <  tx_s_t 
          SET tx_w_t  =  999 
                SET haqout[7,2]  =  age_death-b_age 
        SET haqout[8,2]  =  dead_tx 
                (Disabled) IF trip  =  1 
          (Disabled) SET t  =  t-0.01 
        (Disabled) SET trip  =  0 
        SET LYG  =  t 
        'debug 
        (Disabled) SET LYG  =  age_death-b_age 
        SET dLYG  =  LYG/[[1+i_d_qaly]^LYG] 
        SET output[1,4+ID]  =  ID 
        SET output[2,4+ID]  =  LYG 
        SET output[3,4+ID]  =  Cost 
        SET output[4,4+ID]  =  QALY 
        SET output[5,4+ID]  =  dLYG 
        SET output[6,4+ID]  =  dCost 
        SET output[7,4+ID]  =  dQALY 
        SET output[8,4+ID]  =  b_age 
        SET output[9,4+ID]  =  b_sex 
        SET output[10,4+ID]  =  b_dd 
        SET output[11,4+ID]  =  b_haq 
        SET output[12,4+ID]  =  b_das 
        SET output[13,4+ID]  =  b_dmards 
        SET output[14,4+ID]  =  b_weight 
        SET output[15,4+ID]  =  age_death 
        SET output[16,4+ID]  =  dead_tx 
        SET output[17,4+ID]  =  output[2,4+ID] 
        SET output[18,4+ID]  =  [age_death-b_age] 
        SET output[19,4+ID]  =  [age_death-b_age]-t 
        SET output[20,4+ID]  =  t 
        IF ID  =  sim_nbr 
          Sum Sheet Area    output[2,5] ,  1 ,  sim_nbr ,  output[2,3] 
          Sum Sheet Area    output[3,5] ,  1 ,  sim_nbr ,  output[3,3] 
          Sum Sheet Area    output[4,5] ,  1 ,  sim_nbr ,  output[4,3] 
          Sum Sheet Area    output[5,5] ,  1 ,  sim_nbr ,  output[5,3] 
          Sum Sheet Area    output[6,5] ,  1 ,  sim_nbr ,  output[6,3] 
          Sum Sheet Area    output[7,5] ,  1 ,  sim_nbr ,  output[7,3] 
          Sum Sheet Area    output[8,5] ,  1 ,  sim_nbr ,  output[8,3] 
          Sum Sheet Area    output[9,5] ,  1 ,  sim_nbr ,  output[9,3] 
          Sum Sheet Area    output[10,5] ,  1 ,  sim_nbr ,  output[10,3] 
          Sum Sheet Area    output[11,5] ,  1 ,  sim_nbr ,  output[11,3] 
          Sum Sheet Area    output[12,5] ,  1 ,  sim_nbr ,  output[12,3] 
          Sum Sheet Area    output[13,5] ,  1 ,  sim_nbr ,  output[13,3] 
          Sum Sheet Area    output[14,5] ,  1 ,  sim_nbr ,  output[14,3] 
          Sum Sheet Area    output[15,5] ,  1 ,  sim_nbr ,  output[15,3] 
          Sum Sheet Area    output[16,5] ,  1 ,  sim_nbr ,  output[16,3] 
          SET output[2,4]  =  output[2,3]/sim_nbr 
          SET output[3,4]  =  output[3,3]/sim_nbr 
          SET output[4,4]  =  output[4,3]/sim_nbr 
          SET output[5,4]  =  output[5,3]/sim_nbr 
          SET output[6,4]  =  output[6,3]/sim_nbr 
          SET output[7,4]  =  output[7,3]/sim_nbr 
          SET output[8,4]  =  output[8,3]/sim_nbr 
          SET output[9,4]  =  output[9,3]/sim_nbr 
          SET output[10,4]  =  output[10,3]/sim_nbr 
          SET output[11,4]  =  output[11,3]/sim_nbr 
          SET output[12,4]  =  output[12,3]/sim_nbr 
          SET output[13,4]  =  output[13,3]/sim_nbr 
          SET output[14,4]  =  output[14,3]/sim_nbr 
          SET output[15,4]  =  output[15,3]/sim_nbr 
          SET output[16,4]  =  output[16,3]/sim_nbr 
          SET m_LYG_nbr  =  output[2,4] 
          SET m_Cost_nbr  =  output[3,4] 
          SET m_QALY_nbr  =  output[4,4] 
          SET m_dLYG_nbr  =  output[5,4] 
          SET m_dCost_nbr  =  output[6,4] 
          SET m_dQALY_nbr  =  output[7,4] 
          SET m_age_nbr  =  output[8,4] 
          SET m_sex_nbr  =  output[9,4] 
          SET m_dd_nbr  =  output[10,4] 
          SET m_haq_nbr  =  output[11,4] 
          SET m_das_nbr  =  output[12,4] 
          SET m_dmards_nbr  =  output[13,4] 
          SET m_weight_nbr  =  output[14,4] 
          SET m_age_death_nbr  =  output[15,4] 
          SET m_tx_nbr  =  output[16,4] 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
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  Activity 
    Withdraw 
    -------- 
      Display Parameters 4 
      X:396 Y:204 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Response 
          Maintenance Router 
      Require resources before collecting any work items 
    Routing Out 
      Circulate 
      Preference only 
        Route Out Objects 
          Treatment Start 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Withdraw Work Complete Logic 
        SET tx_w_t  =  t 
        SET tx_w_haq  =  haq 
         
        SET haqout[3,[3*tx_count]+1]  =  tx_w_haq 
        SET haqout[2,[3*tx_count]+1]  =  tx_w_t 
        SET haqout[6,3*tx_count]  =  tx_response 
        (Disabled) CALL qaly 
        IF tx_discrete  =  0 
          CALL continuouscost 
        (Disabled) SET ttd  =  ttd-ttw 
        (Disabled) SET tx_count  =  tx_count+1 
        (Disabled) SET tx  =  seq[2,tx_count+2] 
        (Disabled) SET tx_class  =  seq[3,tx_count+2] 
        (Disabled) SET tx_discrete  =  seq[4,tx_count+2] 
        (Disabled) SET tx_weight  =  seq[5,tx_count+2] 
        (Disabled) IF tx_discrete  =  1 
          (Disabled) IF tx  =  "ABT" 
            (Disabled) SET tx_tta  =  costs[4,2] 
          (Disabled) IF tx  =  "IFX" 
            (Disabled) SET tx_tta  =  costs[4,8] 
          (Disabled) IF tx  =  "RTX" 
            (Disabled) SET tx_tta  =  costs[4,9] 
          (Disabled) IF tx  =  "TCZ" 
            (Disabled) SET tx_tta  =  costs[4,10] 
          (Disabled) ELSE 
            (Disabled) SET tx_tta  =  large_nbr 
        (Disabled) ELSE 
          (Disabled) SET tx_tta  =  large_nbr 
        (Disabled) SET tta  =  tx_tta 
        SET haq  =  haq+gainhaq 
        CALL haqadjust 
        SET t  =  t+withdraw_time_nbr 
        SET ttd  =  ttd-withdraw_time_nbr 
        CALL qaly 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Maintenance Router 
    ------------------ 
      Display Parameters 4 
      X:491 Y:145 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Progression 
          Maintenance Administration 
          Response 
      Require resources before collecting any work items 
    Routing Out 
      Label 
      On label: router 
      Preference only 
        Route Out Objects 
          Progression 
          Withdraw 
          Dead 
          Maintenance Administration 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Maintenance Router Work Complete Logic ,  
LOCALDATA: u:[NUMBER] ,  q:[NUMBER] ,  S:[NUMBER] 
        CALL haqcost 
        (Disabled) SET tx_discrete  =  0 
        SET timex  =  0 
        CALL min_maintenance 
        SET t  =  t+timex 
        IF router  =  3 
          CALL haqcost 
          SET dead_tx  =  tx_count 
          SET dead_flag  =  1 
          SET ttd  =  0 
        IF router  =  4 
          SET ttd  =  ttd-tta 
          SET ttw  =  ttw-tta 
          SET tth  =  tth-tta 
        IF router  =  1 
          SET ttd  =  ttd-tth 
          SET ttw  =  ttw-tth 
          SET tta  =  tta-tth 
        IF router  =  2 
          SET ttd  =  ttd-ttw 
        (Disabled) SET tx_discrete  =  seq[4,tx_count+1] 
      Financial Information 
        Capital: 10 
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        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Progression 
    ----------- 
      Display Parameters 4 
      X:561 Y:209 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Maintenance Router 
      Require resources before collecting any work items 
    Routing Out 
      Circulate 
      Preference only 
        Route Out Objects 
          Maintenance Router 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Progression Work Complete Logic 
        CALL haqprog 
        CALL qaly 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Response Administration 
    ----------------------- 
      Display Parameters 4 
      X:231 Y:80 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Treatment Router 
      Require resources before collecting any work items 
    Routing Out 
      Circulate 
      Preference only 
        Route Out Objects 
          Treatment Router 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Response Administration Work Complete Logic 
        CALL discretecost 
        (Disabled) CALL qaly 
        CALL haqcost 
        SET tta  =  tx_tta 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Maintenance Administration 
    -------------------------- 
      Display Parameters 4 
      X:560 Y:79 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Maintenance Router 
      Require resources before collecting any work items 
    Routing Out 
      Circulate 
      Preference only 
        Route Out Objects 
          Maintenance Router 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Maintenance Administration Work Complete Logic 
        CALL discretecost 
        CALL haqcost 
        SET tta  =  tx_tta 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 
        Per Unit: 1 
   
  Activity 
    Treatment Start 
    --------------- 
      Display Parameters 4 
      X:127 Y:145 W:32 H:32 
       Xinc -10 Yinc 0 
      Show Title 
      Show Count 
      Show Image 
    Replicate 1 
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    Priority 50 
    Routing In 
      Priority 
        Route In Objects 
          Model Entry 
          Withdraw 
      Require resources before collecting any work items 
    Routing Out 
      Label 
      On label: router 
      Preference only 
        Route Out Objects 
          Treatment Router 
      Release resources as soon as task complete 
    Operation Time 
      Distribution Detail: 
        Fixed 0 0 0 0 
    On End Visual Logic: 
      VL SECTION: Treatment Start Work Complete Logic ,  
LOCALDATA: u:[NUMBER] ,  q:[NUMBER] ,  S:[NUMBER] 
        'Increment the treatment counter 
        SET tx_count  =  tx_count+1 
        SET admin_count  =  0 
        SET prog_count  =  0 
        SET c_dmards  =  c_dmards+1 
        SET tx_s_haq  =  haq 
        SET tx_s_t  =  t 
        IF c_dmards  >  2 
          SET failed2dmards  =  1 
        'Pickup the treatment parameters and values 
        IF seq[2,tx_count+1]  =  1 
          SET tx  =  "ABT" 
        IF seq[2,tx_count+1]  =  2 
          SET tx  =  "ABTS" 
        IF seq[2,tx_count+1]  =  3 
          SET tx  =  "ADA" 
        IF seq[2,tx_count+1]  =  4 
          SET tx  =  "CTZ" 
        IF seq[2,tx_count+1]  =  5 
          SET tx  =  "ETN" 
        IF seq[2,tx_count+1]  =  6 
          SET tx  =  "GOL" 
        IF seq[2,tx_count+1]  =  7 
          SET tx  =  "HCQ" 
        IF seq[2,tx_count+1]  =  8 
          SET tx  =  "IFX" 
        IF seq[2,tx_count+1]  =  9 
          SET tx  =  "MTX" 
        IF seq[2,tx_count+1]  =  10 
          SET tx  =  "RTX" 
        IF seq[2,tx_count+1]  =  11 
          SET tx  =  "PC" 
        IF seq[2,tx_count+1]  =  12 
          SET tx  =  "SSZ" 
        IF seq[2,tx_count+1]  =  13 
          SET tx  =  "TCZ" 
        IF seq[2,tx_count+1]  =  14 
          SET tx  =  "TICORA" 
        SET tx_weight  =  seq[5,tx_count+1] 
        SET tx_discrete  =  seq[4,tx_count+1] 
        IF seq[3,tx_count+1]  =  1 
          SET tx_class  =  "bDMARD" 
        IF seq[3,tx_count+1]  =  2 
          SET tx_class  =  "cDMARD" 
        IF seq[3,tx_count+1]  =  3 
          SET tx_class  =  "PALLIATIVE CARE" 
          SET tx_discrete  =  0 
        IF tx_class  =  "PALLIATIVE CARE" 
          SET tx_mod  =  0 
          SET tx_good  =  0 
        'Set treatment administration time (large number if a 
continuous tx) 
        IF tx_discrete  =  1 
          IF tx  =  "ABT" 
            SET tx_tta  =  costs[4,2] 
          IF tx  =  "IFX" 
            SET tx_tta  =  costs[4,8] 
          IF tx  =  "RTX" 
            SET tx_tta  =  costs[4,9] 
          IF tx  =  "TCZ" 
            SET tx_tta  =  costs[4,10] 
        ELSE 
          SET tx_tta  =  large_nbr 
        'Set timing labels 
        SET tta  =  tx_tta 
        SET ttr  =  response_time_nbr 
        'Set Costs 
        IF tx  =  "ABT" 
          SET response_cost  =  data[11,4+ID] 
          SET tx_cost  =  data[24,4+ID] 
        IF tx  =  "ABTS" 
          SET response_cost  =  data[12,4+ID] 
          SET tx_cost  =  data[25,4+ID] 
        IF tx  =  "ADA" 
          SET response_cost  =  data[13,4+ID] 
          SET tx_cost  =  data[26,4+ID] 
        IF tx  =  "CTZ" 
          SET response_cost  =  data[14,4+ID] 
          SET tx_cost  =  data[27,4+ID] 
        IF tx  =  "ETN" 
          SET response_cost  =  data[15,4+ID] 
          SET tx_cost  =  data[28,4+ID] 
        IF tx  =  "GOL" 
          SET response_cost  =  data[16,4+ID] 
          SET tx_cost  =  data[29,4+ID] 
        IF tx  =  "IFX" 
          SET response_cost  =  data[17,4+ID] 
          SET tx_cost  =  data[30,4+ID] 
        IF tx  =  "RTX" 
          SET response_cost  =  data[18,4+ID] 
          SET tx_cost  =  data[31,4+ID] 
        IF tx  =  "TCZ" 
          SET response_cost  =  data[19,4+ID] 
          SET tx_cost  =  data[32,4+ID] 
        IF tx  =  "HCQ" 
          SET response_cost  =  data[20,4+ID] 
          SET tx_cost  =  data[33,4+ID] 
        IF tx  =  "MTX" 
          SET response_cost  =  data[21,4+ID] 
          SET tx_cost  =  data[34,4+ID] 
        IF tx  =  "SSZ" 
          SET response_cost  =  data[22,4+ID] 
          SET tx_cost  =  data[35,4+ID] 
        IF tx  =  "TICORA" 
          SET response_cost  =  data[23,4+ID] 
          SET tx_cost  =  data[36,4+ID] 
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        IF tx_class  =  "bDMARD" 
          SET c_bdmards  =  c_bdmards+1 
        'Set router to Treatment Router 
        SET router  =  1 
        IF tx_count  =  1 
          IF tx  =  "ADA" 
            SET tx_mod  =  data[84,4+ID] 
            SET tx_good  =  data[92,4+ID] 
          IF tx  =  "ETN" 
            SET tx_mod  =  data[85,4+ID] 
            SET tx_good  =  data[93,4+ID] 
          IF tx  =  "GOL" 
            SET tx_mod  =  data[86,4+ID] 
            SET tx_good  =  data[94,4+ID] 
          IF tx  =  "IFX" 
            SET tx_mod  =  data[87,4+ID] 
            SET tx_good  =  data[95,4+ID] 
          IF tx  =  "HCQ" 
            SET tx_mod  =  data[88,4+ID] 
            SET tx_good  =  data[96,4+ID] 
          IF tx  =  "MTX" 
            SET tx_mod  =  data[89,4+ID] 
            SET tx_good  =  data[97,4+ID] 
          IF tx  =  "SSZ" 
            SET tx_mod  =  data[90,4+ID] 
            SET tx_good  =  data[98,4+ID] 
          IF tx  =  "TICORA" 
            SET tx_mod  =  data[91,4+ID] 
            SET tx_good  =  data[99,4+ID] 
        IF tx_count  =  2 
          IF tx  =  "ABT" 
            SET tx_mod  =  data[100,4+ID] 
            SET tx_good  =  data[113,4+ID] 
          IF tx  =  "ABTS" 
            SET tx_mod  =  data[101,4+ID] 
            SET tx_good  =  data[114,4+ID] 
          IF tx  =  "ADA" 
            SET tx_mod  =  data[102,4+ID] 
            SET tx_good  =  data[115,4+ID] 
          IF tx  =  "CTZ" 
            SET tx_mod  =  data[103,4+ID] 
            SET tx_good  =  data[116,4+ID] 
          IF tx  =  "ETN" 
            SET tx_mod  =  data[104,4+ID] 
            SET tx_good  =  data[117,4+ID] 
          IF tx  =  "GOL" 
            SET tx_mod  =  data[105,4+ID] 
            SET tx_good  =  data[118,4+ID] 
          IF tx  =  "IFX" 
            SET tx_mod  =  data[106,4+ID] 
            SET tx_good  =  data[119,4+ID] 
          IF tx  =  "RTX" 
            SET tx_mod  =  data[107,4+ID] 
            SET tx_good  =  data[120,4+ID] 
          IF tx  =  "TCZ" 
            SET tx_mod  =  data[108,4+ID] 
            SET tx_good  =  data[121,4+ID] 
          IF tx  =  "HCQ" 
            SET tx_mod  =  data[109,4+ID] 
            SET tx_good  =  data[122,4+ID] 
          IF tx  =  "MTX" 
            SET tx_mod  =  data[110,4+ID] 
            SET tx_good  =  data[124,4+ID] 
          IF tx  =  "SSZ" 
            SET tx_mod  =  data[111,4+ID] 
            SET tx_good  =  data[124,4+ID] 
          IF tx  =  "TICORA" 
            SET tx_mod  =  data[112,4+ID] 
            SET tx_good  =  data[125,4+ID] 
        IF tx_count  >  2 
          IF tx  =  "ABT" 
            SET tx_mod  =  data[100,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[113,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "ABTS" 
            SET tx_mod  =  data[101,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[114,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "ADA" 
            SET tx_mod  =  data[102,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[115,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "CTZ" 
            SET tx_mod  =  data[103,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[116,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "ETN" 
            SET tx_mod  =  data[104,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[117,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "GOL" 
            SET tx_mod  =  data[105,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[118,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "IFX" 
            SET tx_mod  =  data[106,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[119,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "RTX" 
            SET tx_mod  =  data[107,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[120,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "TCZ" 
            SET tx_mod  =  data[108,4+ID]*[1-[t_dec*c_bdmards]] 
            SET tx_good  =  data[121,4+ID]*[1-[t_dec*c_bdmards]] 
          IF tx  =  "HCQ" 
            SET tx_mod  =  data[109,4+ID]*[1-[t_dec*c_dmards]] 
            SET tx_good  =  data[122,4+ID]*[1-[t_dec*c_dmards]] 
          IF tx  =  "MTX" 
            SET tx_mod  =  data[110,4+ID]*[1-[t_dec*c_dmards]] 
            SET tx_good  =  data[124,4+ID]*[1-[t_dec*c_dmards]] 
          IF tx  =  "SSZ" 
            SET tx_mod  =  data[111,4+ID]*[1-[t_dec*c_dmards]] 
            SET tx_good  =  data[124,4+ID]*[1-[t_dec*c_dmards]] 
          IF tx  =  "TICORA" 
            SET tx_mod  =  data[112,4+ID]*[1-[t_dec*c_dmards]] 
            SET tx_good  =  data[125,4+ID]*[1-[t_dec*c_dmards]] 
          IF tx_mod  <  0 
            SET tx_mod  =  0 
          IF tx_good  <  0 
            SET tx_good  =  0 
        'Set haqout values 
        SET haqout[3,[3*tx_count]-1]  =  tx_s_haq 
        SET haqout[2,[3*tx_count]-1]  =  tx_s_t 
        SET haqout[4,[3*tx_count]-1]  =  tx 
        SET haqout[5,[3*tx_count]-1]  =  tx_class 
        (Disabled) 'Debug option (set common effectiveness for all 
treatments) 
        (Disabled) SET tx_mod  =  0.5 
        (Disabled) SET tx_good  =  0.2 
        (Disabled) 'debug option (set common costs for all treatments) 
        (Disabled) SET tx_cost  =  100 
        (Disabled) SET response_cost  =  100 
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        (Disabled) 'debug option (set discrete tx's to the same 
administration time) 
        (Disabled) IF tx_discrete  =  1 
          (Disabled) SET tx_tta  =  1 
          (Disabled) SET tta  =  tx_tta 
        (Disabled) IF tx_class  =  "PALLIATIVE CARE" 
          (Disabled) SET tx_mod  =  0 
          (Disabled) SET tx_good  =  0 
        (Disabled) IF tx_class  =  "bDMARD" 
          (Disabled) SET tx_mod  =  0.6 
          (Disabled) SET tx_good  =  0.3 
        (Disabled) IF tx_class  =  "cDMARD" 
          (Disabled) SET tx_mod  =  0.4 
          (Disabled) SET tx_good  =  0.1 
      Financial Information 
        Capital: 10 
        Per Unit: 1 
      Carbon Emissions Information 
        Carbon Footprint: 10 




   
  Simulation Time 
  --------------- 
    SIMUL8 Data 
    Current Value 0 
   
  Warm Up Period 
  -------------- 
    SIMUL8 Data 
    Current Value 0 
   
  Results Collection Period 
  ------------------------- 
    SIMUL8 Data 
    Current Value 2000 
   
  Current Work Item 
  ----------------- 
    SIMUL8 Data 
    Current Value 0 
   
  Overhead Cost 
  ------------- 
    SIMUL8 Data 
    Current Value 0 
   
  Overhead Revenue 
  ---------------- 
    SIMUL8 Data 
    Current Value 0 
   
  Graph Sync Interval 
  ------------------- 
    SIMUL8 Data 
    Current Value 5 
   
  large_nbr 
  --------- 
    Number 
    Current Value 1000000 
    Reset Value 1000000 
   
  sim_nbr 
  ------- 
    Number 
    Current Value 47 
    Reset Value 47 
   
  data 
  ---- 
    Spreadsheet 
   
  output 
  ------ 
    Spreadsheet 
   
  m_age_death_nbr 
  --------------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_LYG_nbr 
  --------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dLYG_nbr 
  ---------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_Cost_nbr 
  ---------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dCost_nbr 
  ----------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_QALY_nbr 
  ---------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dQALY_nbr 
  ----------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_age_nbr 
  --------- 
    Number 
    Current Value 0 
    Reset Value 0 
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  m_sex_nbr 
  --------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dd_nbr 
  -------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_haq_nbr 
  --------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_das_nbr 
  --------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dmards_nbr 
  ------------ 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_weight_nbr 
  ------------ 
    Number 
    Current Value 0 
    Reset Value 0 
   
  response_time_nbr 
  ----------------- 
    Number 
    Current Value 0.5 
    Reset Value 0.5 
   
  haqlook 
  ------- 
    Spreadsheet 
   
  m_tx_nbr 
  -------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  withdraw_time_nbr 
  ----------------- 
    Number 
    Current Value 0.5 
    Reset Value 0.5 
   
  seq 
  --- 
    Spreadsheet 
   
  costs 
  ----- 
    Spreadsheet 
   
  d_cost 
  ------ 
    Number 
    Current Value 0.035 
    Reset Value 0.035 
   
  d_qaly 
  ------ 
    Number 
    Current Value 0.035 
    Reset Value 0.035 
   
  m_age 
  ----- 
    Number 
    Current Value 51.4 
    Reset Value 51.4 
   
  m_sex 
  ----- 
    Number 
    Current Value 0.73 
    Reset Value 0.73 
   
  m_das 
  ----- 
    Number 
    Current Value 6.5 
    Reset Value 6.5 
   
  m_dmards 
  -------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  m_dd 
  ---- 
    Number 
    Current Value 0.75 
    Reset Value 0.75 
   
  iDR_c nbr 
  --------- 
    Number 
    Current Value -0.0344 
    Reset Value -0.0344 
   
  iDR_q nbr 
  --------- 
    Number 
    Current Value -0.0344 
    Reset Value -0.0344 
   
  dmard_prog_i1 
  ------------- 
    Number 
    Current Value 0.238 
    Reset Value 0.238 
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  dmard_prog_i2 
  ------------- 
    Number 
    Current Value 1.084 
    Reset Value 1.084 
   
  dmard_prog_i3 
  ------------- 
    Number 
    Current Value 0.728 
    Reset Value 0.728 
   
  dmard_prog_i4 
  ------------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  dmard_prog_s1 
  ------------- 
    Number 
    Current Value -0.257 
    Reset Value -0.257 
   
  dmard_prog_s2 
  ------------- 
    Number 
    Current Value 0.023 
    Reset Value 0.023 
   
  dmard_prog_s3 
  ------------- 
    Number 
    Current Value -0.153 
    Reset Value -0.153 
   
  dmard_prog_s4 
  ------------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  dmard_prog_q1 
  ------------- 
    Number 
    Current Value 0.037 
    Reset Value 0.037 
   
  dmard_prog_q2 
  ------------- 
    Number 
    Current Value 0.011 
    Reset Value 0.011 
   
  dmard_prog_q3 
  ------------- 
    Number 
    Current Value 0.031 
    Reset Value 0.031 
   
  dmard_prog_q4 
  ------------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  dmard_prog_c1 
  ------------- 
    Number 
    Current Value -0.001 
    Reset Value -0.001 
   
  dmard_prog_c2 
  ------------- 
    Number 
    Current Value -0.001 
    Reset Value -0.001 
   
  dmard_prog_c3 
  ------------- 
    Number 
    Current Value -0.001 
    Reset Value -0.001 
   
  dmard_prog_c4 
  ------------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  dmard_prog_int1 
  --------------- 
    Number 
    Current Value 11.718 
    Reset Value 11.718 
   
  dmard_prog_int2 
  --------------- 
    Number 
    Current Value 5.611 
    Reset Value 5.611 
   
  dmard_prog_int3 
  --------------- 
    Number 
    Current Value 8.874 
    Reset Value 8.874 
   
  dmard_prog_age1 
  --------------- 
    Number 
    Current Value -0.088 
    Reset Value -0.088 
   
  dmard_prog_age2 
  --------------- 
    Number 
    Current Value -0.042 
    Reset Value -0.042 
   
  dmard_prog_age3 
  --------------- 
    Number 
    Current Value -0.063 
    Reset Value -0.063 
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  dmard_prog_sex1 
  --------------- 
    Number 
    Current Value -1.78 
    Reset Value -1.78 
   
  dmard_prog_sex2 
  --------------- 
    Number 
    Current Value -0.479 
    Reset Value -0.479 
   
  dmard_prog_sex3 
  --------------- 
    Number 
    Current Value -1.195 
    Reset Value -1.195 
   
  dmard_prog_das1 
  --------------- 
    Number 
    Current Value -0.731 
    Reset Value -0.731 
   
  dmard_prog_das2 
  --------------- 
    Number 
    Current Value -0.287 
    Reset Value -0.287 
   
  dmard_prog_das3 
  --------------- 
    Number 
    Current Value -0.474 
    Reset Value -0.474 
   
  dmard_prog_dd1 
  -------------- 
    Number 
    Current Value -0.021 
    Reset Value -0.021 
   
  dmard_prog_dd2 
  -------------- 
    Number 
    Current Value 0.011 
    Reset Value 0.011 
   
  dmard_prog_dd3 
  -------------- 
    Number 
    Current Value -0.003 
    Reset Value -0.003 
   
  dprog 
  ----- 
    Spreadsheet 
   
  dmard_prog_dep1 
  --------------- 
    Number 
    Current Value -1.333 
    Reset Value -1.333 
   
  dmard_prog_dep2 
  --------------- 
    Number 
    Current Value -0.547 
    Reset Value -0.547 
   
  dmard_prog_dep3 
  --------------- 
    Number 
    Current Value -0.56 
    Reset Value -0.56 
   
  dmard_prog_rf1 
  -------------- 
    Number 
    Current Value -0.204 
    Reset Value -0.204 
   
  dmard_prog_rf2 
  -------------- 
    Number 
    Current Value 0.11 
    Reset Value 0.11 
   
  dmard_prog_rf3 
  -------------- 
    Number 
    Current Value -0.209 
    Reset Value -0.209 
   
  dmard_prog_acr1 
  --------------- 
    Number 
    Current Value -1.036 
    Reset Value -1.036 
   
  dmard_prog_acr2 
  --------------- 
    Number 
    Current Value -0.576 
    Reset Value -0.576 
   
  dmard_prog_acr3 
  --------------- 
    Number 
    Current Value -0.753 
    Reset Value -0.753 
   
  dmard_prog_f2d1 
  --------------- 
    Number 
    Current Value -2.361 
    Reset Value -2.361 
   
  dmard_prog_f2d2 
  --------------- 
    Number 
    Current Value -0.181 
    Reset Value -0.181 
   
  dmard_prog_f2d3 
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  --------------- 
    Number 
    Current Value -1.148 
    Reset Value -1.148 
   
  dmard_prog_r6m1 
  --------------- 
    Number 
    Current Value 2.543 
    Reset Value 2.543 
   
  dmard_prog_r6m2 
  --------------- 
    Number 
    Current Value 0.965 
    Reset Value 0.965 
   
  dmard_prog_r6m3 
  --------------- 
    Number 
    Current Value 1.392 
    Reset Value 1.392 
   
  m_dep 
  ----- 
    Number 
    Current Value 0.49 
    Reset Value 0.49 
   
  m_rf 
  ---- 
    Number 
    Current Value 0.73 
    Reset Value 0.73 
   
  m_acr 
  ----- 
    Number 
    Current Value 1 
    Reset Value 1 
   
  m_r6m 
  ----- 
    Number 
    Current Value 1 
    Reset Value 1 
   
  haqout 
  ------ 
    Spreadsheet 
   
  Var86 
  ----- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  Var87 
  ----- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  start_time 
  ---------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  end_time 
  -------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  runtime 
  ------- 
    Number 
    Current Value 0 
    Reset Value 0 
   
  end 
  --- 
    Spreadsheet 
 
Start Run Visual Logic: 
  VL SECTION: Start Run Logic 
    'Warning: This code can run at any simulation time when the 
user click the RUN button 
    'load sequence details 
    Get PC Clock    start_time 
    SET sim_nbr  =  Results Collection Period 
    SET sim_nbr  =  sim_nbr 
End Run Visual Logic: 
  VL SECTION: End Run Logic ,  LOCALDATA: u:[NUMBER] ,  
q:[NUMBER] ,  S:[NUMBER] 
    'Obeyed when the simulation reaches end of "Results Collection 
Period" 
    SET Model Entry.Interarrival Time  =  0.00001 
    Get PC Clock    end_time 
    SET runtime  =  [end_time-start_time]*100000 
    (Disabled) Call COM Event    "Finished" 
    SET seq[6,2]  =  1 
Other Visual Logic: 
  VL SECTION: Reset Logic 
    Get Throughput    ???? ,  0 ,  0 ,  ???? 
    SET Model Entry.Interarrival Time  =  0.00001 
    Get from EXCEL    data[2,5] ,  "[test.XLS]Export" ,  2 ,  5 ,  8 ,  100 
Other Visual Logic: 
  VL SECTION: haqadjust ,  LOCALDATA: RESULT:[NUMBER] 
    IF haq  <  0 
      SET haq  =  0 
    ELSE IF haq  >  3 
      SET haq  =  3 
    ELSE 
      SET lhaq  =  [TRUNC[haq/0.125]*0.125] 
      SET hhaq  =  lhaq+0.125 
      IF RANDOM[0]  >=  [[haq-lhaq]/[hhaq-haq]] 
        SET haq  =  lhaq 
      ELSE 
        SET haq  =  hhaq 
Other Visual Logic: 
  VL SECTION: discretecost ,  LOCALDATA: c:[NUMBER] 
    SET c  =  Cost 
    SET Cost  =  c+tx_cost 
    SET c  =  dCost 
339 
 
    SET dCost  =  c+[tx_cost/[1+d_cost]^t] 
Other Visual Logic: 
  VL SECTION: cresponsecost ,  LOCALDATA: c:[NUMBER] ,  
temp:[NUMBER] 
    IF tx  =  "PC" 
      SET response_cost  =  200*6 
    SET c  =  Cost 
    SET Cost  =  c+response_cost 
    SET temp  =  response_time_nbr/2 
    SET c  =  dCost 
    SET dCost  =  c+[response_cost/[[1+d_cost]^[temp+t]]] 
Other Visual Logic: 
  VL SECTION: haqcost ,  LOCALDATA: haq_temp:[NUMBER] ,  
c:[NUMBER] ,  DiscTemp1:[NUMBER] ,  DiscTemp2:[NUMBER] 
    IF haq  <=  3 
      SET haq_temp  =  2687.97 
    IF haq  <=  2.5 
      SET haq_temp  =  1246.26 
    IF haq  <=  2 
      SET haq_temp  =  523.68 
    IF haq  <=  1.5 
      SET haq_temp  =  364.68 
    IF haq  <=  1 
      SET haq_temp  =  102.54 
    IF haq  <=  0.5 
      SET haq_temp  =  167.41 
    SET tc2  =  t 
    SET c  =  Cost 
    SET Cost  =  c+[haq_temp*[tc2-tc1]] 
    SET c  =  dCost 
    SET DiscTemp2  =  EXP[iDR_c nbr*tc2] 
    SET DiscTemp1  =  EXP[iDR_c nbr*tc1] 
    SET dCost  =  c+[[[1/iDR_c nbr]*[DiscTemp2-
DiscTemp1]]*haq_temp] 
    SET tc1  =  t 
Other Visual Logic: 
  VL SECTION: haqprog ,  LOCALDATA: p1:[NUMBER] ,  
p2:[NUMBER] ,  p3:[NUMBER] ,  p4:[NUMBER] ,  y1:[NUMBER] ,  
y2:[NUMBER] ,  y3:[NUMBER] ,  y4:[NUMBER] ,  cdf1:[NUMBER] ,  
cdf2:[NUMBER] ,  cdf3:[NUMBER] ,  cdf4:[NUMBER] ,  
pdf1:[NUMBER] ,  pdf2:[NUMBER] ,  pdf3:[NUMBER] ,  
pdf4:[NUMBER] ,  haq1:[NUMBER] ,  haq2:[NUMBER] ,  
haq3:[NUMBER] ,  haq4:[NUMBER] ,  dm_age:[NUMBER] ,  
dm_sex:[NUMBER] ,  dm_dd:[NUMBER] ,  dm_das:[NUMBER] ,  
dm_dmards:[NUMBER] ,  i:[NUMBER] ,  S:[NUMBER] ,  
prob1:[NUMBER] ,  prob2:[NUMBER] ,  prob3:[NUMBER] ,  
prob4:[NUMBER] ,  Local_t_p:[NUMBER] 
    IF tx_class  =  "bDMARD" 
      IF tx_response  =  "MOD" 








        IF prog_count  =  1 
          SET haq  =  
haq+[[[i+[S*bio_prog_mod_xt3]]+[bio_prog_mod_rho3*haq]]-
[[i+[S*bio_prog_mod_xt2]]+[bio_prog_mod_rho2*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  2 
          SET haq  =  
haq+[[[i+[S*bio_prog_mod_xt4]]+[bio_prog_mod_rho4*haq]]-
[[i+[S*bio_prog_mod_xt3]]+[bio_prog_mod_rho3*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  3 
          SET haq  =  
haq+[[[i+[S*bio_prog_mod_xt5]]+[bio_prog_mod_rho5*haq]]-
[[i+[S*bio_prog_mod_xt4]]+[bio_prog_mod_rho4*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  4 
          SET haq  =  
haq+[[[i+[S*bio_prog_mod_xt5]]+[bio_prog_mod_rho6*haq]]-
[[i+[S*bio_prog_mod_xt5]]+[bio_prog_mod_rho5*phaq]]] 
          SET tth  =  0.5 
        ELSE 
          SET tth  =  large_nbr 
      ELSE 









        IF prog_count  =  1 
          SET haq  =  
haq+[[[i+[S*bio_prog_good_xt3]]+[bio_prog_good_rho3*haq]]-
[[i+[S*bio_prog_good_xt2]]+[bio_prog_good_rho2*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  2 
          SET haq  =  
haq+[[[i+[S*bio_prog_good_xt4]]+[bio_prog_good_rho4*haq]]-
[[i+[S*bio_prog_good_xt3]]+[bio_prog_good_rho3*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  3 
          SET haq  =  
haq+[[[i+[S*bio_prog_good_xt5]]+[bio_prog_good_rho5*haq]]-
[[i+[S*bio_prog_good_xt4]]+[bio_prog_good_rho4*phaq]]] 
          SET tth  =  0.5 
        ELSE IF prog_count  =  4 
          SET haq  =  
haq+[[[i+[S*bio_prog_good_xt5]]+[bio_prog_good_rho6*haq]]-
[[i+[S*bio_prog_good_xt5]]+[bio_prog_good_rho5*phaq]]] 
          SET tth  =  0.5 
        ELSE 
          SET tth  =  large_nbr 
    IF tx_class  =  "cDMARD" 




















      SET p4  =  1 
      SET prob1  =  p1/[[[p1+p2]+p3]+p4] 
      SET prob2  =  p2/[[[p1+p2]+p3]+p4] 
      SET prob3  =  p3/[[[p1+p2]+p3]+p4] 
      SET prob4  =  p4/[[[p1+p2]+p3]+p4] 
      SET haq1  =  dprog[6,[[t_p*2]+3]] 
      SET haq2  =  dprog[7,[[t_p*2]+3]] 
      SET haq3  =  dprog[8,[[t_p*2]+3]] 
      SET haq4  =  dprog[9,[[t_p*2]+3]] 
      SET t_haq_entry  =  
[[[prob1*haq1]+[prob2*haq2]]+[prob3*haq3]]+[prob4*haq4] 
      SET t_haq  =  t_haq_entry 
      SET entry_t_p  =  t_p 
      SET loop_check  =  0 
      SET loop_count  =  0 
      WHILE loop_check  =  0 
        SET haq1  =  dprog[6,[[t_p*2]+3]] 
        SET haq2  =  dprog[7,[[t_p*2]+3]] 
        SET haq3  =  dprog[8,[[t_p*2]+3]] 
        SET haq4  =  dprog[9,[[t_p*2]+3]] 
        SET t_haq  =  
[[[prob1*haq1]+[prob2*haq2]]+[prob3*haq3]]+[prob4*haq4] 
        SET loop_count  =  loop_count+1 
        SET t_p  =  t_p+0.5 
        IF loop_count  >  [26-t_p] 
          SET loop_check  =  1 
        IF [ABS[t_haq-t_haq_entry]]  >=  [0.125] 
          SET loop_check  =  1 
      SET haq  =  [haq+t_haq]-t_haq_entry 
      SET tth  =  t_p-entry_t_p 
      IF loop_count  >  [26-t_p] 
        SET tth  =  large_nbr 
      (Disabled) SET haq  =  haq+0.125 
      (Disabled) SET tth  =  3 
      'fix this!!! 
    IF tx_class  =  "PALLIATIVE CARE" 
      SET tth  =  [1/0.045]*0.125 
      SET haq  =  haq+0.125 
    CALL haqadjust 
    SET prog_count  =  prog_count+1 
    SET phaq  =  haq 
    IF prog_count  >  10 
      SET prog_count  =  prog_count 
Other Visual Logic: 
  VL SECTION: continuouscost ,  LOCALDATA: C:[NUMBER] ,  
DiscTemp1:[NUMBER] ,  DiscTemp2:[NUMBER] 
    SET C  =  Cost 
    SET Cost  =  C+[[tx_w_t-tx_r_t]*[12*tx_cost]] 
    SET C  =  dCost 
    SET DiscTemp2  =  EXP[iDR_c nbr*tx_w_t] 
    SET DiscTemp1  =  EXP[iDR_c nbr*tx_r_t] 
    SET dCost  =  C+[[[1/iDR_c nbr]*[DiscTemp2-
DiscTemp1]]*[tx_cost*12]] 
    (Disabled) SET dCost  =  
C+[[[tx_c*12]*[[[1/NEG[i_d_cost]]*EXP[NEG[i_d_cost]*tx_w_t]]]]-
[[1/NEG[i_d_cost]]*EXP[NEG[i_d_cost]*tx_r_t]]] 
    SET admin_count  =  admin_count+1 
Other Visual Logic: 
  VL SECTION: qaly ,  LOCALDATA: q:[NUMBER] ,  u:[NUMBER] ,  
DiscTemp2:[NUMBER] ,  DiscTemp1:[NUMBER] ,  h:[NUMBER] ,  
h2:[NUMBER] ,  a:[NUMBER] ,  a2:[NUMBER] 
    SET c_age  =  b_age+t 
    SET tq2  =  t 
    SET u2  =  
[[[[0.91002]+[haq*NEG[0.20418]]]+[[haq^2]*NEG[0.01291]]]+[c_a
ge*NEG[0.00097]]]+[[c_age^2]*NEG[0.00001]] 
    'debug option 
    (Disabled) SET u2  =  1 
    SET q  =  QALY 
    SET QALY  =  [[[[u2+u1]*[tq2-tq1]]]/2]+q 
    SET q  =  dQALY 
    SET DiscTemp2  =  EXP[iDR_q nbr*tq2] 
    SET DiscTemp1  =  EXP[iDR_q nbr*tq1] 
    SET dQALY  =  q+[[[1/iDR_q nbr]*[DiscTemp2-
DiscTemp1]]*[[u2+u1]/2]] 
    'debug option 
    (Disabled) SET dQALY  =  QALY 
    SET u1  =  u2 
    SET tq1  =  t 
Other Visual Logic: 
  VL SECTION: min_maintenance 
    'this avoids competing events with the same time, which causes 
issues for routing 
    IF ttd  =  ttw 
      SET ttw  =  ttw+0.0001 
    IF ttd  =  tth 
      SET tth  =  tth+0.0001 
    IF ttd  =  tta 
      SET tta  =  tta+0.0001 
    IF ttw  =  tth 
      SET tth  =  tth+0.0001 
    IF ttw  =  tta 
      SET tta  =  tta+0.0001 
    IF tta  =  tth 
      SET tth  =  tth+0.0001 
    'this returns the minimum of (ttw, ttd, tth, tta) 
    IF [ttd < tta] & [ttd < tth] & [ttd < ttw]  =  1 
      SET timex  =  ttd 
      SET router  =  3 
    IF [tth < tta] & [tth < ttd] & [tth < ttw]  =  1 
      SET timex  =  tth 
      SET router  =  1 
    IF [tta < ttd] & [tta < tth] & [tta < ttw]  =  1 
      SET timex  =  tta 
      SET router  =  4 
    IF [ttw < ttd] & [ttw < tth] & [ttw < tta]  =  1 
      SET timex  =  ttw 
      SET router  =  2 
Other Visual Logic: 
  VL SECTION: haqresponse ,  LOCALDATA: dm_age:[NUMBER] ,  
dm_sex:[NUMBER] ,  dm_dd:[NUMBER] ,  dm_das:[NUMBER] ,  
dm_dmards:[NUMBER] ,  i:[NUMBER] ,  S:[NUMBER] 
    'this is the haqchange given a response to a tx (cDMARD or 
bDMARD) 
    IF prog_count  =  0 
      SET c_age  =  b_age+t 
      SET c_dd  =  b_dd+t 
      SET c_das  =  b_das 
      SET dm_age  =  [c_age-m_age]/10 
      SET dm_sex  =  b_sex 
      SET dm_dd  =  c_dd-m_dd 
      SET dm_das  =  c_das-m_das 
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      SET dm_dmards  =  c_dmards-m_dmards 
      SET phaq  =  haq 
    IF tx_response  =  "GOOD" 









      SET haq  =  
haq+[[[i+[S*bio_prog_good_xt2]]+[bio_prog_good_rho2*haq]]-
[[i+[S*0]]+[bio_prog_good_rho1*phaq]]] 
    IF tx_response  =  "MOD" 








      SET haq  =  
haq+[[[i+[S*bio_prog_mod_xt2]]+[bio_prog_mod_rho2*haq]]-
[[i+[S*0]]+[bio_prog_mod_rho1*phaq]]] 
    IF tx_response  =  "NONE" 
      SET haq  =  haq 
      SET tth  =  large_nbr 
    IF tx_class  =  "PALLIATIVE CARE" 
      SET tth  =  [1/0.045]*0.125 
      SET haq  =  haq 
    CALL haqadjust 
    SET prog_count  =  prog_count+1 
    SET phaq  =  haq 
Other Visual Logic: 
  VL SECTION: min_response ,  LOCALDATA: RESULT:[NUMBER] ,  
temp1:[NUMBER] 
    'this avoids having competing events with the same times, which 
causes issues for routing 
    IF ttd  =  ttr 
      SET ttr  =  ttr+0.0001 
    IF ttd  =  tta 
      SET tta  =  tta+0.0001 
    IF ttd  <  0 
      SET ttd  =  ttd 
    'this returns the minimum of (ttd, ttr, tta) 
    IF [ttd < tta] & [ttd < ttr]  =  1 
      SET timex  =  ttd 
      SET router  =  2 
    IF [ttr < tta] & [ttr < ttd]  =  1 
      SET timex  =  ttr 
      SET router  =  1 
    IF [tta < ttd] & [tta < ttr]  =  1 
      SET timex  =  tta 
      SET router  =  3 
 
****************************************************** 
SIMUL8 Profit Financial Information 
----------------------------------- 
  Currency: £ 
  Fixed Cost: 0 
  Fixed Revenue: 0 
 
******************************************************
Carbon Emissions Information 
---------------------------- 
  Carbon Footprint Unit: CO2e 
  Fixed Carbon Footprint: 0 




APPENDIX D: SIMULATION OPTIMISATION MODEL 
























APPENDIX D.2: MODEL CODE 
 
CALL SIMUL8 MODEL 
Sub runmodel(i, numsim) 
 
Dim tabl As Range 
Dim max_runs, lambda, evaluate_switch As Integer 
Dim t_dec As Double 
Dim s As Integer 
Calculate 
t_dec = Range("t_dec").Value 
Set tabl = ThisWorkbook.Names("tabl").RefersToRange 
max_runs = Range("max_runs").Value 
lambda = Range("lambda").Value 
evaluate_switch = Range("evaluate_switch").Value 
 
Range("S20").Value = i 
s = Range("S20").Value 
 
If evaluate_switch = 1 Then 
 
    Set MYSIMUL8 = GetObject("", "SIMUL8.S8Simulation") 
     
    MYSIMUL8.Open "C:\model8.s8" 
     
    line = 1 
     
    MYSIMUL8.GDValueDouble("seq", 6, 2) = -1 
    MYSIMUL8.GDValueDouble("seq", 7, 2) = t_dec 
     
    Do Until line > 14 
        tx = Worksheets("Frontsheet").Range("B35").Offset(i - 1, line - 1).Value 
         
        If tx <> "" Then 
            MYSIMUL8.GDValueDouble("seq", 2, line + 1) = Application.VLookup(tx, tabl, 11, 0)   'tx 
            MYSIMUL8.GDValueDouble("seq", 3, line + 1) = Application.VLookup(tx, tabl, 8, 0)    'class 
            MYSIMUL8.GDValueDouble("seq", 4, line + 1) = Application.VLookup(tx, tabl, 9, 0)    'discrete 
            MYSIMUL8.GDValueDouble("seq", 5, line + 1) = Application.VLookup(tx, tabl, 10, 0)   'weight 
        End If 
 
        line = line + 1 
    Loop 
     
    MYSIMUL8.RunSim numsim 
     
    'this makes the VBA wait until the model completes and then SIMUL8 makes the cell equal 1 on the run 
end. this is the trigger for VBA to progress. 
    Do Until MYSIMUL8.GDValueDouble("seq", 6, 2) = 1 
        Sleep (100) 
    Loop 
     
    Worksheets("Frontsheet").Range("Q35:Q35").Offset(s - 1, 0).Value = MYSIMUL8.GDValue("output", 6, 
4) 
    Worksheets("Frontsheet").Range("R35:R35").Offset(s - 1, 0).Value = MYSIMUL8.GDValue("output", 7, 4) 
     
    'extra debugging outputs from SIMUL8 model 
'    Worksheets("Frontsheet").Range("AE35:AE35").Offset(s - 1, 0).Value = MYSIMUL8.GDValue("output", 
2, 4) 
'    Worksheets("Frontsheet").Range("AF35:AF35").Offset(s - 1, 0).Value = MYSIMUL8.GDValue("output", 
18, 5) 
     
    nmb = (MYSIMUL8.GDValue("output", 7, 4) * lambda - MYSIMUL8.GDValue("output", 6, 4)) 
    Worksheets("Frontsheet").Range("P35:P35").Offset(s - 1, 0).Value = nmb 





SIMULATION OPTIMISATION CODE 
 
Private Sub CommandButton1_Click() 
 
Dim numsim, i, max_runs, export_switch, gen_export_switch, exp_cooling_active, linear_cooling_active, _ 
 lambda, evaluate_switch, init_sol, currentseqlength, cache_search_active, temp_algorith_start, 
email_notification, _ 
 mintempstop, min_init_length, max_length, min_length, acceptworsecount, worsecount, restart_rule, _ 
 restarts, programme, line, sequence_generation, repetition_schedulestopsim, worseloop, 
end_run_search, _ 




 max_failed_attempts, max_failed_attempts_active, evaluationsetnum, duplicate, duplicate_index, 
total_i, _ 
 overallbestseq_index, overallbestseqlength, currentruns, totalruns, percentcomplete, 
lundy_cooling_active As Integer 
 
Dim r_seq, r_seq2, start_time, end_time, eval_start_time, eval_end_time, best_cost, best_qaly, 
temperature, _ 
 initial_temperature, current_nmb, current_cost, current_qaly, best_nmb, p_accept_target, p_accept, _ 
 best_nmb_index, exp_cooling, linear_cooling, previous_nmb, p_remove, p_add, bp_remove, _ 
 bp_add, p_add2, p_remove2, bp_add2, bp_remove2, overall_best_nmb, lundy_cooling As Double 
 
Dim currentseq, prevseq, bestseq, overallbestseq 
Dim tabl, rng As Range 
Dim tx, pc_name As String 
 
evaluate_switch = Range("evaluate_switch").Value 
init_sol = Range("init_sol").Value 
bp_remove = Range("p_remove").Value 
bp_add = Range("p_add").Value 
bp_remove2 = Range("p_remove2").Value 
bp_add2 = Range("p_add2").Value 
min_init_length = Range("min_init_length").Value 
sequence_generation = Range("sequence_generation").Value 
numsim = Range("numsim").Value 
export_switch = Range("export_switch").Value 
gen_export_switch = Range("gen_export_switch").Value 
lambda = Range("lambda").Value 
max_runs = Range("max_runs").Value 
restarts = Range("restarts").Value 
initial_temperature = Range("init_temp").Value 
programme = Range("programme").Value 
repetition_schedule = Range("rep_sched").Value 
exp_cooling = Range("exp_cooling").Value 
exp_cooling_active = Range("exp_cooling_active").Value 
linear_cooling = Range("linear_cooling").Value 
linear_cooling_active = Range("linear_cooling_active").Value 
lundy_cooling = Range("lundy_cooling").Value 
lundy_cooling_active = Range("lundy_cooling_active").Value 
end_run_search_active = Range("end_run_search_active").Value 
end_run_search = Range("end_run_search").Value 
restart_rule = Range("restart_rule").Value 
email_notification = Range("email_notification").Value 
pc_name = Range("pc_name").Value 
 
min_temp_stop = Range("min_temp_stop").Value 
min_temp_stop_active = Range("min_temp_stop_active").Value 
max_failed_attempts = Range("max_failed_attempts").Value 
max_failed_attempts_active = Range("max_failed_attempts_active").Value 
cache_search_active = Range("cache_search_active").Value 
p_accept_target = Range("p_accept_target").Value 
temp_algorithm_increment = Range("temp_algorithm_increment").Value 
temp_algorithm_start = Range("temp_algorithm_start").Value 
worseloop = Range("worseloop").Value 
totalruns = max_runs * restarts 
 
tabl = ThisWorkbook.Names("tabl").RefersToRange 
max_length = 14 
min_length = 1 
duplicate = 0 
acceptworsecount = 0 
worsecount = 0 
p_accept = 0 
overall_best_nmb = 0 
total_i = 1 
'prevrestartbestseq_index = 0 
'overallbestseq_index = 0 
'Range("V20:V21").ClearContents 
If programme = 5 Then 
    max_runs = 10000 
    Range("X23:X32").ClearContents 
    end_run_search_active = 0 
End If 
 
If lundy_cooling_active = 1 Then 




ReDim currentseq(0 To 0) 
 
If evaluate_switch = 1 Then             'Debug option to turn off evaluation 






Range("B35:AJ10034").Interior.ColorIndex = 0 















evaluationsetnum = 1000 - Application.WorksheetFunction.CountBlank( _ 
    Worksheets("Evaluation Set").Range("A2:A1002")) + 1 
start_time = Now() 
 
If gen_export_switch = 1 Then           'Generate a fresh patient dataset 
    Call gen_export 
End If 
 
If exp_cooling_active + linear_cooling_active = 2 Then   'check a cooling schedule is selected 
    MsgBox "ERROR: Define the cooling schedule properly" 
    End 
End If 
 
If exp_cooling_active + lundy_cooling_active = 2 Then 'check a cooling schedule is selected 
    MsgBox "ERROR: Define the cooling schedule properly" 
    End 
End If 
 
If lundy_cooling_active + linear_cooling_active = 2 Then 'check a cooling schedule is selected 
    MsgBox "ERROR: Define the cooling schedule properly" 
    End 
End If 
 
If lundy_cooling_active + linear_cooling_active + exp_cooling_active = 3 Then 'check a cooling schedule is 
selected 
    MsgBox "ERROR: Define the cooling schedule properly" 
    End 
End If 
 
If export_switch = 1 Then               'export the dataset to SIMUL8 
    Dim length, width, L, W, x, y As Integer 
    L = 1 
    W = 1 
    x = 1 
    y = 1 
    length = numsim 
    width = 124 
     
    MYSIMUL8.Open "C:\model8.s8" 
     
    Do Until x > width 
        Do Until L > length 
            W = L 
            y = x 
            MYSIMUL8.GDValueDouble("data", x + 1, L + 4) = _ 
                Worksheets("Export").Cells(W + 4, y + 1).Value 
            Application.StatusBar = _ 
                "Row " & L & " out of " & length & _ 
                    ". Column " & x & " out of " & width 
            L = L + 1 
            Calculate 
        Loop 
        x = x + 1 
        L = 1 
    Loop 
     
    MYSIMUL8.Save "C:\model8.s8" 
    
End If 
 
temploop = 0 
b = 1 
 
Do While b <= restarts                  '########### main 'restart' loop 
    Range("B35:AJ10034").ClearContents 
    Range("B35:AJ10034").Interior.ColorIndex = 0 
    Range("B35:AJ10034").Font.Bold = False 
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    If programme <> 5 Then 
        If mintempstop > initial_temperature Then   'check that the initial temp > min temp 
            MsgBox "ERROR: Minimum Temperature value > Initial Temperature." 
            End 
        End If 
    End If 
     
    i = 0 
 
    If programme = 4 Then               'Runs a set of sequences as defined in "Evaluation Set" 
        Worksheets("Evaluation Set").Range("O2:Q20002").ClearContents 
         
        Do 
            i = i + 1 
            total_i = total_i + 1 
             
            If Worksheets("Evaluation Set").Range("A2:A2").Offset(i - 1, 0) = "" Then 
                end_time = Now() 
                Range("S21").Value = SecondsToDateTimeSerial(DateDiff("s", start_time, end_time)) 
                i = i - 1 
                MsgBox i & " Evaluations. Model Run Time = " _ 
                    & SecondsToDateTimeSerial(DateDiff("s", start_time, end_time)) 
 
                Exit Do 
            Else 
                Worksheets("Frontsheet").Range("B21:O21").Value = _ 
                    Worksheets("Evaluation Set").Range("A2:N2").Offset(i - 1, 0).Value 
                Application.StatusBar = "Running evaluation programme: Iteration " _ 
                    & i & " out of " & evaluationsetnum 
                insert_length = 14 - Application.WorksheetFunction.CountBlank(Range("B21:O21")) 
                ReDim currentseq(1 To insert_length) 
                currentseqlength = insert_length 
                a = 1 
                Do Until a > insert_length 
                    currentseq(a) = Range("B21").Offset(0, a - 1).Value 
                    Range("B35").Offset(i - 1, a - 1).Value = currentseq(a) 
                    a = a + 1 
                Loop 
                Call eligible(currentseq, currentseqlength, seqfault) 
            End If 
             
            duplicate = 0 
            duplicate_index = 0 
            eval_start_time = 0 
            eval_end_time = 0 
             
            If total_i > 1 Then 
                If cache_search_active = 1 Then 
                    eval_start_time = Now() 
                    Call cache_search(total_i, i, duplicate, duplicate_index, currentseqlength) 
                    eval_end_time = Now() 
                End If 
            End If 
             
            If duplicate = 1 Then 
                Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("P2").Offset(duplicate_index - 1, 0).Value 
                Worksheets("Frontsheet").Range("Q35:Q35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("Q2").Offset(duplicate_index - 1, 0).Value 
                Worksheets("Frontsheet").Range("R35:R35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("R2").Offset(duplicate_index - 1, 0).Value 
                Worksheets("Frontsheet").Range("AE35:AE35").Offset(i - 1, 0).Value = "DUPLICATE" 
                Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
            Else 
                eval_start_time = Now() 
                Call runmodel(i, numsim)        'run model to evaluate 
                If Worksheets("Frontsheet").Range("AC35:AC35").Offset(i - 1, 0).Value = 1 Then 
                    nmb = -999999999 
                    Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = nmb 
                End If 
                 
                eval_end_time = Now() 
                Worksheets("Frontsheet").Range("AE35:Ae35").Offset(i - 1, 0).Value = "EVALUATE" 
                Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
            End If 
             
            Worksheets("Evaluation Set").Range("O2:Q2").Offset(i - 1, 0).Value = _ 
                Worksheets("Frontsheet").Range("P35:R35").Offset(i - 1, 0).Value 
             
        Loop 
        End                             'Once the programme is run, exit the simulation. 
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    End If 
        
    i = 1 
 
    stopsim = 0 
    failed_attempts = 0 
    acceptworsecount = 0 
    Do While stopsim = 0                '########### main 'iteration' loop 
        
        Calculate 
         
        Range("S21").Value = SecondsToDateTimeSerial(DateDiff("s", start_time, Now())) 
         
        currentruns = ((b - 1) * max_runs) + i 
        percentcomplete = Int(currentruns / totalruns * 100) 
         
        Application.StatusBar = "Restart " & b & " out of " _ 
            & restarts & ": Evaluation " & i & " out of " & max_runs & " (" & percentcomplete & "%)" 
                 
        If programme = 5 Then 
            If i = 1 Then 
                temperature = temp_algorithm_start 
                p_accept = 0 
                prevseqlength = currentseqlength 
            End If 
        Else 
            If i = 1 Then                   'set temperature 
                temperature = initial_temperature 
                prevseqlength = currentseqlength 
            Else 
                temperature = temperature 
            End If 
             
            If temploop = repetition_schedule Then  'cooling schedule temp reduction 
                 
                If exp_cooling_active = 1 Then 
                    temperature = temperature * exp_cooling 
                    temploop = 0 
                End If 
                 
                If linear_cooling_active = 1 Then 
                    temperature = temperature - linear_cooling 
                    temploop = 0 
                End If 
                 
                If lundy_cooling_active = 1 Then 
                    temperature = temperature / (1 + (lundy_cooling * temperature)) 
                    temploop = 0 
                End If 
                 
            End If 
            If temperature < 0 Then 
                MsgBox "MAJOR ERROR: TEMPERATURE NEGATIVE" 
                End 
            End If 
        End If 
        
        temploop = temploop + 1 
                 
        If i = 1 Then                   '########### FIRST ITERATION 
            If b = 1 Then                   'First Restart 
                If init_sol = 1 Then        'Random Seq to start 
                    Call gen_random_seq(i, currentseq, currentseqlength) 
                Else                        'or insert Seq to start 
                                            '(to check performance with same starting sequence) 
                    insert_length = 14 - Application.WorksheetFunction.CountBlank(Range("B21:O21")) 
                    ReDim currentseq(1 To insert_length) 
                    currentseqlength = insert_length 
                    a = 1 
                    Do Until a > insert_length 
                        currentseq(a) = Range("B21").Offset(0, a - 1).Value 
                        Range("B35").Offset(i - 1, a - 1).Value = currentseq(a) 
                        a = a + 1 
                    Loop 
                    Call eligible(currentseq, currentseqlength, seqfault) 
                    If seqfault = 1 Then 
                        MsgBox "MAJOR ERROR: INITIAL SEQUENCE NOT ELIGIBLE" 
                        End 
                    End If 
                End If 
            Else                            'next restarts 
                Select Case restart_rule 
                    Case 1                  'random restart 
                        If init_sol = 1 Then        'Random Seq to start 
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                            Call gen_random_seq(i, currentseq, currentseqlength) 
                        Else                        'or insert Seq to start 
                                                    '(to check performance with same starting sequence) 
                            insert_length = 14 - Application.WorksheetFunction.CountBlank(Range("B21:O21")) 
                            ReDim currentseq(1 To insert_length) 
                            currentseqlength = insert_length 
                            a = 1 
                            Do Until a > insert_length 
                                currentseq(a) = Range("B21").Offset(0, a - 1).Value 
                                Range("B35").Offset(i - 1, a - 1).Value = currentseq(a) 
                                a = a + 1 
                            Loop 
                            Call eligible(currentseq, currentseqlength, seqfault) 
                            If seqfault = 1 Then 
                                MsgBox "MAJOR ERROR: INITIAL SEQUENCE NOT ELIGIBLE" 
                                End 
                            End If 
                        End If 
                    Case 2                  'restart with overall best seq 
                        insert_length = 14 - 
Application.WorksheetFunction.CountBlank(Range("B23:O23").Offset(overallbestseq_index - 1, 0)) 
                        ReDim currentseq(1 To insert_length) 
                        currentseqlength = insert_length 
                        a = 1 
                        Do Until a > insert_length 
                            currentseq(a) = Range("B23").Offset(overallbestseq_index - 1, a - 1).Value 
                            Range("B35").Offset(0, a - 1).Value = currentseq(a) 
                            a = a + 1 
                        Loop 
                        Call eligible(currentseq, currentseqlength, seqfault) 
                        If seqfault = 1 Then 
                            MsgBox "MAJOR ERROR: INITIAL SEQUENCE NOT ELIGIBLE" 
                            End 
                        End If 
                End Select 
                prevseqlength = currentseqlength 
            End If 
              
        Else                            '########### SUBSEQUENT ITERATIONS 
            If sequence_generation = 1 Then     'Generate a random sequence 
                Call gen_random_seq(i, currentseq, currentseqlength) 
            ElseIf sequence_generation = 2 Then     'Pairwise swap 
                'Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                 
                Select Case currentseqlength    'addition/remove 1 or 2 tx, 
                                                'dependent on probs & length of sequence 
                    Case 1 To 2 
                        p_add = 1 
                        p_add2 = bp_add2 
                        p_remove = 0 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 3 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
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                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 4 To 10 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 11 To 12 
                        p_add = bp_add 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 13 To 14 
                        p_add = 0 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                End Select 
            ElseIf sequence_generation = 3 Then     'Random swap + Add/Subtract (DEFAULT) 
                Select Case currentseqlength    'addition/remove 1 or 2 tx, 
                                                'dependent on probs & length of sequence 
                    Case 1 To 2 
                        p_add = 1 
                        p_add2 = bp_add2 
                        p_remove = 0 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
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                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 3 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 4 To 10 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 11 To 12 
                        p_add = bp_add 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 13 To 14 
                        p_add = 0 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
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                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                End Select 
            End If 
        End If 
         
        duplicate = 0 
        duplicate_index = 0 
        eval_start_time = 0 
        eval_end_time = 0 
         
        If total_i > 1 Then 
            If cache_search_active = 1 Then 
                eval_start_time = Now() 
                Call cache_search(total_i, i, duplicate, duplicate_index, currentseqlength) 
                eval_end_time = Now() 
            End If 
        End If 
         
        If duplicate = 1 Then 
            Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("P2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("Q35:Q35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("Q2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("R35:R35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("R2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("AE35:AE35").Offset(i - 1, 0).Value = "DUPLICATE" 
            Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
            Worksheets("Frontsheet").Range("AG35:AG35").Offset(i - 1, 0).Value = duplicate_index 
        Else 
            eval_start_time = Now() 
            Range("U20").Value = total_i 
            Call runmodel(i, numsim)        'run model to evaluate 
            If Worksheets("Frontsheet").Range("AC35:AC35").Offset(i - 1, 0).Value = 1 Then 
                nmb = -999999999 
                Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = nmb 
            End If 
            eval_end_time = Now() 
            Worksheets("Frontsheet").Range("AE35:Ae35").Offset(i - 1, 0).Value = "EVALUATE" 
            Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
        End If 
         
        current_nmb = Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value 
        current_cost = Worksheets("Frontsheet").Range("Q35:Q35").Offset(i - 1, 0).Value 
        current_qaly = Worksheets("Frontsheet").Range("R35:R35").Offset(i - 1, 0).Value 
         
        Sheets("Cache").Range("B2:R2").Offset(total_i - 1, 0).Value = 
Worksheets("Frontsheet").Range("B35:R35").Offset(i - 1, 0).Value 
         
     
        If i = 1 Then                   'update current best results 
            best_nmb = current_nmb 
            best_cost = current_cost 
            best_qaly = current_qaly 
            previous_nmb = current_nmb 
            bestseq = currentseq 
            Worksheets("Frontsheet").Range("T35:T35").Value = best_nmb 
            best_nmb_index = i 
            Worksheets("Frontsheet").Range("S35:S35").Value = best_nmb_index 
        Else 
            If current_nmb > best_nmb Then      'improvement. update current best 
                best_nmb = current_nmb 
                best_cost = current_cost 
                best_qaly = current_qaly 
                bestseq = currentseq 
                 
                Worksheets("Frontsheet").Range("T35:T35").Offset(i - 1, 0).Value = best_nmb 
                best_nmb_index = i 
                Worksheets("Frontsheet").Range("S35:S35").Offset(i - 1, 0).Value = i 
            Else                        'otherwise retain the current best 
                Worksheets("Frontsheet").Range("T35:T35").Offset(i - 1, 0).Value = best_nmb 
                Worksheets("Frontsheet").Range("S35:S35").Offset(i - 1, 0).Value = best_nmb_index 
            End If 
        End If 
                 
        Worksheets("Frontsheet").Range("W35:W35").Offset(i - 1, 0).Value = temperature 
             
        If temperature = 0 Then 
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            temperature = 1 
        End If 
             
        If programme = 1 Then           'random search (every sequence accepted) 
            If i = 1 Then 
                prevseq = currentseq 
                previous_nmb = current_nmb 
                prevseqlength = currentseqlength 
            Else 
                If current_nmb > previous_nmb Then 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 1 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                    prevseq = currentseq 
                    prevseqlength = currentseqlength 
                    previous_nmb = current_nmb 
                Else 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                    prevseq = currentseq 
                    prevseqlength = currentseqlength 
                    previous_nmb = current_nmb 
                    acceptworsecount = acceptworsecount + 1 
                End If 
                prevseq = currentseq 
            End If 
        ElseIf programme = 2 Then       '########### SIMULATED ANNEALING 
            If i = 1 Then 
                prevseq = currentseq 
                previous_nmb = current_nmb 
                prevseqlength = currentseqlength 
            Else 
                If current_nmb > previous_nmb Then      'Improvement = Accept 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 1 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                    prevseq = currentseq 
                    prevseqlength = currentseqlength 
                    previous_nmb = current_nmb 
                    failed_attempts = 0 
                Else 
                    r_sa = Rnd 
                    If r_sa < Exp((current_nmb - previous_nmb) / temperature) Then              'Accept 
                        Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0 
                        Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                        prevseq = currentseq 
                        prevseqlength = currentseqlength 
                        previous_nmb = current_nmb 
                        failed_attempts = 0 
                        acceptworsecount = acceptworsecount + 1 
                    Else 
                        Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0    'Reject 
                        Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 0 
                        prevseq = prevseq 
                        prevseqlength = prevseqlength 
                        previous_nmb = previous_nmb 
                        failed_attempts = failed_attempts + 1 
                    End If 
                End If 
            End If 
        ElseIf programme = 3 Then       'Local search (only improving moves accepted) 
            If i = 1 Then 
                prevseq = currentseq 
                previous_nmb = current_nmb 
                prevseqlength = currentseqlength 
            Else 
                If current_nmb > previous_nmb Then          'Improvement = Accept 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 1 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                    prevseq = currentseq 
                    prevseqlength = currentseqlength 
                    previous_nmb = current_nmb 
                    failed_attempts = 0 
                Else                                        'Reject 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 0 
                    prevseq = prevseq 
                    prevseqlength = prevseqlength 
                    previous_nmb = previous_nmb 
                    failed_attempts = failed_attempts + 1 
                End If 
            End If 
        ElseIf programme = 5 Then                       'INITIAL TEMP SETTING ALGORITHM 
            If i = 1 Then 
                prevseq = currentseq 
                previous_nmb = current_nmb 
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                prevseqlength = currentseqlength 
            Else 
                If current_nmb > previous_nmb Then      'Improvement = Accept 
                    Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 1 
                    Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                    prevseq = currentseq 
                    prevseqlength = currentseqlength 
                    previous_nmb = current_nmb 
                    failed_attempts = 0 
                Else 
                    worsecount = worsecount + 1 
                    r_sa = Rnd 
                    If r_sa < Exp((current_nmb - previous_nmb) / temperature) Then              'Accept 
                        Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0 
                        Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                        prevseq = currentseq 
                        prevseqlength = currentseqlength 
                        previous_nmb = current_nmb 
                        failed_attempts = 0 
                        acceptworsecount = acceptworsecount + 1 
                    Else 
                        Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0    'Reject 
                        Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 0 
                        prevseq = prevseq 
                        prevseqlength = prevseqlength 
                        previous_nmb = previous_nmb 
                        failed_attempts = failed_attempts + 1 
                    End If 
                End If 
            End If 
        End If 
         
        If temperature = 1 Then 
            temperature = 0 
        End If 
                                                            '####STOPPING RULE 
        If i = max_runs Then                                'Maximum runs reached = stop 
            stopsim = 1 
            stopsimreason = 1 
        End If 
        
        If min_temp_stop_active = 1 Then                    'Minimum temperature reached 
            If temperature < min_temp_stop Then 
                stopsim = 1 
                stopsimreason = 2 
            End If 
        End If 
         
        If max_failed_attempts_active = 1 Then 
            If failed_attempts >= max_failed_attempts Then  'Max consecutive failed attempts reached 
                stopsim = 1 
                stopsimreason = 3 
            End If 
        End If 
         
        If programme = 5 Then 
            If worsecount > 0 Then 
                p_accept = acceptworsecount / worsecount 
            End If 
 
            If worsecount = worseloop Then 
                temperature = temperature + temp_algorithm_increment 
 
                If p_accept >= p_accept_target Then 
                    stopsim = 1 
                    Worksheets("Frontsheet").Range("X23:X23").Offset(b - 1, 0).Value = temperature 
                Else 
                    acceptworsecount = 0 
                    worsecount = 0 
                End If 
            End If 
            Worksheets("Frontsheet").Range("AH35:AH35").Offset(i - 1, 0).Value = p_accept 
            Worksheets("Frontsheet").Range("AI35:AI35").Offset(i - 1, 0).Value = acceptworsecount 
            Worksheets("Frontsheet").Range("AJ35:AJ35").Offset(i - 1, 0).Value = worsecount 
        End If 
 
        i = i + 1 
        total_i = total_i + 1 
        ActiveWindow.ScrollRow = i 
    Loop 
     
    Calculate 
     
    a = 1 
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    Do Until a > UBound(bestseq)                            'Update the best sequence in the spreadsheet 
        Range("B23").Offset(b - 1, a - 1).Value = bestseq(a) 
        a = a + 1 
    Loop 
'    prevrestartbestseq = bestseq 
'    prevrestartbestseq_index = b 
     
    If b = 1 Then 
        overall_best_nmb = best_nmb 
        overallbestseq = bestseq 
        overallbestseq_index = b 
    Else 
        overall_best_nmb = best_nmb 
        overallbestseq = bestseq 
        overallbestseq_index = b 
    End If 
    Range("V20").Value = overallbestseq_index 
'    Range("V21").Value = prevrestartbestseq_index 
     
    Worksheets("Frontsheet").Range("P23:P23").Offset(b - 1, 0).Value = best_nmb 
    Worksheets("Frontsheet").Range("Q23:Q23").Offset(b - 1, 0).Value = best_cost 
    Worksheets("Frontsheet").Range("R23:R23").Offset(b - 1, 0).Value = best_qaly 
    Worksheets("Frontsheet").Range("S23:S23").Offset(b - 1, 0).Value = best_nmb_index 
    Worksheets("Frontsheet").Range("T23:T23").Offset(b - 1, 0).Value = i - 1 
    Worksheets("Frontsheet").Range("U23:U23").Offset(b - 1, 0).Value = stopsimreason 
     
    Select Case b 
        Case 1 
            Sheets("R1").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 2 
            Sheets("R2").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 3 
            Sheets("R3").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 4 
            Sheets("R4").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 5 
            Sheets("R5").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 6 
            Sheets("R6").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 7 
            Sheets("R7").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 8 
            Sheets("R8").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 9 
            Sheets("R9").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
        Case 10 
            Sheets("R10").Range("B2:AJ10002").Value = Sheets("Frontsheet").Range("B35:AJ10035").Value 
    End Select 
       
    b = b + 1                                               'Next Restart (if relevent) 
Loop 
         
If programme = 5 Then 
    stopsimreason = 4 
End If 
 
If end_run_search_active = 1 Then 
    Range("B35:AJ999999").ClearContents 
    i = 1 
     
    Do Until i > end_run_search 
        Calculate 
        Application.StatusBar = "End Run Evaluation " & i & " out of " & end_run_search 
         
        If i = 1 Then 
            a = 1 
            overallbestseqlength = UBound(overallbestseq) 
            Do Until a > UBound(overallbestseq)                            'Update the best sequence in the spreadsheet 
                Range("B35").Offset(i - 1, a - 1).Value = overallbestseq(a) 
            a = a + 1 
            Loop 
            prevseq = overallbestseq 
        Else 
            duplicate = 0 
            duplicate_index = 0 
            eval_start_time = 0 
            eval_end_time = 0 
             
            If sequence_generation = 1 Then     'Generate a random sequence 
                Call gen_random_seq(i, currentseq, currentseqlength) 
            ElseIf sequence_generation = 2 Then     'Pairwise swap 
                Call pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
            ElseIf sequence_generation = 3 Then     'Random swap + Add/Subtract (DEFAULT) 
                Select Case currentseqlength    'addition/remove 1 or 2 tx, 
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                                                'dependent on probs & length of sequence 
                    Case 1 To 2 
                        p_add = 1 
                        p_add2 = bp_add2 
                        p_remove = 0 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 3 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = 0 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 4 To 10 
                        p_add = bp_add 
                        p_add2 = bp_add2 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 11 To 12 
                        p_add = bp_add 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        ElseIf r_seq < p_add Then 
                            If r_seq2 < p_add2 / p_add Then 
                                Call addseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
357 
 
                                Call addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                    Case 13 To 14 
                        p_add = 0 
                        p_add2 = 0 
                        p_remove = bp_remove 
                        p_remove2 = bp_remove2 
                        r_seq = Rnd 
                        r_seq2 = Rnd 
                        If r_seq > 1 - p_remove Then 
                            If r_seq2 < p_remove2 / p_remove Then 
                                Call removeseq2(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            Else 
                                Call removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                            End If 
                        Else 
                            Call randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
                        End If 
                End Select 
            End If 
        End If 
         
        duplicate = 0 
        duplicate_index = 0 
        eval_start_time = 0 
        eval_end_time = 0 
     
        If total_i > 1 Then 
            If cache_search_active = 1 Then 
                eval_start_time = Now() 
                Call cache_search(total_i, i, duplicate, duplicate_index, currentseqlength) 
                eval_end_time = Now() 
            End If 
        End If 
     
        If duplicate = 1 Then 
            Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("P2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("Q35:Q35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("Q2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("R35:R35").Offset(i - 1, 0).Value = 
Worksheets("Cache").Range("R2").Offset(duplicate_index - 1, 0).Value 
            Worksheets("Frontsheet").Range("AE35:AE35").Offset(i - 1, 0).Value = "DUPLICATE" 
            Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
            Worksheets("Frontsheet").Range("AG35:AG35").Offset(i - 1, 0).Value = duplicate_index 
        Else 
            eval_start_time = Now() 
            Range("U20").Value = total_i 
            Call runmodel(i, numsim)        'run model to evaluate 
            If Worksheets("Frontsheet").Range("AC35:AC35").Offset(i - 1, 0).Value = 1 Then 
                nmb = -999999999 
                Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value = nmb 
            End If 
             
            eval_end_time = Now() 
            Worksheets("Frontsheet").Range("AE35:Ae35").Offset(i - 1, 0).Value = "EVALUATE" 
            Worksheets("Frontsheet").Range("AF35:AF35").Offset(i - 1, 0).Value = 
SecondsToDateTimeSerial(DateDiff("s", eval_start_time, eval_end_time)) 
        End If 
     
        current_nmb = Worksheets("Frontsheet").Range("P35:P35").Offset(i - 1, 0).Value 
        current_cost = Worksheets("Frontsheet").Range("Q35:Q35").Offset(i - 1, 0).Value 
        current_qaly = Worksheets("Frontsheet").Range("R35:R35").Offset(i - 1, 0).Value 
        Sheets("Cache").Range("B2:R2").Offset(total_i - 1, 0).Value = 
Worksheets("Frontsheet").Range("B35:R35").Offset(i - 1, 0).Value 
        If i = 1 Then                   'update current best results 
            best_nmb = current_nmb 
            best_cost = current_cost 
            best_qaly = current_qaly 
            previous_nmb = current_nmb 
            bestseq = currentseq 
            Worksheets("Frontsheet").Range("T35:T35").Value = best_nmb 
            best_nmb_index = i 
            Worksheets("Frontsheet").Range("S35:S35").Value = best_nmb_index 
        Else 
            If current_nmb > best_nmb Then      'improvement. update current best 
                best_nmb = current_nmb 
                best_cost = current_cost 
                best_qaly = current_qaly 
358 
 
                bestseq = currentseq 
                 
                Worksheets("Frontsheet").Range("T35:T35").Offset(i - 1, 0).Value = best_nmb 
                best_nmb_index = i 
                Worksheets("Frontsheet").Range("S35:S35").Offset(i - 1, 0).Value = i 
            Else                        'otherwise retain the current best 
                Worksheets("Frontsheet").Range("T35:T35").Offset(i - 1, 0).Value = best_nmb 
                Worksheets("Frontsheet").Range("S35:S35").Offset(i - 1, 0).Value = best_nmb_index 
            End If 
            Worksheets("Frontsheet").Range("W35:W35").Offset(i - 1, 0).Value = "LOCAL" 
        End If 
 
        If i = 1 Then 
            currentseq = bestseq 
            prevseq = currentseq 
            previous_nmb = current_nmb 
            currenseqlength = UBound(currentseq) 
            prevseqlength = currentseqlength 
        Else 
            If current_nmb > previous_nmb Then          'Improvement = Accept 
                Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 1 
                Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 1 
                prevseq = currentseq 
                prevseqlength = currentseqlength 
                previous_nmb = current_nmb 
                failed_attempts = 0 
            Else                                        'Reject 
                Worksheets("Frontsheet").Range("U35:U35").Offset(i - 1, 0).Value = 0 
                Worksheets("Frontsheet").Range("V35:V35").Offset(i - 1, 0).Value = 0 
                prevseq = prevseq 
                prevseqlength = prevseqlength 
                previous_nmb = previous_nmb 
                failed_attempts = failed_attempts + 1 
            End If 
        End If 
     
        i = i + 1 
        total_i = total_i + 1 
        ActiveWindow.ScrollRow = i 
    Loop 
     
    If best_nmb > overall_best_nmb Then 
        overall_best_nmb = best_nmb 
        overallbestseq = bestseq 
    End If 
     
    a = 1 
    Do Until a > UBound(overallbestseq)                            'Update the best sequence in the spreadsheet 
        Range("B33").Offset(0, a - 1).Value = bestseq(a) 
        a = a + 1 
    Loop 
 
    Worksheets("Frontsheet").Range("P33:P33").Value = best_nmb 
    Worksheets("Frontsheet").Range("Q33:Q33").Value = best_cost 
    Worksheets("Frontsheet").Range("R33:R33").Value = best_qaly 
    Worksheets("Frontsheet").Range("S33:S33").Value = best_nmb_index 
  
End If 
                                                            'End of simulation 
end_time = Now() 
Range("S21").Value = SecondsToDateTimeSerial(DateDiff("s", start_time, end_time)) 
Set MYSIMUL8 = Nothing 
 
If email_notification = 1 Then 
  
    Dim iMsg As Object 
    Dim iConf As Object 
    Dim strbody As String 
    Dim Flds As Variant 
      
    Set iMsg = CreateObject("CDO.Message") 
    Set iConf = CreateObject("CDO.Configuration") 
      
    iConf.Load -1 ' CDO Source Defaults 
    Set Flds = iConf.Fields 
    With Flds 
        .Item("http://schemas.microsoft.com/cdo/configuration/smtpusessl") = True 
        .Item("http://schemas.microsoft.com/cdo/configuration/smtpauthenticate") = 1 
        .Item("http://schemas.microsoft.com/cdo/configuration/sendusername") = "**********" 
        .Item("http://schemas.microsoft.com/cdo/configuration/sendpassword") = *********" 
        .Item("http://schemas.microsoft.com/cdo/configuration/smtpserver") = "smtp.gmail.com" 
          
        .Item("http://schemas.microsoft.com/cdo/configuration/sendusing") = 2 
        .Item("http://schemas.microsoft.com/cdo/configuration/smtpserverport") = 465 
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        .Update 
    End With 
      
    strbody = "Hi there" & vbNewLine & vbNewLine & _ 
    "Simulation is complete. MESSAGE FROM " & pc_name & vbNewLine & _ 
    "Number of restarts: " & b - 1 & vbNewLine & _ 
    "Number of evaluations: " & i & vbNewLine & _ 
    "Best NMB: " & overall_best_nmb 
      
    With iMsg 
        Set .Configuration = iConf 
        .To = "*********" 
        .CC = "********" 
        .BCC = "" 
         ' Note: The reply address is not working if you use this Gmail example 
         ' It will use your Gmail address automatic. But you can add this line 
         ' to change the reply address  .ReplyTo = "Reply@something.nl" 
        .From = """TOSHALERT"" <t******t@gmail.com>" 
        .Subject = "Simulation complete" 
        .TextBody = strbody 
        .Send 
    End With 
      
End If 
 
Select Case stopsimreason 
    Case 1 
        MsgBox "REASON FOR STOPPING = MAXIMUM RUNS REACHED. " & i - 1 & _ 
            " Evaluations. Model Run Time = " & SecondsToDateTimeSerial(DateDiff("s", start_time, end_time)) 
    Case 2 
        MsgBox "REASON FOR STOPPING = MINIMUM TEMPERATURE REACHED. " & i - 1 & _ 
            " Evaluations. Model Run Time = " & SecondsToDateTimeSerial(DateDiff("s", start_time, end_time)) 
    Case 3 
        MsgBox "REASON FOR STOPPING = MAXIMUM NUMBER OF FAILED ATTEMPTS REACHED. " & _ 
            i - 1 & " Evaluations. Model Run Time = " & SecondsToDateTimeSerial(DateDiff("s", start_time, 
end_time)) 
    Case 4 






GENERATE RANDOM SEQUENCE 
 
Sub gen_random_seq(i, currentseq, currentseqlength) 
 
Dim t As String 
Dim c1_flag, c2_flag, c3_flag, c4_flag, first_line_flag, _ 
    line, tx, shift, flag, bestseqnum, min_init_length, sim, _ 
    numsim, loopcount, init_sol As Integer 
Dim c1_flag_arr, c2_flag_arr, c3_flag_arr, c4_flag_arr As Variant 
Dim tabl As Range 
Dim checklist, bestseq 
Dim p_short, p_length, random As Double 
 
Sheets("Frontsheet").Activate 
Set tabl = ThisWorkbook.Names("tabl").RefersToRange 
Set c1_flag_arr = ThisWorkbook.Names("_c1_array").RefersToRange 
Set c2_flag_arr = ThisWorkbook.Names("_c2_array").RefersToRange 
Set c3_flag_arr = ThisWorkbook.Names("_c3_array").RefersToRange 
Set c4_flag_arr = ThisWorkbook.Names("_c4_array").RefersToRange 
 
seqfault = 1 
min_init_length = Range("min_init_length").Value 
 
Do Until seqfault = 0 
    ReDim checklist(1 To 1) 
    ReDim currentseq(1 To 1) 
     
    If i = 1 Then 
        Range("B35:V35").ClearContents 
    End If 
     
    tx = 0 
    c4_flag = 0 
    first_line_flag = 0 
    c1_flag = 0 
    c2_flag = 0 
    c3_flag = 0 
    c4_flag = 0 
    flag = 0 
    shift = 0 
    random = Rnd 
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    Do Until c4_flag = 1 
        tx = tx + 1 
        loopcount = 0 
         
        Do 
            Calculate 
            t = Application.WorksheetFunction.Index(Range("R4:R17"), _ 
                Application.WorksheetFunction.Rank(Range("S4"), Range("S4:S17"))) 
             
            flag = Application.VLookup(t, tabl, 3 + shift, 0) 
             
            'loop until eligible treatment is selected based on option matrix (flag) 
            'which is offset depending on previous class flags (see later) 
             
            loopcount = loopcount + 1 
             
            If IsError(Application.Match(t, checklist, 0)) Then 
                Exit Do 
            End If 
        Loop 
             
        If tx = 1 Then 
            first_line_flag = 1 
        Else 
            first_line_flag = 0 
        End If 
         
        'UPDATE FLAGS (if it's an error it means that a match hasn't been found) 
        If IsError(Application.Match(t, c4_flag_arr, 0)) Then 
        Else 
            c4_flag = 1 
            shift = 4 
        End If 
         
        If IsError(Application.Match(t, c3_flag_arr, 0)) Then 
        Else 
            c3_flag = 1 
            shift = 3 
        End If 
         
        If IsError(Application.Match(t, c2_flag_arr, 0)) Then 
        Else 
            c2_flag = 1 
            shift = 2 
        End If 
         
        If IsError(Application.Match(t, c1_flag_arr, 0)) Then 
        Else 
            c1_flag = 1 
            shift = 1 
        End If 
         
        If c1_flag = 1 Then 
            shift = 1 
            If c2_flag = 1 Then 
                shift = 2 
                If c3_flag = 1 Then 
                    shift = 3 
                    If c4_flag = 1 Then 
                        shift = 4 
                    End If 
                End If 
            End If 
        End If 
         
        'UPDATE WORKSHEET 
        Range("B35").Offset(i - 1, tx - 1).Value = t 
               
        ReDim Preserve checklist(1 To tx) 
        ReDim Preserve currentseq(1 To tx) 
        checklist(tx) = t 
        If tx = 1 Then 
            If t = "PC" Then 
                t = t 
            End If 
        End If 
 
    Loop 
         
    currentseq = checklist 
    currentseqlength = tx 
    Call eligible(currentseq, currentseqlength, seqfault) 
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    If i = 1 Then 
        If currentseqlength < min_init_length Then 
            seqfault = 1 
        End If 






CHECK SEQUENCE ELIGIBILITY 
 
Sub eligible(currentseq, currentseqlength, seqfault) 
Dim t, fault As String 
Dim loopexit, loopcount, tx, shift, flag As Integer 
Dim c1_flag, c2_flag, c3_flag, c4_flag, first_line_flag As Integer 
Dim c1_flag_arr, c2_flag_arr, c3_flag_arr, c4_flag_arr As Variant 
Dim line As Integer 
Dim tabl As Range 
 
Set tabl = ThisWorkbook.Names("tabl").RefersToRange 
Set c1_flag_arr = ThisWorkbook.Names("_c1_array").RefersToRange 
Set c2_flag_arr = ThisWorkbook.Names("_c2_array").RefersToRange 
Set c3_flag_arr = ThisWorkbook.Names("_c3_array").RefersToRange 
Set c4_flag_arr = ThisWorkbook.Names("_c4_array").RefersToRange 
 
loopcount = 0 
shift = 0 
seqfault = 0 
 
Do Until loopcount = currentseqlength 
     
    loopcount = loopcount + 1 
    t = currentseq(loopcount) 
     
    flag = Application.VLookup(t, tabl, 3 + shift, 0) 
     
    If flag = 1 Then 
        fault = "No" 
    Else 
        fault = "Yes" 
        seqfault = 1 
    End If 
     
    If IsError(Application.Match(t, c4_flag_arr, 0)) Then 
    Else 
        c4_flag = 1 
        shift = 4 
    End If 
     
    If IsError(Application.Match(t, c3_flag_arr, 0)) Then 
    Else 
        c3_flag = 1 
        shift = 3 
    End If 
     
    If IsError(Application.Match(t, c2_flag_arr, 0)) Then 
    Else 
        c2_flag = 1 
        shift = 2 
    End If 
     
    If IsError(Application.Match(t, c1_flag_arr, 0)) Then 
    Else 
        c1_flag = 1 
        shift = 1 
    End If 
     
    If c1_flag = 1 Then 
        shift = 1 
        If c2_flag = 1 Then 
            shift = 2 
            If c3_flag = 1 Then 
                shift = 3 
                If c4_flag = 1 Then 
                    shift = 4 
                End If 
            End If 
        End If 
    End If 
         
    If loopcount > 1 Then 
        a = 1 
        Do Until a = loopcount 
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            If t = currentseq(a) Then 
                seqfault = 1 
            End If 
             
            a = a + 1 
        Loop 









Sub pairswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
Dim sequence 
Dim selection_index1, selection_index2, throwaway, a As Integer 
Dim selection_tx1, selection_tx2 As String 
Dim r_num As Double 
seqfault = 1 
throwaway = 0 
Do Until seqfault = 0 
    r_num = Rnd 
    sequence = prevseq 
     
    If prevseqlength > 2 Then 
     
        selection_index1 = Int(((prevseqlength - 2) - 1 + 1) * r_num + 1) 
         
        selection_tx1 = sequence(selection_index1) 
        selection_index2 = selection_index1 + 1 
        selection_tx2 = sequence(selection_index2) 
         
        Range("Y35").Offset(i - 1, 0).Value = selection_index1 
        Range("Z35").Offset(i - 1, 0).Value = selection_tx1 
        Range("AA35").Offset(i - 1, 0).Value = selection_index2 
        Range("AB35").Offset(i - 1, 0).Value = selection_tx2 
         
        If currentseqlength > 3 Then    'swap elements 
            temp = sequence(selection_index1) 
            sequence(selection_index1) = sequence(selection_index2) 
            sequence(selection_index2) = temp 
        End If 
     
    End If 
     
    a = 1 
    Do Until a > prevseqlength 
        Range("B35").Offset(i - 1, a - 1).Value = sequence(a) 
        a = a + 1 
    Loop 
     
    currentseq = sequence 
    currentseqlength = prevseqlength 
    Call eligible(currentseq, currentseqlength, seqfault) 
    Range("AC35").Offset(i - 1, 0).Value = seqfault 
    Range("AD35").Offset(i - 1, 0).Value = throwaway 
     
    throwaway = throwaway + 1 
    If throwaway > 200 Then 
        throwaway = throwaway 
        currentseq = prevseq 
        seqfault = 0 
    End If 
     
Loop 







Sub randomswap(i, prevseq, currentseq, currentseqlength, prevseqlength) 
Dim sequence 
Dim selection_index1, selection_index2, loopcount, a, throwaway As Integer 
Dim selection_tx1, selection_tx2 As String 
Dim r_num1, r_num2 As Double 
seqfault = 1 
throwaway = 0 
 
Do Until seqfault = 0 
    sequence = prevseq 
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    selection_index1 = 0 
    selection_index2 = 0 
    If prevseqlength > 2 Then 
        loopcount = 1 
         
        Do Until selection_index1 <> selection_index2 
             
            r_num1 = Rnd 
            r_num2 = Rnd 
 
            selection_index1 = Int(r_num1 * (prevseqlength - 1)) + 1 
            selection_index2 = Int(r_num2 * (prevseqlength - 1)) + 1 
            selection_tx1 = sequence(selection_index1) 
            selection_tx2 = sequence(selection_index2) 
             
            Range("Y35").Offset(i - 1, 0).Value = selection_index1 
            Range("Z35").Offset(i - 1, 0).Value = selection_tx1 
            Range("AA35").Offset(i - 1, 0).Value = selection_index2 
            Range("AB35").Offset(i - 1, 0).Value = selection_tx2 
             
            If loopcount = 1000 Then 
                Exit Do 
            End If 
            loopcount = loopcount + 1 
    
        Loop 
         
        If prevseqlength >= 3 Then      'swap elements 
            temp = sequence(selection_index1) 
            sequence(selection_index1) = sequence(selection_index2) 
            sequence(selection_index2) = temp 
        End If 
         
    End If 
     
    a = 1 
    Do Until a > prevseqlength 
        Range("B35").Offset(i - 1, a - 1).Value = sequence(a) 
        a = a + 1 
    Loop 
     
    currentseq = sequence 
    currentseqlength = prevseqlength 
    Call eligible(currentseq, currentseqlength, seqfault) 
    Range("AC35").Offset(i - 1, 0).Value = seqfault 
    Range("AD35").Offset(i - 1, 0).Value = throwaway 
     
    throwaway = throwaway + 1 
    If throwaway > 200 Then 
        throwaway = throwaway 
        currentseq = prevseq 
        seqfault = 0 
    End If 
     
Loop 
'Range("B35").Offset(i - 1, selection_index1 - 1).Font.Bold = True 
'Range("B35").Offset(i - 1, selection_index2 - 1).Font.Bold = True 
'Range("B35").Offset(i - 2, selection_index1 - 1).Font.Bold = True 
'Range("B35").Offset(i - 2, selection_index2 - 1).Font.Bold = True 







Sub removeseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
Dim sequence 
Dim selection_index, a, throwaway As Integer 
Dim selection_tx As String 
Dim r_num As Double 
ReDim sequence(1 To prevseqlength) As String 
seqfault = 1 
throwaway = 0 
Do Until seqfault = 0 
    sequence = prevseq 
    r_num = Rnd 
    selection_index = Int(r_num * (prevseqlength - 1)) + 1 
    selection_tx = sequence(selection_index) 
    Range("Y35").Offset(i - 1, 0).Value = selection_index 
    Range("Z35").Offset(i - 1, 0).Value = selection_tx 
     
    If selection_index > 1 Then 
        ReDim arr1(1 To selection_index - 1) As String 
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        ReDim arr2(1 To prevseqlength - selection_index) As String 
        ReDim newseq(1 To prevseqlength - 1) As String 
         
        For n = 1 To UBound(arr1) 
            newseq(n) = sequence(n) 
        Next n 
         
        For n = 1 To UBound(arr2) 
            newseq(n + selection_index - 1) = sequence(n + selection_index) 
        Next n 
    Else 
        ReDim newseq(1 To prevseqlength - 1) As String 
        For n = 1 To UBound(newseq) 
            newseq(n) = sequence(n + 1) 
        Next n 
    End If 
     
    a = 1 
    Do Until a > prevseqlength - 1 
        Range("B35").Offset(i - 1, a - 1).Value = newseq(a) 
        a = a + 1 
    Loop 
    currentseq = newseq 
    currentseqlength = prevseqlength - 1 
     
    Call eligible(currentseq, currentseqlength, seqfault) 
    Range("AC35").Offset(i - 1, 0).Value = seqfault 
    Range("AD35").Offset(i - 1, 0).Value = throwaway 
    throwaway = throwaway + 1 
    If throwaway > 200 Then 
        throwaway = throwaway 
        currentseq = prevseq 
        seqfault = 0 
    End If 
Loop 
 
Range("X35").Offset(i - 1, 0).Value = "REMOVAL" 







Sub addseq(i, prevseq, currentseq, currentseqlength, prevseqlength) 
Dim sequence 
Dim selection_index, insert_selection_index, a, throwaway As Integer 
Dim selection_tx, insert_selection_tx As String 
Dim r_num, r_num2 As Double 
ReDim sequence(1 To prevseqlength) As String 
Dim txlist(1 To 14) As String 
txlist(1) = "ABT" 
txlist(2) = "ABTS" 
txlist(3) = "ADA" 
txlist(4) = "CTZ" 
txlist(5) = "ETN" 
txlist(6) = "GOL" 
txlist(7) = "HCQ" 
txlist(8) = "IFX" 
txlist(9) = "MTX" 
txlist(10) = "RTX" 
txlist(11) = "PC" 
txlist(12) = "SSZ" 
txlist(13) = "TCZ" 
txlist(14) = "TICORA" 
seqfault = 1 
throwaway = 0 
 
Do Until seqfault = 0 
    sequence = prevseq 
    r_num = Rnd 
    selection_index = Int(r_num * (prevseqlength - 1)) + 1 
    selection_tx = sequence(selection_index) 
    Range("Y35").Offset(i - 1, 0).Value = selection_index + 1 
     
    If selection_index > 1 Then 
             
        ReDim arr1(1 To selection_index) As String 
        ReDim arr2(1 To prevseqlength - selection_index) As String 
        ReDim newseq(1 To prevseqlength + 1) As String 
         
        For n = 1 To UBound(arr1) 
            newseq(n) = sequence(n) 
        Next n 
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        loopcount = 1 
         
        Do 
            r_num2 = Rnd 
            insert_selection_index = Int(r_num2 * 14) + 1 
            insert_selection_tx = txlist(insert_selection_index) 
            Range("Z35").Offset(i - 1, 0).Value = insert_selection_tx 
            If IsInArray(insert_selection_tx, sequence) Then 
                 
            Else 
                Exit Do 
            End If 
            If loopcount = 1000 Then 
                Exit Do 
            End If 
            loopcount = loopcount + 1 
        Loop 
        newseq(selection_index + 1) = insert_selection_tx 
         
        For n = 1 To UBound(arr2) 
            newseq(n + selection_index + 1) = sequence(n + selection_index) 
        Next n 
    Else 
        ReDim newseq(1 To prevseqlength + 1) As String 
        loopcount = 1 
        Do 
            r_num2 = Rnd 
            insert_selection_index = Int(r_num2 * 14) + 1 
            insert_selection_tx = txlist(insert_selection_index) 
            Range("Z35").Offset(i - 1, 0).Value = insert_selection_tx 
            If IsInArray(insert_selection_tx, sequence) Then 
                 
            Else 
                Exit Do 
            End If 
                        If loopcount = 1000 Then 
                Exit Do 
            End If 
            loopcount = loopcount + 1 
        Loop 
        newseq(selection_index) = insert_selection_tx 
         
        For n = 1 To UBound(newseq) - 1 
            newseq(n + 1) = sequence(n) 
        Next n 
    End If 
     
    a = 1 
    Do Until a > prevseqlength + 1 
        Range("B35").Offset(i - 1, a - 1).Value = newseq(a) 
        a = a + 1 
    Loop 
 
    currentseqlength = prevseqlength + 1 
    Call eligible(newseq, currentseqlength, seqfault) 
    Range("AC35").Offset(i - 1, 0).Value = seqfault 
    currentseqlength = prevseqlength - 1 
    Range("AD35").Offset(i - 1, 0).Value = throwaway 
     
    throwaway = throwaway + 1 
    If throwaway > 200 Then 
        throwaway = throwaway 
        currentseq = prevseq 
        seqfault = 0 
    End If 
Loop 
 
'If selection_index > 1 Then 
'    Range("B35").Offset(i - 1, selection_index).Interior.ColorIndex = 4 
'Else 
'    Range("B35").Offset(i - 1, selection_index - 1).Interior.ColorIndex = 4 
'End If 
 
currentseq = newseq 
If throwaway > 200 Then 
    currentseqlength = prevseqlength 
    currentseq = prevseq 
Else 
    currentseqlength = prevseqlength + 1 
End If 
 
Range("X35").Offset(i - 1, 0).Value = "ADDITION" 
 
End Sub 
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